=    O
=    O
=    O
---    O
bariatric    B-MetabolicDisorder114084502
surgery    I-MetabolicDisorder114084502

---    O
biliopancreatic    B-MetabolicDisorder114084502
diversion    I-MetabolicDisorder114084502

---    O
biliopancreatic    B-MetabolicDisorder114084502
diversion    I-MetabolicDisorder114084502

Vertical    O
banded    O
gastroplasty    O
(    O
VBG    O
)    O
,    O
also    O
known    O
as    O
stomach    O
stapling    O
,    O
is    O
a    O
form    O
of    O
bariatric    B-MetabolicDisorder114084502
surgery    I-MetabolicDisorder114084502
for    O
weight    O
control    O
.    O

The    O
hospital    O
performs    O
bariatric    B-MetabolicDisorder114084502
surgery    I-MetabolicDisorder114084502
and    O
head    O
and    O
neck    O
surgery    O
on    O
top    O
of    O
standard    O
surgery    O
.    O

Bariatric    B-MetabolicDisorder114084502
surgery    I-MetabolicDisorder114084502

"    O
Bariatric    B-MetabolicDisorder114084502
surgery    I-MetabolicDisorder114084502
"    O
is    O
the    O
term    O
encompassing    O
"    O
all    O
"    O
of    O
the    O
surgical    O
treatments    O
for    O
morbid    O
obesity    O
,    O
not    O
just    O
gastric    O
bypasses    O
,    O
which    O
make    O
up    O
only    O
one    O
class    O
of    O
such    O
operations    O
.    O

It    O
is    O
not    O
intended    O
for    O
use    O
with    O
surgical    B-MetabolicDisorder114084502
and    O
medicinal    O
approaches    O
to    O
weight    O
management    O
,    O
or    O
in    O
broader    O
programmes    O
that    O
include    O
changes    O
to    O
the    O
built    O
environment    O
.    O

It    O
is    O
rare    O
among    O
other    O
patients    O
,    O
but    O
,    O
for    O
example    O
,    O
some    O
cases    O
have    O
been    O
observed    O
after    O
bariatric    B-MetabolicDisorder114084502
surgeries    I-MetabolicDisorder114084502
,    O
when    O
deficiency    O
was    O
not    O
prevented    O
by    O
use    O
of    O
nutritional    O
supplements    O
.    O

Lubomyr    O
Kuzmak    O
was    O
a    O
pioneer    O
within    O
the    O
bariatric    B-MetabolicDisorder114084502
surgical    I-MetabolicDisorder114084502
community    O
inventing    O
the    O
adjustable    B-MetabolicDisorder114084502
silicone    I-MetabolicDisorder114084502
band    I-MetabolicDisorder114084502
.    O

In    O
February    O
2013    O
the    O
Chairman    O
Dr    O
David    O
Haslam    O
called    O
for    O
stomach    B-MetabolicDisorder114084502
surgery    I-MetabolicDisorder114084502
to    O
be    O
offered    O
to    O
obese    O
children    O
.    O

Jen    O
-    O
Ai    O
Hospital    O
–    O
Dali    O
provides    O
medical    O
services    O
in    O
more    O
than    O
40    O
different    O
departments    O
including    O
Bariatric    B-MetabolicDisorder114084502
Surgery    I-MetabolicDisorder114084502
,    O
Cardiac    O
Surgery    O
,    O
Neurosurgery    O
,    O
Oncology    O
,    O
Plastic    O
Surgery    O
,    O
etc    O
.    O

It    O
can    O
also    O
occur    O
after    O
bariatric    B-MetabolicDisorder114084502
surgery    I-MetabolicDisorder114084502
,    O
mercury    O
exposure    O
and    O
tartrazine    O
.    O

However    O
,    O
the    O
risk    O
is    O
also    O
increased    O
in    O
those    O
who    O
lose    O
weight    O
rapidly    O
(    O
e.g.    O
after    O
weight    B-MetabolicDisorder114084502
loss    I-MetabolicDisorder114084502
surgery    I-MetabolicDisorder114084502
)    O
due    O
to    O
alterations    O
in    O
the    O
composition    O
of    O
the    O
bile    O
that    O
makes    O
it    O
prone    O
to    O
form    O
stones    O
.    O

Big    O
Medicine    O
is    O
an    O
American    O
reality    O
television    O
show    O
that    O
examines    O
the    O
effects    O
of    O
bariatric    B-MetabolicDisorder114084502
surgery    I-MetabolicDisorder114084502
,    O
both    O
physical    O
and    O
emotional    O
,    O
on    O
obese    O
patients    O
.    O

Cerebrotendineous    B-MetabolicDisorder114084502
xanthomatosis    I-MetabolicDisorder114084502
or    O
cerebrotendinous    B-MetabolicDisorder114084502
xanthomatosis    I-MetabolicDisorder114084502
(    O
CTX    B-MetabolicDisorder114084502
)    O
,    O
also    O
called    O
cerebral    B-MetabolicDisorder114084502
cholesterosis    I-MetabolicDisorder114084502
,    O
is    O
an    O
autosomal    O
recessive    O
form    O
of    O
xanthomatosis    O
.    O

Mutations    O
in    O
CYP27A1    O
are    O
associated    O
with    O
cerebrotendineous    B-MetabolicDisorder114084502
xanthomatosis    I-MetabolicDisorder114084502
,    O
a    O
rare    O
lipid    O
storage    O
disease    O
.    O

Cerebrotendinous    B-MetabolicDisorder114084502
cholesterosis    I-MetabolicDisorder114084502
(    O
van    O
Bogaert    O
-    O
Scherer    O
-    O
Epstein    O
)    O

Additional    O
research    O
conclude    O
a    O
cytosine    O
to    O
thymidine    O
nonsense    O
mutation    O
such    O
as    O
that    O
of    O
trichothiodystrophy    B-MetabolicDisorder114084502
discussed    O
above    O
has    O
resulted    O
in    O
abnormal    O
development    O
in    O
which    O
tissues    O
of    O
the    O
ectoderm    O
germ    O
layer    O
are    O
affected    O
.    O

Brittle    B-MetabolicDisorder114084502
hair–intellectual    I-MetabolicDisorder114084502
impairment–decreased    I-MetabolicDisorder114084502
fertility–short    I-MetabolicDisorder114084502
stature    I-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502

Ichthyosis–brittle    B-MetabolicDisorder114084502
hair–impaired    I-MetabolicDisorder114084502
intelligence–decreased    I-MetabolicDisorder114084502
fertility–short    I-MetabolicDisorder114084502
stature    I-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
(    O
IBIDS    O
syndrome    O
,    O
sulfur    O
-    O
deficient    O
brittle    O
hair    O
syndrome    O
,    O
Tay    O
's    O
syndrome    O
,    O
trichothiodystrophy    O
,    O
trichothiodystrophy    O
with    O
ichthyosis    O
)    O

Trichothiodystrophy    B-MetabolicDisorder114084502
(    O
ILDS    O
Q84.169    O
)    O

A    O
deficiency    O
associated    O
with    O
lysosomal    B-MetabolicDisorder114084502
acid    I-MetabolicDisorder114084502
lipase    I-MetabolicDisorder114084502
deficiency    I-MetabolicDisorder114084502
,    O
Wolman    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
and    O
cholesteryl    B-MetabolicDisorder114084502
ester    I-MetabolicDisorder114084502
storage    I-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

Wolman's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502

Born    O
:    O
Tod    O
Andrews    O
,    O
American    O
actor    O
,    O
best    O
known    O
for    O
his    O
role    O
as    O
American    O
Civil    O
War    O
Confederate    O
General    O
John    O
S.    O
Mosby    O
in    O
the    O
1950s    O
TV    O
series    O
"    O
The    O
Gray    O
Ghost    O
"    O
,    O
in    O
Buffalo    O
,    O
New    O
York    O
(    O
d.    O
1972    O
)    O
;    O
Barbara    O
Washburn    O
,    O
American    O
mountaineer    O
,    O
first    O
woman    O
to    O
climb    O
Mount    O
McKinley    O
(    O
now    O
Denali    O
)    O
,    O
Alaska    O
,    O
in    O
Boston    O
(    O
d.    O
2014    O
)    O
;    O
Moshe    O
Wolman    O
,    O
Polish    O
-    O
Israeli    O
medical    O
researcher    O
,    O
leading    O
researcher    O
of    O
biochemistry    O
and    O
the    O
first    O
to    O
diagnose    O
the    O
genetic    O
disorder    O
Wolman    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
in    O
Warsaw    O
(    O
d.    O
2009    O
)    O

Sebelipase    O
alfa    O
is    O
a    O
recombinant    O
form    O
of    O
the    O
enzyme    O
lysosomal    O
acid    O
lipase    O
(    O
LAL    O
)    O
that    O
was    O
approved    O
in    O
2015    O
under    O
the    O
tradename    O
Kanuma    O
in    O
the    O
US    O
and    O
EU    O
for    O
the    O
treatment    O
of    O
people    O
with    O
lysosomal    B-MetabolicDisorder114084502
acid    I-MetabolicDisorder114084502
lipase    I-MetabolicDisorder114084502
deficiency    I-MetabolicDisorder114084502
(    O
LAL    O
-    O
D    O
)    O
.    O

Cholesteryl    B-MetabolicDisorder114084502
ester    I-MetabolicDisorder114084502
storage    I-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502

Farber's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
(    O
ILDS    O
E75.240    O
)    O

They    O
further    O
investigated    O
the    O
role    O
of    O
steroid    O
sulfatases    O
in    O
metachromatic    B-MetabolicDisorder114084502
leukodystrophy    I-MetabolicDisorder114084502
and    O
multiple    B-MetabolicDisorder114084502
sulfatase    I-MetabolicDisorder114084502
deficiency    I-MetabolicDisorder114084502
,    O
and    O
they    O
identified    O
acid    O
ceramidase    O
as    O
the    O
enzyme    O
deficient    O
in    O
Farber’s    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

triose-phosphate    B-MetabolicDisorder114084502
isomerase    I-MetabolicDisorder114084502
deficiency    I-MetabolicDisorder114084502

asterixis    B-MetabolicDisorder114084502

A    O
“    O
flapping    O
tremor    O
,    O
”    O
or    O
asterixis    B-MetabolicDisorder114084502
,    O
is    O
characterized    O
by    O
irregular    O
flapping    O
-    O
hand    O
movement    O
,    O
which    O
appears    O
most    O
often    O
with    O
outstretched    O
arms    O
and    O
wrist    O
extension    O
.    O

The    O
most    O
common    O
source    O
is    O
dystrophic    B-MetabolicDisorder114084502
calcification    I-MetabolicDisorder114084502
,    O
which    O
occurs    O
in    O
soft    O
tissue    O
as    O
a    O
response    O
to    O
injury    O
.    O

Dystrophic    B-MetabolicDisorder114084502
calcification    I-MetabolicDisorder114084502
(    O
DC    B-MetabolicDisorder114084502
)    O
is    O
the    O
calcification    O
occurring    O
in    O
degenerated    O
or    O
necrotic    O
tissue    O
,    O
as    O
in    O
hyalinized    O
scars    O
,    O
degenerated    O
foci    O
in    O
leiomyomas    O
,    O
and    O
caseous    O
nodules    O
.    O

Microcystins    O
covalently    O
bond    O
to    O
and    O
inhibit    O
protein    O
phosphatases    O
PP1    O
and    O
PP2A    O
and    O
can    O
thus    O
cause    O
pansteatitis    B-MetabolicDisorder114084502
.    O

Salla    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
(    O
"    O
Finnish    O
type    O
sialuria    O
"    O
)    O

Salla    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
a    O
lysosomal    B-MetabolicDisorder114084502
storage    I-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502

In    O
an    O
experiment    O
directed    O
by    O
John    O
C.    O
Fyfea    O
,    O
Rebeccah    O
L.    O
Kurzhals    O
,    O
and    O
others    O
,    O
it    O
was    O
concluded    O
that    O
a    O
complex    O
rearrangement    O
in    O
the    O
breed    O
's    O
Glycogen    O
branching    O
enzyme    O
(    O
GBE1    O
)    O
can    O
cause    O
both    O
a    O
perinatal    O
hypoglycemic    O
collapse    O
and    O
a    O
late    O
-    O
juvenile    O
-    O
onset    O
neuromuscular    O
degeneration    O
in    O
glycogen    B-MetabolicDisorder114084502
storage    I-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
type    B-MetabolicDisorder114084502
IV    I-MetabolicDisorder114084502
in    O
the    O
breed    O
.    O

Glycogen    B-MetabolicDisorder114084502
storage    I-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
type    I-MetabolicDisorder114084502
IV    I-MetabolicDisorder114084502

|    O
GSD    B-MetabolicDisorder114084502
type    I-MetabolicDisorder114084502
IV    I-MetabolicDisorder114084502

Niemann    B-MetabolicDisorder114084502
Pick    I-MetabolicDisorder114084502
type    I-MetabolicDisorder114084502
C    I-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502

When    O
cells    O
from    O
Niemann–Pick    B-MetabolicDisorder114084502
Type    I-MetabolicDisorder114084502
C    I-MetabolicDisorder114084502
individuals    O
lacking    O
this    O
transporter    O
were    O
exposed    O
to    O
Ebola    O
virus    O
in    O
the    O
laboratory    O
,    O
the    O
cells    O
survived    O
and    O
appeared    O
impervious    O
to    O
the    O
virus    O
,    O
further    O
indicating    O
that    O
Ebola    O
relies    O
on    O
NPC1    O
to    O
enter    O
cells    O
;    O
mutations    O
in    O
the    O
NPC1    O
gene    O
in    O
humans    O
were    O
conjectured    O
as    O
a    O
possible    O
mode    O
to    O
make    O
some    O
individuals    O
resistant    O
to    O
this    O
deadly    O
viral    O
disease    O
.    O

Niemann-Pick    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
type    I-MetabolicDisorder114084502
C    I-MetabolicDisorder114084502
,    O
another    O
lipid    O
storage    O
disease    O
,    O
includes    O
abnormal    O
lipid    O
storage    O
in    O
sweat    O
glands    O
.    O

The    O
syndrome    O
involves    O
defects    O
in    O
the    O
nervous    O
,    O
auditory    O
,    O
skeletal    O
,    O
visual    O
,    O
and    O
endocrine    O
systems    O
and    O
encompasses    O
numerous    O
symptoms    O
,    O
bearing    O
striking    O
similarity    O
to    O
other    O
known    O
syndromes    O
of    O
neuroectodermal    O
nature    O
such    O
as    O
:    O
Werner    O
syndrome    O
,    O
Cockayne    O
syndrome    O
and    O
Refsum    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
.    O

Refsum's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502

The    O
symptoms    O
are    O
similar    O
to    O
those    O
of    O
adult    O
Refsum    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
and    O
usually    O
appear    O
in    O
the    O
late    O
teens    O
or    O
early    O
twenties    O
.    O

This    O
deficiency    O
falls    O
within    O
a    O
class    O
of    O
disorders    O
called    O
peroxisome    O
biogenesis    O
disorders    O
(    O
PBDs    O
)    O
,    O
although    O
it    O
is    O
quite    O
different    O
from    O
other    O
peroxisomal    O
disorders    O
and    O
does    O
not    O
share    O
classic    O
Refsum    B-MetabolicDisorder114084502
disorder    I-MetabolicDisorder114084502
symptoms    O
.    O

Pipecolic    O
acidemia    O
can    O
also    O
be    O
an    O
associated    O
component    O
of    O
Refsum    O
disease    O
with    O
increased    O
pipecolic    O
acidemia    O
(    O
RDPA    O
)    O
,    O
as    O
well    O
as    O
other    O
peroxisomal    O
disorders    O
,    O
including    O
both    O
infantile    O
and    O
adult    B-MetabolicDisorder114084502
Refsum    I-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
and    O
Zellweger    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
.    O

Creatine    O
treatment    O
does    O
not    O
appear    O
to    O
improve    O
muscle    O
strength    O
in    O
people    O
who    O
have    O
metabolic    B-MetabolicDisorder114084502
myopathies    I-MetabolicDisorder114084502
.    O

Lipoatrophy    O
occurs    O
in    O
HIV-associated    B-MetabolicDisorder114084502
lipodystrophy    I-MetabolicDisorder114084502
,    O
one    O
cause    O
of    O
which    O
is    O
an    O
adverse    O
drug    O
reaction    O
that    O
is    O
associated    O
with    O
some    O
antiretroviral    O
drugs    O
.    O

HIV-associated    B-MetabolicDisorder114084502
lipodystrophy    I-MetabolicDisorder114084502

Cerebrohepatorenal    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502

Zellweger's    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
(    O
EUROCAT    O
Q87.83    O
)    O

Deficits    O
in    O
plasmalogen    O
levels    O
contribute    O
to    O
pathology    O
in    O
Zellweger    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
.    O

Zellweger    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502

Certain    O
peroxisomal    O
disorders    O
,    O
such    O
as    O
adrenoleukodystrophy    B-MetabolicDisorder114084502
and    O
Zellweger    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
,    O
can    O
be    O
associated    O
with    O
an    O
accumulation    O
of    O
VLCFAs    O
.    O

Pipecolic    O
acidemia    O
can    O
also    O
be    O
an    O
associated    O
component    O
of    O
Refsum    O
disease    O
with    O
increased    O
pipecolic    O
acidemia    O
(    O
RDPA    O
)    O
,    O
as    O
well    O
as    O
other    O
peroxisomal    O
disorders    O
,    O
including    O
both    O
infantile    O
and    O
adult    B-MetabolicDisorder114084502
Refsum    I-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
and    O
Zellweger    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
.    O

Biotinidase    B-MetabolicDisorder114084502
deficiency    I-MetabolicDisorder114084502

Enzyme    O
assays    O
are    O
used    O
to    O
screen    O
for    O
galactosemia    O
and    O
biotinidase    B-MetabolicDisorder114084502
deficiency    I-MetabolicDisorder114084502
.    O

Biotinidase    B-MetabolicDisorder114084502
deficiency    I-MetabolicDisorder114084502
(    O
BIOT    O
)    O
>    O
1    O
in    O
75,000    O

Another    O
disease    O
,    O
dopamine    B-MetabolicDisorder114084502
beta    I-MetabolicDisorder114084502
hydroxylase    I-MetabolicDisorder114084502
deficiency    I-MetabolicDisorder114084502
,    O
also    O
thought    O
to    O
be    O
underdiagnosed    O
,    O
causes    O
loss    O
of    O
sympathetic    O
noradrenergic    O
function    O
and    O
is    O
characterized    O
by    O
a    O
low    O
or    O
extremely    O
low    O
levels    O
of    O
norepinephrine    O
,    O
but    O
an    O
excess    O
of    O
dopamine    O
.    O

Such    O
diseases    O
include    O
Mendelian    O
diseases    O
and    O
complex    O
genetic    O
disorders    O
such    O
as    O
cystic    O
fibrosis    O
,    O
adrenoleukodystrophy    B-MetabolicDisorder114084502
,    O
Stargardt    O
disease    O
,    O
Tangier    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
immune    O
deficiencies    O
,    O
progressive    O
familial    O
intraheptic    O
cholestasis    O
,    O
Dubin-Johnson    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
,    O
Pseudoxanthoma    O
elasticum    O
,    O
persistent    O
hyperinsulinemic    O
hypoglycemia    O
of    O
infancy    O
due    O
to    O
focal    O
adenomatous    O
hyperplasia    O
,    O
X    O
-    O
linked    O
sideroblastosis    O
and    O
anemia    O
,    O
age    O
-    O
related    O
macular    O
degeneration    O
,    O
familial    O
hypoapoproteinemia    O
,    O
Retinitis    O
pigmentosum    O
,    O
cone    O
rod    O
dystrophy    O
,    O
and    O
others    O
.    O

Dubin-Johnson    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502

Pentosuria    B-MetabolicDisorder114084502
is    O
a    O
condition    O
where    O
the    O
sugar    O
xylitol    O
,    O
a    O
pentose    O
,    O
presents    O
in    O
the    O
urine    O
in    O
unusually    O
high    O
concentrations    O
.    O

Names    O
for    O
conditions    O
associated    O
with    O
these    O
subtypes    O
include    O
infantile    B-MetabolicDisorder114084502
neuronal    I-MetabolicDisorder114084502
ceroid    I-MetabolicDisorder114084502
lipofuscinosis    I-MetabolicDisorder114084502
,    O
Jansky–Bielschowsky    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
and    O
northern    O
epilepsy    O
syndrome    O
.    O

Glycogen    B-MetabolicDisorder114084502
storage    I-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
type    I-MetabolicDisorder114084502
V    I-MetabolicDisorder114084502
(    O
GSD-V    B-MetabolicDisorder114084502
)    O
is    O
a    O
metabolic    O
disorder    O
,    O
more    O
specifically    O
a    O
glycogen    B-MetabolicDisorder114084502
storage    I-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
caused    O
by    O
a    O
deficiency    O
of    O
myophosphorylase    O
.    O

|    O
GSD    B-MetabolicDisorder114084502
type    I-MetabolicDisorder114084502
V    I-MetabolicDisorder114084502

Glycogen    B-MetabolicDisorder114084502
storage    I-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
type    I-MetabolicDisorder114084502
V    I-MetabolicDisorder114084502
-    O
muscle    O
glycogen    O

Menkes    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
;    O
sparse    O
and    O
coarse    O
hair    O
,    O
growth    O
failure    O
,    O
and    O
deterioration    O
of    O
the    O
nervous    O
system    O

Other    O
associated    O
defects    O
in    O
elastin    O
include    O
Marfan    O
syndrome    O
,    O
emphysema    O
caused    O
by    O
α1-antitrypsin    O
deficiency    O
,    O
atherosclerosis    O
,    O
Buschke    O
-    O
Ollendorff    O
syndrome    O
,    O
Menkes    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
,    O
pseudoxanthoma    O
elasticum    O
,    O
and    O
Williams    O
syndrome    O
.    O

This    O
phenotype    O
is    O
noted    O
in    O
Menkes    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

Low    O
ceruloplasmin    O
is    O
also    O
found    O
in    O
Menkes    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
and    O
aceruloplasminemia    B-MetabolicDisorder114084502
,    O
which    O
are    O
related    O
to    O
,    O
but    O
much    O
rarer    O
than    O
Wilson    O
's    O
disease    O
.    O

Menkes    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502

Menkes    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502

Smith-Lemli-Opitz    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502

Interruptions    O
in    O
the    O
delivery    O
of    O
cholesterol    O
include    O
Smith-Lemli-Opitz    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
and    O
abetalipoproteinemia    O
.    O

Smith-Lemli-Opitz    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502

Smith-Lemli-Opitz    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
,    O
a    O
metabolic    O
and    O
developmental    O
disorder    O

Smith-Lemli-Opitz    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502

Psychogenic    B-MetabolicDisorder114084502
polydipsia    I-MetabolicDisorder114084502
may    O
lead    O
to    O
polyuria    O
.    O

In    O
the    O
absence    O
of    O
diabetes    O
mellitus    O
,    O
the    O
most    O
common    O
causes    O
are    O
decreased    O
secretion    O
of    O
aldosterone    O
due    O
to    O
adrenal    O
cortical    O
tumor    O
,    O
primary    B-MetabolicDisorder114084502
polydipsia    I-MetabolicDisorder114084502
(    O
excessive    O
fluid    O
drinking    O
)    O
,    O
central    O
diabetes    O
insipidus    O
and    O
nephrogenic    O
diabetes    O
insipidus    O
.    O

Psychogenic    B-MetabolicDisorder114084502
polydipsia    I-MetabolicDisorder114084502
is    O
the    O
psychiatric    O
condition    O
in    O
which    O
patients    O
feel    O
compelled    O
to    O
drink    O
large    O
quantities    O
of    O
water    O
,    O
thus    O
putting    O
them    O
at    O
risk    O
of    O
water    O
intoxication    O
.    O

A    O
subtype    O
present    O
in    O
the    O
N    O
-    O
terminal    O
region    O
of    O
the    O
amyloid    B-MetabolicDisorder114084502
precursor    I-MetabolicDisorder114084502
protein    I-MetabolicDisorder114084502
is    O
a    O
member    O
of    O
the    O
heparin    O
-    O
binding    O
class    O
of    O
GFLDs    O
and    O
may    O
itself    O
have    O
growth    O
factor    O
function    O
,    O
particularly    O
in    O
promoting    O
neuronal    O
development    O
.    O

Ongoing    O
work    O
:    O
Genentech    O
is    O
working    O
on    O
DR6    O
blocking    O
and    O
anti    O
-    O
N    O
-    O
APP    B-MetabolicDisorder114084502
monoclonal    O
antibodies    O
as    O
a    O
potential    O
treatment    O
to    O
delay    O
progression    O
of    O
neuronal    O
destruction    O
in    O
early    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

Most    O
of    O
autosomal    O
dominant    O
familial    O
AD    O
can    O
be    O
attributed    O
to    O
mutations    O
in    O
one    O
of    O
three    O
genes    O
:    O
those    O
encoding    O
amyloid    B-MetabolicDisorder114084502
precursor    I-MetabolicDisorder114084502
protein    I-MetabolicDisorder114084502
(    O
APP    O
)    O
and    O
presenilins    O
1    O
and    O
2    O
.    O

Support    O
for    O
this    O
postulate    O
comes    O
from    O
the    O
location    O
of    O
the    O
gene    O
for    O
the    O
amyloid    B-MetabolicDisorder114084502
precursor    I-MetabolicDisorder114084502
protein    I-MetabolicDisorder114084502
(    O
APP    O
)    O
on    O
chromosome    O
21    O
,    O
together    O
with    O
the    O
fact    O
that    O
people    O
with    O
trisomy    O
21    O
(    O
Down    O
Syndrome    O
)    O
who    O
have    O
an    O
extra    O
gene    O
copy    O
almost    O
universally    O
exhibit    O
at    O
least    O
the    O
earliest    O
symptoms    O
of    O
AD    O
by    O
40    O
years    O
of    O
age    O
.    O

Aβ    O
is    O
a    O
fragment    O
from    O
the    O
larger    O
amyloid    B-MetabolicDisorder114084502
precursor    I-MetabolicDisorder114084502
protein    I-MetabolicDisorder114084502
(    O
APP    O
)    O
.    O

Familial    O
Alzheimer    O
disease    O
is    O
caused    O
by    O
a    O
mutation    O
in    O
one    O
of    O
at    O
least    O
3    O
genes    O
:    O
presenilin    O
1    O
,    O
presenilin    O
2    O
and    O
amyloid    B-MetabolicDisorder114084502
precursor    I-MetabolicDisorder114084502
protein    I-MetabolicDisorder114084502
(    O
APP    O
)    O
.    O

Mutations    O
to    O
the    O
amyloid    B-MetabolicDisorder114084502
beta    I-MetabolicDisorder114084502
A4    I-MetabolicDisorder114084502
precursor    I-MetabolicDisorder114084502
protein    I-MetabolicDisorder114084502
(APP)    I-MetabolicDisorder114084502
located    O
on    O
the    O
long    O
arm    O
of    O
chromosome    O
21    O
(    O
21q21.3    O
)    O
cause    O
familial    O
Alzheimer    O
disease    O
.    O

Furthermore    O
,    O
stimulation    O
of    O
the    O
M1    O
receptor    O
activates    O
AF267B    O
,    O
which    O
in    O
turn    O
blocks    O
B    O
-    O
secretase    O
,    O
which    O
cleaves    O
the    O
amyloid    B-MetabolicDisorder114084502
precursor    I-MetabolicDisorder114084502
protein    I-MetabolicDisorder114084502
to    O
produce    O
the    O
amyloid-beta    B-MetabolicDisorder114084502
peptide    I-MetabolicDisorder114084502
.    O

Amyloid    B-MetabolicDisorder114084502
precursor    I-MetabolicDisorder114084502
protein    I-MetabolicDisorder114084502
,    O

When    O
Aβ    O
peptide    O
is    O
released    O
by    O
proteolytic    O
cleavage    O
of    O
amyloid    B-MetabolicDisorder114084502
precursor    I-MetabolicDisorder114084502
protein    I-MetabolicDisorder114084502
,    O
some    O
Aβ    O
peptides    O
that    O
are    O
solubilized    O
are    O
detected    O
in    O
CSF    O
and    O
blood    O
plasma    O
which    O
makes    O
AB    O
peptides    O
a    O
promising    O
candidate    O
for    O
biological    O
markers    O
.    O

Aβ    O
is    O
composed    O
of    O
a    O
family    O
of    O
peptides    O
produced    O
by    O
proteolytic    O
cleavage    O
of    O
the    O
type    O
I    O
transmembrane    O
spanning    O
glycoprotein    O
amyloid    B-MetabolicDisorder114084502
precursor    I-MetabolicDisorder114084502
protein    I-MetabolicDisorder114084502
(    O
APP    O
)    O
.    O

Concentrated    O
in    O
the    O
synapse    O
of    O
neurons    O
is    O
an    O
amyloid    B-MetabolicDisorder114084502
precursor    I-MetabolicDisorder114084502
protein    I-MetabolicDisorder114084502
(    O
APP    O
)    O
that    O
extends    O
across    O
the    O
plasma    O
membrane    O
.    O

γ-secretase    O
activating    O
protein    O
(    O
GSAP    O
)    O
increases    O
β-amyloid    B-MetabolicDisorder114084502
production    O
through    O
a    O
mechanism    O
involving    O
its    O
interactions    O
with    O
both    O
γ-secretase    O
and    O
its    O
substrate    O
,    O
the    O
amyloid    B-MetabolicDisorder114084502
precursor    I-MetabolicDisorder114084502
protein    I-MetabolicDisorder114084502
(    O
APP    O
)    O
.    O

Deficiency    O
of    O
this    O
enzyme    O
results    O
in    O
the    O
accumulation    O
of    O
undergraded    O
substrate    O
and    O
the    O
lysosomal    B-MetabolicDisorder114084502
storage    I-MetabolicDisorder114084502
disorder    I-MetabolicDisorder114084502
mucopolysaccharidosis    O
type    O
IIID    O
(    O
Sanfilippo    O
D    O
syndrome    O
)    O
.    O

Biologically    O
,    O
deficiencies    O
in    O
endoglycosidases    O
can    O
lead    O
to    O
several    O
diseases    O
,    O
including    O
lysosomal    B-MetabolicDisorder114084502
storage    I-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
and    O
multisystem    O
diseases    O
,    O
most    O
of    O
which    O
involve    O
the    O
nervous    O
system    O
.    O

Infantile    O
free    O
sialic    O
acid    O
storage    O
disease    O
(    O
ISSD    O
)    O
is    O
a    O
lysosomal    B-MetabolicDisorder114084502
storage    I-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
Occurs    O
when    O
a    O
sialic    O
acid    O
,    O
is    O
unable    O
to    O
be    O
transported    O
out    O
of    O
the    O
lysosomal    O
membrane    O
and    O
instead    O
,    O
accumulates    O
in    O
the    O
tissue    O
and    O
free    O
sialic    O
acid    O
is    O
excreted    O
in    O
the    O
urine    O
.    O

Galactosialidosis    B-MetabolicDisorder114084502
is    O
a    O
lysosomal    B-MetabolicDisorder114084502
storage    I-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

Sphingolipidoses    O
,    O
in    O
turn    O
,    O
are    O
included    O
in    O
the    O
larger    O
family    O
of    O
lysosomal    B-MetabolicDisorder114084502
storage    I-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

In    O
the    O
early    O
research    O
years    O
,    O
Hugo    O
and    O
Ann    O
worked    O
on    O
lysosomal    B-MetabolicDisorder114084502
disorders    I-MetabolicDisorder114084502
.    O

In    O
1964    O
,    O
Moser    O
returned    O
to    O
the    O
Joseph    O
P.    O
Kennedy    O
research    O
laboratories    O
at    O
MGH    O
,    O
and    O
with    O
Mary    O
Efron    O
and    O
her    O
junior    O
faculty    O
staff    O
,    O
Harvey    O
Levy    O
and    O
Vivian    O
Shih    O
,    O
he    O
started    O
screening    O
programs    O
for    O
amino    O
acid    O
disorders    O
and    O
lysosomal    B-MetabolicDisorder114084502
disorders    I-MetabolicDisorder114084502
.    O

Genzyme    O
focuses    O
on    O
six    O
areas    O
of    O
medicine    O
relating    O
to    O
lysosomal    B-MetabolicDisorder114084502
storage    I-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
renal    O
disease    O
,    O
orthopedics    O
,    O
transplant    O
and    O
immune    O
diseases    O
,    O
oncology    O
,    O
genetics    O
and    O
diagnostics    O
.    O

Ashkenazi    O
Jews    O
are    O
also    O
highly    O
affected    O
by    O
other    O
lysosomal    B-MetabolicDisorder114084502
storage    I-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
particularly    O
in    O
the    O
form    O
of    O
lipid    O
storage    O
disorders    O
.    O

Aspartylglucosaminuria    O
,    O
a    O
lysosomal    B-MetabolicDisorder114084502
storage    I-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502

Salla    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
a    O
lysosomal    B-MetabolicDisorder114084502
storage    I-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502

Alpha-mannosidosis    B-MetabolicDisorder114084502
is    O
a    O
lysosomal    B-MetabolicDisorder114084502
storage    I-MetabolicDisorder114084502
disorder    I-MetabolicDisorder114084502
caused    O
by    O
deficient    O
activity    O
of    O
the    O
enzyme    O
alpha    O
-    O
D    O
-    O
mannosidase    O
.    O

Basil    O
Stuart    O
Hetzel    O
aka    O
"    O
Old    O
White    O
"    O
(    O
13    O
June    O
1922    O
–    O
4    O
February    O
2017    O
)    O
was    O
an    O
Australian    O
medical    O
researcher    O
who    O
made    O
a    O
major    O
contribution    O
to    O
combating    O
iodine    B-MetabolicDisorder114084502
deficiency    I-MetabolicDisorder114084502
,    O
a    O
major    O
cause    O
of    O
goitre    O
and    O
cretinism    O
worldwide    O
.    O

Eastman    O
is    O
an    O
endocrinologist    O
and    O
has    O
directed    O
or    O
conducted    O
research    O
and    O
public    O
health    O
projects    O
into    O
elimination    O
of    O
iodine    B-MetabolicDisorder114084502
deficiency    I-MetabolicDisorder114084502
disorders    I-MetabolicDisorder114084502
(    O
IDD    O
)    O
in    O
Malaysia    O
,    O
Indonesia    O
,    O
Laos    O
,    O
Cambodia    O
,    O
Thailand    O
,    O
several    O
Pacific    O
Islands    O
,    O
Hong    O
Kong    O
,    O
China    O
and    O
Tibet    O
and    O
Australia    O
.    O

Severe    O
iodine    B-MetabolicDisorder114084502
deficiency    I-MetabolicDisorder114084502
can    O
likely    O
lead    O
to    O
cretinism    O
if    O
it    O
occurs    O
in    O
a    O
child    O
's    O
early    O
development    O
.    O

This    O
disease    O
,    O
caused    O
by    O
various    O
environmental    O
factors    O
including    O
iodine    B-MetabolicDisorder114084502
deficiency    I-MetabolicDisorder114084502
,    O
is    O
a    O
form    O
of    O
dwarfism    O
which    O
can    O
still    O
be    O
found    O
among    O
the    O
local    O
Indonesian    O
population    O
.    O

Iodine-deficiency    B-MetabolicDisorder114084502
-    O
related    O
thyroid    O
disorders    O
and    O
allied    O
conditions    O

Other    O
iodine-deficiency    B-MetabolicDisorder114084502
-    O
related    O
thyroid    O
disorders    O
and    O
allied    O
condition    O

Subclinical    O
iodine-deficiency    B-MetabolicDisorder114084502
hypothyroidism    O

In    O
contrast    O
,    O
a    O
multinodular    O
goiter    O
is    O
usually    O
thought    O
to    O
result    O
from    O
a    O
hyperplastic    O
response    O
of    O
the    O
entire    O
thyroid    O
gland    O
to    O
a    O
stimulus    O
,    O
such    O
as    O
iodine    B-MetabolicDisorder114084502
deficiency    I-MetabolicDisorder114084502
.    O

Countless    O
people    O
were    O
saved    O
from    O
a    O
life    O
of    O
disabilities    O
such    O
as    O
polio    O
(    O
An    O
estimated    O
3    O
million    O
people    O
saved    O
)    O
,    O
blindness    O
from    O
lack    O
of    O
Vitamin    O
A    O
(    O
An    O
estimated    O
million    O
people    O
saved    O
)    O
,    O
and    O
brain    O
damaged    O
caused    O
from    O
iodine    B-MetabolicDisorder114084502
deficiencies    I-MetabolicDisorder114084502
(    O
An    O
estimated    O
10    O
million    O
people    O
saved    O
)    O
.    O

Iodine    B-MetabolicDisorder114084502
deficiency    I-MetabolicDisorder114084502
affects    O
about    O
two    O
billion    O
people    O
and    O
is    O
the    O
leading    O
preventable    O
cause    O
of    O
intellectual    O
disabilities    O
.    O

Some    O
of    O
the    O
most    O
common    O
diseases    O
that    O
these    O
young    O
children    O
are    O
facing    O
are    O
hunger    O
:    O
iron    O
deficiency    O
anaemia    O
,    O
vitamin    O
A    O
deficiency    O
,    O
and    O
mentally    O
impaired    O
(    O
iodine    B-MetabolicDisorder114084502
deficiency    I-MetabolicDisorder114084502
)    O
,    O
and    O
childhood    O
diseases    O
:    O
acute    O
respiratory    O
infections    O
,    O
diarrhoeal    O
disease    O
,    O
and    O
malaria    O
.    O

If    O
the    O
person    O
has    O
inborn    O
errors    O
in    O
the    O
methyltransfer    O
pathway    O
(    O
cobalamin    O
C    O
disease    O
,    O
combined    O
methylmalonic    O
aciduria    O
and    O
homocystinuria    B-MetabolicDisorder114084502
)    O
,    O
treatment    O
with    O
intravenous    O
,    O
intramuscular    O
hydroxocobalamin    O
or    O
transdermal    O
B12    O
is    O
needed    O
.    O

At    O
the    O
same    O
time    O
,    O
since    O
DNA    O
synthetic    O
-    O
sensitive    O
tests    O
for    O
anemia    O
and    O
erythrocyte    O
size    O
are    O
routinely    O
done    O
in    O
even    O
simple    O
medical    O
test    O
clinics    O
(    O
so    O
that    O
these    O
folate    O
-    O
mediated    O
biochemical    O
effects    O
are    O
more    O
often    O
directly    O
detected    O
)    O
,    O
the    O
MTR    O
-    O
dependent    O
effects    O
of    O
B12    O
deficiency    O
are    O
becoming    O
apparent    O
not    O
as    O
anemia    O
due    O
to    O
DNA    O
-    O
synthetic    O
problems    O
(    O
as    O
they    O
were    O
classically    O
)    O
,    O
but    O
now    O
mainly    O
as    O
a    O
simple    O
and    O
less    O
obvious    O
elevation    O
of    O
homocysteine    O
in    O
the    O
blood    O
and    O
urine    O
(    O
homocysteinuria    B-MetabolicDisorder114084502
)    O
.    O

Homocystinuria    B-MetabolicDisorder114084502

Homocystinuria    B-MetabolicDisorder114084502

The    O
"    O
CBS    O
"    O
gene    O
is    O
the    O
most    O
common    O
locus    O
for    O
mutations    O
associated    O
with    O
homocystinuria    B-MetabolicDisorder114084502
.    O

Homocystinuria    B-MetabolicDisorder114084502
due    O
to    O
CBS    O
deficiency    O
is    O
a    O
special    O
type    O
of    O
hyperhomocysteinemia    O
.    O

Homocystinuria    B-MetabolicDisorder114084502

The    O
strength    O
of    O
skeletal    O
muscle    O
contractions    O
can    O
be    O
broadly    O
separated    O
into    O
twitch    O
,    O
summation    O
,    O
and    O
tetanus    B-MetabolicDisorder114084502
.    O

The    O
initial    O
electric    O
burst    O
is    O
very    O
short    O
,    O
containing    O
only    O
10–64    O
pulses    O
,    O
but    O
is    O
still    O
strong    O
enough    O
to    O
cause    O
tetanic    B-MetabolicDisorder114084502
contraction    I-MetabolicDisorder114084502
in    O
the    O
body    O
of    O
the    O
prey    O
fish    O
,    O
often    O
breaking    O
its    O
vertebral    O
column    O
.    O

Advanced    B-MetabolicDisorder114084502
glycation    I-MetabolicDisorder114084502
end-product    I-MetabolicDisorder114084502

Deficiency    O
of    O
G6PD    O
in    O
the    O
alternative    O
pathway    O
causes    O
the    O
buildup    O
of    O
glucose    O
and    O
thus    O
there    O
is    O
an    O
increase    O
of    O
advanced    B-MetabolicDisorder114084502
glycation    I-MetabolicDisorder114084502
endproduct    I-MetabolicDisorder114084502
(    O
AGE    O
)    O
.    O

Procyanidin    O
B2    O
has    O
been    O
shown    O
to    O
inhibit    O
the    O
formation    O
of    O
the    O
advanced    B-MetabolicDisorder114084502
glycation    I-MetabolicDisorder114084502
end-product    I-MetabolicDisorder114084502
pentosidine    O
,    O
carboxymethyllysine    O
(    O
CML    O
)    O
,    O
and    O
methylglyoxal    O
(    O
MGO    O
)    O
.    O

Advanced    B-MetabolicDisorder114084502
glycation    I-MetabolicDisorder114084502
end-product    I-MetabolicDisorder114084502

Glycation    B-MetabolicDisorder114084502
theory    I-MetabolicDisorder114084502
of    I-MetabolicDisorder114084502
aging    I-MetabolicDisorder114084502

A    O
significant    O
amount    O
of    O
oil    O
is    O
absorbed    O
into    O
cheese    O
when    O
it    O
is    O
fried    O
,    O
and    O
the    O
frying    O
of    O
cheeses    O
adds    O
advanced    O
lipid    O
end    O
products    O
and    O
dicarbonyls    O
to    O
advanced    B-MetabolicDisorder114084502
glycation    I-MetabolicDisorder114084502
end-product    I-MetabolicDisorder114084502
that    O
are    O
already    O
present    O
in    O
cheeses    O
.    O

Compounds    O
butein    O
and    O
sulfuretin    O
are    O
antioxidants    O
,    O
and    O
have    O
inhibitory    O
effects    O
on    O
aldose    O
reductase    O
and    O
advanced    B-MetabolicDisorder114084502
glycation    I-MetabolicDisorder114084502
processes    O
.    O

Glycation    B-MetabolicDisorder114084502
theory    I-MetabolicDisorder114084502
of    I-MetabolicDisorder114084502
aging    I-MetabolicDisorder114084502

Danon    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
(    O
or    O
glycogen    B-MetabolicDisorder114084502
storage    I-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
Type    I-MetabolicDisorder114084502
IIb    I-MetabolicDisorder114084502
)    O
is    O
a    O
metabolic    O
disorder    O
.    O

;    O
Armchair    B-MetabolicDisorder114084502
enthusiast    I-MetabolicDisorder114084502
:    O
Alternatively    O
armchair    O
racer    O
,    O
an    O
individual    O
who    O
follows    O
motor    O
sports    O
primarily    O
on    O
television    O
and    O
or    O
the    O
internet    O
and    O
reads    O
books    O
and    O
magazines    O
about    O
the    O
subject    O
.    O

Chango    O
communities    O
were    O
organised    O
into    O
either    O
nomadic    O
or    O
sedentary    B-MetabolicDisorder114084502
groups    O
based    O
on    O
nuclear    O
family    O
units    O
.    O

Many    O
animal    O
models    O
serving    O
as    O
test    O
subjects    O
in    O
biomedical    O
research    O
,    O
such    O
as    O
rats    O
and    O
mice    O
,    O
may    O
be    O
selectively    O
sedentary    B-MetabolicDisorder114084502
,    O
obese    O
and    O
glucose    O
intolerant    O
.    O

Persons    O
using    O
a    O
treadmill    O
desk    O
seek    O
to    O
change    O
the    O
sedentary    B-MetabolicDisorder114084502
lifestyle    I-MetabolicDisorder114084502
associated    O
with    O
being    O
an    O
office    O
worker    O
and    O
to    O
integrate    O
gentle    O
exercise    O
into    O
their    O
working    O
day    O
.    O

Persons    O
with    O
a    O
sedentary    B-MetabolicDisorder114084502
lifestyle    I-MetabolicDisorder114084502
are    O
at    O
increased    O
risk    O
for    O
heart    O
disease    O
,    O
diabetes    O
,    O
and    O
lower    O
than    O
average    O
life    O
expectancy    O
.    O

Sedentary    B-MetabolicDisorder114084502
lifestyle    I-MetabolicDisorder114084502

The    O
toxic    O
environment    O
is    O
the    O
result    O
of    O
ubiquity    O
of    O
unhealthy    O
,    O
processed    O
foods    O
,    O
an    O
increasingly    O
sedentary    B-MetabolicDisorder114084502
lifestyle    I-MetabolicDisorder114084502
in    O
which    O
individuals    O
spend    O
more    O
time    O
watching    O
TV    O
and    O
using    O
computers    O
than    O
they    O
spend    O
exercising    O
,    O
the    O
explosion    O
of    O
fast    O
food    O
restaurants    O
,    O
the    O
enormous    O
growth    O
of    O
portion    O
sizes    O
,    O
the    O
power    O
of    O
food    O
advertising    O
and    O
marketing    O
,    O
and    O
the    O
junk    O
food    O
industry    O
’s    O
take    O
-    O
over    O
of    O
schools    O
by    O
selling    O
unhealthy    O
items    O
in    O
vending    O
machines    O
,    O
cafeterias    O
,    O
and    O
through    O
school    O
fundraisers    O
.    O

The    O
Kelteminar    O
culture    O
(    O
5500–3500    O
BCE    O
)    O
was    O
a    O
Neolithic    O
archaeological    O
culture    O
of    O
sedentary    B-MetabolicDisorder114084502
fishermen    O
occupying    O
the    O
semi    O
-    O
desert    O
and    O
desert    O
areas    O
of    O
the    O
Karakum    O
and    O
Kyzyl    O
Kum    O
deserts    O
and    O
the    O
deltas    O
of    O
the    O
Amu    O
Darya    O
and    O
Zeravshan    O
rivers    O
in    O
the    O
territories    O
of    O
ancient    O
Kazakhstan    O
,    O
Turkmenistan    O
,    O
and    O
Uzbekistan    O
,    O
dated    O
to    O
the    O
6th-3rd    O
millennium    O
BCE    O
.    O

The    O
ostensible    O
reason    O
was    O
that    O
a    O
'    O
martial    O
race    O
'    O
was    O
typically    O
brave    O
and    O
well    O
-    O
built    O
for    O
fighting    O
,    O
while    O
the    O
'    O
non    O
-    O
martial    O
races    O
'    O
were    O
those    O
whom    O
the    O
British    O
believed    O
to    O
be    O
unfit    O
for    O
battle    O
because    O
of    O
their    O
sedentary    B-MetabolicDisorder114084502
lifestyle    I-MetabolicDisorder114084502
.    O

Mike    O
Duff    O
(    O
Peter    O
Benson)Elaine    O
Duff    O
's    O
couch    B-MetabolicDisorder114084502
potato    I-MetabolicDisorder114084502
teenage    O
son    O
who    O
knows    O
the    O
real    O
identities    O
of    O
the    O
Nielsens    O
,    O
as    O
he    O
is    O
something    O
of    O
a    O
television    O
junkie    O
.    O

Established    O
in    O
1969    O
,    O
the    O
Duke    O
Diet    O
and    O
Fitness    O
Center    O
is    O
one    O
of    O
America    O
's    O
longest    O
running    O
treatment    O
centers    O
for    O
individuals    O
who    O
struggle    O
with    O
excess    O
weight    O
,    O
a    O
sedentary    B-MetabolicDisorder114084502
lifestyle    I-MetabolicDisorder114084502
,    O
and    O
associated    O
health    O
problems    O
.    O

His    O
sedentary    B-MetabolicDisorder114084502
lifestyle    I-MetabolicDisorder114084502
may    O
have    O
contributed    O
to    O
the    O
onset    O
of    O
his    O
morbid    O
obesity    O
since    O
it    O
appears    O
to    O
be    O
,    O
according    O
to    O
a    O
scientific    O
study    O
published    O
in    O
"    O
Clinical    O
Cardiology    O
"    O
,    O
one    O
of    O
the    O
major    O
risk    O
factors    O
along    O
with    O
genetics    O
and    O
a    O
poor    O
diet    O
.    O

The    O
vast    O
majority    O
of    O
cancer    O
cases    O
are    O
due    O
to    O
environmental    O
risk    O
factors    O
,    O
and    O
many    O
,    O
but    O
not    O
all    O
,    O
of    O
these    O
environmental    O
factors    O
are    O
controllable    O
lifestyle    O
choices    O
.    O
Greater    O
than    O
75%    O
of    O
cancer    O
deaths    O
could    O
be    O
prevented    O
by    O
avoiding    O
risk    O
factors    O
including    O
:    O
tobacco    O
,    O
overweight    O
/    O
obesity    O
,    O
an    O
insufficient    O
diet    O
,    O
physical    B-MetabolicDisorder114084502
inactivity    I-MetabolicDisorder114084502
,    O
alcohol    O
,    O
sexually    O
transmitted    O
infections    O
,    O
and    O
air    O
pollution    O
.    O

At    O
the    O
beginning    O
of    O
the    O
Archaic    O
Era    O
,    O
they    O
began    O
to    O
adopt    O
a    O
sedentary    B-MetabolicDisorder114084502
approach    O
to    O
subsistence    O
.    O

I    O
'm    O
jealous    O
,    O
spendthrift    O
,    O
a    O
total    O
couch    B-MetabolicDisorder114084502
potato    I-MetabolicDisorder114084502
and    O
absent    O
-    O
minded    O
–    O
I    O
've    O
got    O
my    O
real    O
Professor    O
Nimbus    O
side    O
.    O
"    O

"    O
E.    O
aurinia    O
"    O
butterflies    O
tend    O
to    O
exhibit    O
sedentary    B-MetabolicDisorder114084502
behavior    O
,    O
which    O
leads    O
to    O
an    O
increase    O
in    O
local    O
dispersal    O
rather    O
than    O
regional    O
or    O
long    O
-    O
distance    O
dispersal    O
.    O

As    O
the    O
mother    O
and    O
daughter    O
make    O
themselves    O
comfortable    O
,    O
the    O
father    O
,    O
a    O
potato    O
-    O
like    O
humanoid    O
with    O
one    O
hand    O
mostly    O
root    O
-    O
shaped    O
and    O
molting    O
green    O
(    O
a    O
literal    O
"    O
couch    B-MetabolicDisorder114084502
potato    I-MetabolicDisorder114084502
"    O
)    O
,    O
makes    O
a    O
noise    O
of    O
surprise    O
as    O
the    O
mother    O
exclaims    O
,    O
"    O
It    O
's    O
"    O
Monsters    O
"    O
,    O
our    O
favorite    O
show    O
!    O
"    O
The    O
daughter    O
quietly    O
replies    O
,    O
"    O
Shh    O
,    O
it    O
's    O
starting    O
.    O
"    O

He    O
compared    O
the    O
heart    O
size    O
of    O
cross    O
-    O
country    O
skiers    O
to    O
those    O
who    O
lived    O
sedentary    B-MetabolicDisorder114084502
lives    O
.    O

This    O
is    O
also    O
as    O
a    O
result    O
of    O
an    O
increase    O
in    O
more    O
sedentary    B-MetabolicDisorder114084502
forms    O
of    O
leisure    O
(    O
TV    O
,    O
video    O
games    O
)    O
and    O
to    O
low    O
levels    O
of    O
walking    O
and    O
cycling    O
.    O

Other    O
themes    O
like    O
a    O
horse    O
,    O
nomadic    O
culture    O
vs.    O
a    O
car    O
sedentary    B-MetabolicDisorder114084502
culture    O
are    O
explored    O
to    O
lesser    O
degrees    O
,    O
yet    O
are    O
very    O
deliberate    O
and    O
help    O
symbolize    O
the    O
divide    O
in    O
society    O
.    O

MMA    O
is    O
an    O
autosomal    O
recessive    O
inherited    O
inborn    O
error    O
of    O
metabolism    O
,    O
characterized    O
by    O
recurrent    O
episodes    O
of    O
vomiting    O
,    O
lethargy    O
,    O
profound    O
ketoacidosis    O
,    O
hyperammonemia    B-MetabolicDisorder114084502
,    O
and    O
pancytopenia    O
in    O
infancy    O
,    O
and    O
may    O
cause    O
early    O
death    O
.    O

dehydration    O
,    O
malnutrition    O
,    O
hypoglycemia    O
,    O
hypotonia    O
,    O
metabolic    O
acidosis    O
,    O
ketoacidosis    O
,    O
hyperammonemia    B-MetabolicDisorder114084502
,    O
and    O
if    O
left    O
untreated    O
,    O
death    O
.    O

These    O
mutations    O
results    O
in    O
early    O
onset    O
hypoglycemia    O
,    O
hyperammonemia    B-MetabolicDisorder114084502
,    O
rhabdomyolysis    O
,    O
cardiac    O
arrhythmias    O
,    O
and    O
encephalopathy    O
that    O
later    O
develops    O
into    O
cognitive    O
impairment    O
.    O

Liver    O
dysfunction    O
,    O
such    O
as    O
that    O
seen    O
in    O
cirrhosis    O
,    O
may    O
lead    O
to    O
elevated    O
amounts    O
of    O
ammonia    O
in    O
the    O
blood    O
(    O
hyperammonemia    B-MetabolicDisorder114084502
)    O
.    O

A    O
disorder    O
is    O
associated    O
with    O
ornithine    O
translocase    O
deficiency    O
,    O
and    O
a    O
form    O
of    O
hyperammonemia    B-MetabolicDisorder114084502
.    O

Signs    O
of    O
metabolic    O
acidosis    O
and    O
significant    O
hyperammonemia    B-MetabolicDisorder114084502
have    O
been    O
reported    O
in    O
infantile    O
and    O
neonatal    O
cases    O
.    O

The    O
condition    O
has    O
many    O
causes    O
,    O
but    O
is    O
most    O
commonly    O
seen    O
when    O
malnourished    O
patients    O
(    O
especially    O
chronic    O
alcoholics    O
)    O
are    O
given    O
large    O
amounts    O
of    O
carbohydrates    O
,    O
which    O
creates    O
a    O
high    O
phosphorus    O
demand    O
by    O
cells    O
,    O
removing    O
phosphate    O
from    O
the    O
blood    O
(    O
"    O
refeeding    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
"    O
)    O
.    O

Refeeding    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
–    O
This    O
causes    O
a    O
demand    O
for    O
phosphate    O
in    O
cells    O
due    O
to    O
the    O
action    O
of    O
hexokinase    O
,    O
an    O
enzyme    O
that    O
attaches    O
phosphate    O
to    O
glucose    O
to    O
begin    O
metabolism    O
of    O
glucose    O
.    O

MCADD    B-MetabolicDisorder114084502
,    O
LCHADD    B-MetabolicDisorder114084502
,    O
and    O
VLCADD    O

An    O
association    O
has    O
been    O
demonstrated    O
between    O
long    O
chain    O
long-chain    B-MetabolicDisorder114084502
3-hydroxyacyl-coenzyme    I-MetabolicDisorder114084502
A    I-MetabolicDisorder114084502
dehydrogenase    I-MetabolicDisorder114084502
deficiency    I-MetabolicDisorder114084502
(    O
LCHAD    O
)    O
of    O
the    O
child    O
and    O
maternal    O
HELLP    O
and    O
acute    O
fatty    O
liver    O
of    O
pregnancy    O
(    O
AFLP    O
)    O
.    O

Long-chain    B-MetabolicDisorder114084502
acyl-CoA    I-MetabolicDisorder114084502
dehydrogenase    I-MetabolicDisorder114084502
deficiency    I-MetabolicDisorder114084502
(    O
LCAD    O
)    O

Liver    O
disease    O
may    O
present    O
itself    O
as    O
tiredness    O
,    O
increased    O
bleeding    O
tendency    O
or    O
confusion    O
(    O
due    O
to    O
hepatic    B-MetabolicDisorder114084502
encephalopathy    I-MetabolicDisorder114084502
)    O
and    O
portal    O
hypertension    O
.    O

When    O
these    O
irritate    O
the    O
brain    O
,    O
the    O
person    O
develops    O
hepatic    B-MetabolicDisorder114084502
encephalopathy    I-MetabolicDisorder114084502
(    O
confusion    O
,    O
coma    O
,    O
seizures    O
and    O
finally    O
life    O
-    O
threatening    O
swelling    O
of    O
the    O
brain    O
)    O
.    O

In    O
hyperacute    O
and    O
acute    O
liver    O
failure    O
the    O
clinical    O
picture    O
develops    O
rapidly    O
with    O
progressive    O
encephalopathy    B-MetabolicDisorder114084502
and    O
multiorgan    O
dysfunction    O
such    O
as    O
hyperdynamic    O
circulation    O
,    O
coagulopathy    O
,    O
acute    O
renal    O
and    O
respiratory    O
insufficiency    O
,    O
severe    O
metabolic    O
alterations    O
and    O
cerebral    O
edema    O
that    O
can    O
lead    O
to    O
brain    O
death    O
.    O

Adams    O
tells    O
her    O
theory    O
to    O
Wilson    O
about    O
House    O
,    O
and    O
says    O
that    O
House    O
is    O
suffering    O
from    O
hepatic    B-MetabolicDisorder114084502
encephalopathy    I-MetabolicDisorder114084502
due    O
to    O
continued    O
Vicodin    O
abuse    O
.    O

Rifaximin    O
,    O
sold    O
under    O
the    O
trade    O
name    O
Xifaxan    O
among    O
others    O
,    O
is    O
an    O
antibiotic    O
used    O
to    O
treat    O
traveler    O
's    O
diarrhea    O
,    O
irritable    O
bowel    O
syndrome    O
,    O
and    O
hepatic    B-MetabolicDisorder114084502
encephalopathy    I-MetabolicDisorder114084502
.    O

In    O
the    O
United    O
States    O
,    O
rifaximin    O
has    O
orphan    O
drug    O
status    O
for    O
the    O
treatment    O
of    O
hepatic    B-MetabolicDisorder114084502
encephalopathy    I-MetabolicDisorder114084502
.    O

Hepatic    B-MetabolicDisorder114084502
encephalopathy    I-MetabolicDisorder114084502

Hepatic    B-MetabolicDisorder114084502
encephalopathy    I-MetabolicDisorder114084502

Hepatic    B-MetabolicDisorder114084502
Encephalopathy    I-MetabolicDisorder114084502
:    O
ALCAR    O
has    O
been    O
studied    O
in    O
hepatic    O
encephalopathy    O
,    O
a    O
complication    O
of    O
cirrhosis    O
involving    O
neuropsychiatric    O
impairment    O
;    O
ALCAR    O
improves    O
blood    O
ammonia    O
levels    O
and    O
generates    O
a    O
modest    O
improvement    O
in    O
psychometric    O
scores    O
but    O
does    O
not    O
resolve    O
the    O
condition    O
—    O
it    O
may    O
play    O
a    O
minor    O
role    O
in    O
managing    O
the    O
condition    O
.    O

Late    O
complications    O
of    O
cirrhosis    O
or    O
liver    O
failure    O
include    O
portal    O
hypertension    O
(    O
high    O
blood    O
pressure    O
in    O
the    O
portal    O
vein    O
due    O
to    O
the    O
increased    O
flow    O
resistance    O
through    O
the    O
damaged    O
liver    O
)    O
,    O
coagulation    O
disorders    O
(    O
due    O
to    O
impaired    O
production    O
of    O
coagulation    O
factors    O
)    O
,    O
ascites    O
(    O
heavy    O
abdominal    O
swelling    O
due    O
to    O
buildup    O
of    O
fluids    O
in    O
the    O
tissues    O
)    O
and    O
other    O
complications    O
,    O
including    O
hepatic    B-MetabolicDisorder114084502
encephalopathy    I-MetabolicDisorder114084502
and    O
the    O
hepatorenal    O
syndrome    O
.    O

Hyperammonemia    O
contributes    O
to    O
the    O
confusion    O
and    O
coma    O
of    O
hepatic    B-MetabolicDisorder114084502
encephalopathy    I-MetabolicDisorder114084502
,    O
as    O
well    O
as    O
the    O
neurologic    O
disease    O
common    O
in    O
people    O
with    O
urea    O
cycle    O
defects    O
and    O
organic    B-MetabolicDisorder114084502
aciduria    I-MetabolicDisorder114084502
.    O

In    O
the    O
acute    O
setting    O
,    O
this    O
may    O
be    O
a    O
cause    O
of    O
hepatic    B-MetabolicDisorder114084502
encephalopathy    I-MetabolicDisorder114084502
and    O
hepatorenal    O
syndrome    O
.    O

These    O
bariatric    O
procedures    O
include    O
the    O
Laparoscopic    O
Adjustable    B-MetabolicDisorder114084502
Gastric    I-MetabolicDisorder114084502
Band    I-MetabolicDisorder114084502
(    O
LAP    O
-    O
BAND    O
)    O
System    O
,    O
Laparoscopic    O
Roux    O
-    O
en    O
-    O
Y    O
Gastric    O
Bypass    O
,    O
Open    O
or    O
Laparoscopic    O
Duodenal    O
Switch    O
and    O
Laparoscopic    O
Sleeve    B-MetabolicDisorder114084502
Gastrectomy    I-MetabolicDisorder114084502
.    O

Each    O
episode    O
follows    O
a    O
year    O
in    O
the    O
life    O
of    O
a    O
morbidly    O
obese    O
person    O
(    O
who    O
starts    O
the    O
episode    O
weighing    O
around    O
)    O
and    O
their    O
attempts    O
to    O
reduce    O
their    O
weight    O
to    O
a    O
healthy    O
level    O
,    O
usually    O
with    O
the    O
assistance    O
of    O
gastric    O
bypass    O
surgery    O
or    O
Sleeve    B-MetabolicDisorder114084502
gastrectomy    I-MetabolicDisorder114084502
performed    O
by    O
Houston    O
-    O
area    O
surgeon    O
Younan    O
Nowzaradan    O
.    O

In    O
2010    O
,    O
he    O
went    O
on    O
an    O
extreme    O
diet    O
and    O
had    O
gastric    B-MetabolicDisorder114084502
sleeve    I-MetabolicDisorder114084502
surgery    O
,    O
resulting    O
in    O
an    O
over    O
100    O
lb    O
.    O
weight    O
loss    O
.    O

Acrodermatitis    B-MetabolicDisorder114084502
enteropathica    I-MetabolicDisorder114084502

Acrodermatitis    B-MetabolicDisorder114084502
enteropathica    I-MetabolicDisorder114084502
is    O
an    O
inherited    O
deficiency    O
of    O
the    O
zinc    O
carrier    O
protein    O
ZIP4    O
resulting    O
in    O
inadequate    O
zinc    O
absorption    O
.    O

Takahara    O
Shigeo    O
-    O
One‐time    O
Professor    O
who    O
discovered    O
Acatalasia    B-MetabolicDisorder114084502

Acatalasia    B-MetabolicDisorder114084502
(    O
Takahara    O
)    O

Maroteaux–Lamy    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
(    O
also    O
known    O
as    O
mucopolysaccharidosis    B-MetabolicDisorder114084502
type    I-MetabolicDisorder114084502
VI    I-MetabolicDisorder114084502
,    O
MPS    B-MetabolicDisorder114084502
VI    I-MetabolicDisorder114084502
,    O
or    O
polydystrophic    O
dwarfism    O
)    O
is    O
a    O
form    O
of    O
mucopolysaccharidosis    O
caused    O
by    O
a    O
deficiency    O
in    O
arylsulfatase    O
B    O
(    O
ARSB    O
)    O
.    O

Mucopolysaccharidosis    B-MetabolicDisorder114084502
type    I-MetabolicDisorder114084502
6    I-MetabolicDisorder114084502

.    O
They    O
can    O
be    O
distinguished    O
from    O
a    O
partially    O
leucistic    B-MetabolicDisorder114084502
common    O
swift    O
by    O
the    O
deeper    O
tail    O
fork    O
,    O
longer    O
wings    O
,    O
bigger    O
head    O
and    O
larger    O
white    O
throat    O
patch    O
.    O

.    O
They    O
can    O
be    O
distinguished    O
from    O
a    O
partially    O
leucistic    B-MetabolicDisorder114084502
common    O
swift    O
by    O
the    O
deeper    O
tail    O
fork    O
,    O
longer    O
wings    O
,    O
bigger    O
head    O
and    O
larger    O
white    O
throat    O
patch    O
.    O

Leucism    B-MetabolicDisorder114084502

The    O
adjacent    O
mainland    O
population    O
split    O
into    O
the    O
subtropical    O
and    O
partially    O
leucistic    B-MetabolicDisorder114084502
Elliot    O
's    O
pheasant    O
(    O
"    O
S.    O
ellioti    O
"    O
)    O
and    O
the    O
tropical    O
Mrs.    O
Hume    O
's    O
pheasant    O
only    O
in    O
the    O
Middle    O
Pleistocene    O
,    O
around    O
half    O
a    O
million    O
years    O
ago    O
.    O

Leucistic    B-MetabolicDisorder114084502
or    O
'    O
blonde    O
'    O
hedgehogs    O
occasionally    O
occur    O
.    O

A    O
white    O
stag    O
(    O
or    O
white    O
hind    O
for    O
the    O
female    O
)    O
is    O
a    O
white    O
-    O
colored    O
red    O
deer    O
or    O
fallow    O
deer    O
,    O
explained    O
by    O
a    O
condition    O
known    O
as    O
leucism    B-MetabolicDisorder114084502
that    O
causes    O
its    O
hair    O
and    O
skin    O
to    O
lose    O
its    O
natural    O
colour    O
.    O

Leucism    B-MetabolicDisorder114084502
is    O
a    O
rare    O
genetic    O
pattern    O
that    O
causes    O
a    O
reduction    O
in    O
the    O
pigment    O
of    O
an    O
animal    O
's    O
hair    O
and    O
skin    O
.    O

Abnormally    O
leucistic    B-MetabolicDisorder114084502
or    O
near    O
albino    O
birds    O
have    O
been    O
reported    O
.    O

The    O
star    O
of    O
the    O
attraction    O
is    O
a    O
leucistic    B-MetabolicDisorder114084502
alligator    O
named    O
Bouya    O
,    O
a    O
white    O
gator    O
with    O
blue    O
eyes    O
.    O

Selective    O
breeding    O
has    O
resulted    O
in    O
a    O
leucistic    B-MetabolicDisorder114084502
strain    O
,    O
which    O
lacks    O
the    O
dark    O
barring    O
of    O
the    O
wild    O
type    O
.    O

Leucism    B-MetabolicDisorder114084502

Leucism    B-MetabolicDisorder114084502
occurs    O
only    O
in    O
this    O
type    O
of    O
lion    O
,    O
but    O
is    O
quite    O
rare    O
.    O

Inclusion    O
-    O
cell    O
(    O
I    O
-    O
cell    O
)    O
disease    O
,    O
also    O
referred    O
to    O
as    O
mucolipidosis    B-MetabolicDisorder114084502
II    O
(    O
ML    O
II    O
)    O
,    O
is    O
part    O
of    O
the    O
lysosomal    B-MetabolicDisorder114084502
storage    I-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
family    O
and    O
results    O
from    O
a    O
defective    O
phosphotransferase    O
(    O
an    O
enzyme    O
of    O
the    O
Golgi    O
apparatus    O
)    O
.    O

(    O
E77.0-E77.1    O
)    O
mucolipidoses    B-MetabolicDisorder114084502

Compared    O
to    O
other    O
ethnic    O
groups    O
,    O
they    O
more    O
frequently    O
act    O
as    O
carriers    O
of    O
mucolipidosis    B-MetabolicDisorder114084502
and    O
Niemann–    O

Crigler-Najjar    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502

Childs    O
studied    O
the    O
genetics    O
of    O
adrenal    O
hyperplasia    O
,    O
Crigler-Najjar    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
,    O
and    O
propionic    O
acidemia    O
.    O

This    O
is    O
in    O
contrast    O
to    O
primarily    O
unconjugated    O
hyperbilirubinemia    O
which    O
is    O
the    O
water    O
-    O
insoluble    O
form    O
that    O
is    O
bound    O
to    O
serum    O
albumin    O
;    O
the    O
liver    O
has    O
not    O
had    O
a    O
chance    O
to    O
conjugate    O
the    O
bilirubin    O
yet    O
and    O
can    O
be    O
caused    O
either    O
because    O
too    O
much    O
unconjugated    O
bilirubin    O
is    O
made    O
(    O
such    O
as    O
in    O
massive    O
hemolysis    O
or    O
ineffective    O
erythropoiesis    O
)    O
or    O
because    O
too    O
little    O
is    O
conjugated    O
(    O
Gilbert's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
or    O
Crigler-Najjar    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
)    O
.    O

Her    O
laboratory    O
was    O
the    O
first    O
to    O
identify    O
a    O
genetic    O
defect    O
,    O
in    O
the    O
gene    O
UGT1A1    O
,    O
that    O
leads    O
to    O
Crigler-Najjar    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
.    O

6-Pyruvoyltetrahydropterin    B-MetabolicDisorder114084502
synthase    I-MetabolicDisorder114084502
deficiency    I-MetabolicDisorder114084502

Milk-alkali    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502

Cystinosis    B-MetabolicDisorder114084502

A    O
protein    O
mutated    O
in    O
the    O
rare    O
human    O
genetic    O
disease    O
,    O
nephropathic    O
intermediate    O
cystinosis    B-MetabolicDisorder114084502
,    O
also    O
called    O
cystinosin    O
(    O
TC    O
#    O
2.A.43.1.1    O
)    O
,    O
is    O
encoded    O
by    O
the    O
CTNS    O
gene    O
.    O

Cystinosis    B-MetabolicDisorder114084502

Other    O
organisations    O
Overtone    O
has    O
affiliated    O
with    O
include    O
the    O
Make    O
-    O
A    O
-    O
Wish    O
Foundation    O
and    O
Natalie    O
's    O
Wish    O
,    O
a    O
foundation    O
dedicated    O
to    O
finding    O
a    O
cure    O
for    O
Cystinosis    B-MetabolicDisorder114084502
.    O

Mutations    O
in    O
the    O
SLC3A1    O
gene    O
are    O
associated    O
with    O
cystinuria    B-MetabolicDisorder114084502
.    O

In    O
collaboration    O
with    O
Charles    O
Enrique    O
Dent    O
and    O
William    O
Warren    O
,    O
Harris    O
focused    O
on    O
cystinuria    B-MetabolicDisorder114084502
.    O

It    O
is    O
widely    O
used    O
to    O
treat    O
urinary    O
calculi    O
(    O
kidney    O
stones    O
)    O
and    O
is    O
often    O
used    O
by    O
patients    O
with    O
cystinuria    B-MetabolicDisorder114084502
.    O

Minor    O
problems    O
include    O
obesity    O
,    O
osteosarcoma    O
,    O
and    O
cystinuria    B-MetabolicDisorder114084502
.    O

MDP    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
,    O
a    O
rare    O
genetic    O
disorder    O

The    O
study    O
asked    O
the    O
question    O
"    O
Which    O
children    O
develop    O
insulin    B-MetabolicDisorder114084502
resistance    I-MetabolicDisorder114084502
and    O
why    O
?    O
"    O
and    O
was    O
predicated    O
on    O
the    O
Accelerator    O
Hypothesis    O
for    O
type    O
1    O
diabetes    O
published    O
in    O
2001    O
.    O

First    O
-    O
phase    O
release    O
and    O
insulin    B-MetabolicDisorder114084502
sensitivity    I-MetabolicDisorder114084502
are    O
independent    O
predictors    O
of    O
diabetes    O
.    O

Findings    O
suggest    O
that    O
insulin-resistant    B-MetabolicDisorder114084502
adipocytes    O
fail    O
to    O
regulate    O
EC    O
metabolism    O
and    O
decrease    O
intracellular    O
EC    O
levels    O
in    O
response    O
to    O
insulin    O
stimulation    O
,    O
whereby    O
obese    O
insulin    O
-    O
resistant    O
individuals    O
exhibit    O
increased    O
concentrations    O
of    O
ECs    O
.    O

Type    B-MetabolicDisorder114084502
2    I-MetabolicDisorder114084502
–    O
either    O
inadequate    O
insulin    O
production    O
by    O
the    O
β-cells    O
or    O
insulin    B-MetabolicDisorder114084502
resistance    I-MetabolicDisorder114084502
or    O
both    O
because    O
of    O
reasons    O
not    O
completely    O
understood    O
.    O

During    O
illness    O
or    O
stress    O
,    O
when    O
basal    O
demand    O
increases    O
due    O
to    O
insulin    B-MetabolicDisorder114084502
resistance    I-MetabolicDisorder114084502
.    O

Insulin    B-MetabolicDisorder114084502
resistance    I-MetabolicDisorder114084502
is    O
a    O
term    O
and    O
concept    O
of    O
his    O
coinage    O
.    O

Hyperinsulinemia    O
(    O
insulin    O
excess    O
)    O
or    O
hypoinsulinemia    O
(    O
insulin    O
deficiency    O
or    O
resistance    B-MetabolicDisorder114084502
as    O
in    O
diabetes    O
)    O
.    O

Lifestyle    O
change    O
,    O
including    O
reducing    O
excessive    O
weight    O
and    O
addressing    O
insulin    B-MetabolicDisorder114084502
resistance    I-MetabolicDisorder114084502
,    O
may    O
be    O
beneficial    O
.    O

The    O
role    O
of    O
insulin    B-MetabolicDisorder114084502
resistance    I-MetabolicDisorder114084502
in    O
the    O
pathogenesis    O
of    O
psoriasis    O
is    O
currently    O
under    O
investigation    O
.    O

Insulin    B-MetabolicDisorder114084502
resistance    I-MetabolicDisorder114084502

Obese    O
Zucker    O
rats    O
have    O
high    O
levels    O
of    O
lipids    O
and    O
cholesterol    O
in    O
their    O
bloodstream    O
,    O
are    O
resistant    B-MetabolicDisorder114084502
to    I-MetabolicDisorder114084502
insulin    I-MetabolicDisorder114084502
without    O
being    O
hyperglycemic    O
,    O
and    O
gain    O
weight    O
from    O
an    O
increase    O
in    O
both    O
the    O
size    O
and    O
number    O
of    O
fat    O
cells    O
.    O

Traditional    O
focus    O
of    O
therapeutic    O
strategies    O
for    O
diabetes    O
have    O
been    O
to    O
enhance    O
endogenous    O
insulin    O
secretion    O
and/or    O
to    O
improve    O
insulin    B-MetabolicDisorder114084502
sensitivity    I-MetabolicDisorder114084502
.    O

Traditional    O
focus    O
of    O
therapeutic    O
strategies    O
for    O
diabetes    O
have    O
been    O
to    O
enhance    O
endogenous    O
insulin    O
secretion    O
and/or    O
to    O
improve    O
insulin    B-MetabolicDisorder114084502
sensitivity    I-MetabolicDisorder114084502
.    O

Traditional    O
focus    O
of    O
therapeutic    O
strategies    O
for    O
diabetes    O
have    O
been    O
to    O
enhance    O
endogenous    O
insulin    O
secretion    O
and/or    O
to    O
improve    O
insulin    B-MetabolicDisorder114084502
sensitivity    I-MetabolicDisorder114084502
.    O

Traditional    O
focus    O
of    O
therapeutic    O
strategies    O
for    O
diabetes    O
have    O
been    O
to    O
enhance    O
endogenous    O
insulin    O
secretion    O
and/or    O
to    O
improve    O
insulin    B-MetabolicDisorder114084502
sensitivity    I-MetabolicDisorder114084502
.    O

Traditional    O
focus    O
of    O
therapeutic    O
strategies    O
for    O
diabetes    O
have    O
been    O
to    O
enhance    O
endogenous    O
insulin    O
secretion    O
and/or    O
to    O
improve    O
insulin    B-MetabolicDisorder114084502
sensitivity    I-MetabolicDisorder114084502
.    O

Traditional    O
focus    O
of    O
therapeutic    O
strategies    O
for    O
diabetes    O
have    O
been    O
to    O
enhance    O
endogenous    O
insulin    O
secretion    O
and/or    O
to    O
improve    O
insulin    B-MetabolicDisorder114084502
sensitivity    I-MetabolicDisorder114084502
.    O

Traditional    O
focus    O
of    O
therapeutic    O
strategies    O
for    O
diabetes    O
have    O
been    O
to    O
enhance    O
endogenous    O
insulin    O
secretion    O
and/or    O
to    O
improve    O
insulin    B-MetabolicDisorder114084502
sensitivity    I-MetabolicDisorder114084502
.    O

Traditional    O
focus    O
of    O
therapeutic    O
strategies    O
for    O
diabetes    O
have    O
been    O
to    O
enhance    O
endogenous    O
insulin    O
secretion    O
and/or    O
to    O
improve    O
insulin    B-MetabolicDisorder114084502
sensitivity    I-MetabolicDisorder114084502
.    O

Such    O
downregulation    O
underlies    O
insulin    B-MetabolicDisorder114084502
resistance    I-MetabolicDisorder114084502
,    O
which    O
is    O
common    O
in    O
type    B-MetabolicDisorder114084502
2    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
.    O

This    O
mechanism    O
is    O
thought    O
to    O
be    O
responsible    O
for    O
salsalate    O
's    O
insulin-sensitizing    B-MetabolicDisorder114084502
and    O
blood    O
sugar    O
lowering    O
properties    O
.    O

Salsalate    O
has    O
been    O
proposed    O
for    O
the    O
prevention    O
and    O
treatment    O
of    O
type    B-MetabolicDisorder114084502
2    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
mellitus    O
due    O
to    O
its    O
ability    O
to    O
lower    O
insulin    B-MetabolicDisorder114084502
resistance    I-MetabolicDisorder114084502
associated    O
with    O
inflammation    O
and    O
may    O
be    O
useful    O
in    O
prediabetes    O
.    O

Hyperglycemia    O
due    O
to    O
increased    O
gluconeogenesis    O
,    O
insulin    B-MetabolicDisorder114084502
resistance    I-MetabolicDisorder114084502
,    O
and    O
impaired    O
glucose    O
tolerance    O
(    O
"    O
steroid    O
diabetes    O
"    O
)    O
;    O
caution    O
in    O
those    O
with    O
diabetes    O
mellitus    O

In    O
obesity    O
,    O
similar    O
to    O
resistance    B-MetabolicDisorder114084502
of    I-MetabolicDisorder114084502
insulin    I-MetabolicDisorder114084502
in    O
type    B-MetabolicDisorder114084502
2    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
,    O
a    O
decreased    O
sensitivity    O
to    O
leptin    O
occurs    O
,    O
resulting    O
in    O
an    O
inability    O
to    O
detect    O
satiety    O
despite    O
high    O
energy    O
stores    O
.    O

These    O
people    O
show    O
resistance    O
to    O
leptin    O
,    O
similar    O
to    O
resistance    B-MetabolicDisorder114084502
of    I-MetabolicDisorder114084502
insulin    I-MetabolicDisorder114084502
in    O
type    B-MetabolicDisorder114084502
2    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
,    O
with    O
the    O
elevated    O
levels    O
failing    O
to    O
control    O
hunger    O
and    O
modulate    O
their    O
weight    O
.    O

This    O
is    O
the    O
more    O
common    O
process    O
of    O
insulin    B-MetabolicDisorder114084502
resistance    I-MetabolicDisorder114084502
,    O
which    O
leads    O
to    O
adult    O
-    O
onset    O
diabetes    O
.    O

Oral    O
use    O
of    O
cortisone    O
has    O
a    O
number    O
of    O
potential    O
systemic    O
side    O
-    O
effects    O
:    O
hyperglycemia    O
,    O
insulin    B-MetabolicDisorder114084502
resistance    I-MetabolicDisorder114084502
,    O
diabetes    O
mellitus    O
,    O
osteoporosis    O
,    O
anxiety    O
,    O
depression    O
,    O
amenorrhoea    O
,    O
cataracts    O
,    O
Cushing's    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
and    O
glaucoma    O
,    O
among    O
other    O
problems    O
.    O

It    O
has    O
also    O
been    O
shown    O
that    O
chromium(III    O
)    O
can    O
alleviate    O
insulin    B-MetabolicDisorder114084502
resistance    I-MetabolicDisorder114084502
by    O
reducing    O
endoplasmic    O
reticulum    O
(    O
ER    O
)    O
stress    O
.    O

There    O
are    O
claims    O
that    O
the    O
picolinate    O
form    O
of    O
chromium    O
supplementation    O
aids    O
in    O
reducing    O
insulin    B-MetabolicDisorder114084502
resistance    I-MetabolicDisorder114084502
,    O
particularly    O
in    O
type    O
2    O
diabetics    O
,    O
but    O
a    O
meta    O
-    O
analysis    O
of    O
chromium(III    O
)    O
supplementation    O
studies    O
showed    O
no    O
association    O
between    O
chromium    O
and    O
glucose    O
or    O
insulin    O
concentrations    O
for    O
non    O
-    O
diabetics    O
,    O
and    O
inconclusive    O
results    O
for    O
diabetics    O
.    O

Cattle    O
that    O
are    O
over    O
-    O
conditioned    O
are    O
also    O
more    O
insulin    B-MetabolicDisorder114084502
resistant    I-MetabolicDisorder114084502
compared    O
to    O
their    O
leaner    O
counterparts    O
.    O

There    O
is    O
also    O
evidence    O
that    O
it    O
plays    O
a    O
part    O
in    O
insulin    B-MetabolicDisorder114084502
sensitivity    I-MetabolicDisorder114084502
in    O
other    O
cells    O
.    O

This    O
is    O
of    O
great    O
relevance    O
in    O
the    O
context    O
of    O
malabsorption    O
diseases    O
as    O
well    O
as    O
metabolic    O
diseases    O
such    O
as    O
obesity    O
,    O
insulin    B-MetabolicDisorder114084502
resistance    I-MetabolicDisorder114084502
,    O
and    O
diabetes    O
.    O

"    O
Lipin"-1    O
deficiency    O
in    O
mice    O
results    O
in    O
lipodystrophy    B-MetabolicDisorder114084502
,    O
insulin    B-MetabolicDisorder114084502
resistance    I-MetabolicDisorder114084502
,    O
and    O
neuropathy    O
.    O

In    O
humans    O
,    O
variations    O
in    O
"    O
Lipin"-1    O
expression    O
levels    O
can    O
result    O
in    O
insulin    B-MetabolicDisorder114084502
sensitivity    I-MetabolicDisorder114084502
,    O
hypertension    O
,    O
and    O
risk    O
for    O
metabolic    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
.    O

In    O
these    O
cases    O
,    O
many    O
medicines    O
for    O
type    B-MetabolicDisorder114084502
II    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
mellitus    I-MetabolicDisorder114084502
are    O
not    O
effective    O
,    O
because    O
MODY2    O
does    O
not    O
cause    O
insulin    B-MetabolicDisorder114084502
resistance    I-MetabolicDisorder114084502
.    O

A    O
study    O
suggests    O
that    O
marijuana    O
may    O
improve    O
blood    O
sugar    O
levels    O
by    O
decreasing    O
insulin    B-MetabolicDisorder114084502
resistance    I-MetabolicDisorder114084502
.    O

Lafora's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502

Neurodegenerative    O
diseases    O
such    O
as    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
and    O
Lafora    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
show    O
as    O
a    O
marker    O
,    O
an    O
atrophy    O
of    O
the    O
grey    O
matter    O
of    O
the    O
cerebral    O
cortex    O
.    O

Lafora    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
is    O
a    O
rare    O
genetic    O
disorder    O
marked    O
by    O
the    O
presence    O
of    O
abnormal    O
polyglucosan    O
deposits    O
.    O

Metastatic    B-MetabolicDisorder114084502
calcification    I-MetabolicDisorder114084502
is    O
deposition    O
of    O
calcium    O
salts    O
in    O
otherwise    O
normal    O
tissue    O
,    O
because    O
of    O
elevated    O
serum    O
levels    O
of    O
calcium    O
,    O
which    O
can    O
occur    O
because    O
of    O
deranged    O
metabolism    O
as    O
well    O
as    O
increased    O
absorption    O
or    O
decreased    O
excretion    O
of    O
calcium    O
and    O
related    O
minerals    O
,    O
as    O
seen    O
in    O
hyperparathyroidism    O
.    O

(    O
A    O
systemic    O
mineral    O
imbalance    O
would    O
elevate    O
calcium    O
levels    O
in    O
the    O
blood    O
and    O
all    O
tissues    O
and    O
cause    O
metastatic    B-MetabolicDisorder114084502
calcification    I-MetabolicDisorder114084502
.    O
)    O

Lucey-Driscoll    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502

Mevalonic    B-MetabolicDisorder114084502
aciduria    I-MetabolicDisorder114084502

Other    O
characteristics    O
common    O
in    O
SHORT    O
syndrome    O
are    O
a    O
triangular    O
face    O
,    O
small    O
chin    O
with    O
a    O
dimple    O
,    O
a    O
loss    O
of    O
fat    O
under    O
the    O
skin    O
(    O
lipodystrophy    B-MetabolicDisorder114084502
)    O
,    O
abnormal    O
position    O
of    O
the    O
ears    O
,    O
hearing    O
loss    O
and    O
delayed    O
speech    O
.    O

Lipoatrophy    B-MetabolicDisorder114084502
/    O
lipodystrophy    B-MetabolicDisorder114084502
(    O
fat    O
redistribution    O
/    O
accumulation    O
)    O

It    O
is    O
also    O
one    O
of    O
the    O
most    O
likely    O
antiviral    O
drugs    O
to    O
cause    O
lipodystrophy    B-MetabolicDisorder114084502
,    O
and    O
for    O
this    O
reason    O
it    O
is    O
no    O
longer    O
considered    O
an    O
appropriate    O
treatment    O
for    O
most    O
patients    O
in    O
developed    O
countries    O
.    O

However    O
,    O
she    O
is    O
now    O
clinically    O
recognized    O
as    O
having    O
likely    O
had    O
the    O
Queen    O
of    O
Punt    O
syndrome    O
,    O
a    O
suite    O
of    O
conditions    O
that    O
include    O
familial    O
obesity    O
,    O
Launois    O
Bensaude    O
lipomatosis    O
,    O
Dercum    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
neurofibromatosis    O
,    O
congenital    O
lipodystrophy    B-MetabolicDisorder114084502
,    O
achondroplasia    O
,    O
X-linked    B-MetabolicDisorder114084502
hypophosphatemia    I-MetabolicDisorder114084502
,    O
and    O
Proteus    O
syndrome    O
.    O

The    O
fatty    O
cells    O
can    O
indeed    O
easily    O
present    O
unpleasant    O
and    O
unaesthetic    O
scars    O
called    O
lipodystrophies    B-MetabolicDisorder114084502
.    O

Leptin    O
was    O
approved    O
in    O
the    O
United    O
States    O
in    O
2014    O
for    O
use    O
in    O
congenital    O
leptin    O
deficiency    O
and    O
generalized    O
lipodystrophy    B-MetabolicDisorder114084502
.    O

In    O
the    O
US    O
it    O
is    O
indicated    O
as    O
a    O
treatment    O
for    O
complications    O
of    O
leptin    O
deficiency    O
,    O
and    O
for    O
the    O
diabetes    O
and    O
hypertriglyceridemia    B-MetabolicDisorder114084502
associated    O
with    O
congenital    O
or    O
acquired    O
generalized    O
lipodystrophy    B-MetabolicDisorder114084502
.    O

"    O
Lipin"-1    O
deficiency    O
in    O
mice    O
results    O
in    O
lipodystrophy    B-MetabolicDisorder114084502
,    O
insulin    B-MetabolicDisorder114084502
resistance    I-MetabolicDisorder114084502
,    O
and    O
neuropathy    O
.    O

A    O
more    O
general    O
term    O
for    O
an    O
abnormal    O
or    O
degenerative    O
condition    O
of    O
the    O
entire    O
body    O
's    O
adipose    O
tissue    O
is    O
"    O
lipodystrophy    B-MetabolicDisorder114084502
"    O
.    O

Kayser-Fleischer    B-MetabolicDisorder114084502
ring    I-MetabolicDisorder114084502

Some    O
confusion    O
exists    O
between    O
Fleischer    O
rings    O
and    O
Kayser-Fleischer    B-MetabolicDisorder114084502
rings    I-MetabolicDisorder114084502
.    O

Common    O
ADRs    O
include    O
:    O
hyponatremia    O
,    O
hypokalemia    O
,    O
hypomagnesemia    O
,    O
dehydration    O
,    O
hyperuricemia    B-MetabolicDisorder114084502
,    O
gout    O
,    O
dizziness    O
,    O
postural    O
hypotension    O
,    O
syncope    O
.    O

Hyperuricaemia    B-MetabolicDisorder114084502
without    O
signs    O
of    O
inflammatory    O
arthritis    O
and    O
tophaceous    O
disease    O

Also    O
,    O
it    O
is    O
a    O
xanthine    O
oxidase    O
inhibitor    O
,    O
hence    O
a    O
potential    O
drug    O
for    O
treatment    O
of    O
hyperuricemia    B-MetabolicDisorder114084502
and    O
related    O
medical    O
conditions    O
including    O
gout    O
.    O

Antiuricosuric    O
drugs    O
are    O
useful    O
for    O
treatment    O
of    O
hypouricemia    O
and    O
perhaps    O
also    O
hyperuricosuria    O
,    O
but    O
are    O
contraindicated    O
in    O
persons    O
with    O
conditions    O
including    O
hyperuricemia    B-MetabolicDisorder114084502
and    O
gout    O
.    O

Hyperuricemia    B-MetabolicDisorder114084502

These    O
waters    O
can    O
be    O
used    O
for    O
baths    O
and    O
inhalations    O
for    O
theraupetic    O
purposes    O
;    O
their    O
muds    O
are    O
used    O
to    O
treat    O
rheumatisms    O
,    O
arthritis    O
,    O
arthrosis    O
,    O
sciatica    O
,    O
hyperuricemia    B-MetabolicDisorder114084502
,    O
gout    O
and    O
skin    O
diseases    O
.    O

People    O
with    O
kidney    O
disease    O
,    O
hyperuricemia    B-MetabolicDisorder114084502
,    O
or    O
gout    O
should    O
not    O
take    O
aspirin    O
because    O
it    O
inhibits    O
the    O
kidneys    O
'    O
ability    O
to    O
excrete    O
uric    O
acid    O
,    O
thus    O
may    O
exacerbate    O
these    O
conditions    O
.    O

Hyperuricaemia    B-MetabolicDisorder114084502
and    O
early    O
onset    O
gout    O
have    O
occurred    O
.    O

Consequences    O
of    O
the    O
alcohol    O
induced    O
redox    O
changes    O
in    O
the    O
human    O
body    O
include    O
increased    O
triglyceride    B-MetabolicDisorder114084502
production    O
,    O
increased    O
amino    O
acid    O
catabolism    O
,    O
inhibition    O
of    O
the    O
citric    O
acid    O
cycle    O
,    O
lactic    B-MetabolicDisorder114084502
acidosis    I-MetabolicDisorder114084502
,    O
ketoacidosis    O
,    O
hyperuricemia    B-MetabolicDisorder114084502
,    O
disturbance    O
in    O
cortisol    O
and    O
androgen    O
metabolism    O
and    O
increased    O
fibrogenesis    O
.    O

Additionally    O
,    O
there    O
have    O
been    O
case    O
reports    O
of    O
fatal    O
lactic    B-MetabolicDisorder114084502
acidosis    I-MetabolicDisorder114084502
in    O
pregnant    O
women    O
receiving    O
combination    O
therapy    O
of    O
stavudine    O
and    O
didanosine    O
with    O
other    O
antiviral    O
agents    O
.    O

Lactic    B-MetabolicDisorder114084502
acidosis    I-MetabolicDisorder114084502

Serious    O
side    O
effects    O
include    O
liver    O
disease    O
,    O
lactic    B-MetabolicDisorder114084502
acidosis    I-MetabolicDisorder114084502
,    O
and    O
worsening    O
hepatitis    O
B    O
among    O
those    O
already    O
infected    O
.    O

More    O
severe    O
side    O
effects    O
include    O
hypersensitivity    O
,    O
liver    O
damage    O
,    O
and    O
lactic    B-MetabolicDisorder114084502
acidosis    I-MetabolicDisorder114084502
.    O
Genetic    O
testing    O
can    O
indicate    O
whether    O
a    O
person    O
is    O
at    O
higher    O
risk    O
of    O
developing    O
hypersensitivity    O
.    O

The    O
use    O
of    O
nucleoside    O
drugs    O
such    O
as    O
abacavir    O
can    O
very    O
rarely    O
cause    O
lactic    B-MetabolicDisorder114084502
acidosis    I-MetabolicDisorder114084502
.    O

Lactic    B-MetabolicDisorder114084502
acidosis    I-MetabolicDisorder114084502
,    O
due    O
to    O
anaerobic    O
metabolism    O
during    O
heavy    O
exercise    O
or    O
hypoxia    O

Biochemically    O
,    O
arsenic    O
prevents    O
use    O
of    O
thiamine    O
resulting    O
in    O
a    O
clinical    O
picture    O
resembling    O
thiamine    O
deficiency    O
.    O
Poisoning    O
with    O
arsenic    O
can    O
raise    O
lactate    O
levels    O
and    O
lead    O
to    O
lactic    B-MetabolicDisorder114084502
acidosis    I-MetabolicDisorder114084502
.    O

A    O
deficiency    O
of    O
pyruvate    O
carboxylase    O
can    O
cause    O
lactic    B-MetabolicDisorder114084502
acidosis    I-MetabolicDisorder114084502
as    O
a    O
result    O
of    O
lactate    O
build    O
up    O
.    O

The    O
authors    O
proposed    O
that    O
chronic    O
exposure    O
to    O
alpha    O
-    O
mangostin    O
,    O
a    O
xanthone    O
,    O
could    O
be    O
toxic    O
to    O
mitochondrial    O
function    O
,    O
leading    O
to    O
impairment    O
of    O
cellular    O
respiration    O
and    O
production    O
of    O
lactic    B-MetabolicDisorder114084502
acidosis    I-MetabolicDisorder114084502
.    O

GRACILE    O
is    O
an    O
acronym    O
for    O
growth    O
retardation    O
,    O
amino    O
aciduria    O
(    O
amino    O
acids    O
in    O
the    O
urine    O
)    O
,    O
cholestasis    O
,    O
iron    O
overload    O
,    O
lactic    B-MetabolicDisorder114084502
acidosis    I-MetabolicDisorder114084502
,    O
and    O
early    O
death    O
.    O

It    O
was    O
marketed    O
as    O
DBI    O
by    O
Ciba    O
-    O
Geigy    O
,    O
but    O
was    O
withdrawn    O
from    O
most    O
markets    O
in    O
the    O
late    O
1970s    O
due    O
to    O
a    O
high    O
risk    O
of    O
lactic    B-MetabolicDisorder114084502
acidosis    I-MetabolicDisorder114084502
,    O
which    O
was    O
fatal    O
in    O
50%    O
of    O
cases    O
.    O

Consequences    O
of    O
the    O
alcohol    O
induced    O
redox    O
changes    O
in    O
the    O
human    O
body    O
include    O
increased    O
triglyceride    B-MetabolicDisorder114084502
production    O
,    O
increased    O
amino    O
acid    O
catabolism    O
,    O
inhibition    O
of    O
the    O
citric    O
acid    O
cycle    O
,    O
lactic    B-MetabolicDisorder114084502
acidosis    I-MetabolicDisorder114084502
,    O
ketoacidosis    O
,    O
hyperuricemia    B-MetabolicDisorder114084502
,    O
disturbance    O
in    O
cortisol    O
and    O
androgen    O
metabolism    O
and    O
increased    O
fibrogenesis    O
.    O

Sea-blue    B-MetabolicDisorder114084502
histiocyte    I-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502

|    O
Sea-blue    B-MetabolicDisorder114084502
histiocytosis    I-MetabolicDisorder114084502

Kidney    O
and    O
Adrenal    O
issues    O
:    O
Kidney    O
disease    O
,    O
Kidney    O
Cancer    O
,    O
Renal    O
Cell    O
Carcinoma    O
,    O
Adrenal    O
Cancer    O
,    O
Nephrotic    O
Syndrome    O
,    O
Fanconi's    B-MetabolicDisorder114084502
Syndrome    I-MetabolicDisorder114084502
,    O

CLU    O
expression    O
in    O
the    O
kidney    O
also    O
plays    O
a    O
role    O
in    O
renal    O
diseases    O
,    O
such    O
as    O
nephropathic    B-MetabolicDisorder114084502
cystinosis    I-MetabolicDisorder114084502
,    O
which    O
is    O
a    O
major    O
cause    O
of    O
Fanconi    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
.    O

Expired    O
tetracyclines    O
or    O
tetracyclines    O
allowed    O
to    O
stand    O
at    O
a    O
pH    O
less    O
than    O
2    O
are    O
reported    O
to    O
be    O
nephrotoxic    O
due    O
to    O
the    O
formation    O
of    O
a    O
degradation    O
product    O
,    O
anhydro-4-epitetracycline    O
causing    O
Fanconi    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
.    O

It    O
should    O
not    O
be    O
confused    O
with    O
Fanconi    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
,    O
a    O
kidney    O
disorder    O
also    O
named    O
after    O
Fanconi    O
.    O

Intrinsic    O
disorders    O
-    O
Fanconi's    B-MetabolicDisorder114084502
,    O
Kostmann    O
's    O
,    O
cyclic    O
neutropenia    O
,    O
Chédiak    O

Fanconi    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502

Xanthinuria    B-MetabolicDisorder114084502
,    O
also    O
known    O
as    O
xanthine    B-MetabolicDisorder114084502
oxidase    I-MetabolicDisorder114084502
deficiency    I-MetabolicDisorder114084502
,    O
is    O
a    O
rare    O
genetic    O
disorder    O
causing    O
the    O
accumulation    O
of    O
xanthine    O
.    O

Hereditary    O
xanthinuria    B-MetabolicDisorder114084502

Hyperammonemia    O
contributes    O
to    O
the    O
confusion    O
and    O
coma    O
of    O
hepatic    B-MetabolicDisorder114084502
encephalopathy    I-MetabolicDisorder114084502
,    O
as    O
well    O
as    O
the    O
neurologic    O
disease    O
common    O
in    O
people    O
with    O
urea    O
cycle    O
defects    O
and    O
organic    B-MetabolicDisorder114084502
aciduria    I-MetabolicDisorder114084502
.    O

This    O
deficiency    O
belongs    O
to    O
a    O
more    O
general    O
class    O
of    O
disorders    O
known    O
as    O
organic    B-MetabolicDisorder114084502
acidemias    I-MetabolicDisorder114084502
,    O
in    O
which    O
the    O
dysfunction    O
of    O
a    O
specific    O
step    O
of    O
amino    O
acid    O
catabolism    O
results    O
in    O
the    O
excretion    O
of    O
non    O
-    O
amino    O
acids    O
in    O
the    O
urine    O
.    O

The    O
test    O
can    O
be    O
used    O
to    O
exclude    O
the    O
possibility    O
that    O
a    O
person    O
has    O
an    O
inborn    O
error    O
of    O
metabolism    O
,    O
usually    O
one    O
of    O
the    O
organic    B-MetabolicDisorder114084502
acidemias    I-MetabolicDisorder114084502
.    O

Fructose    B-MetabolicDisorder114084502
intolerance    I-MetabolicDisorder114084502

Hereditary    B-MetabolicDisorder114084502
fructose    I-MetabolicDisorder114084502
intolerance    I-MetabolicDisorder114084502

Hydrogen    O
breath    O
test    O
-    O
it    O
is    O
becoming    O
more    O
and    O
more    O
common    O
for    O
people    O
to    O
undertake    O
a    O
medical    O
test    O
for    O
clinical    O
diagnosis    O
of    O
dietary    O
disabilities    O
such    O
as    O
fructose    B-MetabolicDisorder114084502
intolerance    I-MetabolicDisorder114084502
,    O
fructose    B-MetabolicDisorder114084502
malabsorption    I-MetabolicDisorder114084502
,    O
lactose    O
intolerance    O
and    O
lactulose    O
intolerance    O
.    O

Some    O
defects    O
in    O
aldolase    O
B    O
cause    O
hereditary    B-MetabolicDisorder114084502
fructose    I-MetabolicDisorder114084502
intolerance    I-MetabolicDisorder114084502
.    O

More    O
rare    O
causes    O
include    O
inherited    O
disorders    O
,    O
such    O
as    O
Dubin-Johnson    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
and    O
Rotor    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
.    O

Rotor's    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502

Mutations    O
in    O
this    O
gene    O
have    O
been    O
associated    O
with    O
Gaucher    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
Tay-Sachs    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
and    O
metachromatic    B-MetabolicDisorder114084502
leukodystrophy    I-MetabolicDisorder114084502
.    O

Bimal    O
Kumar    O
Bachhawat    O
(    O
1925–1996    O
)    O
was    O
an    O
Indian    O
neurochemist    O
and    O
glycobiologist    O
,    O
known    O
for    O
his    O
discovery    O
of    O
HMG    O
-    O
CoA    O
lyase    O
,    O
an    O
intermediate    O
in    O
the    O
mevalonate    O
and    O
ketogenesis    O
pathway    O
,    O
and    O
for    O
the    O
elucidation    O
of    O
the    O
molecular    O
cause    O
of    O
Metachromatic    B-MetabolicDisorder114084502
leukodystrophy    I-MetabolicDisorder114084502
,    O
a    O
hereditary    O
disease    O
of    O
the    O
brain    O
His    O
studies    O
on    O
sugar    O
-    O
bearing    O
liposomes    O
led    O
to    O
its    O
use    O
as    O
a    O
carrier    O
for    O
in    O
situ    O
delivery    O
of    O
drugs    O
and    O
hormones    O
to    O
diseased    O
organs    O
and    O
he    O
pioneered    O
the    O
therapy    O
of    O
systemic    O
fungal    O
infections    O
using    O
liposomal    O
formulations    O
.    O

His    O
researches    O
revealed    O
,    O
for    O
the    O
first    O
time    O
,    O
that    O
Metachromatic    B-MetabolicDisorder114084502
leukodystrophy    I-MetabolicDisorder114084502
,    O
an    O
autosomal    O
recessive    O
disease    O
,    O
was    O
caused    O
by    O
the    O
absence    O
of    O
Arylsulfatase    O
A    O
,    O
an    O
enzyme    O
responsible    O
for    O
the    O
breaking    O
down    O
on    O
sulfatides    O
.    O

His    O
proposals    O
on    O
the    O
biosynthesis    O
and    O
degradation    O
of    O
cerebroside-3-sulfate    O
,    O
a    O
lipid    O
found    O
in    O
high    O
concentrations    O
in    O
patients    O
afflicted    O
with    O
Metachromatic    B-MetabolicDisorder114084502
leukodystrophy    I-MetabolicDisorder114084502
were    O
known    O
to    O
have    O
helped    O
in    O
the    O
later    O
-    O
day    O
therapeutic    O
protocols    O
.    O

Metachromatic    B-MetabolicDisorder114084502
leukodystrophy    I-MetabolicDisorder114084502

Hugo    O
set    O
up    O
the    O
test    O
for    O
urinary    O
sulfatides    O
and    O
compared    O
the    O
composition    O
of    O
urinary    O
lipids    O
with    O
that    O
of    O
brain    O
in    O
metachromatic    B-MetabolicDisorder114084502
leukodystrophy    I-MetabolicDisorder114084502
.    O

They    O
further    O
investigated    O
the    O
role    O
of    O
steroid    O
sulfatases    O
in    O
metachromatic    B-MetabolicDisorder114084502
leukodystrophy    I-MetabolicDisorder114084502
and    O
multiple    B-MetabolicDisorder114084502
sulfatase    I-MetabolicDisorder114084502
deficiency    I-MetabolicDisorder114084502
,    O
and    O
they    O
identified    O
acid    O
ceramidase    O
as    O
the    O
enzyme    O
deficient    O
in    O
Farber’s    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

Metachromatic    B-MetabolicDisorder114084502
leukodystrophy    I-MetabolicDisorder114084502
,    O
a    O
lysosomal    O
storage    O
disease    O
,    O
leads    O
to    O
the    O
accumulation    O
of    O
lipopigments    O
and    O
lysosomal    O
residual    O
bodies    O
in    O
the    O
epithelial    O
cells    O
of    O
sweat    O
glands    O
.    O

Hurler–Scheie    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
or    O
mucopolysaccharidosis    O
type    O
I    O
H    O
-    O
S    O

Winchester    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502

Familial    B-MetabolicDisorder114084502
Mediterranean    I-MetabolicDisorder114084502
fever    I-MetabolicDisorder114084502
,    O
a    O
hereditary    O
inflammatory    O
disorder    O

Familial    B-MetabolicDisorder114084502
Mediterranean    I-MetabolicDisorder114084502
fever    I-MetabolicDisorder114084502

Internet    O
sites    O
promote    O
the    O
anecdotal    O
claim    O
that    O
Melungeons    O
are    O
more    O
prone    O
to    O
certain    O
diseases    O
,    O
such    O
as    O
sarcoidosis    O
or    O
familial    B-MetabolicDisorder114084502
Mediterranean    I-MetabolicDisorder114084502
fever    I-MetabolicDisorder114084502
.    O

Familial    B-MetabolicDisorder114084502
Mediterranean    I-MetabolicDisorder114084502
fever    I-MetabolicDisorder114084502
(    O
FMF    O
)    O

Familial    B-MetabolicDisorder114084502
Mediterranean    I-MetabolicDisorder114084502
fever    I-MetabolicDisorder114084502

familial    B-MetabolicDisorder114084502
Mediterranean    I-MetabolicDisorder114084502
fever    I-MetabolicDisorder114084502
-    O
fibroblasts    O
-    O
fluorescence    O
in    O
situ    O
hybridization    O
-    O
footprinting    O
-    O
Fragile    O
X    O
syndrome    O
-    O
frameshift    O
mutation    O
-    O
fusion    O
protein    O
-    O

Hirschhorn    O
syndrome    O
,    O
Andersen    O
–    O
Tawil    O
syndrome    O
,    O
Waardenburg    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
and    O
cri    O
du    O
chat    O
syndrome    O
,    O
along    O
with    O
piebaldism    O
,    O
prominent    O
inner    O
third    O
of    O
the    O
eyebrows    O
,    O
irises    O
of    O
different    O
color    O
,    O
spondyloepiphyseal    O
dysplasia    O
,    O
mucopolysaccharide    O
metabolism    O
disorders    O
(    O
Morquio    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
and    O
Hurler's    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
)    O
,    O
deafness    O
and    O
also    O
in    O
hypothyroidism    O
.    O

Children    O
with    O
Maroteaux    O
–    O
Lamy    O
syndrome    O
usually    O
have    O
normal    O
intellectual    O
development    O
but    O
share    O
many    O
of    O
the    O
physical    O
symptoms    O
found    O
in    O
Hurler    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
.    O

Hurler    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502

Hurler    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
,    O
genetic    O
disorder    O
also    O
known    O
as    O
mucopolysaccharidosis    O
type    O
I    O
(    O
MPS    O
I    O
)    O
,    O
Hurler    O
's    O
disease    O
,    O
or    O
gargoylism    O

Hurler    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502

A    O
pilot    O
screening    O
program    O
for    O
four    O
lysosomal    O
storage    O
diseases    O
(    O
Gaucher    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
Pompe    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
Fabry    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
and    O
Niemann-Pick    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
was    O
undertaken    O
using    O
anonymised    O
dried    O
blood    O
spots    O
was    O
completed    O
in    O
Austria    O
in    O
2010    O
.    O

Gaucher's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502

Approximately    O
1    O
in    O
4    O
Ashkenazi    O
Jews    O
are    O
carriers    O
for    O
at    O
least    O
one    O
genetic    O
disorder    O
,    O
which    O
include    O
Tay-Sachs    B-MetabolicDisorder114084502
disease    O
,    O
familial    O
dysautonomia    O
,    O
and    O
Gaucher    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

It    O
may    O
have    O
an    O
increased    O
prevalence    O
in    O
Gaucher's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

This    O
discovery    O
assisted    O
other    O
scientists    O
in    O
the    O
elucidation    O
of    O
similar    O
glycolipid    O
storage    O
diseases    O
such    O
as    O
Gaucher's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
and    O
Tay–Sachs    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
and    O
in    O
their    O
prenatal    O
diagnosis    O
.    O

Gaucher's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502

In    O
1984    O
,    O
Robin    O
Berman    O
,    O
MD    O
,    O
who    O
volunteered    O
at    O
the    O
NIH    O
,    O
had    O
a    O
three    O
-    O
year    O
-    O
old    O
son    O
Brian    O
,    O
who    O
had    O
Gaucher's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

Ceredase    O
was    O
the    O
first    O
effective    O
treatment    O
for    O
Gaucher's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
a    O
previously    O
rare    O
,    O
untreatable    O
and    O
potentially    O
fatal    O
genetic    O
disorder    O
.    O

The    O
first    O
orphan    O
-    O
drug    O
for    O
Genzyme    O
that    O
FDA    O
approved    O
was    O
Ceredase    O
,    O
a    O
drug    O
for    O
treating    O
Gaucher    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

The    O
FDA    O
found    O
these    O
materials    O
in    O
Cerezyme    O
,    O
Genzyme    O
's    O
treatment    O
for    O
Gaucher    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
a    O
rare    O
genetic    O
disorder    O
that    O
can    O
lead    O
to    O
life    O
-    O
threatening    O
organ    O
damage    O
.    O

For    O
example    O
,    O
two    O
different    O
mutations    O
in    O
the    O
glucocerebrosidase    O
gene    O
causes    O
Gaucher's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
in    O
Ashkenazis    O
,    O
which    O
is    O
their    O
most    O
common    O
genetic    O
disease    O
,    O
but    O
only    O
one    O
of    O
these    O
mutations    O
is    O
found    O
in    O
non    O
-    O
Jewish    O
groups    O
.    O

Gaucher's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
in    O
which    O
lipids    O
accumulate    O
in    O
inappropriate    O
locations    O
,    O
occurs    O
most    O
frequently    O
among    O
Ashkenazi    O
Jews    O
;    O
the    O
mutation    O
is    O
carried    O
by    O
roughly    O
one    O
in    O
every    O
15    O
Ashkenazi    O
Jews    O
,    O
compared    O
to    O
one    O
in    O
100    O
of    O
the    O
general    O
American    O
population    O
.    O

Gaucher    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
which    O
is    O
caused    O
by    O
deficiency    O
of    O
the    O
enzyme    O
glucocerebrosidase    O
.    O

Gaucher's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502

Gaucher    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502

He    O
is    O
remembered    O
for    O
providing    O
a    O
description    O
of    O
a    O
disorder    O
that    O
was    O
to    O
become    O
known    O
as    O
'    O
Gaucher's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
"    O
.    O

gestational    B-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502

She    O
became    O
diabetic    B-MetabolicDisorder114084502
and    O
had    O
to    O
take    O
insulin    O
the    O
rest    O
of    O
her    O
life    O
.    O

Maternal    O
conditions    O
such    O
as    O
gestational    B-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
or    O
chronic    O
kidney    O
disease    O

Factors    O
that    O
may    O
make    O
a    O
birth    O
high    O
risk    O
include    O
prematurity    O
,    O
high    O
blood    O
pressure    O
,    O
gestational    B-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
and    O
a    O
previous    O
cesarean    O
section    O
.    O

As    O
it    O
occurs    O
infrequently    O
,    O
many    O
cases    O
of    O
MODY    O
are    O
initially    O
assumed    O
to    O
be    O
more    O
common    O
forms    O
of    O
diabetes    O
:    O
type    O
1    O
if    O
the    O
patient    O
is    O
young    O
and    O
not    O
overweight    O
,    O
type    O
2    O
if    O
the    O
patient    O
is    O
overweight    O
,    O
or    O
gestational    B-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
if    O
the    O
patient    O
is    O
pregnant    O
.    O

The    O
association    O
funds    O
research    O
to    O
manage    O
,    O
cure    O
and    O
prevent    O
diabetes    O
(    O
including    O
type    B-MetabolicDisorder114084502
1    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
,    O
type    B-MetabolicDisorder114084502
2    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
,    O
gestational    B-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
,    O
and    O
pre    O
-    O
diabetes    O
)    O
;    O
delivers    O
services    O
to    O
hundreds    O
of    O
communities    O
;    O
provides    O
information    O
for    O
both    O
patients    O
and    O
health    O
care    O
professionals    O
;    O
and    O
advocates    O
on    O
behalf    O
of    O
people    O
denied    O
their    O
rights    O
because    O
of    O
diabetes    O
.    O

Problems    O
during    O
pregnancy    O
may    O
include    O
preeclampsia    O
,    O
maternal    B-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
with    O
vascular    O
disease    O
,    O
congenital    O
fetal    O
infections    O
,    O
drug    O
/    O
alcohol    O
abuse    O
,    O
severe    O
fetal    O
anemia    O
,    O
cardiac    O
disease    O
,    O
lung    O
malformations    O
,    O
or    O
problems    O
with    O
blood    O
flow    O
to    O
the    O
placenta    O
.    O

Women    O
's    O
Preventive    O
Services    O
–    O
including    O
:    O
well    O
-    O
woman    O
visits    O
;    O
gestational    B-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
screening    O
;    O
human    O
papillomavirus    O
(    O
HPV    O
)    O
DNA    O
testing    O
for    O
women    O
age    O
30    O
and    O
older    O
;    O
sexually    O
transmitted    O
infection    O
counseling    O
;    O
human    O
immunodeficiency    O
virus    O
(    O
HIV    O
)    O
screening    O
and    O
counseling    O
;    O
FDA    O
-    O
approved    O
contraceptive    O
methods    O
and    O
contraceptive    O
counseling    O
;    O
breastfeeding    O
support    O
,    O
supplies    O
and    O
counseling    O
;    O
and    O
domestic    O
violence    O
screening    O
and    O
counseling    O
–    O
will    O
be    O
covered    O
without    O
cost    O
sharing    O
.    O

Women    O
's    O
Preventive    O
Services    O
–    O
including    O
:    O
well    O
-    O
woman    O
visits    O
;    O
gestational    B-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
screening    O
;    O
human    O
papillomavirus    O
(    O
HPV    O
)    O
DNA    O
testing    O
for    O
women    O
age    O
30    O
and    O
older    O
;    O
sexually    O
transmitted    O
infection    O
counseling    O
;    O
human    O
immunodeficiency    O
virus    O
(    O
HIV    O
)    O
screening    O
and    O
counseling    O
;    O
FDA    O
-    O
approved    O
contraceptive    O
methods    O
and    O
contraceptive    O
counseling    O
;    O
breastfeeding    O
support    O
,    O
supplies    O
and    O
counseling    O
;    O
and    O
domestic    O
violence    O
screening    O
and    O
counseling    O
–    O
will    O
be    O
covered    O
without    O
cost    O
sharing    O
.    O

Gestational    B-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
causing    O
a    O
larger    O
baby    O

Specific    O
examples    O
of    O
covered    O
services    O
include    O
:    O
mammograms    O
and    O
colonoscopies    O
,    O
wellness    O
visits    O
,    O
gestational    B-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
screening    O
,    O
HPV    O
testing    O
,    O
STI    O
counseling    O
,    O
HIV    O
screening    O
and    O
counseling    O
,    O
contraceptive    O
methods    O
,    O
breastfeeding    O
support    O
/    O
supplies    O
and    O
domestic    O
violence    O
screening    O
and    O
counseling    O
.    O

The    O
rarest    O
is    O
congenital    O
erythropoietic    O
porphyria    O
(    O
C.E.P.    O
)    O
,    O
otherwise    O
known    O
as    O
Gunther's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

Gunther's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
(    O
ILDS    O
(    O
ILDS    O
E80.020    O
)    O

There    O
is    O
often    O
presence    O
of    O
Rosenthal    B-MetabolicDisorder114084502
fiber    I-MetabolicDisorder114084502
,    O
eosinophilic    O
granular    O
bodies    O
and    O
microcysts    O
.    O

This    O
variant    O
of    O
haploinsufficiency    O
is    O
only    O
seen    O
in    O
two    O
other    O
human    O
diseases    O
:    O
Erythropoietic    B-MetabolicDisorder114084502
protoporphyria    I-MetabolicDisorder114084502
,    O
caused    O
by    O
mutations    O
in    O
the    O
FECH    O
gene    O
;    O
and    O
hereditary    O
elliptocytosis    O
,    O
caused    O
by    O
mutations    O
in    O
the    O
spectrin    O
gene    O
.    O

The    O
non    O
-    O
acute    O
porphyrias    O
are    O
X    O
-    O
linked    O
dominant    O
protoporphyria    O
(    O
XLDPP    O
)    O
,    O
congenital    O
erythropoietic    O
porphyria    O
(    O
CEP    O
)    O
,    O
porphyria    B-MetabolicDisorder114084502
cutanea    I-MetabolicDisorder114084502
tarda    I-MetabolicDisorder114084502
(    O
PCT    O
)    O
,    O
and    O
erythropoietic    B-MetabolicDisorder114084502
protoporphyria    I-MetabolicDisorder114084502
(    O
EPP    O
)    O
.    O

Erythropoietic    B-MetabolicDisorder114084502
protoporphyria    I-MetabolicDisorder114084502
(    O
ILDS    O
E80.010    O
)    O

Erythropoietic    B-MetabolicDisorder114084502
protoporphyria    I-MetabolicDisorder114084502

Sitosterolemia    B-MetabolicDisorder114084502

A    O
potential    O
safety    O
concern    O
regarding    O
phytosterol    O
consumption    O
is    O
in    O
patients    O
with    O
phytosterolaemia    B-MetabolicDisorder114084502
,    O
a    O
rare    O
genetic    O
disorder    O
which    O
results    O
in    O
a    O
50-    O
to    O
100-fold    O
increase    O
in    O
blood    O
plant    O
sterol    O
levels    O
and    O
is    O
associated    O
with    O
rapid    O
development    O
of    O
coronary    O
atherosclerosis    O
.    O

Trimethylaminuria    B-MetabolicDisorder114084502
(    O
TMAU    B-MetabolicDisorder114084502
;    O
primary    B-MetabolicDisorder114084502
trimethylaminuria    I-MetabolicDisorder114084502
)    O
,    O
also    O
known    O
as    O
fish    B-MetabolicDisorder114084502
odor    I-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
or    O
fish    B-MetabolicDisorder114084502
malodor    I-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
,    O
is    O
a    O
rare    O
metabolic    O
disorder    O
that    O
causes    O
a    O
defect    O
in    O
the    O
normal    O
production    O
of    O
an    O
enzyme    O
named    O
flavin    O
-    O
containing    O
monooxygenase    O
3    O
(    O
"    O
FMO3    O
"    O
)    O
.    O

A    O
variant    O
of    O
TMAU    O
(    O
secondary    B-MetabolicDisorder114084502
trimethylaminuria    I-MetabolicDisorder114084502
or    O
TMAU2    O
)    O
exists    O
where    O
there    O
is    O
no    O
genetic    O
cause    O
,    O
yet    O
excessive    O
TMA    O
is    O
secreted    O
,    O
possibly    O
due    O
to    O
intestinal    O
dysbiosis    O
,    O
altered    O
metabolism    O
,    O
or    O
hormonal    O
causes    O
.    O

Trimethylaminuria    B-MetabolicDisorder114084502

Schindler    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
a    O
congenital    O
metabolic    O
disorder    O
in    O
humans    O

Schindler    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
causes    O
cytoplasmic    O
vacuoles    O
that    O
appear    O
to    O
be    O
empty    O
or    O
contain    O
filamentous    O
material    O
to    O
manifest    O
in    O
eccrine    O
sweat    O
gland    O
cells    O
.    O

Hyaluronidase    B-MetabolicDisorder114084502
deficiency    I-MetabolicDisorder114084502

The    O
loss    O
of    O
magnesium    O
as    O
a    O
result    O
of    O
loop    O
diuretics    O
has    O
also    O
been    O
suggested    O
as    O
a    O
possible    O
cause    O
of    O
pseudogout    O
(    O
chondrocalcinosis    B-MetabolicDisorder114084502
)    O

Other    O
chondrocalcinosis    B-MetabolicDisorder114084502

Deficiency    O
of    O
magnesium    O
can    O
cause    O
tiredness    O
,    O
generalized    O
weakness    O
,    O
muscle    O
cramps    O
,    O
abnormal    O
heart    O
rhythms    O
,    O
increased    O
irritability    O
of    O
the    O
nervous    O
system    O
with    O
tremors    O
,    O
paresthesias    O
,    O
palpitations    O
,    O
hypokalemia    O
,    O
hypoparathyroidism    O
which    O
might    O
result    O
in    O
hypocalcemia    O
,    O
chondrocalcinosis    B-MetabolicDisorder114084502
,    O
spasticity    O
and    O
tetany    O
,    O
epileptic    O
seizures    O
,    O
basal    O
ganglia    O
calcifications    O
and    O
in    O
extreme    O
and    O
prolonged    O
cases    O
coma    O
,    O
intellectual    O
disability    O
or    O
death    O
.    O

Priapism    O
may    O
be    O
associated    O
with    O
haematological    O
disorders    O
,    O
especially    O
sickle    O
-    O
cell    O
disease    O
,    O
sickle    O
-    O
cell    O
trait    O
,    O
and    O
other    O
conditions    O
such    O
as    O
leukemia    O
,    O
thalassemia    O
,    O
and    O
Fabry's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
and    O
neurologic    O
disorders    O
such    O
as    O
spinal    O
cord    O
lesions    O
and    O
spinal    O
cord    O
trauma    O
(    O
priapism    O
has    O
been    O
reported    O
in    O
people    O
who    O
have    O
been    O
hanged    O
;    O
see    O
death    O
erection    O
)    O
.    O

Migalastat    O
(    O
INN    O
/    O
USAN    O
)    O
,    O
or    O
1-deoxygalactonojirimycin    O
,    O
trade    O
name    O
Galafold    O
(    O
formerly    O
known    O
as    O
Amigal    O
)    O
is    O
a    O
drug    O
for    O
the    O
treatment    O
of    O
Fabry    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
a    O
rare    O
genetic    O
disorder    O
.    O

Large    O
Scale    O
Biology    O
Corporation    O
(    O
LSBC    O
)    O
(    O
"    O
bankrupt    O
"    O
)    O
–    O
used    O
Tobacco    O
mosaic    O
virus    O
to    O
develop    O
reagents    O
and    O
patient    O
-    O
specific    O
vaccines    O
for    O
Non    O
-    O
Hodgkin    O
's    O
lymphoma    O
,    O
Papillomavirus    O
vaccine    O
,    O
parvovirus    O
vaccine    O
,    O
alpha    O
galactosidase    O
for    O
Fabry    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
lysosomal    O
acid    O
lipase    O
,    O
aprotinin    O
,    O
interferon    O
Alpha    O
2a    O
and    O
2b    O
,    O
G    O
-    O
CSF    O
,    O
and    O
Hepatitis    O
B    O
vaccine    O
antigens    O
in    O
tobacco    O
.    O

Fabry's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
(    O
ILDS    O
E75.250    O
)    O

A    O
pilot    O
screening    O
program    O
for    O
four    O
lysosomal    O
storage    O
diseases    O
(    O
Gaucher    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
Pompe    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
Fabry    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
and    O
Niemann-Pick    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
was    O
undertaken    O
using    O
anonymised    O
dried    O
blood    O
spots    O
was    O
completed    O
in    O
Austria    O
in    O
2010    O
.    O

Other    O
important    O
drugs    O
made    O
by    O
Genzyme    O
are    O
Renagel    O
,    O
used    O
in    O
treatment    O
of    O
dialysis    O
patients    O
,    O
and    O
Fabrazyme    O
,    O
used    O
to    O
treat    O
patients    O
with    O
Fabry's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

Supplies    O
of    O
Fabrazyme    O
,    O
Genzyme    O
's    O
treatment    O
for    O
Fabry    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
have    O
been    O
rationed    O
to    O
one    O
-    O
third    O
the    O
recommended    O
dose    O
prompting    O
patients    O
to    O
file    O
a    O
petition    O
asking    O
for    O
a    O
license    O
to    O
produce    O
Fabrazyme    O
by    O
other    O
manufacturers    O
to    O
make    O
up    O
the    O
deficit    O
under    O
the    O
Bayh    O
–    O
Dole    O
Act    O
.    O

It    O
is    O
seen    O
in    O
Fabry    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
or    O
in    O
case    O
of    O
prolonged    O
amiodarone    O
intake    O
.    O

Fabry    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
characterized    O
by    O
excess    O
globotriaosylceramide    O
(    O
GL3    O
)    O
,    O
causes    O
a    O
decrease    O
in    O
sweat    O
gland    O
function    O
due    O
to    O
GL3    O
deposits    O
in    O
the    O
eccrine    O
glands    O
.    O

Fabry    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502

Alpha    O
-    O
N    O
-    O
acetylglucosaminidase    O
(    O
,    O
"    O
alpha    O
-    O
acetylglucosaminidase    O
"    O
,    O
"    O
N    O
-    O
acetyl    O
-    O
alpha    O
-    O
D    O
-    O
glucosaminidase    O
"    O
,    O
"    O
N    O
-    O
acetyl    O
-    O
alpha    O
-    O
glucosaminidase    O
"    O
,    O
"    O
alpha    O
-    O
D-2-acetamido-2-deoxyglucosidase    O
"    O
)    O
is    O
a    O
protein    O
associated    O
with    O
Sanfilippo    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
.    O

This    O
enzyme    O
is    O
deficient    O
in    O
Sanfilippo    B-MetabolicDisorder114084502
Syndrome    I-MetabolicDisorder114084502
type    O
IIId    O
.    O

Mucopolysaccharidosis    O
type    O
IIID    O
is    O
the    O
least    O
common    O
of    O
the    O
four    O
subtypes    O
of    O
Sanfilippo    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
.    O

Sanfilippo    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502

Hypophosphatasia    B-MetabolicDisorder114084502

Hypophosphatasia    B-MetabolicDisorder114084502

Rapid    O
PC    O
depletion    O
due    O
to    O
biliary    O
PC    O
secretion    O
,    O
as    O
well    O
as    O
protein    O
leakage    O
from    O
loss    O
of    O
membrane    O
integrity    O
due    O
to    O
lowered    O
PC    O
/    O
PE    O
ratios    O
,    O
led    O
to    O
steatosis    O
and    O
steatohepatitis    B-MetabolicDisorder114084502
.    O

It    O
funds    O
Professor    O
Jacob    O
Georgetown    O
to    O
undertake    O
research    O
that    O
focuses    O
on    O
non    O
-    O
alcoholic    O
steatohepatitis    B-MetabolicDisorder114084502
and    O
hepatic    O
fibrosis    O
.    O

Aramchol    O
is    O
an    O
investigational    O
drug    O
being    O
developed    O
by    O
Galmed    O
Pharmaceuticals    O
as    O
a    O
first    O
-    O
in    O
-    O
class    O
,    O
potentially    O
disease    O
modifying    O
treatment    O
for    O
nonalcoholic    O
steatohepatitis    B-MetabolicDisorder114084502
,    O
or    O
NASH    O
,    O
a    O
more    O
advanced    O
condition    O
of    O
non    O
-    O
alcoholic    O
fatty    O
liver    O
disease    O
.    O

Obesity    O
has    O
emerged    O
as    O
an    O
important    O
risk    O
factor    O
as    O
it    O
can    O
lead    O
to    O
steatohepatitis    B-MetabolicDisorder114084502
.    O

Medium    B-MetabolicDisorder114084502
chain    I-MetabolicDisorder114084502
acyl-CoA    I-MetabolicDisorder114084502
dehydrogenase    I-MetabolicDisorder114084502
deficiency    I-MetabolicDisorder114084502
(    O
MCADD    O
)    O
,    O
which    O
had    O
been    O
implicated    O
in    O
several    O
cases    O
of    O
sudden    O
infant    O
death    O
syndrome    O
was    O
one    O
of    O
the    O
first    O
conditions    O
targeted    O
for    O
inclusion    O
.    O

Medium-chain    B-MetabolicDisorder114084502
acyl-CoA    I-MetabolicDisorder114084502
dehydrogenase    I-MetabolicDisorder114084502
deficiency    I-MetabolicDisorder114084502
(    O
MCAD    O
)    O
>    O
1    O
in    O
25,000    O

This    O
condition    O
is    O
sometimes    O
mistaken    O
for    O
fatty    O
acid    O
and    O
ketogenesis    O
disorders    O
such    O
as    O
Medium-chain    B-MetabolicDisorder114084502
acyl-coenzyme    I-MetabolicDisorder114084502
A    I-MetabolicDisorder114084502
dehydrogenase    I-MetabolicDisorder114084502
deficiency    I-MetabolicDisorder114084502
(    O
MCAD    O
)    O
,    O
other    O
long    O
-    O
chain    O
fatty    O
acid    O
oxidation    O
disorders    O
such    O
as    O
Carnitine    O
palmitoyltransferase    O
II    O
deficiency    O
(    O
CPT    O
-    O
II    O
)    O
and    O
Reye    O
syndrome    O
.    O

Lipoprotein    B-MetabolicDisorder114084502
lipase    I-MetabolicDisorder114084502
deficiency    I-MetabolicDisorder114084502

Lipoprotein    B-MetabolicDisorder114084502
lipase    I-MetabolicDisorder114084502
deficiency    I-MetabolicDisorder114084502
(    O
also    O
known    O
as    O
"    O
familial    B-MetabolicDisorder114084502
chylomicronemia    I-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
"    O
,    O
"    O
chylomicronemia    B-MetabolicDisorder114084502
"    O
,    O
"    O
chylomicronemia    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
"    O
and    O
"    O
hyperlipoproteinemia    O
type    O
Ia    O
"    O
)    O
is    O
a    O
rare    O
autosomal    O
recessive    O
lipid    O
disorder    O
caused    O
by    O
a    O
mutation    O
in    O
the    O
gene    O
which    O
codes    O
lipoprotein    O
lipase    O
.    O

Salicylate    B-MetabolicDisorder114084502
sensitivity    I-MetabolicDisorder114084502

Aspirin    O
should    O
not    O
be    O
taken    O
by    O
people    O
who    O
are    O
allergic    O
to    O
ibuprofen    O
or    O
naproxen    O
,    O
or    O
who    O
have    O
salicylate    B-MetabolicDisorder114084502
intolerance    I-MetabolicDisorder114084502
or    O
a    O
more    O
generalized    O
drug    O
intolerance    O
to    O
NSAIDs    O
,    O
and    O
caution    O
should    O
be    O
exercised    O
in    O
those    O
with    O
asthma    O
or    O
NSAID    O
-    O
precipitated    O
bronchospasm    O
.    O

The    O
reaction    O
is    O
caused    O
by    O
salicylate    B-MetabolicDisorder114084502
intolerance    I-MetabolicDisorder114084502
and    O
is    O
not    O
a    O
true    O
allergy    O
,    O
but    O
rather    O
an    O
inability    O
to    O
metabolize    O
even    O
small    O
amounts    O
of    O
aspirin    O
,    O
resulting    O
in    O
an    O
overdose    O
.    O

Hunter    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502

Mucopolysaccharidosis    B-MetabolicDisorder114084502
type    I-MetabolicDisorder114084502
2    I-MetabolicDisorder114084502
Hunter    I-MetabolicDisorder114084502
syndrome-    I-MetabolicDisorder114084502
mild    I-MetabolicDisorder114084502
form    I-MetabolicDisorder114084502

Mucopolysaccharidosis    B-MetabolicDisorder114084502
type    I-MetabolicDisorder114084502
2    I-MetabolicDisorder114084502
Hunter    I-MetabolicDisorder114084502
syndrome-    I-MetabolicDisorder114084502
severe    I-MetabolicDisorder114084502
form    I-MetabolicDisorder114084502

Hunter    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502

Hunter    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
can    O
include    O
metachromin    O
granules    O
and    O
mucin    O
in    O
the    O
cytoplasm    O
of    O
the    O
eccrine    O
sweat    O
gland    O
cells    O
.    O

'    O
'    O
Lorenzo    O
's    O
Oil    O
''    O
(    O
1992    O
)    O
–    O
based    O
on    O
the    O
true    O
story    O
of    O
Augusto    O
and    O
Michaela    O
Odone    O
,    O
two    O
parents    O
in    O
a    O
relentless    O
search    O
for    O
a    O
cure    O
for    O
their    O
son    O
Lorenzo    O
's    O
adrenoleukodystrophy    B-MetabolicDisorder114084502
(    O
ALD    O
)    O

Adrenoleukodystrophy    B-MetabolicDisorder114084502
,    O
can    O
be    O
accompanied    O
by    O
adrenal    O
insufficiency    O

Adrenoleukodystrophy    B-MetabolicDisorder114084502
(    O
ALD    O
)    O
,    O
a    O
peroxisomal    O
disease    O
that    O
has    O
a    O
variable    O
clinical    O
presentation    O
is    O
one    O
of    O
the    O
disorders    O
that    O
has    O
become    O
a    O
target    O
for    O
those    O
seeking    O
to    O
identify    O
patients    O
early    O
.    O

Adrenoleukodystrophy    B-MetabolicDisorder114084502
(ALD)    I-MetabolicDisorder114084502
,    O
is    O
the    O
build    O
up    O
of    O
long    O
chain    O
fatty    O
acids    O
in    O
the    O
brain    O
and    O
adrenal    O
cortex    O
,    O
because    O
of    O
the    O
decreased    O
activity    O
of    O
long    O
chain    O
fatty    O
acyl    O
coa    O
synthetase    O
.    O

Dr.    O
Yasuo    O
Kishimoto    O
,    O
who    O
had    O
helped    O
Kuni    O
Suzuki    O
make    O
the    O
discovery    O
of    O
elevated    O
very    O
long    O
chain    O
fatty    O
acids    O
in    O
Adrenoleukodystrophy    B-MetabolicDisorder114084502
brains    O
at    O
Albert    O
Einstein    O
College    O
of    O
Medicine    O
,    O
followed    O
Moser    O
from    O
the    O
Shriver    O
Center    O
to    O
the    O
Kennedy    O
Inistitute    O
.    O

Beyond    O
establishing    O
the    O
diagnostic    O
testing    O
for    O
X-linked    B-MetabolicDisorder114084502
adrenoleukodystrophy    I-MetabolicDisorder114084502
,    O
Hugo    O
Moser    O
also    O
contributed    O
to    O
the    O
discovery    O
of    O
the    O
gene    O
for    O
X    O
-    O
ALD    O
.    O

In    O
1985    O
,    O
Augusto    O
Odone    O
,    O
with    O
the    O
help    O
of    O
British    O
chemist    O
Don    O
Suddaby    O
,    O
combined    O
rapeseed    O
oil    O
with    O
olive    O
oil    O
to    O
create    O
Lorenzo    O
's    O
oil    O
which    O
halted    O
progression    O
of    O
Adrenoleukodystrophy    B-MetabolicDisorder114084502
(    O
ALD    O
)    O
in    O
Lorenzo    O
Odone    O

She    O
had    O
been    O
diagnosed    O
with    O
adrenomyeloneuropathy    B-MetabolicDisorder114084502
,    O
a    O
progressive    O
neurological    O
disorder    O
that    O
limits    O
her    O
ability    O
to    O
walk    O
.    O

Living    O
Tomorrow    O
Today    O
:    O
A    O
Benefit    O
for    O
Ty    O
Cambra    O
is    O
a    O
benefit    O
compilation    O
put    O
together    O
by    O
Asian    O
Man    O
Records    O
to    O
raise    O
money    O
for    O
the    O
family    O
of    O
(    O
at    O
the    O
time    O
)    O
an    O
eleven    O
-    O
year    O
-    O
old    O
boy    O
suffering    O
from    O
Adrenoleukodystrophy    B-MetabolicDisorder114084502
(    O
Lorenzo    O
's    O
Oil    O
Disease    O
)    O
.    O

Santa    O
Maria    O
died    O
of    O
adrenoleukodystrophy    B-MetabolicDisorder114084502
in    O
1996    O
in    O
Lausanne    O
.    O

Certain    O
peroxisomal    O
disorders    O
,    O
such    O
as    O
adrenoleukodystrophy    B-MetabolicDisorder114084502
and    O
Zellweger    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
,    O
can    O
be    O
associated    O
with    O
an    O
accumulation    O
of    O
VLCFAs    O
.    O

Oxaluria    B-MetabolicDisorder114084502

When    O
Ammi    O
Visnaga    O
extract    O
is    O
taken    O
daily    O
,    O
as    O
a    O
tea    O
or    O
as    O
a    O
pill    O
,    O
calcium    O
oxalate    O
kidney    O
stone    O
formation    O
is    O
inhibited    O
,    O
making    O
it    O
a    O
good    O
treatment    O
for    O
hyperoxaluria    B-MetabolicDisorder114084502
(    O
a    O
condition    O
in    O
which    O
there    O
is    O
excessive    O
oxalate    O
excretion    O
in    O
the    O
urine    O
,    O
causing    O
kidney    O
stones    O
)    O
.    O

Blue    B-MetabolicDisorder114084502
diaper    I-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502

However    O
,    O
an    O
increase    O
in    O
muscle    O
insulin    O
resistance    O
,    O
caused    O
by    O
obesity    O
,    O
diabetes    B-MetabolicDisorder114084502
mellitus    I-MetabolicDisorder114084502
type    I-MetabolicDisorder114084502
2    I-MetabolicDisorder114084502
,    O
and    O
metabolic    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
,    O
will    O
result    O
in    O
an    O
excess    O
accumulation    O
of    O
intramyocellular    O
lipids    O
.    O

The    O
following    O
conditions    O
are    O
among    O
those    O
that    O
can    O
be    O
detected    O
through    O
saliva    O
testing    O
(    O
list    O
not    O
comprehensive    O
)    O
:    O
adrenal    O
conditions    O
(    O
such    O
as    O
Cushing    O
's    O
disease    O
/    O
syndrome    O
and    O
Addison    O
’s    O
disease    O
)    O
,    O
altered    O
female    O
hormone    O
states    O
(    O
such    O
as    O
polycystic    O
ovary    O
syndrome    O
[    O
PCOS    O
]    O
,    O
menopause    O
,    O
anovulation    O
,    O
and    O
hormonal    O
alterations    O
in    O
cycling    O
women    O
)    O
,    O
altered    O
male    O
hormone    O
states    O
(    O
such    O
as    O
hypogonadism    O
/    O
andropause    O
and    O
hyperestrogenic    O
states    O
)    O
,    O
metabolic    O
disturbances    O
(    O
such    O
as    O
insulin    B-MetabolicDisorder114084502
resistance    I-MetabolicDisorder114084502
,    O
diabetes    O
,    O
and    O
metabolic    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
)    O
,    O
benign    O
and    O
metastatic    O
neoplasms    O
(    O
such    O
as    O
breast    O
cancer    O
,    O
pancreatic    O
cancer    O
,    O
and    O
oral    O
cancer    O
)    O
,    O
infectious    O
conditions    O
(    O
such    O
as    O
HIV    O
,    O
viral    O
hepatitis    O
,    O
amoebiasis    O
,    O
and    O
helicobacter    O
pylori    O
infection    O
)    O
,    O
and    O
allergic    O
conditions    O
(    O
such    O
as    O
food    O
allergy    O
)    O
.    O

These    O
cases    O
have    O
resulted    O
in    O
the    O
increase    O
of    O
metabolic    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
in    O
the    O
mouse    O
models    O
as    O
well    O
as    O
resulted    O
in    O
obesity    O
.    O

When    O
it    O
was    O
revealed    O
that    O
the    O
Earl    O
and    O
the    O
other    O
Noah    O
were    O
living    O
in    O
the    O
Kamelot    O
family    O
as    O
a    O
normal    O
humans    O
,    O
the    O
author    O
made    O
a    O
joke    O
regarding    O
the    O
Earl    O
was    O
not    O
suffering    O
metabolic    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
based    O
on    O
how    O
much    O
sugar    O
he    O
added    O
to    O
his    O
coffee    O
.    O

Initially    O
titled    O
"    O
syndrome    O
X    O
"    O
,    O
the    O
constellation    O
of    O
symptoms    O
is    O
now    O
known    O
as    O
the    O
metabolic    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
and    O
an    O
object    O
of    O
extensive    O
scientific    O
inquiry    O
,    O
especially    O
given    O
that    O
the    O
combination    O
strongly    O
predisposes    O
for    O
cardiovascular    O
disease    O
.    O

A    O
2014    O
meta    O
-    O
analysis    O
found    O
that    O
the    O
cardiorespiratory    O
fitness    O
,    O
as    O
measured    O
by    O
VO2    O
max    O
,    O
of    O
individuals    O
with    O
lifestyle    O
-    O
induced    O
chronic    O
cardiovascular    O
or    O
metabolic    O
diseases    O
(    O
including    O
high    O
blood    O
pressure    O
,    O
obesity    O
,    O
heart    O
failure    O
,    O
coronary    O
artery    O
disease    O
,    O
or    O
metabolic    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
)    O
who    O
completed    O
a    O
HIIT    O
exercise    O
program    O
was    O
nearly    O
double    O
that    O
of    O
individuals    O
who    O
completed    O
a    O
MICT    O
exercise    O
program    O
.    O

HCB    O
-    O
treated    O
seed    O
grain    O
consumption    O
is    O
associated    O
with    O
photosensitive    O
skin    O
lesions    O
,    O
colic    O
,    O
debilitation    O
,    O
and    O
a    O
metabolic    B-MetabolicDisorder114084502
disorder    I-MetabolicDisorder114084502
called    O
porphyria    O
turcica    O
,    O
which    O
can    O
be    O
lethal    O
.    O

Normal    O
tension    O
glaucoma    O
is    O
in    O
many    O
cases    O
closely    O
associated    O
with    O
general    O
issues    O
of    O
blood    O
circulation    O
and    O
of    O
organ    O
perfusion    O
like    O
arterial    O
hypotension    O
,    O
metabolic    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
,    O
and    O
Flammer    O
syndrome    O
.    O

Macrophage    O
mediated    O
inflammation    O
is    O
a    O
key    O
player    O
in    O
the    O
pathophysiology    O
of    O
metabolic    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
related    O
disorders    O
,    O
including    O
diabetes    O
and    O
atherosclerosis    O
.    O

there    O
is    O
correlation    O
with    O
diet    O
,    O
with    O
sedentary    O
lifestyle    O
,    O
with    O
obesity    O
,    O
with    O
age    O
and    O
with    O
metabolic    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
.    O

Metabolic    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
–    O
a    O
poorly    O
understood    O
condition    O
first    O
called    O
Syndrome    O
X    O
by    O
Gerald    O
Reaven    O
.    O

Compared    O
to    O
individuals    O
without    O
psoriasis    O
,    O
those    O
affected    O
by    O
psoriasis    O
are    O
more    O
likely    O
to    O
satisfy    O
the    O
criteria    O
for    O
metabolic    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
.    O

Increased    O
risk    O
of    O
obesity    O
and    O
metabolic    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
in    O
males    O

His    O
research    O
interests    O
included    O
abdominal    O
obesity    O
and    O
Syndrome    B-MetabolicDisorder114084502
X    I-MetabolicDisorder114084502
in    O
Indians    O
and    O
is    O
credited    O
with    O
the    O
development    O
of    O
a    O
new    O
test    O
for    O
monitoring    O
Diabetes    O
.    O

Syndrome    B-MetabolicDisorder114084502
X    I-MetabolicDisorder114084502
(metabolic)    I-MetabolicDisorder114084502

Similar    O
to    O
what    O
is    O
observed    O
in    O
chronic    O
inflammation    O
,    O
chronically    O
elevated    O
leptin    O
levels    O
are    O
associated    O
with    O
obesity    O
,    O
overeating    O
,    O
and    O
inflammation    O
-    O
related    O
diseases    O
,    O
including    O
hypertension    O
,    O
metabolic    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
,    O
and    O
cardiovascular    O
disease    O
.    O

Inhibition    O
of    O
HSD11B1    O
has    O
been    O
suggested    O
as    O
a    O
possible    O
therapy    O
for    O
treatment    O
of    O
obesity    O
and    O
metabolic    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
.    O

A    O
further    O
study    O
on    O
obese    O
adults    O
with    O
metabolic    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
was    O
published    O
in    O
2009    O
,    O
this    O
found    O
no    O
significant    O
effect    O
on    O
insulin    O
sensitivity    O
,    O
but    O
increased    O
short    O
-    O
term    O
levels    O
of    O
insulin    O
.    O

This    O
article    O
provides    O
a    O
global    O
overview    O
of    O
the    O
current    O
trends    O
and    O
distribution    O
of    O
metabolic    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
.    O

Additional    O
risk    O
factors    O
for    O
stone    O
formation    O
during    O
pregnancy    O
include    O
obesity    O
(    O
prior    O
to    O
the    O
pregnancy    O
)    O
,    O
reduced    O
high    O
density    O
lipoprotein    O
(    O
HDL    O
)    O
cholesterol    O
and    O
the    O
metabolic    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
.    O

Obesity    O
in    O
turn    O
results    O
in    O
an    O
abnormally    O
high    O
level    O
of    O
complement    O
activation    O
via    O
production    O
of    O
the    O
c1    O
component    O
of    O
the    O
classical    O
pathway    O
,    O
which    O
can    O
lead    O
to    O
tissue    O
inflammation    O
and    O
eventually    O
insulin    B-MetabolicDisorder114084502
resistance    I-MetabolicDisorder114084502
,    O
however    O
the    O
exact    O
mechanisms    O
that    O
causes    O
this    O
is    O
yet    O
unknown    O
.    O

In    O
humans    O
,    O
variations    O
in    O
"    O
Lipin"-1    O
expression    O
levels    O
can    O
result    O
in    O
insulin    B-MetabolicDisorder114084502
sensitivity    I-MetabolicDisorder114084502
,    O
hypertension    O
,    O
and    O
risk    O
for    O
metabolic    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
.    O

Diabetes    O
,    O
Metabolic    O
Syndrome    O
and    O
Obesity    O
:    O
Targets    O
and    O
Therapy    O
is    O
a    O
peer    O
-    O
reviewed    O
medical    O
journal    O
covering    O
research    O
on    O
diabetes    O
,    O
metabolic    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
,    O
and    O
obesity    O
.    O

A    O
pilot    O
screening    O
program    O
for    O
four    O
lysosomal    O
storage    O
diseases    O
(    O
Gaucher    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
Pompe    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
Fabry    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
and    O
Niemann-Pick    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
was    O
undertaken    O
using    O
anonymised    O
dried    O
blood    O
spots    O
was    O
completed    O
in    O
Austria    O
in    O
2010    O
.    O

Niemann–Pick    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
is    O
a    O
group    O
of    O
inherited    O
,    O
severe    O
metabolic    O
disorders    O
in    O
which    O
sphingomyelin    O
accumulates    O
in    O
lysosomes    O
in    O
cells    O
.    O

His    O
son    O
Albert    O
Niemann    O
(    O
1880–1921    O
)    O
was    O
the    O
paediatrician    O
who    O
described    O
Niemann–Pick    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

Niemann-Pick    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502

Niemann-Pick    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
Type    O
C    O

N    O
terminus    O
-    O
native    O
gel    O
-    O
nested    O
PCR    O
-    O
neurofibromatosis    O
-    O
nick    O
(    O
DNA    O
)    O
-    O
nick    O
translation    O
-    O
Niemann-Pick    B-MetabolicDisorder114084502
disease,    I-MetabolicDisorder114084502
type    I-MetabolicDisorder114084502
C    I-MetabolicDisorder114084502
-    O
non    O
-    O
coding    O
DNA    O
-    O
non    O
-    O
coding    O
strand    O
-    O
non    O
-    O
directiveness    O
-    O
nonconservative    O
substitution    O
-    O
nonsense    O
codon    O
-    O
nonsense    O
mutation    O
-    O
nontranslated    O
RNA    O
-    O
Northern    O
blot    O
-    O
NT    O
-    O
nuclear    O
run    O
-    O
on    O
-    O
nuclease    O
-    O
nuclease    O
protection    O
assay    O
-    O
nucleoside    O
-    O
nucleotide    O
-    O
nucleus    O
-    O

Niemann    B-MetabolicDisorder114084502
Pick    I-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
Type    O
C    O

Ludwig    O
Pick    O
,    O
see    O
Niemann-Pick    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502

Endocrine    O
disease    O
is    O
characterized    O
by    O
irregulated    O
hormone    O
release    O
(    O
a    O
productive    O
pituitary    O
adenoma    O
)    O
,    O
inappropriate    O
response    O
to    O
signaling    O
(    O
hypothyroidism    O
)    O
,    O
lack    O
of    O
a    O
gland    O
(    O
diabetes    B-MetabolicDisorder114084502
mellitus    I-MetabolicDisorder114084502
type    I-MetabolicDisorder114084502
1    I-MetabolicDisorder114084502
,    O
diminished    O
erythropoiesis    O
in    O
chronic    O
renal    O
failure    O
)    O
,    O
or    O
structural    O
enlargement    O
in    O
a    O
critical    O
site    O
such    O
as    O
the    O
thyroid    O
(    O
toxic    B-MetabolicDisorder114084502
multinodular    I-MetabolicDisorder114084502
goitre    I-MetabolicDisorder114084502
)    O
.    O

Thyrotoxicosis    O
with    O
toxic    B-MetabolicDisorder114084502
multinodular    I-MetabolicDisorder114084502
goitre    I-MetabolicDisorder114084502

The    O
Lesch-Nyhan    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
is    O
also    O
associated    O
with    O
extremely    O
high    O
levels    O
of    O
uric    O
acid    O
.    O

Lesch–Nyhan    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
is    O
first    O
described    O
,    O
by    O
Drs    O
Michael    O
Lesch    O
and    O
William    O
Nyhan    O
.    O

Lesch-Nyhan    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502

Lesch-Nyhan    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502

This    O
disease    O
is    O
now    O
known    O
as    O
the    O
Lesch-Nyhan    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
.    O

Lesch-Nyhan    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502

Many    O
methods    O
ranging    O
from    O
comet    O
assay    O
to    O
the    O
HPRT    B-MetabolicDisorder114084502
gene    O
mutation    O
test    O
have    O
found    O
that    O
metal    O
based    O
NPs    O
disrupt    O
DNA    O
and    O
its    O
replication    O
process    O
in    O
a    O
variety    O
of    O
cells    O
.    O

The    O
damage    O
done    O
to    O
the    O
DNA    O
will    O
often    O
result    O
in    O
mutated    O
cells    O
and    O
colonies    O
as    O
found    O
with    O
the    O
HPRT    B-MetabolicDisorder114084502
gene    O
test    O
.    O

Its    O
incidence    O
is    O
reported    O
as    O
1    O
in    O
100,000    O
,    O
approximately    O
the    O
same    O
as    O
glycogen    B-MetabolicDisorder114084502
storage    I-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
type    I-MetabolicDisorder114084502
I    I-MetabolicDisorder114084502

|    O
GSD    B-MetabolicDisorder114084502
type    I-MetabolicDisorder114084502
I    I-MetabolicDisorder114084502

Von    B-MetabolicDisorder114084502
Gierke    I-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502

Infantile    B-MetabolicDisorder114084502
neuronal    I-MetabolicDisorder114084502
ceroid    I-MetabolicDisorder114084502
lipofuscinoses    I-MetabolicDisorder114084502
(    O
INCL    B-MetabolicDisorder114084502
)    O
or    O
Santavuori    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
or    O
Hagberg-Santavuori    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
or    O
Santavuori-Haltia    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
or    O
Infantile    B-MetabolicDisorder114084502
Finnish    I-MetabolicDisorder114084502
type    I-MetabolicDisorder114084502
neuronal    I-MetabolicDisorder114084502
ceroid    I-MetabolicDisorder114084502
lipofuscinosis    I-MetabolicDisorder114084502
or    O
Balkan    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
is    O
a    O
form    O
of    O
NCL    O
and    O
inherited    O
as    O
a    O
recessive    O
autosomal    O
genetic    O
trait    O
.    O

XY    O
individuals    O
with    O
androgen    B-MetabolicDisorder114084502
insensitivity    I-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
due    O
to    O
a    O
dysfunctional    O
gene    O
for    O
the    O
androgen    O
receptor    O
present    O
as    O
women    O
and    O
have    O
feminine    O
digit    O
ratios    O
,    O
as    O
would    O
be    O
predicted    O
if    O
androgenic    O
hormones    O
affect    O
digit    O
ratios    O
.    O

EIS    O
is    O
analogous    O
to    O
androgen    B-MetabolicDisorder114084502
insensitivity    I-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
(    O
AIS    O
)    O
,    O
a    O
condition    O
in    O
which    O
the    O
androgen    O
receptor    O
(    O
AR    O
)    O
is    O
defective    O
and    O
insensitive    O
to    O
androgens    O
,    O
such    O
as    O
testosterone    O
and    O
dihydrotestosterone    O
(    O
DHT    O
)    O
.    O

Mutations    O
involving    O
the    O
corresponding    O
residue    O
in    O
the    O
AR    O
and    O
MR    O
have    O
previously    O
been    O
associated    O
with    O
androgen    B-MetabolicDisorder114084502
insensitivity    I-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
(    O
AIS    O
)    O
and    O
diminished    O
sensitivity    O
to    O
mineralocorticoids    O
,    O
respectively    O
.    O

In    O
contrast    O
to    O
EIS    O
,    O
androgen    B-MetabolicDisorder114084502
insensitivity    I-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
(    O
AIS    O
)    O
,    O
a    O
condition    O
in    O
which    O
the    O
androgen    O
receptor    O
(    O
AR    O
)    O
is    O
defective    O
,    O
is    O
relatively    O
common    O
.    O

Androgen    B-MetabolicDisorder114084502
insensitivity    I-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
,    O
or    O
"    O
Reifenstein    O
syndrome    O
"    O
,    O
a    O
set    O
of    O
disorders    O
of    O
sex    O
development    O

APOD    O
is    O
a    O
biomarker    O
of    O
androgen    O
insensitivity    O
syndrome    O
(    O
AIS    B-MetabolicDisorder114084502
)    O
.    O

MAIS    O
is    O
one    O
of    O
three    O
types    O
of    O
androgen    B-MetabolicDisorder114084502
insensitivity    I-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
,    O
which    O
is    O
divided    O
into    O
three    O
categories    O
that    O
are    O
differentiated    O
by    O
the    O
degree    O
of    O
genital    O
masculinization    O
:    O
complete    O
androgen    O
insensitivity    O
syndrome    O
(    O
CAIS    O
)    O
is    O
indicated    O
when    O
the    O
external    O
genitalia    O
is    O
that    O
of    O
a    O
normal    O
female    O
,    O
mild    O
androgen    O
insensitivity    O
syndrome    O
(    O
MAIS    O
)    O
is    O
indicated    O
when    O
the    O
external    O
genitalia    O
is    O
that    O
of    O
a    O
normal    O
male    O
,    O
and    O
partial    O
androgen    O
insensitivity    O
syndrome    O
(    O
PAIS    O
)    O
is    O
indicated    O
when    O
the    O
external    O
genitalia    O
is    O
partially    O
,    O
but    O
not    O
fully    O
masculinized    O
.    O

XY    O
individuals    O
with    O
androgen    B-MetabolicDisorder114084502
insensitivity    I-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
(    O
AIS    O
)    O
due    O
to    O
a    O
dysfunctional    O
gene    O
for    O
the    O
androgen    O
receptor    O
present    O
as    O
women    O
and    O
have    O
feminine    O
digit    O
ratios    O
on    O
average    O
,    O
as    O
would    O
be    O
predicted    O
if    O
androgenic    O
hormones    O
affect    O
digit    O
ratios    O
.    O

Because    O
of    O
its    O
endocrine    O
manifestations    O
related    O
to    O
the    O
impairment    O
of    O
the    O
"    O
AR    O
"    O
gene    O
,    O
SBMA    O
can    O
be    O
viewed    O
as    O
a    O
variation    O
of    O
the    O
disorders    O
of    O
the    O
androgen    B-MetabolicDisorder114084502
insensitivity    I-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
(    O
AIS    O
)    O
.    O

The    O
repeat    O
expansion    O
likely    O
causes    O
a    O
toxic    O
gain    O
of    O
function    O
in    O
the    O
receptor    O
protein    O
,    O
since    O
loss    O
of    O
receptor    O
function    O
in    O
androgen    B-MetabolicDisorder114084502
insensitivity    I-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
does    O
not    O
cause    O
motor    O
neuron    O
degeneration    O
.    O

The    O
group    O
is    O
run    O
by    O
volunteers    O
,    O
for    O
people    O
with    O
intersex    O
variations    O
such    O
as    O
androgen    B-MetabolicDisorder114084502
insensitivity    I-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
.    O

Androgen    B-MetabolicDisorder114084502
insensitivity    I-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502

The    O
high    O
concentration    O
of    O
acetaldehyde    O
causes    O
the    O
alcohol    B-MetabolicDisorder114084502
flush    I-MetabolicDisorder114084502
reaction    I-MetabolicDisorder114084502
,    O
colloquially    O
known    O
as    O
the    O
"    O
Asian    O
Flush    O
"    O
.    O

Genetics    O
:    O
alleles    O
associated    O
with    O
aldehyde    O
dehydrogenase    O
(    O
ALDH    O
)    O
and    O
flushing    O
phenotypes    O
(    O
alcohol    B-MetabolicDisorder114084502
flush    I-MetabolicDisorder114084502
reaction    I-MetabolicDisorder114084502
)    O
in    O
Asians    O
are    O
known    O
genetic    O
factors    O
that    O
influence    O
alcohol    O
tolerance    O
and    O
the    O
development    O
of    O
hangover    O
effects    O
.    O

Alcohol    B-MetabolicDisorder114084502
flush    I-MetabolicDisorder114084502
reaction    I-MetabolicDisorder114084502
as    O
a    O
result    O
of    O
the    O
accumulation    O
of    O
acetaldehyde    O
,    O
the    O
first    O
metabolite    O
of    O
alcohol    O
.    O

MODY    O
3    O
is    O
a    O
form    O
of    O
maturity    B-MetabolicDisorder114084502
onset    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
of    I-MetabolicDisorder114084502
the    I-MetabolicDisorder114084502
young    I-MetabolicDisorder114084502
.    O

MODY    O
4    O
is    O
a    O
form    O
of    O
maturity    B-MetabolicDisorder114084502
onset    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
of    I-MetabolicDisorder114084502
the    I-MetabolicDisorder114084502
young    I-MetabolicDisorder114084502
.    O

Renal    O
cysts    O
and    O
diabetes    O
syndrome    O
(    O
RCAD    O
)    O
,    O
also    O
known    O
as    O
MODY    O
5    O
,    O
is    O
a    O
form    O
of    O
maturity    B-MetabolicDisorder114084502
onset    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
of    I-MetabolicDisorder114084502
the    I-MetabolicDisorder114084502
young    I-MetabolicDisorder114084502
.    O

This    O
disease    O
is    O
considered    O
to    O
be    O
a    O
type    O
of    O
maturity    B-MetabolicDisorder114084502
onset    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
of    I-MetabolicDisorder114084502
the    I-MetabolicDisorder114084502
young    I-MetabolicDisorder114084502
(    O
MODY    O
)    O
.    O

This    O
disease    O
is    O
considered    O
to    O
be    O
a    O
type    O
of    O
maturity    B-MetabolicDisorder114084502
onset    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
of    I-MetabolicDisorder114084502
the    I-MetabolicDisorder114084502
young    I-MetabolicDisorder114084502
(    O
MODY    O
)    O
.    O

B-mannosidase    B-MetabolicDisorder114084502
deficiency    I-MetabolicDisorder114084502

Beta-mannosidosis    B-MetabolicDisorder114084502

Waardenburg    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
is    O
named    O
after    O
him    O
.    O

Waardenburg    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
,    O
or    O
more    O
fully    O
,    O
the    O
van    O
der    O
Hoeve    O
-    O
Halbertsma    O
-    O
Waardenburg    O
-    O
Klein    O
syndrome    O
,    O
is    O
a    O
rare    O
genetic    O
disorder    O
most    O
often    O
characterized    O
by    O
varying    O
degrees    O
of    O
deafness    O
,    O
minor    O
defects    O
in    O
structures    O
arising    O
from    O
the    O
neural    O
crest    O
,    O
and    O
pigmentation    O
anomalies    O
.    O

Klein    O
made    O
contributions    O
towards    O
the    O
understanding    O
of    O
Waardenburg    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
,    O
or    O
more    O
fully    O
,    O
the    O
"    O
van    O
der    O
Hoeve    O
-    O
Halbertsma    O
-    O
Waardenburg    O
-    O
Klein    O
syndrome    O
"    O
.    O

An    O
auditory    O
-    O
pigmentation    O
disorder    O
in    O
humans    O
,    O
Waardenberg    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
,    O
reflects    O
some    O
of    O
the    O
problems    O
associated    O
with    O
heterozygous    O
and    O
homozygous    O
merle    O
dogs    O
and    O
genetic    O
research    O
in    O
dogs    O
has    O
been    O
undertaken    O
with    O
the    O
goal    O
of    O
better    O
understanding    O
the    O
genetic    O
basis    O
of    O
this    O
human    O
condition    O
.    O

Waardenburg    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
(    O
ILDS    O
E70.320    O
)    O

Waardenburg    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502

Waardenburg    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
,    O
a    O
genetic    O
disorder    O

Waardenburg    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
,    O
a    O
genetic    O
disorder    O

WS2B    O
is    O
a    O
gene    O
associated    O
with    O
Waardenburg    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
.    O

Historically    O
,    O
there    O
were    O
two    O
cases    O
of    O
Tangier    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
a    O
recessive    O
genetic    O
disorder    O
which    O
causes    O
high    O
blood    O
cholesterol    O
,    O
which    O
,    O
following    O
discovery    O
,    O
was    O
named    O
after    O
the    O
island    O
.    O

Tangier    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502

Defects    O
in    O
the    O
gene    O
encoding    O
it    O
are    O
associated    O
with    O
HDL    O
deficiencies    O
,    O
including    O
Tangier    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
and    O
with    O
systemic    O
non    O
-    O
neuropathic    O
amyloidosis    O
.    O

BAL    O
may    O
reveal    O
alternative    O
specific    O
diagnoses    O
:    O
malignancy    O
,    O
infections    O
,    O
eosinophilic    O
pneumonia    O
,    O
histiocytosis    O
X    O
,    O
or    O
alveolar    B-MetabolicDisorder114084502
proteinosis    I-MetabolicDisorder114084502
.    O

Endogenous    O
lipoid    O
pneumonia    O
and    O
non    O
-    O
specific    O
interstitial    O
pneumonitis    O
has    O
been    O
seen    O
prior    O
to    O
the    O
development    O
of    O
pulmonary    B-MetabolicDisorder114084502
alveolar    I-MetabolicDisorder114084502
proteinosis    I-MetabolicDisorder114084502
in    O
a    O
child    O
.    O

Pulmonary    B-MetabolicDisorder114084502
alveolar    I-MetabolicDisorder114084502
proteinosis    I-MetabolicDisorder114084502

The    O
serum    O
anion    B-MetabolicDisorder114084502
gap    I-MetabolicDisorder114084502
is    O
useful    O
for    O
determining    O
whether    O
a    O
base    O
deficit    O
is    O
caused    O
by    O
addition    O
of    O
acid    O
or    O
loss    O
of    O
bicarbonate    O
.    O

A    O
low    O
serum    O
anion    B-MetabolicDisorder114084502
gap    I-MetabolicDisorder114084502
is    O
frequently    O
caused    O
by    O
hypoalbuminemia    O
.    O

|    O
anion    B-MetabolicDisorder114084502
gap    I-MetabolicDisorder114084502

Insulin-dependent    B-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
mellitus    I-MetabolicDisorder114084502

Chromosomal    O
rearrangements    O
and    O
altered    O
expression    O
of    O
this    O
gene    O
have    O
been    O
implicated    O
in    O
several    O
neurological    O
,    O
neoplastic    O
,    O
and    O
other    O
types    O
of    O
diseases    O
,    O
including    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
Down    O
's    O
syndrome    O
,    O
epilepsy    O
,    O
amyotrophic    O
lateral    O
sclerosis    O
,    O
schwannoma    O
,    O
melanoma    O
,    O
and    O
type    B-MetabolicDisorder114084502
I    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
.    O

Roquinimex    O
has    O
been    O
investigated    O
as    O
a    O
treatment    O
for    O
some    O
cancers    O
(    O
including    O
as    O
adjuvant    O
therapy    O
after    O
bone    O
marrow    O
transplantation    O
in    O
acute    O
leukemia    O
)    O
and    O
autoimmune    O
diseases    O
,    O
such    O
as    O
multiple    O
sclerosis    O
and    O
recent    O
-    O
onset    O
type    B-MetabolicDisorder114084502
I    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
.    O

Fuld    O
was    O
diagnosed    O
with    O
type    B-MetabolicDisorder114084502
1    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
at    O
the    O
age    O
of    O
10    O
.    O

Fuld    O
was    O
diagnosed    O
with    O
Type    B-MetabolicDisorder114084502
1    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
when    O
he    O
was    O
10    O
years    O
old    O
.    O

It    O
incorporates    O
a    O
compartmental    O
model    O
that    O
describes    O
glucose    O
-    O
insulin    O
interaction    O
in    O
people    O
completely    O
lacking    O
endogenous    O
insulin    O
secretion    O
—    O
i.e.    O
insulin    O
-    O
dependent    O
patients    O
with    O
type    B-MetabolicDisorder114084502
1    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
mellitus    I-MetabolicDisorder114084502
.    O

The    O
AIDA    O
software    O
comes    O
with    O
forty    O
educational    O
case    O
scenarios    O
as    O
standard    O
,    O
each    O
of    O
which    O
represents    O
a    O
'    O
snapshot    O
'    O
of    O
the    O
metabolic    O
status    O
of    O
a    O
typical    O
person    O
with    O
respect    O
to    O
insulin    O
-    O
dependent    O
type    B-MetabolicDisorder114084502
1    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
mellitus    I-MetabolicDisorder114084502
.    O

Two    O
cases    O
demonstrated    O
glycemic    O
effects    O
and    O
pharmacokinetics    O
of    O
insulin    O
administration    O
,    O
diet    O
,    O
and    O
exercise    O
in    O
insulin    O
-    O
dependent    O
type    B-MetabolicDisorder114084502
1    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
mellitus    I-MetabolicDisorder114084502
and    O
non    O
-    O
insulin    O
-    O
dependent    O
type    B-MetabolicDisorder114084502
2    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
mellitus    I-MetabolicDisorder114084502
.    O

Twenty    O
-    O
four    O
volunteers    O
(    O
12    O
male    O
and    O
12    O
female    O
)    O
with    O
type    B-MetabolicDisorder114084502
1    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
of    O
more    O
than    O
6-years    O
duration    O
,    O
aged    O
19–48    O
years    O
,    O
who    O
gave    O
written    O
informed    O
consent    O
,    O
were    O
randomly    O
assigned    O
to    O
one    O
of    O
two    O
study    O
groups    O
,    O
each    O
receiving    O
different    O
teaching    O
interventions    O
.    O

The    O
plasma    O
protein    O
which    O
led    O
to    O
the    O
distinction    O
between    O
type    B-MetabolicDisorder114084502
1    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
and    O
type    B-MetabolicDisorder114084502
2    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
was    O
discovered    O
by    O
Baker    O
scientists    O

There    O
are    O
thought    O
to    O
be    O
two    O
types    O
of    O
diabetes    O
-    O
type    B-MetabolicDisorder114084502
2    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
,    O
due    O
to    O
metaboliccauses    O
,    O
and    O
Type    B-MetabolicDisorder114084502
1    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
(    O
T1D    O
)    O
.    O

Priscilla    O
White    O
(    O
March    O
17    O
,    O
1900    O
–    O
December    O
16    O
,    O
1989    O
)    O
was    O
a    O
pioneer    O
in    O
the    O
treatment    O
of    O
diabetes    O
during    O
pregnancy    O
and    O
type    B-MetabolicDisorder114084502
1    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
,    O
and    O
was    O
also    O
a    O
founding    O
member    O
of    O
the    O
Joslin    O
Diabetes    O
Center    O
.    O

Delta    O
Epsilon    O
Psi    O
's    O
philanthropies    O
are    O
research    O
towards    O
curing    O
juvenile    B-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
(    O
type    O
1    O
diabetes    O
)    O
through    O
the    O
Juvenile    O
Diabetes    O
Research    O
Foundation    O
(    O
JDRF    O
)    O
,    O
and    O
supporting    O
the    O
National    O
Marrow    O
Donor    O
Program    O
.    O

When    O
Garber    O
was    O
twelve    O
,    O
he    O
was    O
diagnosed    O
with    O
type    B-MetabolicDisorder114084502
1    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
.    O

The    O
title    O
of    O
the    O
album    O
,    O
"    O
A    O
Little    O
Bit    O
Longer    O
"    O
,    O
comes    O
from    O
their    O
song    O
of    O
the    O
same    O
name    O
,    O
which    O
Nick    O
Jonas    O
wrote    O
about    O
his    O
feelings    O
with    O
having    O
type    B-MetabolicDisorder114084502
1    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
.    O

Shortly    O
after    O
this    O
,    O
Morrison    O
was    O
diagnosed    O
with    O
type    B-MetabolicDisorder114084502
1    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
.    O

Morrison    O
was    O
diagnosed    O
with    O
type    B-MetabolicDisorder114084502
1    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
(    O
insulin    O
-    O
dependent    O
diabetes    O
)    O
at    O
age    O
13    O
.    O

At    O
the    O
age    O
of    O
23    O
,    O
six    O
years    O
after    O
signing    O
with    O
the    O
Brisbane    O
Broncos    O
,    O
Renouf    O
was    O
diagnosed    O
with    O
type    B-MetabolicDisorder114084502
1    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
.    O

NK    O
cell    O
dysregulation    O
has    O
been    O
implicated    O
in    O
a    O
number    O
of    O
autoimmune    O
disorders    O
including    O
multiple    O
sclerosis    O
,    O
systemic    O
lupus    O
erythematosus    O
,    O
and    O
type    B-MetabolicDisorder114084502
I    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
mellitus    I-MetabolicDisorder114084502
.    O

Type    O
1    O
Diabetes    O
Mellitus    O
Nocturnal    O
enuresis    O
could    O
be    O
the    O
presenting    O
symptom    O
of    O
type    B-MetabolicDisorder114084502
1    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
mellitus    I-MetabolicDisorder114084502
,    O
classically    O
associated    O
with    O
polyuria    O
,    O
polydipsia    O
,    O
and    O
polyphagia    O
;    O
weight    O
loss    O
,    O
lethargy    O
,    O
and    O
diaper    O
candidiasis    O
may    O
also    O
be    O
present    O
in    O
those    O
with    O
new    O
-    O
onset    O
disease    O
.    O

The    O
disease    O
seems    O
to    O
be    O
more    O
prevalent    O
in    O
African    O
Americans    O
,    O
which    O
can    O
be    O
correlated    O
to    O
the    O
high    O
incidence    O
of    O
diabetes    B-MetabolicDisorder114084502
mellitus    I-MetabolicDisorder114084502
and    O
renal    O
failure    O
in    O
the    O
population    O
.    O

Some    O
common    O
diseases    O
that    O
are    O
generally    O
considered    O
autoimmune    O
include    O
celiac    O
disease    O
,    O
diabetes    B-MetabolicDisorder114084502
mellitus    I-MetabolicDisorder114084502
type    I-MetabolicDisorder114084502
1    I-MetabolicDisorder114084502
,    O
Graves    O
'    O
disease    O
,    O
inflammatory    O
bowel    O
disease    O
,    O
multiple    O
sclerosis    O
,    O
psoriasis    O
,    O
rheumatoid    O
arthritis    O
,    O
and    O
systemic    O
lupus    O
erythematosus    O
.    O

He    O
is    O
best    O
known    O
for    O
publishing    O
research    O
concluding    O
that    O
vaccines    O
,    O
in    O
particular    O
the    O
Hib    O
vaccine    O
,    O
cause    O
insulin-dependent    B-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
mellitus    I-MetabolicDisorder114084502
,    O
a    O
hypothesis    O
he    O
proposed    O
based    O
on    O
experiments    O
he    O
conducted    O
on    O
mice    O
in    O
1996    O
.    O

Autoimmunity    O
has    O
been    O
the    O
accepted    O
explanation    O
for    O
type    B-MetabolicDisorder114084502
1    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
(    O
T1D    O
)    O
for    O
40    O
years    O
,    O
but    O
clinical    O
trials    O
of    O
immunotherapy    O
have    O
proved    O
disappointing    O
,    O
and    O
have    O
not    O
provided    O
a    O
means    O
of    O
prevention    O
.    O

This    O
results    O
in    O
type    B-MetabolicDisorder114084502
1    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
mellitus    I-MetabolicDisorder114084502
,    O
which    O
is    O
characterized    O
by    O
abnormally    O
high    O
blood    O
glucose    O
concentrations    O
,    O
and    O
generalized    O
body    O
wasting    O
.    O

Type    B-MetabolicDisorder114084502
1    I-MetabolicDisorder114084502
–    O
autoimmune    O
-    O
mediated    O
destruction    O
of    O
insulin    O
-    O
producing    O
β-cells    O
in    O
the    O
pancreas    O
,    O
resulting    O
in    O
absolute    O
insulin    O
deficiency    O

Diabetes    B-MetabolicDisorder114084502
mellitus    I-MetabolicDisorder114084502
type    I-MetabolicDisorder114084502
1    I-MetabolicDisorder114084502

It    O
was    O
approved    O
by    O
the    O
US    O
FDA    O
in    O
September    O
2016    O
and    O
was    O
the    O
first    O
approved    O
hybrid    O
closed    O
loop    O
system    O
which    O
senses    O
a    O
diabetic    B-MetabolicDisorder114084502
person    O
's    O
basal    O
insulin    O
requirement    O
and    O
automatically    O
adjusts    O
its    O
delivery    O
to    O
the    O
body    O
.    O

continued    O
beta    O
cell    O
death    O
following    O
diagnosis    O
of    O
type    O
1    O
diabetes    O
(    O
honeymoon    B-MetabolicDisorder114084502
period    I-MetabolicDisorder114084502
)    O

Many    O
diabetes    O
specialists    O
no    O
longer    O
think    O
of    O
flexible    O
insulin    O
therapy    O
as    O
"    O
intensive    O
"    O
or    O
"    O
special    O
"    O
treatment    O
for    O
a    O
select    O
group    O
of    O
patients    O
but    O
simply    O
as    O
standard    O
care    O
for    O
most    O
patients    O
with    O
type    B-MetabolicDisorder114084502
1    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
.    O

Common    O
autoimmune    O
diseases    O
include    O
Hashimoto    O
's    O
thyroiditis    O
,    O
rheumatoid    O
arthritis    O
,    O
diabetes    B-MetabolicDisorder114084502
mellitus    I-MetabolicDisorder114084502
type    I-MetabolicDisorder114084502
1    I-MetabolicDisorder114084502
,    O
and    O
systemic    O
lupus    O
erythematosus    O
.    O

Ragan    O
is    O
a    O
type    B-MetabolicDisorder114084502
1    I-MetabolicDisorder114084502
diabetic    I-MetabolicDisorder114084502
,    O
which    O
he    O
was    O
diagnosed    O
with    O
in    O
the    O
1970s    O
.    O

As    O
an    O
adult    O
,    O
Escrivá    O
suffered    O
from    O
type    B-MetabolicDisorder114084502
1    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
and    O
,    O
according    O
to    O
some    O
sources    O
,    O
also    O
epilepsy    O
.    O

Domi    O
has    O
Type    B-MetabolicDisorder114084502
1    I-MetabolicDisorder114084502
Diabetes    I-MetabolicDisorder114084502
which    O
he    O
was    O
diagnosed    O
at    O
age    O
12    O
following    O
a    O
hockey    O
tournament    O
in    O
Detroit    O
.    O

This    O
reaction    O
is    O
over    O
-    O
activated    O
in    O
patients    O
with    O
diabetes    B-MetabolicDisorder114084502
mellitus    I-MetabolicDisorder114084502
type    I-MetabolicDisorder114084502
1    I-MetabolicDisorder114084502
if    O
left    O
untreated    O
,    O
due    O
to    O
prolonged    O
insulin    O
deficiency    O
and    O
the    O
exhaustion    O
of    O
substrates    O
for    O
gluconeogenesis    O
and    O
the    O
TCA    O
cycle    O
,    O
notably    O
oxaloacetate    O
.    O

"    O
Biobreeding    O
diabetes    O
-    O
prone    O
rat    O
"    O
(    O
a.k.a    O
.    O
biobreeding    O
rat    O
or    O
BBDP    O
rat    O
)    O
is    O
an    O
inbred    O
strain    O
that    O
spontaneously    O
develops    O
autoimmune    O
type    B-MetabolicDisorder114084502
1    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
.    O

Women    O
with    O
type    B-MetabolicDisorder114084502
I    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
mellitus    I-MetabolicDisorder114084502
have    O
a    O
threefold    O
increase    O
in    O
the    O
prevalence    O
of    O
postpartum    O
thyroiditis    O
than    O
non    O
-    O
diabetic    O
women    O
in    O
the    O
same    O
region    O
.    O

Major    O
diseases    O
being    O
modelized    O
with    O
PSCs    O
-    O
derived    O
cells    O
are    O
amyotrophic    O
lateral    O
sclerosis    O
(    O
ALS    O
)    O
,    O
Alzheimer's    B-MetabolicDisorder114084502
(    O
AD    O
)    O
,    O
Parkinson    O
's    O
(    O
PD    O
)    O
,    O
fragile    O
X    O
syndrome    O
(    O
FXS    O
)    O
,    O
Huntington    O
disease    O
(    O
HD    O
)    O
,    O
Down    O
syndrome    O
,    O
Spinal    O
muscular    O
atrophy    O
(    O
SMA    O
)    O
,    O
muscular    O
dystrophies    O
,    O
cystic    O
fibrosis    O
,    O
Long    O
QT    O
syndrome    O
,    O
and    O
Type    B-MetabolicDisorder114084502
I    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
.    O

Diabetes    B-MetabolicDisorder114084502
Type    I-MetabolicDisorder114084502
I    I-MetabolicDisorder114084502
:    O
0.13(0.030    O
)    O
,    O
0.28    O
(    O
0.04    O
)    O
,    O
0.73(0.06    O
)    O
,    O
0.13    O
(    O
0.030    O
)    O

Elizabeth    O
developed    O
diabetes    B-MetabolicDisorder114084502
in    O
1918    O
at    O
age    O
11    O
.    O

In    O
2010    O
the    O
MTG    O
made    O
a    O
Freedom    O
of    O
Information    O
request    O
to    O
Primary    O
Care    O
Trusts    O
in    O
England    O
on    O
the    O
provision    O
of    O
insulin    O
pumps    O
to    O
patients    O
with    O
Type    B-MetabolicDisorder114084502
1    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
.    O

On    O
28    O
September    O
2012    O
,    O
she    O
announced    O
that    O
she    O
had    O
been    O
diagnosed    O
with    O
type    B-MetabolicDisorder114084502
1    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
after    O
collapsing    O
while    O
on    O
a    O
trip    O
to    O
Barcelona    O
,    O
Spain    O
.    O

Diabetes    B-MetabolicDisorder114084502
mellitus    I-MetabolicDisorder114084502
type    I-MetabolicDisorder114084502
1    I-MetabolicDisorder114084502

Note    O
:    O
The    O
females    O
were    O
scheduled    O
to    O
go    O
first    O
,    O
but    O
medical    O
issues    O
with    O
Crystal    O
Bowersox    O
,    O
who    O
was    O
hospitalized    O
on    O
March    O
2    O
with    O
complications    O
from    O
diabetes    B-MetabolicDisorder114084502
,    O
required    O
a    O
switch    O
.    O

She    O
was    O
diagnosed    O
with    O
Type    B-MetabolicDisorder114084502
1    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
when    O
she    O
was    O
six    O
,    O
and    O
while    O
on    O
the    O
show    O
,    O
she    O
suffered    O
diabetic    O
complication    O
and    O
was    O
hospitalized    O
which    O
resulted    O
in    O
the    O
Top    O
20    O
performance    O
nights    O
for    O
the    O
male    O
and    O
female    O
contestants    O
being    O
switched    O
.    O

629    O
patients    O
with    O
type    B-MetabolicDisorder114084502
1    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
were    O
randomized    O
in    O
a    O
3:1    O
ratio    O
to    O
either    O
insulin    O
degludec    O
(    O
n=472    O
)    O
or    O
insulin    O
glargine    O
(    O
n=157    O
)    O
in    O
addition    O
to    O
mealtime    O
insulin    O
aspart    O
.    O

The    O
Network    O
for    O
Pancreatic    O
Organ    O
donors    O
with    O
Diabetes    O
(    O
nPOD    O
)    O
,    O
is    O
a    O
collaborative    O
type    B-MetabolicDisorder114084502
1    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
research    O
project    O
funded    O
by    O
JDRF    O
(    O
formerly    O
known    O
as    O
the    O
Juvenile    O
Diabetes    O
Research    O
Foundation    O
)    O
.    O

Mark    O
Atkinson    O
,    O
Ph.D.    O
(    O
born    O
March    O
27    O
,    O
1961    O
)    O
is    O
a    O
medical    O
researcher    O
best    O
known    O
for    O
his    O
contributions    O
to    O
research    O
seeking    O
to    O
predict    O
,    O
prevent    O
,    O
and    O
cure    O
type    B-MetabolicDisorder114084502
1    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
.    O

Moreover    O
,    O
the    O
trans    O
-    O
differentiated    O
beta    O
-    O
like    O
cells    O
were    O
found    O
to    O
be    O
resistant    O
to    O
the    O
autoimmune    O
attack    O
that    O
characterizes    O
type    B-MetabolicDisorder114084502
1    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
.    O

Canyon    O
was    O
diagnosed    O
with    O
type    B-MetabolicDisorder114084502
1    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
at    O
the    O
age    O
of    O
14    O
and    O
has    O
given    O
talks    O
to    O
children    O
about    O
diabetes    O
.    O

He    O
is    O
currently    O
living    O
with    O
type    B-MetabolicDisorder114084502
1    I-MetabolicDisorder114084502
diabetes    O
,    O
and    O
has    O
been    O
an    O
endorser    O
for    O
several    O
wellness    O
products    O
related    O
to    O
the    O
condition    O
.    O

He    O
has    O
had    O
Type    B-MetabolicDisorder114084502
1    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
since    O
his    O
early    O
20s    O
.    O

Hyperglycemia    O
-    O
induced    O
involuntary    O
movements    O
(    O
in    O
this    O
case    O
,    O
not    O
hemiballismus    O
,    O
but    O
hemichorea    O
(    O
chorea    O
of    O
one    O
side    O
of    O
the    O
body    O
)    O
and    O
bilateral    O
dystonia    O
)    O
in    O
a    O
62-year    O
-    O
old    O
Japanese    O
woman    O
with    O
type    B-MetabolicDisorder114084502
1    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
.    O

80    O
percent    O
of    O
people    O
with    O
diabetes    O
live    O
in    O
developing    O
countries    O
and    O
in    O
2011    O
,    O
diabetes    O
caused    O
4.6    O
million    O
deaths    O
and    O
approximately    O
78,000    O
children    O
were    O
diagnosed    O
with    O
type    B-MetabolicDisorder114084502
1    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
.    O

Roughly    O
8.4%    O
of    O
adults    O
are    O
suffering    O
from    O
the    O
effects    O
of    O
this    O
disease    O
,    O
which    O
caused    O
622,114    O
deaths    O
in    O
the    O
region    O
this    O
year.33    O
IDF    O
studies    O
have    O
also    O
concluded    O
that    O
Europe    O
has    O
the    O
highest    O
number    O
of    O
children    O
with    O
type    B-MetabolicDisorder114084502
1    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
.    O

Loss    O
of    O
function    O
mutations    O
in    O
SIAE    O
are    O
much    O
more    O
frequently    O
found    O
in    O
humans    O
with    O
autoimmune    O
diseases    O
especially    O
rheumatoid    O
arthritis    O
and    O
type    B-MetabolicDisorder114084502
1    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
.    O

Norton    O
has    O
type    B-MetabolicDisorder114084502
1    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
.    O

Santiago    O
was    O
diagnosed    O
with    O
type    B-MetabolicDisorder114084502
1    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
at    O
a    O
young    O
age    O
.    O

Study    O
of    O
Kv1.3    O
blockers    O
such    O
as    O
HsTx1    O
could    O
lead    O
to    O
new    O
treatments    O
to    O
autoimmune    O
disorders    O
such    O
as    O
Multiple    O
Sclerosis    O
,    O
Rheumatoid    O
Arthritis    O
and    O
Type    B-MetabolicDisorder114084502
1    I-MetabolicDisorder114084502
Diabetes    I-MetabolicDisorder114084502
.    O

Hyperglycemia    O
-    O
induced    O
involuntary    O
movements    O
(    O
hemichorea    O
and    O
bilateral    O
dystonia    O
)    O
in    O
a    O
62-year    O
-    O
old    O
Japanese    O
woman    O
with    O
type    B-MetabolicDisorder114084502
1    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
.    O

Due    O
to    O
its    O
exclusive    O
expression    O
in    O
the    O
kidney    O
,    O
research    O
has    O
focused    O
on    O
understanding    O
the    O
potential    O
role    O
of    O
both    O
myo    O
-    O
inositol    O
levels    O
and    O
MIOX    O
activity    O
on    O
metabolic    O
diseases    O
like    O
diabetes    B-MetabolicDisorder114084502
mellitus    I-MetabolicDisorder114084502
and    O
obesity    O
.    O

Individuals    O
susceptible    O
to    O
AIS6    O
may    O
suffer    O
from    O
rheumatoid    O
arthritis    O
,    O
multiple    O
sclerosis    O
,    O
lupus    O
erythematosus    O
,    O
type    B-MetabolicDisorder114084502
1    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
,    O
and    O
other    O
autoimmune    O
diseases    O
.    O

This    O
results    O
in    O
congenital    O
impairment    O
of    O
insulin    O
release    O
,    O
although    O
in    O
the    O
past    O
,    O
this    O
was    O
always    O
being    O
thought    O
to    O
be    O
unusually    O
early    O
type    B-MetabolicDisorder114084502
1    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
mellitus    I-MetabolicDisorder114084502
.    O

A    O
person    O
with    O
type    B-MetabolicDisorder114084502
1    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
should    O
balance    O
insulin    O
delivery    O
to    O
manage    O
their    O
blood    O
glucose    O
level    O
.    O

In    O
2003    O
,    O
Van    O
de    O
Goor    O
was    O
diagnosed    O
with    O
type    B-MetabolicDisorder114084502
1    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
.    O

His    O
contributions    O
to    O
biology    O
include    O
numerous    O
researches    O
in    O
genetic    O
predisposition    O
to    O
diseases    O
such    O
as    O
type    B-MetabolicDisorder114084502
1    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
and    O
β-thalassemia    O
.    O

The    O
Walter    O
and    O
Eliza    O
Hall    O
Institute    O
of    O
Medical    O
Research    O
,    O
more    O
commonly    O
known    O
as    O
the    O
Walter    O
and    O
Eliza    O
Hall    O
Institute    O
,    O
abbreviated    O
as    O
WEHI    O
,    O
is    O
Australia    O
's    O
oldest    O
medical    O
research    O
institute    O
.    O
,    O
the    O
institute    O
hosted    O
more    O
than    O
750    O
researchers    O
who    O
work    O
to    O
understand    O
,    O
prevent    O
and    O
treat    O
diseases    O
including    O
blood    O
,    O
breast    O
and    O
ovarian    O
cancers    O
;    O
inflammatory    O
diseases    O
(    O
autoimmunity    O
)    O
such    O
as    O
rheumatoid    O
arthritis    O
,    O
type    B-MetabolicDisorder114084502
1    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
and    O
coeliac    O
disease    O
;    O
and    O
infectious    O
diseases    O
such    O
as    O
malaria    O
,    O
HIV    O
and    O
hepatitis    O
B    O
and    O
C.    O

CXCR3    O
has    O
been    O
implicated    O
in    O
the    O
following    O
diseases    O
,    O
atherosclerosis    O
,    O
multiple    O
sclerosis    O
,    O
pulmonary    O
fibrosis    O
,    O
type    B-MetabolicDisorder114084502
1    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
,    O
autoimmune    O
myasthenia    O
gravis    O
,    O
nephrotoxic    O
nephritis    O
,    O
acute    O
cardiac    O
allograft    O
rejection    O
and    O
possibly    O
Celiac    O
Disease    O
.    O

Scientists    O
successfully    O
cure    O
type    B-MetabolicDisorder114084502
1    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
in    O
dogs    O
using    O
a    O
pioneering    O
gene    O
therapy    O
.    O

They    O
observe    O
the    O
coincidence    O
of    O
carbohydrate    O
rich    O
diets    O
with    O
the    O
obesity    O
and    O
insulin    B-MetabolicDisorder114084502
resistant    I-MetabolicDisorder114084502
diabetes    B-MetabolicDisorder114084502
epidemics    O
of    O
the    O
last    O
5    O
decades    O
,    O
both    O
risk    O
factors    O
for    O
cardiovascular    O
disease    O
.    O

Patients    O
with    O
Alzheimer's    B-MetabolicDisorder114084502
,    O
rheumatoid    O
arthritis    O
,    O
type    B-MetabolicDisorder114084502
2    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
and    O
other    O
amyloid    O
-    O
related    O
diseases    O
should    O
not    O
eat    O
it    O
.    O

α-hydroxybutyrate    O
may    O
be    O
useful    O
as    O
an    O
early    O
indicator    O
of    O
insulin    B-MetabolicDisorder114084502
resistance    I-MetabolicDisorder114084502
in    O
non-diabetic    B-MetabolicDisorder114084502
subjects    O
.    O

Resistin    O
is    O
an    O
adipose    O
-    O
derived    O
hormone    O
(    O
similar    O
to    O
a    O
cytokine    O
)    O
whose    O
physiologic    O
role    O
has    O
been    O
the    O
subject    O
of    O
much    O
controversy    O
regarding    O
its    O
involvement    O
with    O
obesity    O
and    O
type    O
II    O
diabetes    O
mellitus    O
(    O
T2DM    B-MetabolicDisorder114084502
)    O
.    O

They    O
are    O
antidiabetic    O
drugs    O
widely    O
used    O
in    O
the    O
management    O
of    O
diabetes    O
mellitus    O
type    B-MetabolicDisorder114084502
2    I-MetabolicDisorder114084502
.    O

Bromocriptine    O
(    O
originally    O
marketed    O
as    O
Parlodel    O
,    O
subsequently    O
under    O
many    O
names    O
)    O
is    O
an    O
ergoline    O
derivative    O
,    O
is    O
a    O
dopamine    O
agonist    O
that    O
is    O
used    O
in    O
the    O
treatment    O
of    O
pituitary    O
tumors    O
,    O
Parkinson    O
's    O
disease    O
(    O
PD    O
)    O
,    O
hyperprolactinaemia    O
,    O
neuroleptic    O
malignant    O
syndrome    O
,    O
and    O
type    B-MetabolicDisorder114084502
2    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
.    O

A    O
quick    O
-    O
release    O
formulation    O
of    O
bromocriptine    O
is    O
also    O
used    O
to    O
treat    O
type    B-MetabolicDisorder114084502
2    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
.    O

Several    O
other    O
classes    O
of    O
amyloid    O
proteins    O
also    O
form    O
ion    O
channels    O
,    O
including    O
proteins    O
implicated    O
in    O
type    B-MetabolicDisorder114084502
II    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
mellitus    I-MetabolicDisorder114084502
,    O
prion    O
diseases    O
,    O
Parkinson    O
's    O
disease    O
,    O
and    O
Huntington    O
's    O
disease    O
.    O

This    O
field    O
has    O
shown    O
promise    O
in    O
clinical    O
applications    O
,    O
including    O
the    O
treatment    O
of    O
human    O
eye    O
diseases    O
such    O
as    O
retinitis    O
pigmentosa    O
and    O
diabetes    B-MetabolicDisorder114084502
.    O

In    O
a    O
paper    O
published    O
by    O
Ye    O
and    O
colleagues    O
in    O
2011    O
,    O
melanopsin    O
was    O
utilized    O
to    O
create    O
an    O
optogenetic    O
synthetic    O
transcription    O
device    O
that    O
was    O
tested    O
in    O
a    O
therapeutic    O
setting    O
to    O
produce    O
glucagon    O
-    O
like    O
peptide    O
1    O
(    O
GLP-1    O
)    O
,    O
a    O
protein    O
that    O
helps    O
control    O
blood    O
glucose    O
levels    O
in    O
mammals    O
with    O
Type    B-MetabolicDisorder114084502
II    I-MetabolicDisorder114084502
Diabetes    I-MetabolicDisorder114084502
.    O

GSK-3    O
has    O
recently    O
been    O
the    O
subject    O
of    O
much    O
research    O
because    O
it    O
has    O
been    O
implicated    O
in    O
a    O
number    O
of    O
diseases    O
,    O
including    O
Type    O
II    O
diabetes    O
(    O
Diabetes    B-MetabolicDisorder114084502
mellitus    I-MetabolicDisorder114084502
type    I-MetabolicDisorder114084502
2    I-MetabolicDisorder114084502
)    O
,    O
Alzheimer's    B-MetabolicDisorder114084502
Disease    I-MetabolicDisorder114084502
,    O
inflammation    O
,    O
cancer    O
,    O
and    O
bipolar    O
disorder    O
.    O

GSK-3    O
inhibitors    O
are    O
currently    O
being    O
tested    O
for    O
therapeutic    O
effects    O
in    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
type    B-MetabolicDisorder114084502
2    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
mellitus    I-MetabolicDisorder114084502
(    O
T2DM    O
)    O
,    O
some    O
forms    O
of    O
cancer    O
,    O
and    O
bipolar    O
disorder    O
.    O

Non-insulin-dependent    B-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
mellitus    I-MetabolicDisorder114084502

A    O
2007–2008    O
study    O
revealed    O
that    O
the    O
rate    O
of    O
type    B-MetabolicDisorder114084502
2    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
is    O
among    O
the    O
highest    O
in    O
the    O
world    O
;    O
28%    O
over    O
the    O
age    O
of    O
15    O
;    O
50%    O
over    O
35    O
.    O

The    O
cause    O
of    O
his    O
death    O
,    O
according    O
to    O
Antonio    O
López    O
Alonso    O
,    O
a    O
modern    O
physician    O
who    O
has    O
examined    O
the    O
surviving    O
documentation    O
,    O
was    O
type-2    B-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
,    O
a    O
result    O
of    O
a    O
cirrhosis    O
of    O
the    O
liver    O
.    O

Type    B-MetabolicDisorder114084502
II    I-MetabolicDisorder114084502
Diabetes    I-MetabolicDisorder114084502

Mitiglinide    O
(    O
INN    O
,    O
trade    O
name    O
Glufast    O
)    O
is    O
a    O
drug    O
for    O
the    O
treatment    O
of    O
type    B-MetabolicDisorder114084502
2    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
.    O

It    O
has    O
been    O
associated    O
with    O
an    O
extensive    O
number    O
of    O
cancers    O
,    O
neurodegenerative    O
diseases    O
,    O
cell    O
senescence    O
and    O
aging    O
,    O
and    O
inflammatory    O
diseases    O
such    O
as    O
Diabetes    B-MetabolicDisorder114084502
mellitus    I-MetabolicDisorder114084502
type    I-MetabolicDisorder114084502
2    I-MetabolicDisorder114084502
and    O
rheumatoid    O
arthritis    O
.    O

Complications    O
of    O
the    O
disease    O
may    O
include    O
type    B-MetabolicDisorder114084502
2    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
,    O
sleep    O
apnea    O
,    O
and    O
high    O
blood    O
pressure    O
.    O

On    O
April    O
7    O
,    O
2015    O
,    O
Peterson    O
revealed    O
he    O
has    O
type    B-MetabolicDisorder114084502
two    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
.    O

However    O
,    O
CYP2J2    O
7    O
carriers    O
showed    O
no    O
association    O
with    O
hypertension    O
,    O
heart    O
attack    O
,    O
or    O
stroke    O
in    O
a    O
study    O
of    O
5,740    O
participants    O
of    O
the    O
cardiovascular    O
cohort    O
of    O
the    O
Malmö    O
Diet    O
and    O
Cancer    O
study    O
;    O
since    O
other    O
studies    O
have    O
afforded    O
contradictory    O
results    O
,    O
this    O
allele    O
is    O
currently    O
regarded    O
as    O
not    O
associated    O
with    O
cardiovascular    O
diseases    O
(    O
see    O
Epoxyeicosatrienoic    O
acid#Clinical    O
significance    O
)    O
.    O
Bearers    O
of    O
this    O
SNP    O
in    O
a    O
Chinese    O
Population    O
had    O
a    O
higher    O
risk    O
of    O
younger    O
onset    O
of    O
type    B-MetabolicDisorder114084502
2    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
and    O
among    O
a    O
Chinese    O
Han    O
population    O
had    O
a    O
higher    O
risk    O
of    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

It    O
has    O
not    O
been    O
associated    O
with    O
cardiovascular    O
diseases    O
but    O
has    O
a    O
higher    O
incidence    O
in    O
subjects    O
with    O
type    B-MetabolicDisorder114084502
II    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
in    O
a    O
small    O
sample    O
of    O
Caucasians    O
in    O
Germany    O
.    O

Two    O
cases    O
demonstrated    O
glycemic    O
effects    O
and    O
pharmacokinetics    O
of    O
insulin    O
administration    O
,    O
diet    O
,    O
and    O
exercise    O
in    O
insulin    O
-    O
dependent    O
type    B-MetabolicDisorder114084502
1    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
mellitus    I-MetabolicDisorder114084502
and    O
non    O
-    O
insulin    O
-    O
dependent    O
type    B-MetabolicDisorder114084502
2    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
mellitus    I-MetabolicDisorder114084502
.    O

The    O
current    O
releases    O
of    O
the    O
downloadable    O
AIDA    O
software    O
,    O
and    O
AIDA    O
on    O
-    O
line    O
,    O
do    O
not    O
incorporate    O
functions    O
to    O
model    O
endogenous    O
insulin    O
secretion    O
—    O
which    O
takes    O
place    O
in    O
people    O
with    O
non    O
-    O
insulin    O
dependent    O
diabetes    B-MetabolicDisorder114084502
mellitus    I-MetabolicDisorder114084502
type    I-MetabolicDisorder114084502
2    I-MetabolicDisorder114084502
,    O
and    O
healthy    O
subjects    O
without    O
diabetes    O
.    O

The    O
plasma    O
protein    O
which    O
led    O
to    O
the    O
distinction    O
between    O
type    B-MetabolicDisorder114084502
1    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
and    O
type    B-MetabolicDisorder114084502
2    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
was    O
discovered    O
by    O
Baker    O
scientists    O

In    O
1982    O
,    O
Hemingway    O
committed    O
suicide    O
with    O
a    O
gunshot    O
to    O
the    O
head    O
,    O
after    O
having    O
suffered    O
several    O
years    O
from    O
Type    B-MetabolicDisorder114084502
II    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
,    O
which    O
necessitated    O
numerous    O
operations    O
.    O

There    O
are    O
thought    O
to    O
be    O
two    O
types    O
of    O
diabetes    O
-    O
type    B-MetabolicDisorder114084502
2    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
,    O
due    O
to    O
metaboliccauses    O
,    O
and    O
Type    B-MetabolicDisorder114084502
1    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
(    O
T1D    O
)    O
.    O

One    O
study    O
on    O
type    B-MetabolicDisorder114084502
2    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
concludes    O
that    O
after    O
six    O
months    O
,    O
individuals    O
who    O
were    O
coached    O
showed    O
improvement    O
in    O
medication    O
adherence    O
.    O

Levy    O
has    O
Type-2    B-MetabolicDisorder114084502
Diabetes    I-MetabolicDisorder114084502
.    O

A    O
major    O
goal    O
of    O
his    O
work    O
is    O
to    O
apply    O
these    O
methods    O
and    O
understanding    O
of    O
genomic    O
variation    O
to    O
studies    O
of    O
common    O
diseases    O
(    O
e.g.    O
obesity    O
,    O
type    B-MetabolicDisorder114084502
2    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
,    O
adaptation    O
to    O
altitude    O
,    O
hypertension    O
and    O
prostate    O
cancer    O
)    O
,    O
and    O
to    O
normal    O
variation    O
,    O
in    O
particular    O
skin    O
pigmentation    O
and    O
response    O
to    O
UVR    O
.    O

Atypical    O
antipsychotics    O
may    O
produce    O
weight    O
gains    O
as    O
well    O
as    O
other    O
metabolic    O
problems    O
,    O
including    O
diabetes    B-MetabolicDisorder114084502
mellitus    I-MetabolicDisorder114084502
type    I-MetabolicDisorder114084502
2    I-MetabolicDisorder114084502
and    O
hyperlipidemia    O
.    O

Two    O
novel    O
susceptibility    O
haplotypes    O
(    O
specifically    O
,    O
P2-S2-X1    O
and    O
P1-S2-X1    O
)    O
have    O
been    O
discovered    O
in    O
ApoAI    O
-    O
CIII    O
-    O
AIV    O
gene    O
cluster    O
on    O
chromosome    O
11q23    O
;    O
these    O
confer    O
approximately    O
threefold    O
higher    O
risk    O
of    O
coronary    O
heart    O
disease    O
in    O
normal    O
as    O
well    O
as    O
non-insulin    B-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
mellitus    I-MetabolicDisorder114084502
.    O

In    O
persons    O
with    O
type    B-MetabolicDisorder114084502
2    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
,    O
elevated    O
plasma    O
Apo    O
-    O
CIII    O
is    O
associated    O
with    O
higher    O
plasma    O
triglycerides    O
and    O
greater    O
coronary    O
artery    O
calcification    O
(    O
a    O
measure    O
of    O
subclinical    O
atherosclerosis    O
)    O
.    O

Dr    O
Lutz    O
was    O
to    O
find    O
that    O
his    O
low    O
carbohydrate    O
diet    O
was    O
effective    O
with    O
both    O
childhood    O
obesity    O
and    O
with    O
hyperinsulinism    O
-    O
a    O
hormonal    O
pathway    O
to    O
both    O
common    O
obesity    O
and    O
,    O
through    O
exhaustion    O
of    O
supply    O
,    O
to    O
Type    B-MetabolicDisorder114084502
II    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
:    O
he    O
found    O
that    O
sufficient    O
carbohydrate    O
restriction    O
could    O
prevent    O
the    O
vascular    O
complications    O
of    O
adult    O
onset    O
diabetes    O
.    O

Sugar    O
is    O
seen    O
as    O
a    O
significant    O
contributor    O
to    O
the    O
high    O
levels    O
of    O
obesity    O
,    O
tooth    O
decay    O
and    O
Type    B-MetabolicDisorder114084502
2    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
found    O
in    O
many    O
developed    O
economies    O
such    O
as    O
the    O
United    O
Kingdom    O
.    O

Although    O
not    O
present    O
in    O
all    O
,    O
patients    O
may    O
also    O
present    O
with    O
hypothyroidism    O
and    O
type    B-MetabolicDisorder114084502
II    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
and    O
possibly    O
malignancies    O
such    O
as    O
acute    O
T    O
-    O
cell    O
leukemia    O
.    O

Low    O
expression    O
levels    O
of    O
many    O
types    O
of    O
miRNA    O
have    O
been    O
observed    O
in    O
type    B-MetabolicDisorder114084502
2    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
including    O
:    O
mir-15a    O
,    O
mir-20b    O
,    O
mir-21    O
,    O
mir-124    O
,    O
mir-126    O
,    O
mir-191    O
,    O
mir-197    O
,    O
mir-223    O
,    O
mir-320    O
and    O
mir-486    O
.    O

MicroRNA-223    O
is    O
also    O
associated    O
with    O
rheumatoid    O
arthritis    O
,    O
sepsis    O
,    O
type    B-MetabolicDisorder114084502
2    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
,    O
and    O
hepatic    O
ischemia    O
.    O

Quantitative    O
miRNA    O
expression    O
analyses    O
revealed    O
that    O
miR-223    O
was    O
consistently    O
upregulated    O
in    O
the    O
insulin    O
-    O
resistant    O
hearts    O
of    O
patients    O
with    O
type    B-MetabolicDisorder114084502
2    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
.    O

It    O
appears    O
in    O
products    O
that    O
are    O
referred    O
to    O
as    O
a    O
medical    O
food    O
used    O
for    O
nutritional    O
support    O
for    O
conditions    O
associated    O
with    O
diabetes    B-MetabolicDisorder114084502
mellitus    I-MetabolicDisorder114084502
type    I-MetabolicDisorder114084502
2    I-MetabolicDisorder114084502
.    O

,    O
Intarcia    O
is    O
engaged    O
in    O
development    O
of    O
a    O
"    O
potential    O
once    O
-    O
a    O
-    O
year    O
type    B-MetabolicDisorder114084502
2    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
treatment    O
"    O
.    O
Referred    O
to    O
as    O
ITCA    O
650    O
,    O
the    O
therapeutic    O
consists    O
of    O
exenatide    O
delivered    O
via    O
its    O
Medici    O
Drug    O
Delivery    O
System    O
,    O
"    O
a    O
drug    O
delivery    O
platform    O
that    O
stabilizes    O
and    O
delivers    O
therapeutic    O
proteins    O
and    O
peptides    O
"    O

Among    O
other    O
bioactivities    O
,    O
(    O
-)-catechin    O
from    O
"    O
C.    O
sinensis    O
"    O
acts    O
as    O
an    O
agonist    O
of    O
the    O
nuclear    O
receptor    O
protein    O
peroxisome    O
proliferator    O
-    O
activated    O
receptor    O
gamma    O
,    O
that    O
is    O
a    O
current    O
pharmacological    O
target    O
for    O
the    O
treatment    O
of    O
diabetes    B-MetabolicDisorder114084502
type    I-MetabolicDisorder114084502
2    I-MetabolicDisorder114084502
.    O

Brimley    O
has    O
type    B-MetabolicDisorder114084502
2    I-MetabolicDisorder114084502
adult-onset    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
,    O
and    O
has    O
appeared    O
in    O
related    O
commercials    O
for    O
Liberty    O
Medical    O
.    O

Saroglitazar    O
(    O
INN    O
,    O
trade    O
name    O
Lipaglyn    O
)    O
is    O
a    O
drug    O
for    O
the    O
treatment    O
of    O
type    B-MetabolicDisorder114084502
2    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
mellitus    I-MetabolicDisorder114084502
and    O
dyslipidemia    B-MetabolicDisorder114084502
.    O

Diabetes    B-MetabolicDisorder114084502
mellitus    I-MetabolicDisorder114084502
type    I-MetabolicDisorder114084502
2    I-MetabolicDisorder114084502

Diabetes    B-MetabolicDisorder114084502
mellitus    I-MetabolicDisorder114084502

The    O
only    O
correlation    O
that    O
has    O
shown    O
light    O
is    O
the    O
frequent    O
association    O
with    O
an    O
underlying    O
disorder    O
,    O
such    O
as    O
,    O
diabetes    B-MetabolicDisorder114084502
mellitus    I-MetabolicDisorder114084502
,    O
chronic    O
renal    O
failure    O
,    O
hyperlipoproteinemia    O
,    O
hepatic    O
abnormalities    O
,    O
and    O
congestive    O
heart    O
failure    O
.    O

In    O
addition    O
,    O
performing    O
on    O
patients    O
that    O
had    O
Kyrle    O
disease    O
due    O
to    O
diabetes    B-MetabolicDisorder114084502
mellitus    I-MetabolicDisorder114084502
or    O
have    O
poor    O
circulation    O
can    O
lead    O
to    O
poor    O
healing    O
.    O

The    O
ad    O
depicts    O
polar    O
bears    O
suffering    O
from    O
a    O
wide    O
variety    O
of    O
health    O
problems    O
as    O
a    O
result    O
of    O
soda    O
consumption    O
,    O
such    O
as    O
type    B-MetabolicDisorder114084502
II    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
and    O
erectile    O
dysfunction    O
.    O

It    O
views    O
T1D    O
and    O
type    B-MetabolicDisorder114084502
2    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
(    O
T2D    O
)    O
as    O
disorders    O
of    O
beta    O
cell    O
stress    O
,    O
set    O
against    O
different    O
genetic    O
backgrounds    O
.    O

In    O
type    B-MetabolicDisorder114084502
2    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
mellitus    I-MetabolicDisorder114084502
the    O
destruction    O
of    O
beta    O
cells    O
is    O
less    O
pronounced    O
than    O
in    O
type    O
1    O
diabetes    O
,    O
and    O
is    O
not    O
due    O
to    O
an    O
autoimmune    O
process    O
.    O

Reduced    O
first    O
-    O
phase    O
insulin    O
release    O
may    O
be    O
the    O
earliest    O
detectable    O
beta    O
cell    O
defect    O
predicting    O
onset    O
of    O
type    B-MetabolicDisorder114084502
2    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
.    O

This    O
dysregulation    O
contributes    O
to    O
excessive    O
visceral    O
fat    O
accumulation    O
and    O
reduced    O
adiponectin    O
release    O
from    O
abdominal    O
adipose    O
tissue    O
,    O
and    O
further    O
to    O
the    O
onset    O
of    O
several    O
cardiometabolic    O
risk    O
factors    O
that    O
are    O
associated    O
with    O
obesity    O
and    O
type    B-MetabolicDisorder114084502
2    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
.    O

Type    B-MetabolicDisorder114084502
2    I-MetabolicDisorder114084502
–    O
either    O
inadequate    O
insulin    O
production    O
by    O
the    O
β-cells    O
or    O
insulin    B-MetabolicDisorder114084502
resistance    I-MetabolicDisorder114084502
or    O
both    O
because    O
of    O
reasons    O
not    O
completely    O
understood    O
.    O

Diabetes    B-MetabolicDisorder114084502
mellitus    I-MetabolicDisorder114084502
type    I-MetabolicDisorder114084502
2    I-MetabolicDisorder114084502

Frequent    O
and    O
regular    O
physical    O
exercise    O
boosts    O
the    O
immune    O
system    O
,    O
and    O
helps    O
prevent    O
the    O
"    O
diseases    O
of    O
affluence    O
"    O
such    O
as    O
heart    O
disease    O
,    O
cardiovascular    O
disease    O
,    O
Type    B-MetabolicDisorder114084502
2    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
and    O
obesity    O
.    O

Type    B-MetabolicDisorder114084502
2    I-MetabolicDisorder114084502
Diabetes    I-MetabolicDisorder114084502

The    O
causes    O
of    O
mortality    O
and    O
morbidity    O
include    O
heart    O
disease    O
,    O
obesity    O
,    O
type    B-MetabolicDisorder114084502
2    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
and    O
cancer    O
,    O
specifically    O
,    O
breast    O
,    O
endometrial    O
,    O
colorectal    O
,    O
lung    O
,    O
and    O
epithelial    O
ovarian    O
cancer    O
.    O

Insulin-resistant    B-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
developed    O
,    O
and    O
the    O
patients    O
died    O
during    O
childhood    O
of    O
ketoacidosis    O
and    O
intercurrent    O
infections    O
.    O

Several    O
studies    O
have    O
identified    O
MTNR1B    O
receptor    O
mutations    O
that    O
are    O
associated    O
with    O
increased    O
average    O
blood    O
sugar    O
level    O
and    O
around    O
a    O
20    O
percent    O
elevated    O
risk    O
of    O
developing    O
type    B-MetabolicDisorder114084502
2    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
.    O

Elevated    O
levels    O
of    O
suPAR    O
are    O
associated    O
with    O
increased    O
risk    O
of    O
systemic    O
inflammatory    O
response    O
syndrome    O
(    O
SIRS    O
)    O
,    O
cancer    O
,    O
Focal    O
segmental    O
glomerulosclerosis    O
,    O
cardiovascular    O
disease    O
,    O
type    B-MetabolicDisorder114084502
2    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
,    O
infectious    O
diseases    O
,    O
HIV    O
,    O
and    O
mortality    O
.    O

Allen    O
had    O
a    O
confirmed    O
advanced    O
case    O
of    O
type    B-MetabolicDisorder114084502
2    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
,    O
and    O
he    O
suffered    O
a    O
perhaps    O
related    O
heart    O
attack    O
on    O
September    O
2    O
,    O
2005    O
.    O

In    O
type    B-MetabolicDisorder114084502
2    I-MetabolicDisorder114084502
diabetic    I-MetabolicDisorder114084502
rats    O
,    O
chronic    O
exposure    O
of    O
β-cells    O
to    O
glucose    O
due    O
to    O
peripheral    O
insulin    O
resistance    O
results    O
in    O
decreased    O
PC    O
enzyme    O
activity    O
and    O
decreased    O
pyruvate    O
cycling    O
The    O
continued    O
overproduction    O
of    O
glucose    O
by    O
hepatocytes    O
causes    O
dramatic    O
alteration    O
of    O
β-cell    O
gene    O
expression    O
with    O
large    O
increases    O
in    O
normally    O
suppressed    O
genes    O
,    O
and    O
equivalent    O
decreases    O
in    O
expression    O
of    O
mRNA    O
for    O
insulin    O
,    O
ion    O
pumps    O
necessary    O
for    O
insulin    O
secretion    O
,    O
and    O
metabolic    O
enzymes    O
related    O
to    O
insulin    O
secretion    O
,    O
including    O
pyruvate    O
carboxylase    O

Certain    O
alleles    O
of    O
this    O
gene    O
may    O
increase    O
the    O
risk    O
for    O
developing    O
type    B-MetabolicDisorder114084502
2    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
,    O
but    O
a    O
loss    O
-    O
of    O
-    O
function    O
mutation    O
appears    O
to    O
greatly    O
reduce    O
the    O
risk    O
of    O
diabetes    O
.    O

Gliflozins    O
are    O
a    O
class    O
of    O
drugs    O
in    O
the    O
treatment    O
of    O
type    B-MetabolicDisorder114084502
2    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
(    O
T2D    O
)    O
.    O

Rorsman    O
's    O
research    O
investigates    O
exocytosis    O
,    O
ion    O
channels    O
and    O
diabetes    B-MetabolicDisorder114084502
mellitus    I-MetabolicDisorder114084502
type    I-MetabolicDisorder114084502
2    I-MetabolicDisorder114084502
.    O

Diabetes    B-MetabolicDisorder114084502
type    I-MetabolicDisorder114084502
II    I-MetabolicDisorder114084502
:    O
0.35(0.06    O
)    O
,    O
0.297(0.022    O
)    O
,    O
0.37(0.065    O
)    O
,    O
0.254(0.041    O
)    O
,    O
0.36(0.066    O
)    O
,    O
0.286    O
(    O
?    O
)    O
,    O
0.51(0.065    O
)    O

Type    B-MetabolicDisorder114084502
2    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502

Such    O
downregulation    O
underlies    O
insulin    B-MetabolicDisorder114084502
resistance    I-MetabolicDisorder114084502
,    O
which    O
is    O
common    O
in    O
type    B-MetabolicDisorder114084502
2    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
.    O

Salsalate    O
has    O
been    O
proposed    O
for    O
the    O
prevention    O
and    O
treatment    O
of    O
type    B-MetabolicDisorder114084502
2    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
mellitus    O
due    O
to    O
its    O
ability    O
to    O
lower    O
insulin    B-MetabolicDisorder114084502
resistance    I-MetabolicDisorder114084502
associated    O
with    O
inflammation    O
and    O
may    O
be    O
useful    O
in    O
prediabetes    O
.    O

One    O
collaborative    O
study    O
showed    O
that    O
aqueous    O
hot    O
water    O
honeybush    O
extract    O
,    O
when    O
administered    O
orally    O
to    O
type-2    B-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
rat    O
models    O
,    O
promoted    O
normoglycemia    O
and    O
improved    O
other    O
type-2    O
diabetes    O
associated    O
problems    O
.    O

Long    O
-    O
term    O
side    O
effects    O
include    O
Cushing's    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
,    O
steroid    O
dementia    O
syndrome    O
,    O
truncal    O
weight    O
gain    O
,    O
osteoporosis    O
,    O
glaucoma    O
and    O
cataracts    O
,    O
diabetes    O
mellitus    O
type    B-MetabolicDisorder114084502
2    I-MetabolicDisorder114084502
,    O
and    O
depression    O
upon    O
dose    O
reduction    O
or    O
cessation    O
.    O

In    O
obesity    O
,    O
similar    O
to    O
resistance    B-MetabolicDisorder114084502
of    I-MetabolicDisorder114084502
insulin    I-MetabolicDisorder114084502
in    O
type    B-MetabolicDisorder114084502
2    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
,    O
a    O
decreased    O
sensitivity    O
to    O
leptin    O
occurs    O
,    O
resulting    O
in    O
an    O
inability    O
to    O
detect    O
satiety    O
despite    O
high    O
energy    O
stores    O
.    O

These    O
people    O
show    O
resistance    O
to    O
leptin    O
,    O
similar    O
to    O
resistance    B-MetabolicDisorder114084502
of    I-MetabolicDisorder114084502
insulin    I-MetabolicDisorder114084502
in    O
type    B-MetabolicDisorder114084502
2    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
,    O
with    O
the    O
elevated    O
levels    O
failing    O
to    O
control    O
hunger    O
and    O
modulate    O
their    O
weight    O
.    O

This    O
enzyme    O
participates    O
in    O
29    O
metabolic    O
pathways    O
:    O
inositol    O
phosphate    O
metabolism    O
,    O
erbb    O
signaling    O
pathway    O
,    O
phosphatidylinositol    O
signaling    O
system    O
,    O
mtor    O
signaling    O
pathway    O
,    O
apoptosis    O
,    O
VEGF    O
signaling    O
pathway    O
,    O
focal    O
adhesion    O
,    O
toll    O
-    O
like    O
receptor    O
signaling    O
pathway    O
,    O
jak    O
-    O
stat    O
signaling    O
pathway    O
,    O
natural    O
killer    O
cell    O
mediated    O
cytotoxicity    O
,    O
t    O
cell    O
receptor    O
signaling    O
pathway    O
,    O
b    O
cell    O
receptor    O
signaling    O
pathway    O
,    O
fc    O
epsilon    O
ri    O
signaling    O
pathway    O
,    O
leukocyte    O
transendothelial    O
migration    O
,    O
regulation    O
of    O
actin    O
cytoskeleton    O
,    O
insulin    O
signaling    O
pathway    O
,    O
progesterone    O
-    O
mediated    O
oocyte    O
maturation    O
,    O
Type    B-MetabolicDisorder114084502
II    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
mellitus    I-MetabolicDisorder114084502
,    O
colorectal    O
cancer    O
,    O
renal    O
cell    O
carcinoma    O
,    O
pancreatic    O
cancer    O
,    O
endometrial    O
cancer    O
,    O
glioma    O
,    O
prostate    O
cancer    O
,    O
melanoma    O
,    O
chronic    O
myeloid    O
leukemia    O
,    O
acute    O
myeloid    O
leukemia    O
,    O
small    O
cell    O
lung    O
cancer    O
,    O
and    O
non    O
-    O
small    O
cell    O
lung    O
cancer    O
.    O

In    O
the    O
BEGIN    O
Basal    O
-    O
Bolus    O
Type    O
2    O
trial    O
,    O
insulin    O
degludec    O
was    O
studied    O
as    O
an    O
alternative    O
to    O
insulin    O
glargine    O
in    O
patients    O
with    O
type    B-MetabolicDisorder114084502
2    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
mellitus    I-MetabolicDisorder114084502
.    O

Recent    O
increases    O
in    O
the    O
rates    O
of    O
lifestyle    O
diseases    O
,    O
such    O
as    O
obesity    O
,    O
diabetes    B-MetabolicDisorder114084502
,    O
hypertension    O
,    O
and    O
heart    O
disease    O
,    O
may    O
eventually    O
slow    O
or    O
reverse    O
this    O
trend    O
toward    O
increasing    O
life    O
expectancy    O
in    O
the    O
developed    O
world    O
,    O
but    O
have    O
not    O
yet    O
done    O
so    O
.    O

While    O
recording    O
this    O
album    O
,    O
Fiasco    O
's    O
father    O
died    O
of    O
type    B-MetabolicDisorder114084502
II    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
and    O
his    O
business    O
partner    O
,    O
Charles    O
"    O
Chilly    O
"    O
Patton    O
,    O
was    O
convicted    O
of    O
attempting    O
to    O
supply    O
heroin    O
to    O
a    O
drug    O
ring    O
and    O
was    O
eventually    O
sentenced    O
to    O
44    O
years    O
in    O
a    O
correctional    O
facility    O
.    O

That    O
business    O
also    O
failed    O
,    O
and    O
beset    O
by    O
health    O
problems    O
including    O
Type    B-MetabolicDisorder114084502
2    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
and    O
recurring    O
heart    O
problems    O
,    O
Fehring    O
committed    O
suicide    O
on    O
25    O
July    O
2008    O
.    O

In    O
2015    O
,    O
after    O
the    O
Axalta    O
Faster    O
.    O
Tougher    O
.    O
Brighter    O
.    O
200    O
at    O
Phoenix    O
International    O
Raceway    O
,    O
Dick    O
was    O
reporting    O
signs    O
of    O
dizziness    O
and    O
fatigue    O
,    O
and    O
upon    O
a    O
visit    O
to    O
the    O
infield    O
care    O
center    O
,    O
he    O
was    O
diagnosed    O
with    O
onset    B-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
.    O

He    O
identified    O
type    B-MetabolicDisorder114084502
2    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
(T2D)    I-MetabolicDisorder114084502
as    O
one    O
of    O
the    O
major    O
risk    O
factors    O
that    O
might    O
affect    O
AD    O
neuropathology    O
and    O
synaptic    O
plasticity    O
in    O
part    O
through    O
epigenetic    O
mechanisms    O
.    O

Meanwhile    O
,    O
Turk    O
is    O
challenged    O
with    O
choosing    O
the    O
semi    O
-    O
annual    O
candy    O
bar    O
he    O
is    O
allowed    O
to    O
eat    O
because    O
of    O
his    O
diabetes    B-MetabolicDisorder114084502
.    O

The    O
use    O
of    O
β-blockers    O
in    O
hypertension    O
was    O
downgraded    O
in    O
June    O
2006    O
in    O
the    O
United    O
Kingdom    O
to    O
fourth    O
-    O
line    O
because    O
they    O
perform    O
less    O
well    O
than    O
other    O
drugs    O
,    O
and    O
because    O
atenolol    O
,    O
the    O
most    O
frequently    O
used    O
β-blocker    O
,    O
at    O
usual    O
doses    O
carries    O
an    O
unacceptable    O
risk    O
of    O
provoking    O
type    B-MetabolicDisorder114084502
2    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
.    O

Abdominal    O
fat    O
accumulation    O
with    O
the    O
formation    O
of    O
enlarged    O
lipid    O
engorged    O
adipocytes    O
has    O
emerged    O
as    O
the    O
key    O
risk    O
factor    O
for    O
the    O
onset    O
of    O
type    B-MetabolicDisorder114084502
2    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
,    O
which    O
is    O
often    O
a    O
manifestation    O
of    O
a    O
broader    O
underlying    O
metabolic    O
disorder    O
termed    O
as    O
metabolic    O
syndrome    O
.    O

Balaș    O
was    O
diagnosed    O
with    O
type    B-MetabolicDisorder114084502
II    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
several    O
years    O
before    O
her    O
death    O
and    O
was    O
hospitalized    O
several    O
times    O
after    O
that    O
.    O

The    O
Paleolithic    O
diet    O
has    O
been    O
shown    O
to    O
improve    O
glucose    O
tolerance    O
in    O
people    O
with    O
diabetes    B-MetabolicDisorder114084502
type    I-MetabolicDisorder114084502
2    I-MetabolicDisorder114084502
,    O
ischemic    O
heart    O
disease    O
and    O
glucose    O
intolerance    O
,    O
and    O
in    O
healthy    O
pigs    O
.    O

In    O
these    O
cases    O
,    O
many    O
medicines    O
for    O
type    B-MetabolicDisorder114084502
II    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
mellitus    I-MetabolicDisorder114084502
are    O
not    O
effective    O
,    O
because    O
MODY2    O
does    O
not    O
cause    O
insulin    B-MetabolicDisorder114084502
resistance    I-MetabolicDisorder114084502
.    O

Anderson    O
has    O
Type    B-MetabolicDisorder114084502
2    I-MetabolicDisorder114084502
Diabetes    I-MetabolicDisorder114084502
and    O
has    O
been    O
active    O
in    O
diabetes    O
awareness    O
.    O

Reduction    O
of    O
MACE    O
was    O
more    O
profound    O
in    O
patients    O
with    O
diabetes    B-MetabolicDisorder114084502
mellitus    I-MetabolicDisorder114084502
.    O

The    O
mitochondrial    O
isoform    O
of    O
G3P    O
dehydrogenase    O
is    O
thought    O
to    O
be    O
inhibited    O
by    O
metformin    O
,    O
a    O
first    O
line    O
drug    O
for    O
type    B-MetabolicDisorder114084502
2    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
.    O

Therefore    O
,    O
several    O
drugs    O
target    O
PDK4    O
hoping    O
to    O
treat    O
type    B-MetabolicDisorder114084502
II    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
.    O

Inborn    B-MetabolicDisorder114084502
errors    I-MetabolicDisorder114084502
of    I-MetabolicDisorder114084502
metal    I-MetabolicDisorder114084502
metabolism    I-MetabolicDisorder114084502
refers    O
to    O
metabolic    O
disturbances    O
in    O
the    O
processing    O
or    O
distribution    O
of    O
dietary    O
minerals    O
.    O

Calcinosis    O
cutis    O
(    O
or    O
cutaneous    O
calcification    O
)    O
is    O
a    O
type    O
of    O
calcinosis    B-MetabolicDisorder114084502
wherein    O
calcium    O
deposits    O
form    O
in    O
the    O
skin    O
.    O

Calcinosis    B-MetabolicDisorder114084502

Calcinosis    B-MetabolicDisorder114084502

Norum    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
;    O
;    O
LCAT    O

Lecithin    B-MetabolicDisorder114084502
cholesterol    I-MetabolicDisorder114084502
acyltransferase    I-MetabolicDisorder114084502
deficiency    I-MetabolicDisorder114084502

The    O
Colorado    O
City    O
/    O
Hildale    O
area    O
has    O
the    O
world    O
's    O
highest    O
incidence    O
of    O
fumarase    B-MetabolicDisorder114084502
deficiency    I-MetabolicDisorder114084502
,    O
an    O
extremely    O
rare    O
genetic    O
condition    O
.    O

The    O
Colorado    O
City    O
/    O
Hildale    O
,    O
Utah    O
area    O
has    O
the    O
world    O
's    O
highest    O
incidence    O
of    O
fumarase    B-MetabolicDisorder114084502
deficiency    I-MetabolicDisorder114084502
,    O
an    O
extremely    O
rare    O
genetic    O
condition    O
which    O
causes    O
severe    O
Intellectual    O
disability    O
.    O

Gilbert's    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502

Dolgopolov    O
suffers    O
from    O
a    O
hereditary    O
disorder    O
known    O
as    O
Gilbert's    B-MetabolicDisorder114084502
Syndrome    I-MetabolicDisorder114084502
,    O
which    O
affects    O
his    O
liver    O
,    O
blood    O
and    O
often    O
causes    O
fatigue    O
.    O

This    O
is    O
in    O
contrast    O
to    O
primarily    O
unconjugated    O
hyperbilirubinemia    O
which    O
is    O
the    O
water    O
-    O
insoluble    O
form    O
that    O
is    O
bound    O
to    O
serum    O
albumin    O
;    O
the    O
liver    O
has    O
not    O
had    O
a    O
chance    O
to    O
conjugate    O
the    O
bilirubin    O
yet    O
and    O
can    O
be    O
caused    O
either    O
because    O
too    O
much    O
unconjugated    O
bilirubin    O
is    O
made    O
(    O
such    O
as    O
in    O
massive    O
hemolysis    O
or    O
ineffective    O
erythropoiesis    O
)    O
or    O
because    O
too    O
little    O
is    O
conjugated    O
(    O
Gilbert's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
or    O
Crigler-Najjar    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
)    O
.    O

It    O
is    O
theorised    O
that    O
he    O
may    O
have    O
had    O
a    O
mild    O
form    O
of    O
congenital    O
jaundice    O
known    O
as    O
Gilbert's    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
.    O

Gilbert's    B-MetabolicDisorder114084502
Syndrome    I-MetabolicDisorder114084502

Heredofamilial    B-MetabolicDisorder114084502
amyloidosis    I-MetabolicDisorder114084502
,    O
unspecified    O

Porphyria    B-MetabolicDisorder114084502
cutanea    I-MetabolicDisorder114084502
tarda    I-MetabolicDisorder114084502

Sporadic    B-MetabolicDisorder114084502
porphyria    I-MetabolicDisorder114084502
cutanea    I-MetabolicDisorder114084502
tarda    I-MetabolicDisorder114084502
(    O
ILDS    O
E80.110    O
)    O

Familial    B-MetabolicDisorder114084502
porphyria    I-MetabolicDisorder114084502
cutanea    I-MetabolicDisorder114084502
tarda    I-MetabolicDisorder114084502
(    O
ILDS    O
E80.120    O
)    O

Pseudoporphyria    O
(    O
also    O
known    O
as    O
"    O
Pseudoporphyria    O
cutanea    O
tarda    O
"    O
)    O
is    O
a    O
bullous    O
photosensitivity    O
that    O
clinically    O
and    O
histologically    O
mimics    O
porphyria    B-MetabolicDisorder114084502
cutanea    I-MetabolicDisorder114084502
tarda    I-MetabolicDisorder114084502
.    O

Chloracne    O
is    O
very    O
often    O
seen    O
in    O
combination    O
with    O
hyperhidrosis    O
(    O
clammy    O
,    O
sweaty    O
skin    O
)    O
and    O
porphyria    B-MetabolicDisorder114084502
cutanea    I-MetabolicDisorder114084502
tarda    I-MetabolicDisorder114084502
(    O
a    O
skin    O
condition    O
of    O
increased    O
pigmentation    O
,    O
hair    O
coarsening    O
and    O
blistering    O
)    O
.    O

Porphyria    B-MetabolicDisorder114084502
cutanea    I-MetabolicDisorder114084502
tarda    I-MetabolicDisorder114084502
.    O

|    O
GSD    B-MetabolicDisorder114084502
type    I-MetabolicDisorder114084502
XI    I-MetabolicDisorder114084502

The    O
accumulation    O
of    O
Amyloid    B-MetabolicDisorder114084502
beta    I-MetabolicDisorder114084502
(    O
Aβ    O
)    O
in    O
the    O
prefrontal    O
cortex    O
is    O
associated    O
with    O
the    O
disruption    O
or    O
reduction    O
of    O
slow    O
waves    O
of    O
NREM    O
sleep    O
.    O

After    O
the    O
substance    O
is    O
given    O
intravenously    O
,    O
it    O
accumulates    O
in    O
beta    B-MetabolicDisorder114084502
amyloid    I-MetabolicDisorder114084502
plaques    O
in    O
the    O
patient    O
's    O
brain    O
,    O
which    O
thus    O
become    O
visible    O
via    O
positron    O
emission    O
tomography    O
(    O
PET    O
)    O
.    O

Omigapil    O
rescues    O
"    O
in    O
vitro    O
"    O
PC12    O
cells    O
from    O
rotenone    O
toxicity    O
,    O
β-amyloid    B-MetabolicDisorder114084502
toxicity    O
,    O
nutrition    O
withdrawal    O
,    O
and    O
lactacystin    O
.    O

One    O
approach    O
is    O
to    O
reduce    O
amyloid    B-MetabolicDisorder114084502
beta    I-MetabolicDisorder114084502
,    O
for    O
example    O
with    O
bapineuzumab    O
,    O
an    O
antibody    O
in    O
phase    O
III    O
studies    O
for    O
patients    O
in    O
mild    O
to    O
moderate    O
stage    O
;    O
semagacestat    O
,    O
a    O
γ-secretase    O
inhibitor    O
,    O
MPC-7869    O
;    O
and    O
acc-001    O
or    O
CAD106    O
,    O
vaccines    O
against    O
amyloid    O
beta    O
.    O

Several    O
potential    O
treatments    O
for    O
Alzheimer    O
's    O
disease    O
are    O
under    O
investigation    O
,    O
including    O
several    O
compounds    O
being    O
studied    O
in    O
phase    O
3    O
clinical    O
trials    O
.    O
The    O
most    O
important    O
clinical    O
research    O
is    O
focused    O
on    O
potentially    O
treating    O
the    O
underlying    O
disease    O
pathology    O
,    O
for    O
which    O
reduction    O
of    O
amyloid    B-MetabolicDisorder114084502
beta    I-MetabolicDisorder114084502
is    O
a    O
common    O
target    O
of    O
compounds    O
under    O
investigation    O
.    O

Latrepirdine    O
appears    O
to    O
operate    O
through    O
multiple    O
mechanisms    O
of    O
action    O
,    O
both    O
blocking    O
the    O
action    O
of    O
neurotoxic    O
beta-amyloid    B-MetabolicDisorder114084502
proteins    O
and    O
inhibiting    O
L    O
-    O
type    O
calcium    O
channels    O
,    O
modulating    O
the    O
action    O
of    O
AMPA    O
and    O
NMDA    O
glutamate    O
receptors    O
,    O
and    O
may    O
exert    O
a    O
neuroprotective    O
effect    O
by    O
blocking    O
a    O
novel    O
target    O
that    O
involves    O
mitochondrial    O
pores    O
,    O
which    O
are    O
believed    O
to    O
play    O
a    O
role    O
in    O
the    O
cell    O
death    O
that    O
is    O
associated    O
with    O
neurodegenerative    O
diseases    O
and    O
the    O
aging    O
process    O
.    O

Tenuifolins    O
inhibit    O
beta-amyloid    B-MetabolicDisorder114084502
synthesis    O
"    O
in    O
vitro    O
"    O
.    O

The    O
hypothesis    O
that    O
beta    B-MetabolicDisorder114084502
amyloid    I-MetabolicDisorder114084502
protein    O
is    O
key    O
to    O
IBM    O
has    O
been    O
supported    O
in    O
a    O
mouse    O
model    O
using    O
an    O
Aβ    O
vaccine    O
that    O
was    O
found    O
to    O
be    O
effective    O
against    O
inclusion    O
body    O
myositis    O
in    O
mouse    O
models    O
.    O

Plaques    O
are    O
clumps    O
of    O
a    O
protein    O
called    O
beta-amyloid    B-MetabolicDisorder114084502
.    O

It    O
also    O
degrades    O
the    O
amyloid    B-MetabolicDisorder114084502
beta    I-MetabolicDisorder114084502
peptide    O
whose    O
abnormal    O
misfolding    O
and    O
aggregation    O
in    O
neural    O
tissue    O
has    O
been    O
implicated    O
as    O
a    O
cause    O
of    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

IL-18    O
has    O
also    O
been    O
found    O
to    O
increase    O
the    O
Alzheimer's    B-MetabolicDisorder114084502
disease    O
-    O
associated    O
amyloid-beta    B-MetabolicDisorder114084502
production    O
in    O
human    O
neuron    O
cells    O
.    O

EP2    O
deficient    O
mice    O
exhibit    O
reduced    O
Oxidative    O
stress    O
and    O
beta    B-MetabolicDisorder114084502
amyloid    I-MetabolicDisorder114084502
formation    O
.    O

The    O
data    O
also    O
showed    O
that    O
a    O
modest    O
decrease    O
in    O
SOAT    O
activity    O
led    O
to    O
suppressive    O
effects    O
on    O
Abeta    B-MetabolicDisorder114084502
generation    O
.    O

It    O
is    O
well    O
known    O
that    O
beta    B-MetabolicDisorder114084502
amyloid    I-MetabolicDisorder114084502
(    O
Aβ    O
)    O
is    O
a    O
good    O
indicator    O
of    O
AD    O
disease    O
,    O
which    O
has    O
facilitated    O
doctors    O
to    O
accurately    O
pre    O
-    O
diagnose    O
cases    O
of    O
AD    O
disease    O
.    O

APP    O
is    O
an    O
integral    O
membrane    O
protein    O
whose    O
proteolysis    O
generates    O
beta    B-MetabolicDisorder114084502
amyloid    I-MetabolicDisorder114084502
ranging    O
from    O
39-    O
to    O
42-    O
amino    O
acid    O
peptide    O
.    O

Amyloid    B-MetabolicDisorder114084502
beta    I-MetabolicDisorder114084502

For    O
this    O
reason    O
,    O
norleucine    O
has    O
been    O
used    O
to    O
probe    O
the    O
role    O
of    O
methionine    O
in    O
Amyloid-β    B-MetabolicDisorder114084502
peptide    I-MetabolicDisorder114084502
(    O
AβP    O
)    O
the    O
central    O
constituent    O
of    O
senile    O
plaques    O
in    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

β-amyloid    B-MetabolicDisorder114084502
,    O
a    O
peptide    O
involved    O
in    O
Alzheimer    O
's    O
disease    O
,    O
is    O
also    O
seen    O
in    O
this    O
protein    O
accumulation    O
.    O

By    O
the    O
same    O
mechanism    O
it    O
also    O
raises    O
concentrations    O
of    O
beta    B-MetabolicDisorder114084502
amyloid    I-MetabolicDisorder114084502
,    O
the    O
main    O
constituent    O
of    O
senile    O
plaques    O
.    O

Senile    O
plaques    O
(    O
also    O
known    O
as    O
neuritic    O
plaques    O
)    O
are    O
extracellular    O
deposits    O
of    O
amyloid    B-MetabolicDisorder114084502
beta    I-MetabolicDisorder114084502
in    O
the    O
grey    O
matter    O
of    O
the    O
brain    O
.    O
Degenerative    O
neural    O
structures    O
and    O
an    O
abundance    O
of    O
microglia    O
and    O
astrocytes    O
can    O
be    O
associated    O
with    O
senile    O
plaque    O
deposits    O
.    O

In    O
Alzheimer    O
's    O
disease    O
they    O
are    O
primarily    O
composed    O
of    O
amyloid    B-MetabolicDisorder114084502
beta    I-MetabolicDisorder114084502
peptides    O
.    O

By    O
1985    O
beta    B-MetabolicDisorder114084502
amyloid    I-MetabolicDisorder114084502
formations    O
were    O
successfully    O
identified    O
through    O
biochemical    O
techniques    O
,    O
though    O
many    O
unsolved    O
questions    O
about    O
the    O
importance    O
and    O
formation    O
of    O
senile    O
plaques    O
remained    O
.    O

A    O
portion    O
of    O
this    O
protein    O
contains    O
an    O
Aβ    B-MetabolicDisorder114084502
peptide    O
sequence    O
.    O

The    O
formation    O
of    O
amyloid    B-MetabolicDisorder114084502
beta    I-MetabolicDisorder114084502
fragments    O
is    O
a    O
normal    O
occurrence    O
in    O
the    O
human    O
body    O
.    O

Senile    O
plaques    O
may    O
also    O
be    O
visualized    O
with    O
an    O
immunostain    O
directed    O
against    O
beta    B-MetabolicDisorder114084502
amyloid    I-MetabolicDisorder114084502
.    O

With    O
this    O
in    O
mind    O
,    O
Pasinetti    O
initiated    O
a    O
drug    O
repurposing    O
study    O
for    O
AD    O
,    O
screening    O
FDA    O
-    O
approved    O
drugs    O
and    O
natural    O
compounds    O
for    O
amyloid    O
-    O
lowering    O
and    O
anti-Aβ    B-MetabolicDisorder114084502
aggregation    O
activities    O
,    O
and    O
identified    O
candidates    O
for    O
in    O
vivo    O
testing    O
in    O
AD    O
animal    O
models    O
.    O

γ-secretase    O
activating    O
protein    O
(    O
GSAP    O
)    O
increases    O
β-amyloid    B-MetabolicDisorder114084502
production    O
through    O
a    O
mechanism    O
involving    O
its    O
interactions    O
with    O
both    O
γ-secretase    O
and    O
its    O
substrate    O
,    O
the    O
amyloid    B-MetabolicDisorder114084502
precursor    I-MetabolicDisorder114084502
protein    I-MetabolicDisorder114084502
(    O
APP    O
)    O
.    O

Arakawa's    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
II    I-MetabolicDisorder114084502

Krabbe    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
(    O
KD    B-MetabolicDisorder114084502
)    O
(    O
also    O
known    O
as    O
globoid    B-MetabolicDisorder114084502
cell    I-MetabolicDisorder114084502
leukodystrophy    I-MetabolicDisorder114084502
or    O
galactosylceramide    B-MetabolicDisorder114084502
lipidosis    I-MetabolicDisorder114084502
)    O
is    O
a    O
rare    O
and    O
often    O
fatal    O
lysosomal    B-MetabolicDisorder114084502
storage    I-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
which    O
results    O
in    O
progressive    O
damage    O
to    O
the    O
nervous    O
system    O
.    O

Krabbe    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502

Krabbe    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502

Krabbe    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502

New    O
York    O
State    O
started    O
a    O
pilot    O
study    O
to    O
screen    O
for    O
Krabbe    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
in    O
2006    O
,    O
largely    O
due    O
to    O
the    O
efforts    O
of    O
Jim    O
Kelly    O
,    O
whose    O
son    O
,    O
Hunter    O
,    O
was    O
affected    O
with    O
the    O
disease    O
.    O

Krabbe    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502

Sucrase    B-MetabolicDisorder114084502
deficiency    I-MetabolicDisorder114084502

Congenital    B-MetabolicDisorder114084502
Sucrase-Isomaltase    I-MetabolicDisorder114084502
Deficiency    I-MetabolicDisorder114084502

In    O
Type    B-MetabolicDisorder114084502
I    I-MetabolicDisorder114084502
tyrosinemia    I-MetabolicDisorder114084502
,    O
a    O
different    O
enzyme    O
involved    O
in    O
the    O
breakdown    O
of    O
tyrosine    O
,    O
fumarylacetoacetate    O
hydrolase    O
is    O
mutated    O
and    O
does    O
n't    O
work    O
,    O
leading    O
to    O
very    O
harmful    O
products    O
building    O
up    O
in    O
the    O
body    O
.    O

In    O
Type    B-MetabolicDisorder114084502
I    I-MetabolicDisorder114084502
tyrosinemia    I-MetabolicDisorder114084502
,    O
a    O
different    O
enzyme    O
,    O
fumarylacetoacetate    O
hydrolase    O
is    O
mutated    O
and    O
does    O
n't    O
work    O
,    O
leading    O
to    O
very    O
harmful    O
products    O
building    O
up    O
in    O
the    O
body    O
.    O

This    O
discovery    O
assisted    O
other    O
scientists    O
in    O
the    O
elucidation    O
of    O
similar    O
glycolipid    O
storage    O
diseases    O
such    O
as    O
Gaucher's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
and    O
Tay–Sachs    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
and    O
in    O
their    O
prenatal    O
diagnosis    O
.    O

Tay–Sachs    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502

HEXA    O
:    O
hexosaminidase    O
A    O
(    O
alpha    O
Tay-Sachs    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
)    O

Tay-Sachs    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502

Several    O
organizations    O
,    O
such    O
as    O
Dor    O
Yeshorim    O
,    O
offer    O
screening    O
for    O
Ashkenazi    O
genetic    O
diseases    O
,    O
and    O
these    O
screening    O
programs    O
have    O
had    O
a    O
significant    O
impact    O
,    O
in    O
particular    O
by    O
reducing    O
the    O
number    O
of    O
cases    O
of    O
Tay–Sachs    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

Tay–Sachs    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
which    O
can    O
present    O
as    O
a    O
fatal    O
illness    O
of    O
children    O
that    O
causes    O
mental    O
deterioration    O
prior    O
to    O
death    O
,    O
was    O
historically    O
more    O
prevalent    O
among    O
Ashkenazi    O
Jews    O
,    O
although    O
high    O
levels    O
of    O
the    O
disease    O
are    O
also    O
found    O
in    O
some    O
Pennsylvania    O
Dutch    O
,    O
southern    O
Louisiana    O
Cajun    O
,    O
and    O
eastern    O
Quebec    O
French    O
Canadian    O
populations    O
.    O

He    O
allowed    O
first    O
trimester    O
abortion    O
of    O
a    O
fetus    O
which    O
would    O
be    O
born    O
with    O
a    O
deformity    O
that    O
would    O
cause    O
it    O
to    O
suffer    O
,    O
and    O
termination    O
of    O
a    O
fetus    O
with    O
a    O
lethal    O
fetal    O
defect    O
such    O
as    O
Tay-Sachs    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
up    O
to    O
the    O
end    O
of    O
the    O
second    O
trimester    O
of    O
gestation    O
.    O

Tay–Sachs    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
a    O
genetic    O
disorder    O
,    O
fatal    O
in    O
its    O
most    O
common    O
variant    O

Recessive    O
genetic    O
disorders    O
include    O
albinism    O
,    O
cystic    O
fibrosis    O
,    O
galactosemia    O
,    O
phenylketonuria    O
(    O
PKU    O
)    O
,    O
and    O
Tay–Sachs    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

Tay–Sachs    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502

He    O
is    O
very    O
fond    O
of    O
Reza    O
,    O
who    O
bears    O
a    O
great    O
resemblance    O
to    O
his    O
mother    O
and    O
is    O
dying    O
of    O
Tay–Sachs    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

The    O
rare    O
autosomal    O
recessive    O
neurodegenerative    O
disorder    O
is    O
clinically    O
almost    O
indistinguishable    O
from    O
Tay–Sachs    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
another    O
genetic    O
disorder    O
that    O
disrupts    O
beta    O
-    O
hexosaminidases    O
A    O
and    O
S.    O
There    O
are    O
three    O
subsets    O
of    O
Sandhoff    O
disease    O
based    O
on    O
when    O
first    O
symptoms    O
appear    O
:    O
classic    O
infantile    O
,    O
juvenile    O
and    O
adult    O
late    O
onset    O
.    O

Sandhoff    O
disease    O
symptoms    O
are    O
clinically    O
indeterminable    O
from    O
Tay–Sachs    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

It    O
has    O
a    O
similar    O
pathology    O
to    O
Sandhoff    O
disease    O
and    O
Tay-Sachs    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

Adenosine    B-MetabolicDisorder114084502
deaminase    I-MetabolicDisorder114084502
deficiency    I-MetabolicDisorder114084502

Ernest    O
Beutler    O
and    O
Dennis    O
A.    O
Carson    O
had    O
studied    O
adenosine    B-MetabolicDisorder114084502
deaminase    I-MetabolicDisorder114084502
deficiency    I-MetabolicDisorder114084502
and    O
recognized    O
that    O
because    O
the    O
lack    O
of    O
adenosine    O
deaminase    O
led    O
to    O
the    O
destruction    O
of    O
B    O
cell    O
lymphocytes    O
,    O
a    O
drug    O
designed    O
to    O
inhibit    O
adenosine    O
deaminase    O
might    O
be    O
useful    O
in    O
lymphomas    O
.    O

acrylamide    O
gels    O
-    O
adenine    O
-    O
adenosine    B-MetabolicDisorder114084502
deaminase    I-MetabolicDisorder114084502
deficiency    I-MetabolicDisorder114084502
-    O
adenovirus    O
-    O
agarose    O
gel    O
electrophoresis    O
-    O
agarose    O
gel    O
-    O
Alagille    O
syndrome    O
-    O
alkaline    O
lysis    O
-    O
allele    O
-    O
amino    O
acids    O
-    O
amino    O
terminus    O
-    O
amp    O
resistance    O
-    O
amplification    O
-    O
amplicon    O
-    O
anchor    O
sequence    O
-    O
animal    O
model    O
-    O
anneal    O
-    O
anti    O
-    O
sense    O
strand    O
-    O
antibiotic    O
resistance    O
-    O
antibody    O
-    O
antisense    O
-    O
antisense    O
strand    O
-    O
AP-1    O
site    O
-    O
apoptosis    O
-    O
assembled    O
epitope    O
-    O
ataxia    O
-    O
telangiectasia    O
-    O
ATG    O
or    O
AUG    O
-    O
autoimmune    O
lymphoproliferative    O
syndrome    O
-    O
autoradiography    O
-    O
autosomal    O
dominant    O
-    O
autosome    O
-    O
avidin    O
-    O

A    O
third    O
form    O
,    O
chylomicron    B-MetabolicDisorder114084502
retention    I-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
(    O
CRD    O
)    O
,    O
is    O
associated    O
with    O
SARA2    O
.    O

A    O
congenital    O
molybdenum    B-MetabolicDisorder114084502
cofactor    I-MetabolicDisorder114084502
deficiency    I-MetabolicDisorder114084502
disease    O
,    O
seen    O
in    O
infants    O
,    O
is    O
an    O
inability    O
to    O
synthesize    O
molybdenum    O
cofactor    O
,    O
a    O
heterocyclic    O
molecule    O
that    O
binds    O
molybdenum    O
at    O
the    O
active    O
site    O
in    O
all    O
known    O
human    O
enzymes    O
that    O
use    O
molybdenum    O
.    O

Mutations    O
in    O
this    O
gene    O
may    O
be    O
associated    O
with    O
the    O
neurological    O
condition    O
hyperekplexia    O
and    O
also    O
lead    O
to    O
molybdenum    B-MetabolicDisorder114084502
cofactor    I-MetabolicDisorder114084502
deficiency    I-MetabolicDisorder114084502
.    O

Other    O
causes    O
include    O
mucopolysaccharidosis    O
,    O
neurofibromatosis    O
,    O
multiple    O
endocrine    O
neoplasia    O
type    O
2B    O
,    O
myxedema    O
,    O
acromegaly    O
,    O
angioedema    O
,    O
tumors    O
(    O
e.g.    O
carcinoma    O
)    O
,    O
Glycogen    B-MetabolicDisorder114084502
storage    I-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
type    O
2    O
,    O
Simpson    O
-    O
Golabi    O
-    O
Behmel    O
syndrome    O
,    O
Triploid    O
Syndrome    O
,    O
trisomy    O
4p    O
,    O
fucosidosis    O
,    O
alpha-mannosidosis    B-MetabolicDisorder114084502
,    O
Klippel    O
-    O
Trenaunay    O
-    O
Weber    O
syndrome    O
,    O
cardiofaciocutaneous    O
syndrome    O
,    O
Ras    O
pathway    O
disorders    O
,    O
transient    O
neonatal    O
diabetes    O
,    O
and    O
lingual    O
thyroid    O
.    O

Alpha-mannosidosis    B-MetabolicDisorder114084502
is    O
a    O
lysosomal    B-MetabolicDisorder114084502
storage    I-MetabolicDisorder114084502
disorder    I-MetabolicDisorder114084502
caused    O
by    O
deficient    O
activity    O
of    O
the    O
enzyme    O
alpha    O
-    O
D    O
-    O
mannosidase    O
.    O

It    O
may    O
have    O
use    O
for    O
treatments    O
of    O
Huntington    O
's    O
disease    O
,    O
Parkinson    O
disease    O
,    O
tauopathies    O
or    O
Batten    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
as    O
it    O
may    O
correct    O
defects    O
in    O
autophagy    O
seen    O
in    O
these    O
diseases    O
and    O
improve    O
removal    O
of    O
aggregated    O
proteins    O
and    O
other    O
aberrant    O
storage    O
material    O
.    O

Social    O
,    O
and    O
committee    O
member    O
for    O
the    O
Charlotte    O
and    O
Gwenyth    O
Gray    O
Foundation    O
to    O
cure    O
Batten    B-MetabolicDisorder114084502
Disease    I-MetabolicDisorder114084502
.    O

It    O
was    O
also    O
in    O
aid    O
of    O
research    O
into    O
Batten    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
via    O
the    O
New    O
Zealand    O
charity    O
Cure    O
Kids    O
.    O

He    O
published    O
papers    O
on    O
tuberous    O
sclerosis    O
and    O
Batten    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
and    O
was    O
the    O
author    O
of    O
a    O
handbook    O
on    O
the    O
treatment    O
of    O
nervous    O
diseases    O
.    O

Mitochondrial    B-MetabolicDisorder114084502
diseases    I-MetabolicDisorder114084502

The    O
mitochondrial    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
are    O
genetic    O
disorders    O
carried    O
in    O
mitochondrial    O
DNA    O
,    O
or    O
nuclear    O
DNA    O
coding    O
for    O
mitochondrial    O
components    O
.    O

Because    O
mitochondrial    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
(    O
diseases    O
due    O
to    O
malfunction    O
of    O
mitochondria    O
)    O
can    O
be    O
inherited    O
both    O
maternally    O
and    O
through    O
chromosomal    O
inheritance    O
,    O
the    O
way    O
in    O
which    O
they    O
are    O
passed    O
on    O
from    O
generation    O
to    O
generation    O
can    O
vary    O
greatly    O
depending    O
on    O
the    O
disease    O
.    O

Mitochondrial    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
range    O
in    O
severity    O
from    O
asymptomatic    O
to    O
fatal    O
,    O
and    O
are    O
most    O
commonly    O
due    O
to    O
inherited    O
rather    O
than    O
acquired    O
mutations    O
of    O
mitochondrial    O
DNA    O
.    O

Mitochondria    O
have    O
been    O
implicated    O
in    O
several    O
human    O
diseases    O
,    O
including    O
mitochondrial    B-MetabolicDisorder114084502
disorders    I-MetabolicDisorder114084502
,    O
cardiac    O
dysfunction    O
,    O
heart    O
failure    O
and    O
autism    O
.    O

A    O
mutation    O
in    O
the    O
genes    O
regulating    O
any    O
of    O
these    O
functions    O
can    O
result    O
in    O
mitochondrial    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

Mitochondrial    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502

It    O
is    O
often    O
the    O
only    O
feature    O
of    O
mitochondrial    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
in    O
which    O
case    O
the    O
term    O
CPEO    O
may    O
be    O
given    O
as    O
the    O
diagnosis    O
.    O

Mitochondrial    B-MetabolicDisorder114084502
Disorders    I-MetabolicDisorder114084502

He    O
was    O
born    O
in    O
Morgantown    O
,    O
West    O
Virginia    O
,    O
on    O
February    O
23    O
,    O
1982    O
,    O
with    O
mitochondrial    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

Mitochondriopathies    B-MetabolicDisorder114084502
,    O
such    O
as    O
caused    O
by    O
mutations    O
in    O
"    O
SARS2    O
"    O
,    O
"    O
MT    O
-    O
TI    O
"    O
or    O
as    O
seen    O
with    O
Kearns    O
-    O
Sayre    O
syndrome    O
.    O

With    O
colleagues    O
at    O
the    O
University    O
of    O
Pennsylvania    O
in    O
the    O
1970s    O
,    O
DiMauro    O
studied    O
the    O
second    O
patient    O
ever    O
with    O
Luft    O
's    O
disease    O
,    O
the    O
prototypical    O
(    O
though    O
also    O
the    O
rarest    O
)    O
mitochondrial    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

PYCARD    O
has    O
been    O
shown    O
to    O
interact    O
with    O
MEFV    B-MetabolicDisorder114084502
.    O

Most    O
short    O
NALPs    O
,    O
such    O
as    O
NALP7    O
,    O
have    O
an    O
N    O
-    O
terminal    O
pyrin    O
(    O
MEFV    B-MetabolicDisorder114084502
)    O
domain    O
(    O
PYD    O
)    O
,    O
followed    O
by    O
a    O
NACHT    O
domain    O
,    O
a    O
NACHT    O
-    O
associated    O
domain    O
(    O
NAD    O
)    O
,    O
and    O
a    O
C    O
-    O
terminal    O
leucine    O
-    O
rich    O
repeat    O
(    O
LRR    O
)    O
region    O
.    O

Disorders    O
of    O
the    O
distal    O
urea    O
cycle    O
,    O
such    O
as    O
citrullinemia    B-MetabolicDisorder114084502
,    O
argininosuccinic    O
aciduria    O
and    O
argininemia    B-MetabolicDisorder114084502
are    O
included    O
in    O
newborn    O
screening    O
programs    O
in    O
many    O
jurisdictions    O
that    O
using    O
tandem    O
mass    O
spectrometry    O
to    O
identify    O
key    O
amino    O
acids    O
.    O

Argininemia    B-MetabolicDisorder114084502

As    O
the    O
erythrocyte    O
PFK    O
is    O
composed    O
of    O
both    O
PFKL    O
and    O
PFKM    O
,    O
this    O
heterogeneic    O
composition    O
is    O
attributed    O
with    O
the    O
differential    O
PFK    O
activity    O
and    O
organ    O
involvement    O
observed    O
in    O
some    O
inherited    O
PFK    O
deficiency    O
states    O
in    O
which    O
myopathy    O
or    O
hemolysis    O
or    O
both    O
can    O
occur    O
,    O
such    O
as    O
glycogenosis    B-MetabolicDisorder114084502
type    I-MetabolicDisorder114084502
VII    I-MetabolicDisorder114084502
(    O
Tarui    O
disease    O
)    O
.    O

Phosphofructokinase    B-MetabolicDisorder114084502
deficiency    I-MetabolicDisorder114084502
is    O
a    O
condition    O
caused    O
by    O
a    O
recessive    O
gene    O
in    O
the    O
breed    O
which    O
prevents    O
the    O
metabolism    O
of    O
glucose    O
into    O
energy    O
,    O
causing    O
the    O
dog    O
to    O
have    O
extremely    O
low    O
energy    O
and    O
be    O
unable    O
to    O
exercise    O
.    O

|    O
GSD    B-MetabolicDisorder114084502
type    I-MetabolicDisorder114084502
VII    I-MetabolicDisorder114084502

Iconic    O
memory    O
impairment    O
in    O
those    O
with    O
MCIs    O
may    O
be    O
used    O
as    O
a    O
predictor    O
for    O
the    O
development    O
of    O
more    O
severe    O
deficits    O
such    O
as    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
and    O
dementia    O
later    O
in    O
life    O
.    O

The    O
Associated    O
Press    O
quoted    O
Baugh    O
's    O
son    O
on    O
December    O
17    O
,    O
2008    O
,    O
saying    O
Baugh    O
had    O
died    O
after    O
numerous    O
health    O
issues    O
,    O
including    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
at    O
Fisher    O
County    O
Hospital    O
in    O
Rotan    O
,    O
Texas    O
.    O

Strong    O
,    O
who    O
had    O
suffered    O
from    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
for    O
some    O
years    O
,    O
died    O
at    O
the    O
age    O
of    O
75    O
in    O
a    O
Southport    O
care    O
home    O
on    O
the    O
morning    O
of    O
17    O
June    O
2013    O
.    O

Meanwhile    O
,    O
the    O
long    O
-    O
term    O
effects    O
of    O
the    O
test    O
serum    O
severely    O
damage    O
Isaiah    O
Bradley    O
's    O
mind    O
and    O
body    O
,    O
similar    O
in    O
part    O
to    O
the    O
effects    O
of    O
various    O
steroids    O
and    O
Alzheimer's    B-MetabolicDisorder114084502
.    O

He    O
suffered    O
from    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O
.    O

On    O
muscle    O
biopsy    O
,    O
the    O
typical    O
finding    O
includes    O
inclusion    O
bodies    O
,    O
rimmed    O
vacuoles    O
and    O
accumulation    O
of    O
aberrant    O
proteins    O
similar    O
to    O
those    O
found    O
in    O
senile    O
plaques    O
of    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
(    O
amyloid    O
beta    O
,    O
hyperphosphorylated    O
tau    O
,    O
amongst    O
others    O
)    O

Free    O
radicals    O
may    O
also    O
be    O
involved    O
in    O
Parkinson    O
's    O
disease    O
,    O
senile    O
and    O
drug    O
-    O
induced    O
deafness    O
,    O
schizophrenia    O
,    O
and    O
Alzheimer's    B-MetabolicDisorder114084502
.    O

On    O
October    O
20    O
,    O
2014    O
,    O
he    O
died    O
in    O
Thousand    O
Oaks    O
,    O
California    O
at    O
the    O
age    O
of    O
93    O
of    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

Faculty    O
members    O
of    O
the    O
Barshop    O
Institute    O
are    O
internationally    O
known    O
for    O
their    O
research    O
into    O
disease    O
processes    O
associated    O
with    O
aging    O
,    O
such    O
as    O
Alzheimer’s    B-MetabolicDisorder114084502
Disease    I-MetabolicDisorder114084502
,    O
Cancer    O
,    O
Diabetes    O
,    O
Parkinson    O
’s    O
Disease    O
,    O
and    O
Cardiovascular    O
Disease    O
.    O

The    O
World    O
Foundation    O
for    O
Medical    O
Research    O
and    O
Prevention    O
is    O
a    O
501(c)(3    O
)    O
Houston    O
-    O
based    O
grantmaking    O
public    O
charity    O
established    O
to    O
provide    O
leadership    O
in    O
developing    O
resources    O
to    O
sponsor    O
and    O
fund    O
the    O
projects    O
of    O
Professor    O
Luc    O
Montagnier    O
as    O
well    O
as    O
other    O
research    O
aimed    O
at    O
the    O
design    O
of    O
new    O
types    O
of    O
AIDS    O
vaccines    O
,    O
prolonging    O
the    O
active    O
life    O
of    O
aging    O
people    O
and    O
the    O
diagnosis    O
and    O
treatment    O
of    O
microbial    O
and    O
viral    O
factors    O
associated    O
with    O
cancers    O
,    O
neurodegenerative    O
,    O
auto    O
-    O
immune    O
and    O
other    O
multi    O
-    O
factorial    O
disease    O
processes    O
such    O
as    O
Alzheimer's    B-MetabolicDisorder114084502
Disease    I-MetabolicDisorder114084502
and    O
Parkinson    O
's    O
Disease    O
.    O

It    O
might    O
be    O
possible    O
to    O
prevent    O
or    O
cure    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
and    O
coronary    O
heart    O
disease    O
.    O

Kilbride    O
began    O
showing    O
symptoms    O
of    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
while    O
filming    O
"    O
Ma    O
and    O
Pa    O
Kettle    O
at    O
Home    O
"    O
in    O
1953    O
.    O

The    O
APOE    O
epsilon-4    O
allele    O
,    O
involved    O
in    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
may    O
increase    O
the    O
chance    O
of    O
developing    O
neurological    O
symptoms    O
.    O

He    O
died    O
from    O
alzheimer's    B-MetabolicDisorder114084502
at    O
age    O
71    O
.    O

With    O
Alzheimer    B-MetabolicDisorder114084502
patients    O
,    O
in    O
whom    O
dementia    O
had    O
just    O
started    O
(    O
mild    O
cognitive    O
impairment    O
(    O
MCI    O
)    O
)    O
the    O
MEG    O
proved    O
to    O
be    O
predictive    O
in    O
showing    O
whether    O
a    O
certain    O
MCI    O
patient    O
would    O
develop    O
into    O
an    O
Alzheimer    O
patient    O
.    O

Others    O
are    O
rs737865    O
and    O
rs165599    O
that    O
have    O
been    O
studied    O
,    O
e.g.    O
,    O
for    O
association    O
with    O
personality    O
traits    O
,    O
response    O
to    O
antidepressant    O
medications    O
,    O
and    O
psychosis    O
risk    O
associated    O
with    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

Alteration    O
in    O
some    O
cholinergic    O
neurons    O
may    O
account    O
for    O
the    O
disturbances    O
of    O
Alzheimer    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

The    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
(    O
AD    O
)    O
involves    O
difficulty    O
in    O
memory    O
and    O
cognition    O
.    O

It    O
builds    O
up    O
,    O
out    O
of    O
control    O
,    O
in    O
a    O
subject    O
's    O
system    O
,    O
ultimately    O
giving    O
them    O
symptoms    O
resembling    O
dementia    O
or    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
and    O
eventually    O
resulting    O
in    O
death    O
.    O

He    O
died    O
from    O
complications    O
of    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
on    O
April    O
30    O
,    O

Royce    O
reveals    O
that    O
he    O
had    O
archived    O
most    O
of    O
Jerusalem    O
's    O
evidence    O
and    O
delivers    O
it    O
to    O
him    O
on    O
disk    O
,    O
but    O
during    O
the    O
storm    O
Jerusalem    O
collapses    O
and    O
is    O
diagnosed    O
with    O
an    O
incurable    O
degenerative    O
neurological    O
illness    O
with    O
similar    O
symptoms    O
to    O
Alzheimer's    B-MetabolicDisorder114084502
and    O
Parkinson    O
's    O
disease    O
,    O
caused    O
by    O
constant    O
exposure    O
to    O
the    O
now    O
-    O
defunct    O
informational    O
substance    O
known    O
as    O
I    O
-    O
Pollen    O
.    O

In    O
the    O
months    O
just    O
prior    O
to    O
the    O
"    O
Crisis    O
"    O
"    O
reboot    O
"    O
in    O
1985    O
,    O
it    O
is    O
implied    O
that    O
Perry    O
White    O
is    O
beginning    O
to    O
succumb    O
to    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
manifesting    O
in    O
increased    O
forgetfulness    O
and    O
confusion    O
.    O

Berman    O
died    O
from    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
-    O
related    O
complications    O
at    O
his    O
home    O
in    O
Bell    O
Canyon    O
,    O
California    O
,    O
in    O
the    O
early    O
morning    O
of    O
September    O
1    O
,    O
2017    O
.    O

He    O
played    O
a    O
senior    O
named    O
Eddie    O
Johnson    O
with    O
Alzheimer's    B-MetabolicDisorder114084502
.    O

Other    O
health    O
and    O
social    O
concerns    O
which    O
have    O
adopted    O
coloured    O
ribbons    O
include    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
(    O
purple    O
)    O
,    O
HIV    O
/    O
AIDS    O
(    O
red    O
)    O
,    O
bipolar    O
disorder    O
(    O
green    O
)    O
,    O
and    O
brain    O
disorder    O
or    O
disability    O
(    O
silver    O
)    O
.    O

By    O
2015    O
,    O
Pat    O
had    O
contracted    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

Various    O
studies    O
have    O
shown    O
the    O
role    O
of    O
astrocytes    O
in    O
diseases    O
such    O
as    O
Alzheimer's    B-MetabolicDisorder114084502
,    O
amyotrophic    O
lateral    O
sclerosis    O
(    O
ALS    O
)    O
,    O
Parkinson    O
's    O
,    O
and    O
Huntington    O
's    O
.    O

For    O
example    O
,    O
a    O
few    O
studies    O
have    O
used    O
nerve    O
growth    O
factors    O
to    O
regain    O
some    O
cholinergic    O
function    O
in    O
patients    O
with    O
Alzheimer's    B-MetabolicDisorder114084502
.    O

This    O
drug    O
is    O
in    O
Phase    O
II    O
trials    O
for    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
phase    O
I    O
trials    O
for    O
epilepsy    O
,    O
and    O
in    O
preclinical    O
trials    O
for    O
amyotrophic    O
lateral    O
sclerosis    O
,    O
Parkinson    O
's    O
disease    O
,    O
Rett    O
syndrome    O
,    O
stroke    O
.    O

This    O
enzyme    O
is    O
involved    O
in    O
the    O
formation    O
of    O
Tau    O
plaques    O
,    O
which    O
are    O
common    O
in    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

Moore    O
's    O
father    O
was    O
diagnosed    O
with    O
early    O
onset    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
in    O
the    O
1970s    O
,    O
an    O
experience    O
which    O
later    O
inspired    O
the    O
play    O
"    O
Tom    O
"    O
.    O

The    O
ion    O
channel    O
hypothesis    O
of    O
Alzheimer’s    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
(    O
AD    O
)    O
,    O
also    O
known    O
as    O
the    O
channel    O
hypothesis    O
or    O
the    O
amyloid    B-MetabolicDisorder114084502
beta    I-MetabolicDisorder114084502
ion    O
channel    O
hypothesis    O
,    O
is    O
a    O
more    O
recent    O
variant    O
of    O
the    O
amyloid    O
hypothesis    O
of    O
AD    O
,    O
which    O
identifies    O
amyloid    B-MetabolicDisorder114084502
beta    I-MetabolicDisorder114084502
(    O
Aβ    O
)    O
as    O
the    O
underlying    O
cause    O
of    O
neurotoxicity    O
seen    O
in    O
AD    O
.    O

After    O
retirement    O
,    O
Broomfield    O
started    O
a    O
foundation    O
in    O
Michigan    O
that    O
supports    O
various    O
charities    O
in    O
southeast    O
Michigan    O
,    O
including    O
the    O
efforts    O
to    O
cure    O
cancer    O
,    O
spina    O
bifida    O
,    O
Alzheimer's    B-MetabolicDisorder114084502
,    O
and    O
the    O
Salvation    O
Army    O
.    O

Harry    O
's    O
final    O
months    O
were    O
plagued    O
by    O
Alzheimer's    B-MetabolicDisorder114084502
Disease    I-MetabolicDisorder114084502
;    O
Jimmy    O
Ritz    O
died    O
in    O
1985    O
shortly    O
before    O
Harry    O
,    O
but    O
Harry    O
's    O
health    O
was    O
so    O
delicate    O
that    O
he    O
was    O
never    O
told    O
of    O
his    O
brother    O
's    O
death    O
.    O

"    O
The    O
Wilderness    O
"    O
,    O
2009    O
novel    O
by    O
Samantha    O
Harvey    O
about    O
Alzheimer's    B-MetabolicDisorder114084502

After    O
Ruby    O
moves    O
to    O
America    O
and    O
Val    O
dies    O
of    O
a    O
stroke    O
,    O
Harvie    O
develops    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
and    O
is    O
placed    O
in    O
a    O
nursing    O
home    O
.    O

During    O
this    O
time    O
Santos    O
was    O
also    O
suffering    O
from    O
mental    O
illnesses    O
,    O
including    O
memory    O
loss    O
due    O
to    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

Large    O
stockpiles    O
of    O
HCH    O
isomers    O
exist    O
in    O
the    O
environment    O
.    O
α-HCH    O
and    O
β-HCH    O
are    O
highly    O
persistent    O
in    O
the    O
water    O
of    O
colder    O
regions    O
.    O
α-HCH    O
and    O
β-HCH    O
has    O
been    O
linked    O
Parkinson    O
's    O
and    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

A    O
typical    O
study    O
using    O
the    O
database    O
might    O
compare    O
a    O
sample    O
of    O
participants    O
who    O
developed    O
a    O
particular    O
disease    O
,    O
such    O
as    O
cancer    O
,    O
heart    O
disease    O
,    O
diabetes    O
or    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
with    O
a    O
sample    O
of    O
those    O
that    O
did    O
not    O
,    O
in    O
an    O
attempt    O
to    O
measure    O
the    O

The    O
titles    O
of    O
the    O
photographs    O
,    O
referencing    O
specific    O
case    O
studies    O
such    O
as    O
"    O
Bipolar    O
Disorder    O
"    O
,    O
'    O
'    O
Alzheimer's    B-MetabolicDisorder114084502
"    O
,    O
"    O
Breast    O
Cancer    O
"    O
,    O
and    O
"    O
HIV    O
"    O
,    O
contrast    O
with    O
the    O
mundane    O
visual    O
nature    O
of    O
the    O
subject    O
matter    O
:    O
seemingly    O
ordinary    O
containers    O
covered    O
in    O
frost    O
stored    O
in    O
freezers    O
.    O

Najjar    O
diagnosed    O
Cahalan    O
using    O
a    O
test    O
that    O
involved    O
her    O
drawing    O
a    O
clock    O
,    O
a    O
test    O
normally    O
given    O
to    O
people    O
suspected    O
of    O
having    O
dementia    O
or    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

According    O
to    O
the    O
criminal    O
complaint    O
filed    O
by    O
the    O
U.S.    O
Department    O
of    O
Justice    O
,    O
Martoma    O
allegedly    O
advised    O
Steven    O
A.    O
Cohen    O
to    O
sell    O
shares    O
of    O
pharmaceutical    O
companies    O
Wyeth    O
and    O
Elan    O
Corporation    O
based    O
on    O
tips    O
from    O
two    O
doctors    O
,    O
including    O
Sid    O
Gilman    O
of    O
the    O
University    O
of    O
Michigan    O
,    O
about    O
the    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
drug    O
bapineuzumab    O
during    O
clinical    O
trials    O
overseen    O
by    O
the    O
FDA    O
.    O

Most    O
commonly    O
associated    O
with    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
but    O
also    O
found    O
in    O
those    O
with    O
other    O
forms    O
of    O
dementia    O
,    O
the    O
term    O
"    O
sundowning    O
"    O
was    O
coined    O
due    O
to    O
the    O
timing    O
of    O
the    O
patient    O
's    O
confusion    O
.    O

Former    O
U.S.    O
president    O
Ronald    O
Reagan    O
dies    O
at    O
the    O
age    O
of    O
93    O
after    O
suffering    O
nearly    O
a    O
decade    O
from    O
the    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

A    O
letter    O
by    O
former    O
U.S.    O
President    O
Ronald    O
Reagan    O
,    O
announcing    O
that    O
he    O
has    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
is    O
released    O
.    O

He    O
died    O
in    O
1991    O
from    O
septicemia    O
,    O
following    O
the    O
onset    O
of    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

During    O
the    O
later    O
episodes    O
,    O
Dr.    O
Lawrence    O
was    O
revealed    O
to    O
be    O
suffering    O
from    O
the    O
early    O
stages    O
of    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

After    O
this    O
first    O
cleavage    O
,    O
an    O
enzyme    O
called    O
γ-secretase    O
(    O
which    O
is    O
implicated    O
in    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
)    O
cleaves    O
the    O
remaining    O
part    O
of    O
the    O
notch    O
protein    O
just    O
inside    O
the    O
inner    O
leaflet    O
of    O
the    O
cell    O
membrane    O
of    O
the    O
notch    O
-    O
expressing    O
cell    O
.    O

Several    O
gamma    O
secretase    O
inhibitors    O
that    O
underwent    O
human    O
clinical    O
trials    O
in    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
and    O
MCI    O
patients    O
resulted    O
in    O
statistically    O
significant    O
worsening    O
of    O
cognition    O
relative    O
to    O
controls    O
,    O
which    O
is    O
thought    O
to    O
be    O
due    O
to    O
its    O
incidental    O
effect    O
on    O
Notch    O
signalling    O
.    O

Rita    O
later    O
developed    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
and    O
Miguel    O
became    O
physically    O
frailer    O
.    O

Specifically    O
,    O
like    O
plastoquinol    O
,    O
SkQ1    O
has    O
been    O
shown    O
to    O
scavenge    O
superoxides    O
both    O
within    O
cells    O
(    O
in    O
vivo    O
)    O
and    O
outiside    O
of    O
cells    O
(    O
in    O
vitro    O
)    O
.    O
SkQR1    O
and    O
SkQ1    O
have    O
also    O
been    O
proposed    O
as    O
a    O
possible    O
way    O
to    O
treat    O
brain    O
issues    O
like    O
Alzheimer's    B-MetabolicDisorder114084502
due    O
to    O
their    O
ability    O
to    O
potentially    O
fix    O
damages    O
caused    O
by    O
amyloid    B-MetabolicDisorder114084502
beta    I-MetabolicDisorder114084502
.    O

GSK-3    O
has    O
recently    O
been    O
the    O
subject    O
of    O
much    O
research    O
because    O
it    O
has    O
been    O
implicated    O
in    O
a    O
number    O
of    O
diseases    O
,    O
including    O
Type    O
II    O
diabetes    O
(    O
Diabetes    B-MetabolicDisorder114084502
mellitus    I-MetabolicDisorder114084502
type    I-MetabolicDisorder114084502
2    I-MetabolicDisorder114084502
)    O
,    O
Alzheimer's    B-MetabolicDisorder114084502
Disease    I-MetabolicDisorder114084502
,    O
inflammation    O
,    O
cancer    O
,    O
and    O
bipolar    O
disorder    O
.    O

GSK-3    O
inhibitors    O
are    O
currently    O
being    O
tested    O
for    O
therapeutic    O
effects    O
in    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
type    B-MetabolicDisorder114084502
2    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
mellitus    I-MetabolicDisorder114084502
(    O
T2DM    O
)    O
,    O
some    O
forms    O
of    O
cancer    O
,    O
and    O
bipolar    O
disorder    O
.    O

As    O
Charles    O
Beaumont    O
became    O
increasingly    O
ill    O
from    O
a    O
mysterious    O
brain    O
illness    O
,    O
possibly    O
Pick    O
's    O
disease    O
or    O
very    O
early    O
onset    O
Alzheimer's    B-MetabolicDisorder114084502
,    O
and    O
unable    O
to    O
write    O
,    O
Sohl    O
ghostwrote    O
three    O
episodes    O
of    O
"    O
The    O
Twilight    O
Zone    O
"    O
for    O
him    O
.    O

Fickett    O
died    O
September    O
8    O
,    O
2011    O
,    O
aged    O
83    O
,    O
at    O
her    O
Callao    O
,    O
Virginia    O
home    O
,    O
from    O
complications    O
of    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
according    O
to    O
her    O
daughter    O
.    O

He    O
died    O
on    O
September    O
24    O
,    O
2002    O
,    O
after    O
a    O
long    O
struggle    O
with    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

Cybrids    O
are    O
valuable    O
in    O
mitochondrial    O
research    O
and    O
have    O
been    O
used    O
to    O
provide    O
suggestive    O
evidence    O
of    O
mitochondrial    O
involvement    O
in    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
Parkinson    O
's    O
disease    O
,    O
and    O
other    O
conditions    O
.    O

Christenberry    O
was    O
diagnosed    O
with    O
Alzheimer’s    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
in    O
2011    O
.    O

These    O
drugs    O
are    O
used    O
to    O
slow    O
the    O
progression    O
of    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

Auto    O
-    O
enhancing    O
processes    O
such    O
as    O
these    O
are    O
possible    O
causes    O
of    O
degenerative    O
diseases    O
including    O
Parkinson    O
's    O
,    O
Alzheimer's    B-MetabolicDisorder114084502
,    O
and    O
coronary    O
artery    O
disease    O
.    O

Apart    O
from    O
diseases    O
caused    O
by    O
abnormalities    O
in    O
mitochondrial    O
DNA    O
,    O
many    O
diseases    O
are    O
suspected    O
to    O
be    O
associated    O
in    O
part    O
by    O
mitochondrial    O
dysfunctions    O
,    O
such    O
as    O
diabetes    O
mellitus    O
,    O
forms    O
of    O
cancer    O
and    O
cardiovascular    O
disease    O
,    O
lactic    B-MetabolicDisorder114084502
acidosis    I-MetabolicDisorder114084502
,    O
specific    O
forms    O
of    O
myopathy    O
,    O
osteoporosis    O
,    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
Parkinsons    O
's    O
disease    O
,    O
stroke    O
,    O
male    O
infertility    O
and    O
which    O
are    O
also    O
believed    O
to    O
play    O
a    O
role    O
in    O
the    O
aging    O
process    O
.    O

She    O
writes    O
about    O
women    O
's    O
health    O
issues    O
:    O
osteoporosis    O
,    O
heart    O
disease    O
,    O
cancer    O
,    O
and    O
Alzheimers    B-MetabolicDisorder114084502
,    O
as    O
well    O
as    O
myths    O
and    O
misinformation    O
about    O
fibroids    O
,    O
hysterectomies    O
,    O
aging    O
,    O
and    O
hormone    O
replacement    O
therapy    O
.    O

Dementia    O
in    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502

Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502

It    O
is    O
dedicated    O
to    O
funding    O
scientific    O
studies    O
to    O
find    O
ways    O
to    O
treat    O
,    O
cure    O
or    O
prevent    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
vascular    O
dementia    O
,    O
Lewy    O
Body    O
disease    O
and    O
fronto    O
-    O
temporal    O
dementia    O
.    O

She    O
later    O
becomes    O
a    O
home    O
health    O
aide    O
,    O
and    O
is    O
bequeathed    O
a    O
flat    O
by    O
a    O
pensioner    O
with    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
she    O
patiently    O
cared    O
for    O
.    O

Chromosomal    O
rearrangements    O
and    O
altered    O
expression    O
of    O
this    O
gene    O
have    O
been    O
implicated    O
in    O
several    O
neurological    O
,    O
neoplastic    O
,    O
and    O
other    O
types    O
of    O
diseases    O
,    O
including    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
Down    O
's    O
syndrome    O
,    O
epilepsy    O
,    O
amyotrophic    O
lateral    O
sclerosis    O
,    O
schwannoma    O
,    O
melanoma    O
,    O
and    O
type    B-MetabolicDisorder114084502
I    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
.    O

In    O
January    O
2011    O
,    O
he    O
called    O
his    O
brother    O
Ron    O
Reagan    O
"    O
an    O
embarrassment    O
"    O
for    O
speculating    O
in    O
a    O
memoir    O
that    O
their    O
father    O
suffered    O
from    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
while    O
president    O
.    O

It    O
is    O
dedicated    O
to    O
Manson    O
's    O
mother    O
,    O
who    O
died    O
in    O
May    O
2014    O
after    O
an    O
eight    O
-    O
year    O
battle    O
with    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
and    O
dementia    O
.    O

Other    O
pathologies    O
with    O
etiology    O
involving    O
mitochondrial    O
dysfunction    O
include    O
schizophrenia    O
,    O
bipolar    O
disorder    O
,    O
dementia    O
,    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
Parkinson    O
's    O
disease    O
,    O
epilepsy    O
,    O
stroke    O
,    O
cardiovascular    O
disease    O
,    O
chronic    O
fatigue    O
syndrome    O
,    O
retinitis    O
pigmentosa    O
,    O
and    O
diabetes    O
mellitus    O
.    O

The    O
Mayo    O
Clinic    O
and    O
the    O
University    O
of    O
Minnesota    O
are    O
partners    O
in    O
the    O
Minnesota    O
Partnership    O
for    O
Biotechnology    O
and    O
Medical    O
Genomics    O
,    O
a    O
state    O
-    O
funded    O
program    O
that    O
conducts    O
research    O
into    O
cancer    O
,    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
heart    O
health    O
,    O
obesity    O
,    O
and    O
other    O
areas    O
.    O

By    O
1970    O
he    O
was    O
displaying    O
symptoms    O
indicative    O
of    O
Alzheimer's    B-MetabolicDisorder114084502
Disease    I-MetabolicDisorder114084502
and    O
died    O
in    O
Provincetown    O
on    O
December    O
1    O
,    O
1978    O
.    O

Certain    O
disorders    O
,    O
such    O
as    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
and    O
semantic    O
dementia    O
,    O
are    O
characterized    O
by    O
a    O
patient    O
’s    O
inability    O
to    O
integrate    O
semantic    O
memories    O
,    O
which    O
results    O
in    O
patients    O
being    O
unable    O
to    O
form    O
new    O
memories    O
,    O
lacking    O
awareness    O
of    O
time    O
period    O
,    O
as    O
well    O
as    O
lacking    O
other    O
important    O
cognitive    O
processes    O
.    O

Barr    O
died    O
in    O
2009    O
at    O
age    O
73    O
after    O
a    O
long    O
battle    O
with    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

During    O
the    O
off    O
-    O
season    O
,    O
Hundley    O
regularly    O
conducted    O
basketball    O
clinics    O
around    O
the    O
country    O
and    O
worked    O
with    O
charities    O
in    O
the    O
Salt    O
Lake    O
City    O
area    O
until    O
withdrawing    O
from    O
the    O
public    O
eye    O
due    O
to    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
in    O
his    O
final    O
years    O
.    O

Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502

In    O
1992    O
,    O
Haley    O
and    O
a    O
colleague    O
,    O
upon    O
examining    O
cerebrospinal    O
fluid    O
,    O
reported    O
levels    O
of    O
glutamine    O
synthetase    O
considerably    O
higher    O
in    O
cases    O
of    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
than    O
in    O
a    O
control    O
group    O
,    O
and    O
suggested    O
that    O
this    O
could    O
be    O
a    O
biomarker    O
to    O
aid    O
diagnosis    O
.    O

Research    O
has    O
found    O
that    O
people    O
with    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
(    O
AD    O
)    O
are    O
significantly    O
impaired    O
overall    O
in    O
visual    O
search    O
tasks    O
.    O

Charles    O
Farnsley    O
died    O
on    O
June    O
19    O
,    O
1990    O
from    O
Alzheimer's    B-MetabolicDisorder114084502
Disease    I-MetabolicDisorder114084502
.    O

Uncle    O
Earl    O
already    O
has    O
his    O
hands    O
full    O
with    O
his    O
business    O
and    O
a    O
wife    O
who    O
suffers    O
from    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

They    O
were    O
married    O
over    O
70    O
years    O
when    O
he    O
died    O
in    O
September    O
2011    O
at    O
Bishop    O
Place    O
Retirement    O
Center    O
in    O
Pullman    O
;    O
he    O
was    O
age    O
96    O
and    O
had    O
suffered    O
for    O
several    O
years    O
from    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

Holliday    O
became    O
round    O
-    O
the    O
-    O
clock    O
caregiver    O
for    O
his    O
mother    O
,    O
who    O
suffers    O
from    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
and    O
subsequently    O
became    O
a    O
member    O
of    O
the    O
Alzheimer    O
's    O
Foundation    O
of    O
America    O
.    O

PBMs    O
have    O
been    O
strong    O
proponents    O
in    O
the    O
creation    O
of    O
a    O
U.S.    O
Food    O
and    O
Drug    O
Administration    O
(    O
FDA    O
)    O
pathway    O
to    O
approve    O
similar    O
versions    O
of    O
expensive    O
specialty    O
drug    O
that    O
treat    O
conditions    O
like    O
Alzheimer's    B-MetabolicDisorder114084502
,    O
rheumatoid    O
arthritis    O
and    O
multiple    O
sclerosis    O
.    O

"    O
Iris    O
''    O
(    O
2001    O
)    O
–    O
biographical    O
account    O
of    O
the    O
life    O
of    O
Irish    O
novelist    O
Iris    O
Murdoch    O
and    O
her    O
mental    O
decline    O
from    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502

Those    O
who    O
may    O
need    O
such    O
clothes    O
include    O
older    O
adults    O
with    O
old    O
-    O
age    O
conditions    O
such    O
as    O
Alzheimer's    B-MetabolicDisorder114084502
Disease    I-MetabolicDisorder114084502
,    O
or    O
younger    O
adults    O
and    O
children    O
with    O
disorders    O
from    O
birth    O
.    O

Van    O
Andel    O
Research    O
Institute    O
(    O
VARI    O
)    O
scientists    O
study    O
the    O
epigenetic    O
,    O
genetic    O
,    O
cellular    O
and    O
structural    O
basis    O
of    O
cancer    O
and    O
Parkinson    O
’s    O
disease    O
as    O
well    O
as    O
osteoarthritis    O
,    O
neurofibromatosis    O
type    O
1    O
,    O
Alzheimer’s    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
prion    O
diseases    O
and    O
other    O
conditions    O
,    O
with    O
the    O
goal    O
of    O
identifying    O
new    O
treatments    O
.    O

She    O
died    O
from    O
complications    O
of    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
at    O
the    O
age    O
of    O
94    O
.    O

Morgan    O
died    O
of    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
on    O
July    O
10    O
,    O
2007    O
,    O
aged    O
92    O
.    O

Alternatively    O
,    O
overexpression    O
of    O
Hsp70    O
can    O
mitigate    O
damage    O
from    O
ischemia    O
-    O
reperfusion    O
in    O
cardiac    O
muscle    O
,    O
as    O
well    O
damage    O
from    O
neurodegenerative    O
diseases    O
,    O
such    O
as    O
Alzheimer’s    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
Parkinson    O
’s    O
disease    O
,    O
Huntington    O
’s    O
disease    O
,    O
and    O
spinocerebellar    O
ataxias    O
,    O
and    O
aging    O
and    O
cell    O
senescence    O
,    O
as    O
observed    O
in    O
centenarians    O
subjected    O
to    O
heat    O
shock    O
challenge    O
.    O

In    O
addition    O
to    O
cancers    O
,    O
14    O
-    O
3    O
-    O
3ζ    O
has    O
been    O
implicated    O
in    O
pathogenic    O
infections    O
and    O
neurodegenerative    O
diseases    O
,    O
including    O
Creutzfeldt    O
–    O
Jakob    O
disease    O
,    O
Parkinson    O
’s    O
disease    O
,    O
and    O
Alzheimer’s    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
(    O
AD    O
)    O
.    O

Agustín    O
Cejas    O
died    O
of    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
on    O
14    O
August    O
2015    O
.    O

In    O
November    O
2009    O
it    O
was    O
reported    O
in    O
the    O
"    O
Wirral    O
News    O
"    O
that    O
,    O
aged    O
90    O
,    O
Dodd    O
was    O
battling    O
with    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
and    O
required    O
full    O
-    O
time    O
care    O
at    O
a    O
care    O
home    O
in    O
Cheshire    O
.    O

Cyathane    O
diterpenoids    O
also    O
stimulate    O
nerve    O
growth    O
factor    O
synthesis    O
,    O
and    O
have    O
the    O
potential    O
to    O
be    O
developed    O
into    O
therapeutic    O
agents    O
for    O
neurodegenerative    O
disorders    O
such    O
as    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

Also    O
resulting    O
were    O
increased    O
home    O
care    O
benefits    O
for    O
the    O
aging    O
as    O
well    O
as    O
legislation    O
establishing    O
research    O
and    O
care    O
centers    O
for    O
Alzheimer's    B-MetabolicDisorder114084502
Disease    I-MetabolicDisorder114084502
.    O

In    O
her    O
later    O
years    O
while    O
struggling    O
with    O
Alzheimer's    B-MetabolicDisorder114084502
,    O
she    O
stated    O
"    O
I    O
remember    O
better    O
when    O
I    O
paint    O
"    O
.    O

Alzheimer's    B-MetabolicDisorder114084502
patients    O
are    O
the    O
largest    O
cohort    O
groups    O
that    O
express    O
IA    O
.    O

It    O
is    O
sensitive    O
to    O
detecting    O
cognitive    O
impairment    O
associated    O
with    O
dementia    O
,    O
for    O
example    O
,    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

However    O
,    O
CYP2J2    O
7    O
carriers    O
showed    O
no    O
association    O
with    O
hypertension    O
,    O
heart    O
attack    O
,    O
or    O
stroke    O
in    O
a    O
study    O
of    O
5,740    O
participants    O
of    O
the    O
cardiovascular    O
cohort    O
of    O
the    O
Malmö    O
Diet    O
and    O
Cancer    O
study    O
;    O
since    O
other    O
studies    O
have    O
afforded    O
contradictory    O
results    O
,    O
this    O
allele    O
is    O
currently    O
regarded    O
as    O
not    O
associated    O
with    O
cardiovascular    O
diseases    O
(    O
see    O
Epoxyeicosatrienoic    O
acid#Clinical    O
significance    O
)    O
.    O
Bearers    O
of    O
this    O
SNP    O
in    O
a    O
Chinese    O
Population    O
had    O
a    O
higher    O
risk    O
of    O
younger    O
onset    O
of    O
type    B-MetabolicDisorder114084502
2    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
and    O
among    O
a    O
Chinese    O
Han    O
population    O
had    O
a    O
higher    O
risk    O
of    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

Other    O
possible    O
causes    O
include    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
and    O
infection    O
.    O

In    O
January    O
2016    O
,    O
he    O
described    O
Alzheimer's    B-MetabolicDisorder114084502
as    O
"    O
one    O
of    O
the    O
last    O
great    O
medical    O
terrors    O
"    O
and    O
announced    O
he    O
would    O
be    O
leaving    O
money    O
to    O
the    O
Alzheimer    O
's    O
Society    O
in    O
his    O
will    O
.    O

Except    O
for    O
a    O
few    O
identifiable    O
brain    O
diseases    O
,    O
such    O
as    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
there    O
are    O
"    O
neither    O
biological    O
or    O
chemical    O
tests    O
nor    O
biopsy    O
or    O
necropsy    O
findings    O
for    O
verifying    O
or    O
falsifying    O
"    O
DSM    O
"    O
diagnoses    O
"    O
,    O
i.e.    O
,    O
there    O
are    O
no    O
objective    O
methods    O
for    O
detecting    O
the    O
presence    O
or    O
absence    O
of    O
mental    O
illness    O
.    O

In    O
medicine    O
(    O
in    O
general    O
)    O
diseases    O
are    O
defined    O
in    O
terms    O
of    O
a    O
multitude    O
of    O
criteria    O
,    O
these    O
include    O
:    O
(    O
a    O
)    O
"    O
morbid    O
anatomy    O
"    O
,    O
e.g.    O
,    O
mitral    O
stenosis    O
,    O
cholecystitis    O
;    O
(    O
b    O
)    O
"    O
histologically    O
"    O
,    O
e.g.    O
,    O
most    O
cancers    O
,    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
;    O
(    O
c    O
)    O
"    O
infective    O
organism    O
"    O
,    O
e.g.    O
Tuberculosis    O
,    O
Measles    O
;    O
(    O
d    O
)    O
"    O
physiologically    O
"    O
,    O
e.g.    O
myasthenia    O
gravis    O
;    O
(    O
e    O
)    O
"    O
biochemically    O
"    O
,    O
e.g.    O
aminoaciduria    O
;    O
(    O
e    O
)    O
"    O
chromosomally    O
"    O
,    O
e.g.    O
trisomy    O
21    O
,    O
Turner    O
's    O
syndrome    O
;    O
(    O
f    O
)    O
"    O
molecularly    O
"    O
,    O
e.g.    O
thalassemia    O
;    O
(    O
g    O
)    O
"    O
genetically    O
"    O
,    O
e.g.    O
Huntington    O
's    O
disease    O
,    O
cystic    O
fibrosis    O
;    O
and    O
(    O
h    O
)    O
"    O
syndrome    O
"    O
,    O
e.g.    O
migraine    O
,    O
torticollis    O
,    O
essential    O
tremor    O
,    O
blepharospasm    O
,    O
torsion    O
dystonia    O
and    O
most    O
(    O
so    O
-    O
called    O
)    O
mental    O
disorders    O
.    O

Neurodegenerative    O
diseases    O
such    O
as    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
and    O
Lafora    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
show    O
as    O
a    O
marker    O
,    O
an    O
atrophy    O
of    O
the    O
grey    O
matter    O
of    O
the    O
cerebral    O
cortex    O
.    O

Evidence    O
exists    O
linking    O
elevated    O
homocysteine    O
levels    O
and    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

Roland    O
Boyes    O
(    O
12    O
February    O
1937    O
–    O
16    O
June    O
2006    O
)    O
was    O
a    O
British    O
Labour    O
Party    O
politician    O
,    O
amateur    O
photographer    O
and    O
,    O
in    O
retirement    O
,    O
a    O
fundraiser    O
for    O
research    O
into    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

Following    O
a    O
rapid    O
deterioration    O
in    O
his    O
mental    O
abilities    O
from    O
1993    O
,    O
he    O
was    O
diagnosed    O
with    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
in    O
1995    O
(    O
in    O
which    O
year    O
he    O
turned    O
only    O
58    O
)    O
,    O
and    O
retired    O
at    O
the    O
1997    O
general    O
election    O
,    O
reportedly    O
never    O
knowing    O
that    O
Labour    O
won    O
the    O
election    O
.    O

Johnson    O
's    O
competition    O
talent    O
was    O
a    O
monologue    O
which    O
was    O
correlated    O
to    O
her    O
experience    O
with    O
a    O
patient    O
she    O
had    O
met    O
with    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

The    O
role    O
,    O
if    O
any    O
,    O
that    O
the    O
meningeal    O
lymphatics    O
play    O
in    O
diseases    O
of    O
the    O
nervous    O
system    O
is    O
an    O
area    O
of    O
active    O
research    O
-    O
particularly    O
with    O
regard    O
to    O
neurological    O
disorders    O
in    O
which    O
immunity    O
is    O
a    O
fundamental    O
player    O
such    O
as    O
multiple    O
sclerosis    O
,    O
Alzheimer’s    B-MetabolicDisorder114084502
Disease    I-MetabolicDisorder114084502
,    O
amyotrophic    O
lateral    O
sclerosis    O
,    O
Hennekam    O
syndrome    O
,    O
and    O
Prader    O
-    O
Willi    O
syndrome    O
.    O

During    O
her    O
later    O
years    O
,    O
she    O
appeared    O
as    O
Toshiko    O
Takahashi    O
,    O
a    O
woman    O
with    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
in    O
"    O
"    O
,    O
with    O
Kunihiko    O
Mitamura    O
.    O

SAD    O
measure    O
of    O
men    O
in    O
their    O
40s    O
,    O
greater    O
than    O
25    O
cm    O
,    O
also    O
predicts    O
significantly    O
higher    O
risk    O
of    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
30    O
years    O
later    O
.    O

Deveson    O
was    O
diagnosed    O
with    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
in    O
2014    O
.    O

Cleotha    O
Staples    O
died    O
in    O
Chicago    O
on    O
February    O
21    O
,    O
2013    O
,    O
after    O
suffering    O
from    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
for    O
over    O
a    O
decade    O
.    O

In    O
August    O
2004    O
Osbourne    O
stated    O
her    O
father    O
had    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
and    O
she    O
paid    O
for    O
his    O
care    O
in    O
the    O
last    O
years    O
of    O
his    O
life    O
.    O

Suppose    O
the    O
grantor    O
loses    O
capacity    O
to    O
grant    O
permission    O
after    O
the    O
power    O
of    O
attorney    O
has    O
been    O
created    O
(    O
for    O
example    O
,    O
from    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
or    O
a    O
head    O
injury    O
in    O
a    O
car    O
crash    O
)    O
;    O
then    O
the    O
power    O
will    O
probably    O
no    O
longer    O
be    O
effective    O
.    O

He    O
died    O
22    O
October    O
2004    O
in    O
Paris    O
,    O
a    O
victim    O
of    O
many    O
years    O
of    O
Alzheimer's    B-MetabolicDisorder114084502
.    O

It    O
has    O
therefore    O
been    O
proposed    O
as    O
a    O
potential    O
treatment    O
for    O
sleep    O
disorders    O
such    O
as    O
narcolepsy    O
and    O
to    O
improve    O
vigilance    O
in    O
old    O
age    O
,    O
particularly    O
in    O
the    O
treatment    O
of    O
conditions    O
such    O
as    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

A    O
G    O
/    O
A    O
polymorphism    O
in    O
the    O
promoter    O
of    O
the    O
apo    O
A1    O
gene    O
has    O
been    O
associated    O
with    O
the    O
age    O
at    O
which    O
patients    O
presented    O
with    O
Alzheimer    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

APOD    O
is    O
elevated    O
in    O
patients    O
with    O
schizophrenia    O
,    O
bipolar    O
disorder    O
,    O
and    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

PET    O
imaging    O
of    O
the    O
VAChT    O
may    O
provide    O
insights    O
into    O
early    O
diagnosis    O
of    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

Overall    O
,    O
there    O
are    O
various    O
non    O
-    O
selective    O
calcium    O
channel    O
blockers    O
that    O
help    O
alleviate    O
symptoms    O
of    O
hypertension    O
,    O
schizophrenia    O
,    O
cardiac    O
arrhythmia    O
,    O
epilepsy    O
,    O
pain    O
,    O
asthma    O
,    O
bradycardia    O
,    O
angina    O
pectoris    O
and    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

In    O
Alzheimer    B-MetabolicDisorder114084502
Disease    I-MetabolicDisorder114084502
,    O
there    O
is    O
a    O
progressive    O
accumulation    O
of    O
β-amyloid    B-MetabolicDisorder114084502
protein    I-MetabolicDisorder114084502
(    O
Aβ    O
)    O
in    O
brain    O
.    O

Curtis    O
died    O
from    O
complications    O
from    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
in    O
a    O
Bountiful    O
,    O
Utah    O
nursing    O
home    O
,    O
aged    O
79    O
,    O
and    O
was    O
buried    O
there    O
at    O
Bountiful    O
Memorial    O
Park    O
.    O

After    O
a    O
month    O
abroad    O
,    O
Meredith    O
was    O
called    O
back    O
to    O
care    O
for    O
Ellis    O
,    O
who    O
had    O
developed    O
early    O
-    O
onset    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
and    O
Meredith    O
obtained    O
her    O
M.D.    O

St    O
Vincent    O
's    O
has    O
earned    O
international    O
recognition    O
in    O
the    O
field    O
of    O
medical    O
research    O
,    O
and    O
is    O
at    O
the    O
forefront    O
of    O
developing    O
new    O
therapies    O
for    O
the    O
treatment    O
of    O
many    O
diseases    O
,    O
including    O
cancer    O
,    O
heart    O
disease    O
,    O
HIV    O
/    O
AIDS    O
,    O
Parkinson    O
's    O
disease    O
and    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
arthritis    O
,    O
asthma    O
and    O
diabetes    O
.    O

Often    O
referred    O
to    O
as    O
"    O
one    O
of    O
Canada    O
's    O
national    O
treasures    O
"    O
,    O
Kenney    O
died    O
on    O
February    O
8    O
,    O
2006    O
,    O
aged    O
95    O
,    O
following    O
a    O
lengthy    O
battle    O
with    O
Alzheimer's    B-MetabolicDisorder114084502
and    O
vascular    O
dementia    O
in    O
Mission    O
,    O
BC    O
.    O

He    O
died    O
near    O
Paris    O
of    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
aged    O
73    O
.    O

Humans    O
appear    O
to    O
have    O
lost    O
a    O
functional    O
caspase-12    O
gene    O
,    O
which    O
in    O
other    O
primates    O
codes    O
for    O
an    O
enzyme    O
that    O
may    O
protect    O
against    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

Newman    O
died    O
in    O
1995    O
,    O
after    O
being    O
diagnosed    O
as    O
suffering    O
from    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

Just    O
when    O
Adam    O
's    O
life    O
seems    O
to    O
be    O
on    O
an    O
upswing    O
,    O
he    O
is    O
diagnosed    O
with    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

Byeong    O
-    O
soo    O
(    O
Sol    O
Kyung    O
-    O
gu    O
)    O
was    O
a    O
serial    O
killer    O
in    O
the    O
past    O
,    O
though    O
he    O
now    O
suffers    O
from    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

Towards    O
the    O
end    O
of    O
his    O
life    O
,    O
Davila    O
suffered    O
from    O
Alzheimer's    B-MetabolicDisorder114084502
Disease    I-MetabolicDisorder114084502
,    O
which    O
led    O
to    O
his    O
death    O
on    O
February    O
14    O
,    O
2014    O
.    O

Smith    O
died    O
of    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
in    O
May    O
1995    O
.    O

He    O
has    O
been    O
diagnosed    O
with    O
Alzheimer's    B-MetabolicDisorder114084502
Disease    I-MetabolicDisorder114084502
.    O

Schwartz    O
began    O
suffering    O
from    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
around    O
1970    O
and    O
died    O
in    O
Chicago    O
on    O
February    O
10    O
,    O
1977    O
.    O

Chinoy    O
died    O
at    O
age    O
87    O
on    O
May    O
24    O
,    O
2010    O
,    O
in    O
Turners    O
Falls    O
,    O
Massachusetts    O
due    O
to    O
pneumonia    O
and    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

Batman    O
uses    O
the    O
batplane    O
to    O
blow    O
up    O
the    O
bomb    O
and    O
then    O
deduces    O
that    O
Dedalus    O
is    O
suffering    O
from    O
Alzheimer's    B-MetabolicDisorder114084502
Disease    I-MetabolicDisorder114084502
and    O
has    O
escaped    O
the    O
island    O
to    O
finish    O
his    O
master    O
plan    O
using    O
the    O
supervillain    O
group    O
known    O
as    O
Leviathan    O
.    O

Her    O
closest    O
friend    O
and    O
former    O
employee    O
,    O
Suzanne    O
Pierre    O
,    O
died    O
of    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
in    O
February    O
2011    O
.    O

Constructional    O
apraxia    O
may    O
be    O
caused    O
by    O
lesions    O
in    O
the    O
parietal    O
lobe    O
following    O
stroke    O
or    O
it    O
may    O
serve    O
as    O
an    O
indicator    O
for    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

There    O
are    O
qualitative    O
differences    O
between    O
patients    O
with    O
left    O
hemisphere    O
damage    O
,    O
right    O
hemisphere    O
damage    O
,    O
and    O
Alzheimer's    B-MetabolicDisorder114084502
Disease    I-MetabolicDisorder114084502
.    O

Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
patients    O
with    O
constructional    O
apraxia    O
have    O
unique    O
symptoms    O
.    O

Alzheimer's    B-MetabolicDisorder114084502
Disease    I-MetabolicDisorder114084502

Researchers    O
were    O
looking    O
for    O
the    O
hooks    O
in    O
music    O
to    O
help    O
future    O
research    O
on    O
Alzheimer’s    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

PRA    O
has    O
participated    O
in    O
several    O
Clinical    O
Trials    O
of    O
note    O
such    O
as    O
the    O
Landmark    O
Alzheimer's    B-MetabolicDisorder114084502
Prevention    O
Clinical    O
Trial    O
,    O
a    O
collaborative    O
effort    O
involving    O
the    O
Banner    O
Alzheimer    O
's    O
Institute    O
(    O
BAI    O
)    O
;    O
Genentech    O
,    O
a    O
member    O
of    O
the    O
Roche    O
Group    O
;    O
the    O
University    O
of    O
Antioquia    O
in    O
Colombia    O
;    O
and    O
the    O
National    O
Institutes    O
of    O
Health    O
(    O
NIH    O
)    O
.    O

"    O
A    O
Better    O
Place    O
"    O
(    O
2012    O
)    O
,    O
featuring    O
Josh    O
Homme    O
of    O
Queens    O
of    O
the    O
Stone    O
Age    O
,    O
and    O
"    O
Hey    O
Little    O
One    O
"    O
(    O
2013    O
)    O
,    O
a    O
tribute    O
to    O
Glen    O
's    O
wife    O
,    O
Kimberly    O
Woollen    O
,    O
who    O
helped    O
Campbell    O
in    O
his    O
battle    O
with    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502

The    O
LCD    O
allows    O
neuropsychological    O
assessment    O
for    O
diagnosing    O
Alzheimer's    B-MetabolicDisorder114084502
Disease    I-MetabolicDisorder114084502
,    O
allowing    O
feedback    O
sessions    O
,    O
and    O
using    O
neuropsychological    O
testing    O
for    O
diagnosing    O
Mild    O
Cognitive    O
Impairments    O
,    O
previously    O
detected    O
through    O
interviews    O
alone    O
.    O

Along    O
with    O
Division    O
20    O
and    O
the    O
committee    O
on    O
aging    O
,    O
Division    O
40    O
was    O
involved    O
in    O
drafting    O
APA    O
's    O
response    O
to    O
the    O
first    O
draft    O
of    O
National    O
Framework    O
for    O
Alzheimer's    B-MetabolicDisorder114084502
Disease    I-MetabolicDisorder114084502
(    O
AD    O
)    O
,    O
a    O
federal    O
plan    O
of    O
action    O
based    O
on    O
legislation    O
passed    O
in    O
2011    O
to    O
reduce    O
the    O
burdens    O
of    O
AD    O
.    O

Masitinib    O
is    O
being    O
studied    O
for    O
several    O
human    O
conditions    O
including    O
cancers    O
,    O
Alzheimer    B-MetabolicDisorder114084502
,    O
multiple    O
sclerosis    O
,    O
mastocytosis    O
,    O
and    O
amyotrophic    O
lateral    O
sclerosis    O
.    O

9    O
December    O
-    O
Danny    O
Blanchflower    O
,    O
who    O
captained    O
Tottenham    O
Hotspur    O
to    O
the    O
first    O
league    O
championship    O
and    O
FA    O
Cup    O
double    O
of    O
the    O
20th    O
century    O
in    O
1961    O
and    O
became    O
a    O
football    O
writer    O
after    O
his    O
retirement    O
as    O
a    O
player    O
in    O
1964    O
,    O
dies    O
of    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
aged    O
67    O
.    O

Around    O
1990    O
,    O
Solomon    O
began    O
to    O
display    O
symptoms    O
of    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

Lattimore    O
died    O
on    O
May    O
18    O
,    O
2010    O
in    O
Houston    O
,    O
Texas    O
after    O
suffering    O
from    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

He    O
was    O
the    O
pupil    O
and    O
colleague    O
of    O
Alois    O
Alzheimer    O
and    O
contributed    O
to    O
the    O
definition    O
of    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

It    O
progressed    O
to    O
phase    O
II    O
clinical    O
trials    O
for    O
the    O
treatment    O
of    O
dementia    O
and    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
but    O
is    O
no    O
longer    O
under    O
development    O
.    O

It    O
has    O
nootropic    O
effects    O
and    O
was    O
originally    O
developed    O
as    O
a    O
potential    O
treatment    O
for    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
but    O
a    O
second    O
action    O
that    O
was    O
subsequently    O
found    O
was    O
that    O
it    O
inhibits    O
the    O
production    O
of    O
Interleukin-8    O
and    O
thus    O
produces    O
an    O
antiinflammatory    O
effect    O
,    O
and    O
so    O
it    O
has    O
also    O
been    O
developed    O
as    O
a    O
potential    O
treatment    O
for    O
ulcerative    O
colitis    O
.    O

After    O
a    O
long    O
struggle    O
against    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
Lubis    O
died    O
in    O
Medistra    O
Hospital    O
on    O
2    O
July    O
2004    O
at    O
age    O
82    O
.    O

ABT-418    O
is    O
a    O
drug    O
developed    O
by    O
Abbott    O
,    O
that    O
has    O
nootropic    O
,    O
neuroprotective    O
and    O
anxiolytic    O
effects    O
,    O
and    O
has    O
been    O
researched    O
for    O
treatment    O
of    O
both    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
and    O
ADHD    O
.    O

Both    O
GTS-21    O
itself    O
and    O
its    O
demethylated    O
active    O
metabolite    O
4-OH    O
-    O
GTS-21    O
display    O
nootropic    O
and    O
neuroprotective    O
effects    O
,    O
and    O
GTS-21    O
is    O
being    O
investigated    O
for    O
the    O
treatment    O
of    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
nicotine    O
dependence    O
,    O
and    O
,    O
most    O
significantly    O
,    O
for    O
schizophrenia    O
.    O

This    O
work    O
is    O
relevant    O
to    O
neuropsychiatric    O
disorders    O
including    O
schizophrenia    O
,    O
depression    O
,    O
drug    O
addiction    O
,    O
obsessive    O
compulsive    O
disorder    O
(    O
OCD    O
)    O
,    O
attention    O
deficit    O
hyperactivity    O
disorder    O
(    O
ADHD    O
)    O
,    O
as    O
well    O
as    O
Parkinson    O
's    O
and    O
Alzheimer's    B-MetabolicDisorder114084502
diseases    O
.    O

Apathy    O
affects    O
nearly    O
50–70    O
percent    O
of    O
individuals    O
with    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

It    O
is    O
also    O
known    O
to    O
be    O
a    O
distinct    O
psychiatric    O
syndrome    O
that    O
is    O
associated    O
with    O
many    O
conditions    O
,    O
some    O
of    O
which    O
are    O
:    O
CADASIL    O
syndrome    O
,    O
depression    O
,    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
Chagas    O
disease    O
,    O
Creutzfeldt–    O

The    O
monkeys    O
are    O
used    O
scientific    O
research    O
,    O
including    O
gene    O
therapy    O
,    O
cancer    O
,    O
Parkinson    O
's    O
,    O
Alzheimer's    B-MetabolicDisorder114084502
,    O
stem    O
cells    O
and    O
antibody    O
-    O
based    O
treatments    O
.    O

She    O
had    O
been    O
diagnosed    O
with    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

He    O
was    O
diagnosed    O
with    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
in    O
2003    O
and    O
died    O
in    O
Bethesda    O
,    O
Maryland    O
in    O
2011    O
.    O

Shriver    O
was    O
diagnosed    O
with    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
in    O
2003    O
.    O

In    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
MRI    O
scans    O
of    O
the    O
entire    O
brain    O
can    O
accurately    O
assess    O
the    O
rate    O
of    O
hippocampal    O
atrophy    O
,    O
while    O
PET    O
scans    O
can    O
measure    O
the    O
brain    O
's    O
metabolic    O
activity    O
by    O
measuring    O
regional    O
glucose    O
metabolism    O
,    O
and    O
beta    O
-    O
amyloid    O
plaques    O
using    O
tracers    O
such    O
as    O
Pittsburgh    O
compound    O
B    O
(    O
PiB    O
)    O
.    O

However    O
,    O
he    O
is    O
suffering    O
from    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
and    O
is    O
unable    O
to    O
remember    O
her    O
.    O

Synaptic    O
dysfunction    O
can    O
also    O
occur    O
in    O
neurodegenerative    O
disorders    O
such    O
as    O
Alzheimer's    B-MetabolicDisorder114084502
.    O

Cotinine    O
is    O
currently    O
being    O
studied    O
as    O
a    O
treatment    O
for    O
depression    O
,    O
PTSD    O
,    O
schizophrenia    O
,    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
and    O
Parkinson    O
's    O
disease    O
.    O

Cotinine    O
treatment    O
has    O
also    O
been    O
shown    O
to    O
reduce    O
depression    O
,    O
anxiety    O
,    O
and    O
fear    O
-    O
related    O
behavior    O
as    O
well    O
as    O
memory    O
impairment    O
in    O
animal    O
models    O
of    O
depression    O
,    O
PTSD    O
,    O
and    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

Heap    O
suffered    O
a    O
heart    O
attack    O
in    O
2005    O
and    O
was    O
also    O
diagnosed    O
with    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
in    O
2006    O
.    O

Gagne    O
was    O
diagnosed    O
with    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
(    O
or    O
possibly    O
chronic    O
traumatic    O
encephalopathy    O
caused    O
by    O
a    O
lifetime    O
of    O
head    O
injuries    O
)    O
and    O
had    O
been    O
living    O
in    O
the    O
memory    O
-    O
loss    O
section    O
of    O
a    O
Bloomington    O
,    O
Minnesota    O
health    O
care    O
facility    O
.    O

Ollie    O
Anderson    O
died    O
in    O
Greenwich    O
,    O
Connecticut    O
of    O
Alzheimer    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
on    O
May    O
31    O
,    O
1987    O
.    O

Hurd    O
died    O
of    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
at    O
a    O
San    O
Francisco    O
hospital    O
in    O
1988    O
.    O

Mental    O
health    O
,    O
including    O
schizophrenia    O
,    O
dementia    O
and    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502

Reminyl    O
(    O
against    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
(    O
dementia    O
)    O
.    O

Flutemetamol    O
(    O
18F    O
)    O
(    O
trade    O
name    O
Vizamyl    O
,    O
by    O
GE    O
Healthcare    O
)    O
is    O
a    O
PET    O
scanning    O
radiopharmaceutical    O
containing    O
the    O
radionuclide    O
fluorine-18    O
,    O
used    O
as    O
a    O
diagnostic    O
tool    O
for    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

But    O
right    O
after    O
their    O
reunion    O
,    O
their    O
birth    O
mother    O
,    O
who    O
suffers    O
from    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
suddenly    O
disappears    O
.    O

A    O
member    O
of    O
the    O
National    O
Academy    O
of    O
Science    O
since    O
1960    O
,    O
Puck    O
published    O
more    O
than    O
200    O
papers    O
on    O
topics    O
including    O
Alzheimer's    B-MetabolicDisorder114084502
Disease    I-MetabolicDisorder114084502
and    O
Down    O
syndrome    O
,    O
and    O
optimising    O
radiotherapy    O
dosages    O
for    O
the    O
treatment    O
of    O
cancer    O
.    O

She    O
suffered    O
from    O
Alzheimer's    B-MetabolicDisorder114084502
Disease    I-MetabolicDisorder114084502
and    O
polyneuritis    O
,    O
she    O
lived    O
the    O
last    O
ten    O
years    O
of    O
her    O
life    O
with    O
her    O
daughter    O
and    O
son    O
-    O
in    O
-    O
law    O
in    O
Newcastle    O
upon    O
Tyne    O
.    O

Bellini    O
died    O
on    O
20    O
March    O
2014    O
,    O
aged    O
83    O
,    O
in    O
São    O
Paulo    O
,    O
due    O
to    O
complications    O
caused    O
by    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
culminating    O
with    O
cardiac    O
arrest    O
.    O

She    O
also    O
tries    O
to    O
rebuild    O
her    O
relationship    O
with    O
her    O
estranged    O
mother    O
,    O
her    O
ailing    O
father    O
(    O
who    O
suffers    O
from    O
Alzheimer's    B-MetabolicDisorder114084502
Disease    I-MetabolicDisorder114084502
)    O
,    O
and    O
her    O
daughter    O
,    O
who    O
wants    O
desperately    O
to    O
be    O
with    O
her    O
father    O
and    O
blames    O
her    O
mother    O
for    O
the    O
breakup    O
,    O
even    O
trying    O
to    O
sabotage    O
the    O
romantic    O
overtures    O
Justin    O
makes    O
towards    O
Birdee    O
.    O

Mirrored    O
-    O
self    O
misidentification    O
,    O
a    O
type    O
of    O
DMS    O
,    O
occurs    O
most    O
typically    O
in    O
patients    O
with    O
dementia    O
,    O
especially    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

In    O
April    O
2014    O
there    O
were    O
315    O
open    O
clinical    O
trials    O
under    O
way    O
to    O
understand    O
and    O
treat    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

A    O
2013    O
study    O
showed    O
that    O
translocator    O
protein    O
can    O
prevent    O
and    O
partially    O
treat    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
in    O
mice    O
.    O

Jim    O
Scott    O
died    O
on    O
April    O
13    O
,    O
2017    O
from    O
complications    O
of    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

Andersen    O
died    O
in    O
Los    O
Angeles    O
from    O
complications    O
of    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

Garms    O
was    O
diagnosed    O
with    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
in    O
the    O
1980s    O
,    O
and    O
died    O
on    O
December    O
16    O
,    O
1984    O
.    O

Her    O
mother    O
is    O
ill    O
and    O
apparently    O
suffering    O
from    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
at    O
first    O
not    O
recognising    O
her    O
daughter    O
.    O

He    O
is    O
currently    O
focused    O
on    O
translating    O
his    O
neuroscience    O
and    O
stem    O
cell    O
research    O
to    O
potential    O
therapeutic    O
development    O
for    O
brain    O
disorders    O
such    O
as    O
Parkinson    O
's    O
disease    O
,    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
and    O
inflammatory    O
diseases    O
.    O

Over    O
the    O
last    O
20    O
years    O
,    O
these    O
tests    O
have    O
gone    O
on    O
to    O
be    O
used    O
in    O
more    O
than    O
600    O
published    O
studies    O
of    O
Parkinson    O
's    O
disease    O
,    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
Huntington    O
's    O
disease    O
,    O
Depression    O
,    O
Schizophrenia    O
,    O
Autism    O
,    O
Obsessive    O
-    O
Compulsive    O
Disorder    O
and    O
ADHD    O
,    O
among    O
others    O
.    O

Drinabant    O
(    O
INN    O
;    O
AVE-1625    O
)    O
is    O
a    O
drug    O
that    O
acts    O
as    O
a    O
selective    O
CB1    O
receptor    O
antagonist    O
,    O
which    O
was    O
under    O
investigation    O
varyingly    O
by    O
Sanofi    O
-    O
Aventis    O
as    O
a    O
treatment    O
for    O
obesity    O
,    O
schizophrenia    O
,    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
Parkinson    O
's    O
disease    O
,    O
and    O
nicotine    O
dependence    O
.    O

Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502

The    O
frequency    O
of    O
these    O
corrections    O
increases    O
as    O
the    O
father    O
falls    O
victim    O
to    O
both    O
hubris    O
and    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

He    O
was    O
already    O
83    O
years    O
old    O
and    O
presumably    O
suffering    O
from    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

This    O
process    O
has    O
aided    O
in    O
treating    O
patients    O
diagnosed    O
with    O
Parkinson    O
's    O
disease    O
,    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
Tourette    O
syndrome    O
,    O
epilepsy    O
,    O
chronic    O
headaches    O
,    O
and    O
mental    O
disorders    O
.    O

He    O
has    O
also    O
used    O
comparative    O
genomics    O
to    O
contribute    O
directly    O
to    O
the    O
understanding    O
of    O
chromatin    O
structure    O
and    O
the    O
genetics    O
of    O
numerous    O
conditions    O
including    O
asthma    O
,    O
obesity    O
,    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
retinitis    O
pigmentosa    O
,    O
muscular    O
dystrophies    O
,    O
and    O
Aicardi–    O

In    O
her    O
final    O
years    O
,    O
Murdoch    O
suffered    O
from    O
the    O
early    O
stages    O
of    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
one    O
of    O
the    O
symptoms    O
of    O
which    O
is    O
a    O
reduced    O
vocabulary    O
and    O
decreased    O
word    O
fluency    O
.    O

Further    O
work    O
by    O
Zoghbi    O
,    O
Orr    O
,    O
and    O
colleagues    O
demonstrated    O
that    O
the    O
misfolding    O
,    O
aggregation    O
,    O
and    O
degradation    O
of    O
the    O
protein    O
product    O
of    O
this    O
gene    O
,    O
ataxin-1    O
,    O
play    O
a    O
role    O
in    O
the    O
disorder    O
,    O
a    O
finding    O
relevant    O
to    O
other    O
,    O
more    O
common    O
neurodegenerative    O
diseases    O
such    O
as    O
Alzheimer's    B-MetabolicDisorder114084502
.    O

He    O
is    O
regarded    O
as    O
a    O
leading    O
authority    O
on    O
the    O
causes    O
and    O
prevention    O
of    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
and    O
is    O
the    O
principal    O
author    O
of    O
the    O
inflammatory    O
hypothesis    O
of    O
the    O
disease    O
,    O
which    O
holds    O
that    O
Alzheimer    O
's    O
is    O
an    O
inflammation    O
of    O
the    O
cortex    O
.    O

A    O
specific    O
gene    O
in    O
mouse    O
brain    O
thought    O
to    O
be    O
involved    O
in    O
the    O
onset    O
of    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
which    O
codes    O
for    O
the    O
enzyme    O
cyclin    O
-    O
dependent    O
kinase    O
5    O
(    O
Cdk5    O
)    O
was    O
knocked    O
out    O
.    O

Research    O
was    O
conducted    O
in    O
both    O
Russia    O
and    O
western    O
nations    O
into    O
potential    O
applications    O
as    O
a    O
neuroprotective    O
drug    O
to    O
treat    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
and    O
,    O
possibly    O
,    O
as    O
a    O
nootropic    O
,    O
as    O
well    O
.    O

Latrepirdine    O
attracted    O
renewed    O
interest    O
in    O
2009    O
after    O
being    O
shown    O
in    O
small    O
preclinical    O
trials    O
to    O
have    O
positive    O
effects    O
on    O
persons    O
suffering    O
from    O
Alzheimer's    B-MetabolicDisorder114084502
disease    O
.    O

Yosu    O
died    O
in    O
Santander    O
on    O
20    O
February    O
2016    O
at    O
the    O
age    O
of    O
76    O
,    O
from    O
the    O
effects    O
of    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

Bradanicline    O
was    O
discontinued    O
for    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
and    O
cognitive    O
impairment    O
in    O
schizophrenia    O
in    O
late    O
2013    O
.    O

Morton    O
had    O
struggled    O
for    O
four    O
years    O
with    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
and    O
then    O
developed    O
Parkinson    O
's    O
disease    O
.    O

Meijers    O
suffered    O
from    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
and    O
died    O
on    O
14    O
October    O
2013    O
.    O

Her    O
husband    O
later    O
developed    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
dying    O
after    O
a    O
ten    O
-    O
year    O
struggle    O
with    O
the    O
illness    O
.    O

Silva    O
suffered    O
from    O
senility    O
or    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
in    O
her    O
last    O
years    O
.    O

Mancini    O
was    O
married    O
and    O
divorced    O
twice    O
,    O
and    O
he    O
died    O
of    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
on    O
the    O
day    O
before    O
his    O
75th    O
birthday    O
in    O
London    O
,    O
Ohio    O
.    O

He    O
portrayed    O
a    O
patient    O
suffering    O
from    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
in    O
the    O
2005    O
drama    O
film    O
"    O
Thanmathra    O
"    O
for    O
which    O
he    O
won    O
the    O
Kerala    O
State    O
Film    O
Award    O
for    O
Best    O
Actor    O
and    O
a    O
Filmfare    O
Award    O
for    O
Best    O
Actor    O
–    O
Malayalam    O
.    O

December    O
11    O
–    O
Terry    O
Pratchett    O
informs    O
fans    O
on    O
-    O
line    O
that    O
he    O
has    O
been    O
diagnosed    O
with    O
a    O
rare    O
form    O
of    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

Throughout    O
her    O
career    O
,    O
Potter    O
has    O
championed    O
the    O
Alzheimer    O
's    O
Association    O
in    O
honor    O
of    O
her    O
paternal    O
grandfather    O
's    O
battle    O
with    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

Shortly    O
after    O
,    O
Smith    O
's    O
family    O
released    O
a    O
letter    O
on    O
July    O
17    O
,    O
2010    O
,    O
stating    O
that    O
he    O
had    O
a    O
"    O
progressive    O
neurocognitive    O
disorder    O
"    O
,    O
which    O
has    O
not    O
been    O
publicly    O
disclosed    O
as    O
Alzheimer's    B-MetabolicDisorder114084502
or    O
anything    O
else    O
.    O

Floyd    O
Patterson    O
suffered    O
from    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
and    O
prostate    O
cancer    O
and    O
had    O
been    O
hospitalized    O
for    O
a    O
week    O
prior    O
to    O
his    O
death    O
.    O

Marital    O
problems    O
arise    O
in    O
2006    O
when    O
,    O
following    O
Mike    O
's    O
death    O
from    O
a    O
heart    O
attack    O
whilst    O
suffering    O
from    O
Alzheimer's    B-MetabolicDisorder114084502
,    O
Ken    O
grows    O
jealous    O
of    O
Deirdre    O
's    O
grief    O
reaction    O
;    O
he    O
leaves    O
home    O
and    O
tries    O
to    O
rebuild    O
a    O
relationship    O
with    O
his    O
estranged    O
son    O
Daniel    O
.    O

Mike    O
was    O
killed    O
off    O
,    O
dying    O
of    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
;    O
he    O
died    O
in    O
Ken    O
's    O
arms    O
.    O

The    O
character    O
has    O
been    O
used    O
to    O
portray    O
the    O
effects    O
of    O
depression    O
and    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

In    O
neurodegenerative    O
diseases    O
such    O
as    O
Alzheimer’s    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
dementia    O
with    O
Lewy    O
bodies    O
,    O
and    O
Parkinson    O
’s    O
disease    O
,    O
areas    O
such    O
as    O
the    O
basal    O
ganglia    O
,    O
cerebral    O
cortex    O
,    O
locus    O
coeruleus    O
,    O
temporal    O
,    O
parietal    O
and    O
frontal    O
lobes    O
,    O
and    O
the    O
limbic    O
system    O
,    O
especially    O
the    O
hippocampus    O
and    O
amygdala    O
,    O
are    O
impaired    O
.    O

This    O
systemic    O
or    O
neuro    O
-    O
inflammation    O
and    O
neuroimmune    O
activation    O
have    O
been    O
shown    O
to    O
play    O
a    O
role    O
in    O
the    O
etiology    O
of    O
a    O
variety    O
of    O
neurodegenerative    O
disorders    O
such    O
as    O
Parkinson    O
's    O
and    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
multiple    O
sclerosis    O
,    O
pain    O
,    O
and    O
AIDS    O
-    O
associated    O
dementia    O
.    O

It    O
also    O
degrades    O
the    O
amyloid    B-MetabolicDisorder114084502
beta    I-MetabolicDisorder114084502
peptide    O
whose    O
abnormal    O
misfolding    O
and    O
aggregation    O
in    O
neural    O
tissue    O
has    O
been    O
implicated    O
as    O
a    O
cause    O
of    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

Cystamine    O
has    O
also    O
been    O
studied    O
as    O
a    O
potential    O
medicinal    O
compound    O
in    O
the    O
case    O
of    O
Huntington    O
's    O
disease    O
,    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
and    O
carbon    O
tetrachloride    O
liver    O
damage    O

He    O
suffered    O
from    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
and    O
died    O
at    O
Headbourne    O
Worthy    O
in    O
Hampshire    O
on    O
13    O
July    O
1995    O
.    O

Joanne    O
Koenig    O
Coste    O
is    O
an    O
advocate    O
for    O
patients    O
with    O
Alzheimer's    B-MetabolicDisorder114084502
Disease    I-MetabolicDisorder114084502
and    O
their    O
families    O
.    O

Diseases    O
amenable    O
to    O
UPR    O
inhibition    O
include    O
Creutzfeldt    O
–    O
Jakob    O
disease    O
,    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
Parkinson    O
's    O
disease    O
,    O
and    O
Huntington    O
's    O
disease    O
.    O

At    O
home    O
,    O
she    O
takes    O
of    O
Joe    O
and    O
her    O
aging    O
father    O
,    O
Dr.    O
Secondopinionson    O
,    O
who    O
has    O
alzheimers    B-MetabolicDisorder114084502
.    O

He    O
suffered    O
from    O
Alzheimers    B-MetabolicDisorder114084502
and    O
then    O
he    O
stopped    O
working    O
as    O
a    O
doctor    O
.    O

It    O
deals    O
with    O
people    O
suffering    O
from    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
slowly    O
finding    O
that    O
familiar    O
faces    O
and    O
items    O
long    O
cherished    O
are    O
slipping    O
away    O
from    O
their    O
memory    O
.    O

Following    O
his    O
retirement    O
,    O
Mayor    O
was    O
a    O
long    O
time    O
resident    O
of    O
Tampa    O
,    O
Florida    O
,    O
where    O
he    O
died    O
in    O
2005    O
at    O
the    O
age    O
of    O
89    O
,    O
after    O
dealing    O
with    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
for    O
many    O
years    O
.    O

On    O
October    O
4    O
,    O
Mustaine    O
's    O
Alzheimer's    B-MetabolicDisorder114084502
-    O
afflicted    O
mother    O
-    O
in    O
-    O
law    O
went    O
missing    O
from    O
a    O
campground    O
.    O

James    O
Heller    O
tries    O
to    O
manage    O
a    O
crisis    O
amid    O
the    O
onset    O
of    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

neuGRID    O
’s    O
user    O
-    O
friendly    O
environment    O
is    O
customised    O
to    O
a    O
range    O
of    O
users    O
from    O
students    O
to    O
senior    O
neuroscientists    O
working    O
in    O
the    O
fields    O
of    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
psychiatric    O
diseases    O
,    O
and    O
white    O
matter    O
diseases    O
.    O

In    O
February    O
2008    O
,    O
Reid    O
appeared    O
as    O
the    O
mother    O
of    O
Monica    O
Gallagher    O
,    O
Joan    O
,    O
who    O
was    O
suffering    O
from    O
Alzheimer's    B-MetabolicDisorder114084502
in    O
the    O
Channel    O
4    O
drama    O
"    O
Shameless    O
"    O
.    O

She    O
died    O
of    O
Alzheimer's    B-MetabolicDisorder114084502
in    O
1983    O
.    O

Because    O
the    O
vagus    O
nerve    O
is    O
associated    O
with    O
many    O
different    O
functions    O
and    O
brain    O
regions    O
,    O
clinical    O
research    O
has    O
been    O
done    O
to    O
determine    O
its    O
usefulness    O
in    O
treating    O
other    O
illnesses    O
,    O
including    O
various    O
anxiety    O
disorders    O
,    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
migraines    O
,    O
and    O
obesity    O
.    O

The    O
compounds    O
in    O
its    O
venom    O
have    O
been    O
studied    O
have    O
pharmacological    O
properties    O
relating    O
to    O
diabetes    O
,    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
and    O
even    O
HIV    O
.    O

At    O
sixteen    O
,    O
Lynn    O
penned    O
a    O
song    O
about    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
entitled    O
"    O
Your    O
Favorite    O
Stranger    O
,    O
"    O
which    O
aided    O
in    O
her    O
becoming    O
a    O
published    O
ASCAP    O
writer    O
in    O
the    O
same    O
year    O
.    O

Betty    O
Wagner    O
Spandikow    O
had    O
suffered    O
a    O
stroke    O
and    O
been    O
dealing    O
with    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
at    O
the    O
time    O
of    O
her    O
death    O
at    O
the    O
age    O
of    O
85    O
on    O
October    O
26    O
,    O
2008    O
.    O

Scientists    O
sometimes    O
refer    O
to    O
Parkinson    O
’s    O
disease    O
as    O
a    O
synucleiopathy    O
(    O
due    O
to    O
an    O
abnormal    O
accumulation    O
of    O
alpha    O
-    O
synuclein    O
protein    O
in    O
the    O
brain    O
)    O
to    O
distinguish    O
it    O
from    O
other    O
neurodegenerative    O
diseases    O
,    O
such    O
as    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
where    O
the    O
brain    O
accumulates    O
tau    O
protein    O
.    O

Neurofibrillary    O
tangles    O
and    O
senile    O
plaques    O
,    O
characteristic    O
of    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
are    O
not    O
common    O
unless    O
the    O
person    O
is    O
demented    O
.    O

PD    O
is    O
the    O
second    O
most    O
common    O
neurodegenerative    O
disorder    O
after    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
and    O
affects    O
approximately    O
seven    O
million    O
people    O
globally    O
and    O
one    O
million    O
people    O
in    O
the    O
United    O
States    O
.    O

Spira    O
died    O
from    O
complications    O
of    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
on    O
September    O
2    O
,    O
2007    O
,    O
at    O
his    O
home    O
in    O
Beechhurst    O
,    O
Queens    O
,    O
New    O
York    O
,    O
at    O
the    O
age    O
of    O
83    O
.    O

Alzheimer's    B-MetabolicDisorder114084502
Disease    I-MetabolicDisorder114084502
Research    O
Program    O

There    O
is    O
some    O
evidence    O
from    O
humans    O
and    O
animals    O
that    O
there    O
are    O
reduced    O
levels    O
of    O
plasmalogens    O
in    O
the    O
brain    O
in    O
neurodegenerative    O
disorders    O
including    O
Alzheimer    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
Parkinson    O
's    O
disease    O
,    O
Niemann–    O

Alzheimer's    B-MetabolicDisorder114084502
put    O
a    O
stop    O
to    O
Terry    O
's    O
parties    O
and    O
fun    O
and    O
she    O
eventually    O
died    O
in    O
a    O
Burbank    O
,    O
California    O
hospital    O
on    O
December    O
22    O
,    O
1987    O
.    O

Mainly    O
because    O
a    O
clip    O
from    O
the    O
documentary    O
showed    O
a    O
patient    O
awakening    O
from    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
by    O
listening    O
to    O
songs    O
from    O
his    O
era    O
such    O
as    O
Cab    O
Calloway    O
.    O

Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502

He    O
had    O
Alzheimer's    B-MetabolicDisorder114084502
Disease    I-MetabolicDisorder114084502
and    O
cancer    O
.    O

Presently    O
,    O
animal    O
experimentation    O
continues    O
to    O
be    O
used    O
in    O
research    O
that    O
aims    O
to    O
solve    O
medical    O
problems    O
including    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
multiple    O
sclerosis    O
spinal    O
cord    O
injury    O
,    O
and    O
many    O
more    O
conditions    O
in    O
which    O
there    O
is    O
no    O
useful    O
"    O
in    O
vitro    O
"    O
model    O
system    O
available    O
.    O

IL-18    O
has    O
also    O
been    O
found    O
to    O
increase    O
the    O
Alzheimer's    B-MetabolicDisorder114084502
disease    O
-    O
associated    O
amyloid-beta    B-MetabolicDisorder114084502
production    O
in    O
human    O
neuron    O
cells    O
.    O

Mutations    O
in    O
alpha    O
-    O
synuclein    O
are    O
associated    O
with    O
early    O
-    O
onset    O
familial    O
Parkinson    O
's    O
disease    O
and    O
the    O
protein    O
aggregates    O
abnormally    O
in    O
Parkinson    O
's    O
disease    O
,    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
Lewy    O
body    O
disease    O
,    O
and    O
other    O
neurodegenerative    O
diseases    O
.    O

Activation    O
of    O
this    O
receptor    O
also    O
has    O
neuroprotective    O
effects    O
in    O
models    O
of    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
Amyotrophic    O
lateral    O
sclerosis    O
,    O
multiple    O
sclerosis    O
,    O
and    O
stroke    O
while    O
its    O
inhibition    O
reduces    O
Epileptic    O
seizure    O
.    O

Bob    O
Ward    O
died    O
in    O
one    O
of    O
his    O
sons    O
'    O
homes    O
in    O
Laytonsville    O
,    O
Maryland    O
on    O
April    O
29    O
,    O
2005    O
at    O
the    O
age    O
of    O
77    O
,    O
due    O
to    O
complications    O
related    O
to    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
may    O
also    O
be    O
linked    O
to    O
kalirin-7    O
.    O

Moreover    O
,    O
acetylation    O
by    O
ATAT1    O
could    O
also    O
be    O
implicated    O
in    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502

Previous    O
studies    O
have    O
shown    O
that    O
SOAT    O
modulates    O
proteolytic    O
processing    O
in    O
cell    O
-    O
based    O
and    O
animal    O
models    O
of    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

He    O
had    O
been    O
stricken    O
with    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

In    O
the    O
most    O
extreme    O
cases    O
one    O
might    O
think    O
about    O
the    O
catastrophic    O
results    O
of    O
Alzheimer’s    B-MetabolicDisorder114084502
Disease    I-MetabolicDisorder114084502
.    O

Topographical    O
disorientation    O
may    O
result    O
from    O
a    O
stroke    O
or    O
part    O
of    O
a    O
progressive    O
illness    O
,    O
hemispatial    O
neglect    O
,    O
dementia    O
,    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

Multiple    O
sclerosis    O
,    O
Parkinson    O
's    O
disease    O
,    O
amyotrophic    O
lateral    O
sclerosis    O
(    O
ALS    O
)    O
,    O
and    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
are    O
all    O
believed    O
to    O
be    O
exacerbated    O
by    O
inflammatory    O
processes    O
,    O
resulting    O
in    O
individuals    O
displaying    O
signs    O
of    O
these    O
diseases    O
at    O
an    O
earlier    O
age    O
than    O
is    O
typically    O
expected    O
.    O

Because    O
of    O
its    O
close    O
relationship    O
with    O
memory    O
formation    O
,    O
damage    O
to    O
the    O
hippocampus    O
is    O
closely    O
related    O
to    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

He    O
has    O
placed    O
special    O
emphasis    O
on    O
improving    O
treatments    O
for    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

June    O
22    O
–    O
Glen    O
Campbell    O
announces    O
that    O
he    O
has    O
been    O
diagnosed    O
with    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
;    O
further    O
stating    O
that    O
he    O
was    O
diagnosed    O
about    O
six    O
months    O
prior    O
.    O

The    O
biomarkers    O
can    O
be    O
used    O
to    O
diagnose    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
(    O
AD    O
)    O
in    O
a    O
very    O
early    O
stage    O
,    O
but    O
they    O
also    O
provide    O
objective    O
and    O
reliable    O
measures    O
of    O
disease    O
progress    O
.    O

Alzheimer    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502

APOE    O
:    O
Apolipoprotein    O
E    O
,    O
gene    O
associated    O
with    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502

Van    O
der    O
Hoeven    O
is    O
married    O
to    O
Lou    O
Buytendijk    O
,    O
who    O
was    O
diagnosed    O
with    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
in    O
2005    O
.    O

On    O
March    O
29    O
,    O
2009    O
Ivor    O
Dent    O
died    O
from    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

Two    O
of    O
the    O
most    O
frequent    O
patients    O
are    O
Gary    O
(    O
the    O
only    O
role    O
Whitehouse    O
plays    O
with    O
no    O
make    O
-    O
up    O
)    O
,    O
who    O
initially    O
uses    O
his    O
therapy    O
sessions    O
to    O
escape    O
from    O
his    O
wife    O
;    O
and    O
Monty    O
,    O
an    O
elderly    O
Jewish    O
taxi    O
-    O
driver    O
whose    O
wife    O
is    O
suffering    O
from    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

His    O
public    O
lectures    O
continued    O
until    O
the    O
early    O
1990s    O
,    O
when    O
he    O
started    O
to    O
show    O
signs    O
of    O
deterioration    O
from    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

Gait    O
abnormality    O
is    O
also    O
common    O
in    O
persons    O
with    O
nervous    O
system    O
problems    O
such    O
as    O
cauda    O
equina    O
syndrome    O
,    O
multiple    O
sclerosis    O
,    O
Parkinson    O
's    O
disease    O
,    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
myasthenia    O
gravis    O
,    O
normal    O
pressure    O
hydrocephalus    O
,    O
and    O
Charcot    O
–    O
Marie    O
–    O
Tooth    O
disease    O
.    O

Alzheimer's    B-MetabolicDisorder114084502
Disease    I-MetabolicDisorder114084502

Salman    O
suffers    O
from    O
mild    O
dementia    O
,    O
specifically    O
Alzheimer's    B-MetabolicDisorder114084502
.    O

He    O
died    O
of    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
in    O
1999    O
.    O

Nolan    O
has    O
undertaken    O
charity    O
work    O
for    O
the    O
Alzheimer's    B-MetabolicDisorder114084502
Society    O
,    O
including    O
cycling    O
the    O
River    O
Nile    O
in    O
Egypt    O
.    O

For    O
this    O
reason    O
,    O
norleucine    O
has    O
been    O
used    O
to    O
probe    O
the    O
role    O
of    O
methionine    O
in    O
Amyloid-β    B-MetabolicDisorder114084502
peptide    I-MetabolicDisorder114084502
(    O
AβP    O
)    O
the    O
central    O
constituent    O
of    O
senile    O
plaques    O
in    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

Toward    O
the    O
end    O
of    O
his    O
life    O
,    O
Shumiatcher    O
suffered    O
from    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
and    O
was    O
institutionalized    O
for    O
several    O
years    O
.    O

She    O
had    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

Knockout    O
rat    O
disease    O
models    O
for    O
Parkinson    O
's    O
disease    O
,    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
hypertension    O
,    O
and    O
diabetes    O
,    O
using    O
zinc    O
-    O
finger    O
nuclease    O
technology    O
,    O
are    O
being    O
commercialized    O
by    O
SAGE    O
Labs    O
.    O

In    O
his    O
later    O
years    O
he    O
suffered    O
from    O
Alzheimer's    B-MetabolicDisorder114084502
Disease    I-MetabolicDisorder114084502
and    O
resided    O
in    O
a    O
Fairfax    O
nursing    O
center    O
.    O

After    O
suffering    O
from    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
for    O
many    O
years    O
,    O
Paul    O
Burgess    O
Fay    O
Jr    O
died    O
at    O
his    O
home    O
in    O
Woodside    O
,    O
California    O
on    O
September    O
23    O
,    O
2009    O
.    O

Kleppe    O
died    O
of    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
in    O
Bethesda    O
,    O
Maryland    O
,    O
on    O
March    O
2    O
,    O
2007    O
.    O

Years    O
later    O
Gerda    O
developed    O
Alzheimer's    B-MetabolicDisorder114084502
and    O
died    O
in    O
1998    O
.    O

At    O
the    O
time    O
of    O
his    O
death    O
,    O
news    O
reports    O
said    O
he    O
had    O
suffered    O
from    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

He    O
suffered    O
from    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
and    O
died    O
in    O
Plymouth    O
on    O
1    O
December    O
2009    O
after    O
a    O
long    O
illness    O
.    O

This    O
may    O
prove    O
significant    O
for    O
the    O
development    O
of    O
new    O
Alzheimer's    B-MetabolicDisorder114084502
drugs    O
and    O
for    O
detecting    O
the    O
disease    O
before    O
the    O
onset    O
of    O
clinical    O
symptoms    O
.    O

Henrietta    O
Valor    O
died    O
of    O
complications    O
from    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
on    O
November    O
23    O
,    O
2007    O
.    O

He    O
died    O
from    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
in    O
2004    O
,    O
in    O
Lisbon    O
.    O

It    O
has    O
stimulant    O
and    O
nootropic    O
effects    O
,    O
and    O
has    O
been    O
investigated    O
as    O
a    O
treatment    O
for    O
ADHD    O
,    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
and    O
schizophrenia    O
.    O

Carl    O
Holtz    O
died    O
,    O
quietly    O
,    O
from    O
complications    O
due    O
to    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
early    O
in    O
the    O
morning    O
of    O
July    O
8    O
,    O
2006    O
.    O

At    O
the    O
age    O
of    O
86    O
and    O
dealing    O
with    O
Alzheimer's    B-MetabolicDisorder114084502
Ruth    O
Hubbard    O
Cousins    O
died    O
on    O
Thursday    O
January    O
11th    O
,    O
2007    O
at    O
Erlanger    O
Hospital    O
in    O
Chattanooga    O
,    O
Tennessee    O
.    O

In    O
brains    O
from    O
people    O
with    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
the    O
number    O
of    O
Cajal    O
–    O
Retzius    O
cells    O
(    O
which    O
is    O
highly    O
reduced    O
after    O
maturation    O
and    O
in    O
adult    O
life    O
)    O
,    O
is    O
even    O
further    O
diminished    O
in    O
comparison    O
to    O
normal    O
brains    O
;    O
their    O
morphology    O
is    O
also    O
altered    O
,    O
namely    O
there    O
is    O
a    O
significant    O
reduction    O
of    O
their    O
dendritic    O
arborization    O
,    O
which    O
reduces    O
the    O
number    O
of    O
synapses    O
between    O
these    O
cells    O
and    O
other    O
neurons    O
.    O

Major    O
diseases    O
being    O
modelized    O
with    O
PSCs    O
-    O
derived    O
cells    O
are    O
amyotrophic    O
lateral    O
sclerosis    O
(    O
ALS    O
)    O
,    O
Alzheimer's    B-MetabolicDisorder114084502
(    O
AD    O
)    O
,    O
Parkinson    O
's    O
(    O
PD    O
)    O
,    O
fragile    O
X    O
syndrome    O
(    O
FXS    O
)    O
,    O
Huntington    O
disease    O
(    O
HD    O
)    O
,    O
Down    O
syndrome    O
,    O
Spinal    O
muscular    O
atrophy    O
(    O
SMA    O
)    O
,    O
muscular    O
dystrophies    O
,    O
cystic    O
fibrosis    O
,    O
Long    O
QT    O
syndrome    O
,    O
and    O
Type    B-MetabolicDisorder114084502
I    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
.    O

Another    O
focus    O
is    O
on    O
the    O
hippocampus    O
and    O
medial    O
temporal    O
lobes    O
and    O
their    O
role    O
in    O
supporting    O
new    O
learning    O
by    O
providing    O
contextual    O
and    O
representational    O
constraints    O
on    O
what    O
is    O
learned    O
;    O
this    O
includes    O
clinical    O
studies    O
of    O
patients    O
with    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
mild    O
cognitive    O
impairment    O
,    O
global    O
anterograde    O
amnesia    O
,    O
and    O
posttraumatic    O
stress    O
disorder    O
.    O

Gluck    O
,    O
Myers    O
,    O
and    O
their    O
colleagues    O
have    O
developed    O
hippocampal    O
-    O
sensitive    O
learning    O
tasks    O
that    O
predict    O
future    O
onset    O
of    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
in    O
humans    O
as    O
well    O
as    O
in    O
mouse    O
models    O
.    O

Minority    O
and    O
economically    O
disadvantaged    O
seniors    O
are    O
at    O
greater    O
risk    O
for    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
due    O
to    O
environmental    O
,    O
lifestyle    O
and    O
behavioral    O
factors    O
.    O

In    O
1981    O
DeWitt    O
retired    O
to    O
Isle    O
au    O
Haut    O
,    O
Maine    O
to    O
care    O
for    O
his    O
wife    O
,    O
Barbara    O
Anne    O
DeYoe    O
DeWitt    O
,    O
who    O
had    O
developed    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

Potamkin    O
was    O
married    O
to    O
Luba    O
(    O
née    O
Chalken    O
)    O
for    O
52    O
years    O
;    O
she    O
died    O
in    O
1994    O
of    O
Alzheimer's    B-MetabolicDisorder114084502
Disease    I-MetabolicDisorder114084502
.    O

Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
:    O
0.60(0.05    O
)    O

With    O
his    O
wife    O
,    O
Mitchell    O
helped    O
launch    O
the    O
Douglas    O
County    O
arm    O
of    O
Project    O
Lifesaver    O
,    O
a    O
project    O
that    O
provides    O
tracking    O
devices    O
to    O
Alzheimer's    B-MetabolicDisorder114084502
patients    O
and    O
others    O
with    O
a    O
propensity    O
for    O
wandering    O
.    O

He    O
made    O
significant    O
contributions    O
to    O
the    O
study    O
of    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
during    O
his    O
career    O
.    O

Bobby    O
's    O
failing    O
health    O
turned    O
out    O
to    O
be    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
and    O
he    O
died    O
on    O
April    O
2    O
,    O
1986    O
in    O
a    O
nursing    O
home    O
in    O
Altus    O
,    O
Oklahoma    O
.    O

Due    O
to    O
his    O
battle    O
with    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
Bowlen    O
relinquished    O
control    O
of    O
the    O
team    O
to    O
team    O
president    O
Joe    O
Ellis    O
and    O
executive    O
vice    O
president    O
/    O
general    O
manager    O
John    O
Elway    O
prior    O
to    O
the    O
start    O
of    O
the    O
2014    O
season    O
.    O

The    O
album    O
is    O
dedicated    O
to    O
Manson    O
's    O
mother    O
,    O
who    O
died    O
of    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
during    O
production    O
.    O

He    O
dedicated    O
the    O
record    O
to    O
his    O
mother    O
,    O
Barbara    O
Warner    O
,    O
who    O
died    O
on    O
May    O
13    O
,    O
2014    O
,    O
eight    O
years    O
after    O
being    O
diagnosed    O
with    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

The    O
film    O
centers    O
on    O
Campbell    O
's    O
struggles    O
with    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

The    O
same    O
thing    O
happens    O
gradually    O
when    O
the    O
brain    O
accumulates    O
a    O
protein    O
called    O
beta    O
-    O
amyloid    O
in    O
the    O
tragic    O
disease    O
known    O
as    O
Alzheimer's    B-MetabolicDisorder114084502
.    O

The    O
diet    O
is    O
intended    O
to    O
reduce    O
neurological    O
deterioration    O
(    O
e.g.    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
)    O
but    O
the    O
evidence    O
from    O
research    O
is    O
insufficient    O
to    O
know    O
whether    O
it    O
helps    O
.    O

Earlier    O
in    O
the    O
film    O
,    O
Stiles    O
is    O
diagnosed    O
with    O
early    O
onset    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
something    O
that    O
will    O
end    O
his    O
political    O
career    O
.    O

He    O
died    O
in    O
Coushatta    O
at    O
age    O
71    O
in    O
1999    O
from    O
Alzheimer's    B-MetabolicDisorder114084502
Disease    I-MetabolicDisorder114084502
.    O

The    O
author    O
was    O
gradually    O
distancing    O
herself    O
from    O
public    O
life    O
due    O
to    O
a    O
degenerative    O
disease    O
which    O
affects    O
the    O
memory    O
(    O
Alzheime    B-MetabolicDisorder114084502
)    O
.    O

It    O
has    O
been    O
suggested    O
that    O
consistent    O
practice    O
of    O
a    O
gross    O
motor    O
skill    O
can    O
help    O
a    O
patient    O
with    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
learn    O
and    O
remember    O
that    O
skill    O
.    O

A    O
Silver    O
Alert    O
is    O
a    O
public    O
notification    O
system    O
in    O
the    O
United    O
States    O
to    O
broadcast    O
information    O
about    O
missing    O
persons    O
–    O
especially    O
senior    O
citizens    O
with    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
dementia    O
or    O
other    O
mental    O
disabilities    O
–    O
in    O
order    O
to    O
aid    O
in    O
locating    O
them    O
.    O

She    O
had    O
been    O
suffering    O
from    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
and    O
pneumonia    O
.    O

In    O
1994    O
Mucke    O
developed    O
a    O
new    O
research    O
focus    O
in    O
neuropsychiatry    O
,    O
initially    O
with    O
a    O
focus    O
on    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
and    O
related    O
neurodegenerative    O
diseases    O
.    O

In    O
2002    O
,    O
Love    O
was    O
diagnosed    O
with    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
which    O
forced    O
his    O
retirement    O
the    O
following    O
year    O
and    O
his    O
eventual    O
death    O
in    O
2012    O
at    O
age    O
70    O
.    O

Recent    O
studies    O
suggest    O
the    O
regular    O
consumption    O
of    O
omega-3    O
fatty    O
acids    O
reduces    O
the    O
likelihood    O
of    O
developing    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
and    O
can    O
even    O
boost    O
brain    O
function    O
.    O

In    O
2012    O
,    O
he    O
died    O
of    O
Alzheimer's    B-MetabolicDisorder114084502
complications    O
in    O
Durban    O
.    O

After    O
suffering    O
from    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
for    O
several    O
years    O
,    O
Hilbig    O
died    O
on    O
August    O
22    O
,    O
2015    O
,    O
at    O
the    O
age    O
of    O
73    O
.    O

She    O
died    O
from    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
which    O
she    O
suffered    O
from    O
throughout    O
the    O
1990s    O
.    O

By    O
the    O
final    O
verse    O
,    O
the    O
children    O
have    O
grown    O
up    O
and    O
moved    O
away    O
,    O
the    O
daughter    O
is    O
now    O
a    O
single    O
grandparent    O
,    O
the    O
son    O
is    O
on    O
a    O
diet    O
to    O
control    O
his    O
high    O
cholesterol    O
,    O
the    O
mother    O
is    O
senile    O
(    O
possibly    O
Alzheimer's    B-MetabolicDisorder114084502
)    O
and    O
the    O
father    O
has    O
died    O
.    O

She    O
served    O
as    O
the    O
head    O
coach    O
of    O
the    O
University    O
of    O
Tennessee    O
Lady    O
Vols    O
basketball    O
team    O
from    O
1974    O
to    O
2012    O
,    O
before    O
retiring    O
at    O
age    O
59    O
because    O
of    O
a    O
diagnosis    O
of    O
early    O
-    O
onset    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

This    O
enzyme    O
participates    O
in    O
14    O
metabolic    O
pathways    O
:    O
erbb    O
signaling    O
pathway    O
,    O
cell    O
cycle    O
,    O
wnt    O
signaling    O
pathway    O
,    O
hedgehog    O
signaling    O
pathway    O
,    O
axon    O
guidance    O
,    O
focal    O
adhesion    O
,    O
b    O
cell    O
receptor    O
signaling    O
pathway    O
,    O
insulin    O
signaling    O
pathway    O
,    O
melanogenesis    O
,    O
alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
colorectal    O
cancer    O
,    O
endometrial    O
cancer    O
,    O
prostate    O
cancer    O
,    O
and    O
basal    O
cell    O
carcinoma    O
.    O

In    O
his    O
later    O
life    O
he    O
suffered    O
with    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

She    O
looked    O
after    O
her    O
Portuguese    O
grandmother    O
who    O
suffered    O
from    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
and    O
she    O
is    O
fluent    O
in    O
Portuguese    O
.    O

She    O
died    O
at    O
a    O
Toronto    O
hospital    O
of    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
in    O
1987    O
.    O

.    O
claimed    O
in    O
1991    O
that    O
Berlin    O
,    O
who    O
died    O
in    O
1986    O
,    O
had    O
suffered    O
from    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
starting    O
in    O
the    O
mid-1960s    O
and    O
that    O
caused    O
him    O
to    O
shut    O
down    O
several    O
Hearst    O
newspapers    O
without    O
just    O
cause    O
.    O

Fred    O
Trump    O
suffered    O
from    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
for    O
six    O
years    O
.    O

In    O
-    O
depth    O
pieces    O
include    O
stories    O
such    O
as    O
"    O
Native    O
Environmentalism    O
and    O
the    O
Alberta    O
Oil    O
Boom    O
"    O
,    O
"    O
Global    O
Warming    O
:    O
the    O
Archaeological    O
Frontier    O
"    O
,    O
"    O
When    O
Facebook    O
Is    O
Your    O
Medical    O
Record    O
"    O
,    O
as    O
well    O
as    O
"    O
Art    O
and    O
Alzheimer's    B-MetabolicDisorder114084502
:    O
Another    O
Way    O
of    O
Remembering    O
"    O
,    O
the    O
story    O
of    O
Hilda    O
Goldblatt    O
Gorenstein    O
(    O
Hilgos    O
)    O
and    O
the    O
documentary    O
"    O
"    O
I    O
Remember    O
Better    O
When    O
I    O
Paint    O
"    O
"    O
.    O

Charles    O
Foley    O
(    O
1930–2013    O
)    O
,    O
inventor    O
of    O
the    O
game    O
Twister    O
(    O
lived    O
in    O
a    O
special    O
care    O
facility    O
in    O
St.    O
Louis    O
Park    O
at    O
the    O
time    O
of    O
his    O
death    O
from    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
)    O

modeling    O
of    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502

In    O
addition    O
to    O
study    O
investigating    O
the    O
effects    O
of    O
metastable    O
interactions    O
on    O
traditional    O
social    O
function    O
,    O
much    O
research    O
will    O
likely    O
focus    O
on    O
determining    O
the    O
role    O
of    O
the    O
coordinated    O
dynamic    O
system    O
and    O
the    O
global    O
workspace    O
in    O
the    O
progression    O
of    O
debilitating    O
diseases    O
such    O
as    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
Parkinson    O
's    O
disease    O
,    O
stroke    O
,    O
and    O
schizophrenia    O
.    O

It    O
is    O
suspected    O
that    O
an    O
atypical    O
form    O
of    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
is    O
the    O
most    O
common    O
cause    O
of    O
logopenic    O
progressive    O
aphasia    O
.    O

Carey    O
Mulligan    O
,    O
an    O
Ambassador    O
for    O
the    O
Society's    B-MetabolicDisorder114084502
Alzheimer’s    I-MetabolicDisorder114084502
Society    I-MetabolicDisorder114084502
,    O
was    O
present    O
.    O

He    O
has    O
also    O
mentioned    O
that    O
he    O
grew    O
up    O
in    O
a    O
religious    O
family    O
and    O
revealed    O
that    O
his    O
father    O
has    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

After    O
a    O
long    O
struggle    O
with    O
Alzheimer's    B-MetabolicDisorder114084502
Disease    I-MetabolicDisorder114084502
,    O
Lynch    O
died    O
in    O
Los    O
Angeles    O
on    O
May    O
7    O
,    O
1997    O
.    O

Patients    O
with    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
almost    O
always    O
have    O
an    O
abnormal    O
sense    O
of    O
smell    O
when    O
tested    O
.    O

Non    O
-    O
coding    O
RNAs    O
contribute    O
to    O
diseases    O
including    O
cancers    O
,    O
autism    O
,    O
and    O
Alzheimer's    B-MetabolicDisorder114084502
.    O

The    O
antisense    O
RNA    O
,    O
BACE1-AS    O
is    O
transcribed    O
from    O
the    O
opposite    O
strand    O
to    O
BACE1    O
and    O
is    O
upregulated    O
in    O
patients    O
with    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

Swallowing    O
becomes    O
a    O
great    O
concern    O
for    O
the    O
elderly    O
since    O
strokes    O
and    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
can    O
interfere    O
with    O
the    O
autonomic    O
nervous    O
system    O
.    O

Boxer    O
is    O
an    O
advocate    O
for    O
embryonic    O
stem    O
-    O
cell    O
research    O
,    O
which    O
has    O
the    O
potential    O
to    O
help    O
those    O
with    O
diabetes    O
,    O
Parkinson    O
's    O
disease    O
,    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
spinal    O
cord    O
injuries    O
,    O
and    O
other    O
diseases    O
.    O

The    O
Carter    O
family    O
have    O
appeared    O
heavily    O
in    O
the    O
show    O
from    O
2014    O
,    O
in    O
high    O
-    O
profile    O
storylines    O
including    O
Johnny    O
's    O
homosexuality    O
,    O
the    O
revelation    O
that    O
Shirley    O
is    O
in    O
fact    O
Mick    O
's    O
mother    O
,    O
Linda    O
's    O
rape    O
at    O
the    O
hands    O
of    O
Dean    O
and    O
suffering    O
from    O
bulimia    O
nervosa    O
,    O
Stan    O
's    O
terminal    O
prostate    O
cancer    O
,    O
the    O
domestic    O
violence    O
Tina    O
receives    O
from    O
her    O
partner    O
Tosh    O
,    O
Nancy    O
's    O
epilepsy    O
,    O
Sylvie    O
's    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
Lee    O
's    O
depression    O
,    O
the    O
revelation    O
that    O
Dean    O
has    O
a    O
daughter    O
,    O
Jade    O
with    O
cystic    O
fibrosis    O
,    O
born    O
after    O
a    O
one    O
-    O
night    O
stand    O
with    O
Shabnam    O
Masood    O
(    O
Rakhee    O
Thakrar    O
)    O
,    O
and    O
baby    O
Ollie    O
Carter    O
's    O
accident    O
and    O
potential    O
brain    O
damage    O
.    O

Shirley    O
and    O
Mick    O
discover    O
that    O
it    O
was    O
Babe    O
let    O
Tosh    O
think    O
Tina    O
was    O
having    O
an    O
affair    O
,    O
so    O
they    O
confront    O
her    O
but    O
they    O
find    O
Sylvie    O
,    O
who    O
is    O
suffering    O
from    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

He    O
also    O
played    O
Alvin    O
Newcastle    O
,    O
a    O
man    O
suffering    O
from    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
on    O
an    O
episode    O
of    O
"    O
The    O
Golden    O
Girls    O
"    O
entitled    O
"    O
Old    O
Friends    O
"    O
.    O

Through    O
research    O
on    O
protein    O
networks    O
that    O
control    O
biological    O
systems    O
,    O
Signum    O
is    O
developing    O
therapeutic    O
candidates    O
for    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
Parkinson    O
's    O
,    O
diabetes    O
,    O
asthma    O
and    O
certain    O
skin    O
conditions    O
.    O

Stojack    O
died    O
on    O
August    O
30    O
,    O
1987    O
from    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

The    O
administration    O
building    O
,    O
which    O
is    O
Grade    O
II    O
listed    O
,    O
features    O
an    O
Italian    O
mosaic    O
floor    O
in    O
the    O
main    O
corridor    O
which    O
is    O
intricately    O
decorated    O
with    O
the    O
Yorkshire    O
Rose    O
and    O
black    O
daisies    O
-    O
the    O
latter    O
of    O
which    O
provided    O
inspiration    O
for    O
the    O
title    O
of    O
"    O
Black    O
Daisies    O
"    O
a    O
television    O
screenplay    O
,    O
filmed    O
at    O
High    O
Royds    O
,    O
which    O
took    O
as    O
its    O
subject    O
the    O
experiences    O
of    O
sufferers    O
of    O
Alzheimers    B-MetabolicDisorder114084502
disease    O
.    O

Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
or    O
similar    O
disabilities    O
may    O
result    O
in    O
a    O
person    O
being    O
unable    O
to    O
give    O
legal    O
consent    O
to    O
sexual    O
relations    O
even    O
with    O
their    O
spouse    O
.    O

However    O
,    O
large    O
numbers    O
of    O
senile    O
plaques    O
and    O
neurofibrillary    O
tangles    O
are    O
characteristic    O
features    O
of    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

Towards    O
the    O
end    O
of    O
her    O
life    O
,    O
Margaret    O
Rutherford    O
was    O
diagnosed    O
with    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
and    O
Davis    O
tended    O
to    O
her    O
throughout    O
a    O
long    O
and    O
distressing    O
illness    O
.    O

He    O
died    O
of    O
complications    O
from    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
at    O
the    O
age    O
of    O
82    O
in    O
Lawrence    O
,    O
Kansas    O
.    O

Michel    O
boycotts    O
as    O
much    O
as    O
he    O
can    O
,    O
now    O
knowing    O
his    O
mother    O
suffers    O
a    O
kind    O
of    O
amnesia    O
,    O
most    O
probably    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
according    O
to    O
the    O
mental    O
test    O
.    O

Some    O
examples    O
are    O
infertility    O
,    O
termination    O
of    O
pregnancy    O
,    O
disappearance    O
of    O
a    O
family    O
member    O
,    O
death    O
of    O
an    O
ex    O
-    O
spouse    O
,    O
a    O
family    O
member    O
being    O
physically    O
alive    O
but    O
in    O
a    O
state    O
of    O
cognitive    O
decline    O
due    O
to    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
or    O
dementia    O
,    O
etc    O
.    O

Creating    O
an    O
abstract    O
narrative    O
around    O
the    O
loss    O
of    O
communication    O
,    O
he    O
investigates    O
the    O
effects    O
of    O
the    O
abrupt    O
discontinuation    O
of    O
a    O
radio    O
station    O
on    O
a    O
community    O
and    O
the    O
lingering    O
effects    O
of    O
Alzheimer’s    B-MetabolicDisorder114084502
and    O
aphasia    O
on    O
a    O
family    O
.    O

RA    O
can    O
also    O
progress    O
and    O
further    O
deteriorate    O
memory    O
recollection    O
,    O
as    O
in    O
the    O
case    O
of    O
Korsakoff    O
syndrome    O
and    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
due    O
to    O
the    O
ongoing    O
nature    O
of    O
the    O
damage    O
caused    O
by    O
the    O
illnesses    O
.    O

Brooks    O
died    O
of    O
Alzheimer’s    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
in    O
1989    O
.    O

Excitotoxicity    O
may    O
be    O
involved    O
in    O
spinal    O
cord    O
injury    O
,    O
stroke    O
,    O
traumatic    O
brain    O
injury    O
,    O
hearing    O
loss    O
(    O
through    O
noise    O
overexposure    O
or    O
ototoxicity    O
)    O
,    O
and    O
in    O
neurodegenerative    O
diseases    O
of    O
the    O
central    O
nervous    O
system    O
(    O
CNS    O
)    O
such    O
as    O
multiple    O
sclerosis    O
,    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
amyotrophic    O
lateral    O
sclerosis    O
(    O
ALS    O
)    O
,    O
Parkinson    O
's    O
disease    O
,    O
alcoholism    O
or    O
alcohol    O
withdrawal    O
and    O
especially    O
over    O
-    O
rapid    O
benzodiazepine    O
withdrawal    O
,    O
and    O
also    O
Huntington    O
's    O
disease    O
.    O

Peptoids    O
have    O
been    O
developed    O
as    O
candidates    O
for    O
a    O
range    O
of    O
different    O
biomedical    O
applications    O
,    O
including    O
antimicrobial    O
agents    O
and    O
synthetic    O
lung    O
surfactants    O
,    O
as    O
well    O
as    O
ligands    O
for    O
various    O
proteins    O
including    O
Src    O
Homology    O
3    O
(    O
SH3    O
domain    O
)    O
,    O
Vascular    O
Endothelial    O
Growth    O
Factor    O
(    O
VEGF    O
)    O
receptor    O
2    O
,    O
and    O
antibody    O
Immunoglobulin    O
G    O
biomarkers    O
for    O
the    O
identification    O
of    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

All    O
net    O
profits    O
from    O
Geoffrey    O
Beene    O
products    O
are    O
donated    O
to    O
philanthropic    O
causes    O
,    O
such    O
as    O
cancer    O
research    O
,    O
Alzheimer's    B-MetabolicDisorder114084502
research    O
,    O
domestic    O
violence    O
prevention    O
and    O
response    O
,    O
Save    O
the    O
Children    O
,    O
and    O
educational    O
programs    O
,    O
including    O
scholarships    O
for    O
students    O
majoring    O
in    O
fashion    O
and    O
related    O
disciplines    O
.    O

Dharma    O
Singh    O
Khalsa    O
is    O
widely    O
published    O
researcher    O
and    O
author    O
on    O
healthy    O
lifestyle    O
,    O
specializing    O
in    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

Problems    O
with    O
spatial    O
memory    O
and    O
navigation    O
are    O
thought    O
to    O
be    O
one    O
of    O
the    O
early    O
indications    O
of    O
Alzheimer's    B-MetabolicDisorder114084502
Disease    I-MetabolicDisorder114084502
.    O

In    O
2015    O
Prendergast    O
accepted    O
the    O
role    O
of    O
ambassador    O
for    O
Alzheimer's    B-MetabolicDisorder114084502
New    O
Zealand    O
,    O
having    O
had    O
personal    O
experience    O
of    O
the    O
disease    O
-    O
both    O
her    O
late    O
father    O
Denis    O
and    O
her    O
mother    O
Beverley    O
Ferrier    O
suffered    O
the    O
disease    O
.    O

Earlier    O
in    O
2007    O
,    O
he    O
had    O
also    O
been    O
diagnosed    O
with    O
the    O
beginning    O
stage    O
of    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

Studies    O
linking    O
the    O
Mediterranean    O
diet    O
and    O
decreased    O
risk    O
of    O
illnesses    O
such    O
as    O
lung    O
disease    O
and    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
as    O
well    O
as    O
protection    O
against    O
allergies    O
and    O
asthma    O
have    O
been    O
published    O
.    O

She    O
is    O
particularly    O
known    O
for    O
her    O
work    O
studying    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
and    O
the    O
consequences    O
of    O
repetitive    O
traumatic    O
brain    O
injury    O
.    O

But    O
he    O
was    O
later    O
replaced    O
by    O
Sunny    O
Joseph    O
,    O
since    O
the    O
former    O
fell    O
ill    O
and    O
was    O
later    O
found    O
to    O
be    O
suffering    O
from    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

Pasinetti    O
investigates    O
the    O
biological    O
processes    O
that    O
occur    O
when    O
,    O
during    O
aging    O
,    O
subjects    O
with    O
normal    O
cognitive    O
function    O
convert    O
into    O
the    O
very    O
earliest    O
stages    O
of    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
(    O
AD    O
)    O
and    O
then    O
to    O
frank    O
dementia    O
.    O

In    O
December    O
2012    O
,    O
Arnold    O
announced    O
that    O
Sessions    O
had    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

Klaus    O
Kertess    O
,    O
76    O
,    O
American    O
curator    O
,    O
art    O
gallerist    O
and    O
writer    O
,    O
complications    O
from    O
Alzheimer's    B-MetabolicDisorder114084502
.    O

Ramsey    O
was    O
diagnosed    O
with    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
in    O
1991    O
.    O

In    O
2013    O
,    O
another    O
MDPI    O
journal    O
,    O
"    O
Entropy    O
"    O
,    O
published    O
a    O
review    O
paper    O
claiming    O
glyphosate    O
may    O
be    O
the    O
most    O
important    O
factor    O
in    O
the    O
development    O
of    O
obesity    O
,    O
depression    O
,    O
attention    O
deficit    O
hyperactivity    O
disorder    O
,    O
autism    O
,    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
Parkinson    O
's    O
disease    O
,    O
multiple    O
sclerosis    O
,    O
cancer    O
,    O
and    O
infertility    O
.    O

Such    O
cerebral    O
microbleeds    O
are    O
important    O
,    O
since    O
they    O
often    O
occur    O
prior    O
to    O
ischemic    O
stroke    O
or    O
intracerebral    O
hemorrhage    O
,    O
Binswanger    O
disease    O
,    O
and    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O

frontotemporal    O
dementia    O
/    O
Pick    O
Complex    O
Motor    O
neuron    O
disease    O
,    O
Progressive    O
supranuclear    O
palsy    O
,    O
and    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
which    O
is    O
the    O
gradual    O
process    O
of    O
progressively    O
losing    O
the    O
ability    O
to    O
think    O
.    O

Ronald    O
Reagan    O
–    O
caused    O
by    O
late    O
stages    O
of    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502

1906    O
–    O
Auguste    O
Deter    O
,    O
the    O
first    O
person    O
to    O
be    O
diagnosed    O
with    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
dies    O
.    O

1906    O
–    O
Auguste    O
Deter    O
,    O
German    O
woman    O
,    O
first    O
person    O
diagnosed    O
with    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
(    O
b.    O
1850    O
)    O

Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
a    O
neural    O
disease    O

One    O
of    O
her    O
accomplishments    O
as    O
MP    O
was    O
successfully    O
introducing    O
a    O
bill    O
that    O
created    O
a    O
national    O
Alzheimer's    B-MetabolicDisorder114084502
strategy    O
.    O

Research    O
of    O
the    O
correlation    O
of    O
aluminium    O
and    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
has    O
included    O
the    O
ability    O
of    O
silicic    O
acid    O
in    O
beer    O
reduce    O
aluminium    O
uptake    O
in    O
the    O
digestive    O
system    O
as    O
well    O
as    O
increase    O
renal    O
excretion    O
of    O
aluminium    O

In    O
1983    O
,    O
she    O
portrayed    O
Rose    O
Kennedy    O
in    O
the    O
mini    O
-    O
series    O
"    O
Kennedy    O
''    O
with    O
Martin    O
Sheen    O
,    O
and    O
co    O
-    O
starred    O
as    O
Joanne    O
Woodward    O
's    O
mother    O
in    O
the    O
1985    O
Alzheimer's    B-MetabolicDisorder114084502
drama    O
"    O
Do    O
You    O
Remember    O
Love    O
"    O
.    O

Fitzgerald    O
died    O
at    O
age    O
91    O
in    O
New    O
York    O
City    O
following    O
a    O
long    O
battle    O
with    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

Her    O
later    O
years    O
were    O
devoted    O
to    O
transcribing    O
,    O
performing    O
,    O
and    O
annotating    O
Gershwin    O
's    O
music    O
,    O
which    O
she    O
did    O
until    O
being    O
diagnosed    O
with    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
in    O
1991    O
.    O

Mossell    O
Alexander    O
died    O
on    O
November    O
1    O
,    O
1989    O
at    O
Cathedral    O
Village    O
in    O
Andorra    O
,    O
Philadelphia    O
,    O
from    O
pneumonia    O
as    O
a    O
complication    O
from    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

Dementia    B-MetabolicDisorder114084502
of    I-MetabolicDisorder114084502
the    I-MetabolicDisorder114084502
Alzheimer’s    I-MetabolicDisorder114084502
Type    I-MetabolicDisorder114084502
,    O
with    O
early    O
onset    O

P.    O
Bhaskaran    O
suffered    O
from    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
at    O
the    O
end    O
of    O
his    O
life    O
,    O
and    O
could    O
not    O
recognize    O
anyone    O
who    O
worked    O
with    O
him    O
.    O

Neurogenesis    O
in    O
the    O
adult    O
brain    O
is    O
often    O
associated    O
with    O
diseases    O
that    O
deteriorate    O
the    O
CNS    O
,    O
like    O
Huntington    O
's    O
disease    O
,    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
and    O
Parkinson    O
's    O
disease    O
.    O

She    O
died    O
on    O
5    O
July    O
1992    O
in    O
Mountain    O
View    O
,    O
California    O
from    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

In    O
2005    O
,    O
ΣΑΜ    O
chose    O
the    O
Alzheimer    O
's    O
Association    O
as    O
its    O
service    O
and    O
philanthropy    O
project    O
where    O
they    O
raise    O
donations    O
for    O
Alzheimer's    B-MetabolicDisorder114084502
Research    I-MetabolicDisorder114084502
.    O

He    O
died    O
after    O
a    O
long    O
battle    O
with    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
in    O
1984    O
.    O

He    O
died    O
in    O
2003    O
from    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

A    O
few    O
years    O
after    O
Gurgel    O
's    O
bankruptcy    O
,    O
João    O
do    O
Amaral    O
Gurgel    O
developed    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

TNF    O
-    O
alpha    O
is    O
an    O
important    O
target    O
for    O
research    O
into    O
degenerative    O
conditions    O
such    O
as    O
rheumatoid    O
arthritis    O
and    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
where    O
the    O
disease    O
process    O
involves    O
tissue    O
damage    O
through    O
chronic    O
inflammation    O
.    O

By    O
the    O
1980s    O
the    O
"    O
English    O
Chess    O
Explosion    O
"    O
was    O
in    O
full    O
swing    O
,    O
but    O
Barden    O
took    O
a    O
lesser    O
role    O
due    O
to    O
having    O
to    O
care    O
for    O
his    O
mother    O
,    O
who    O
suffered    O
from    O
Alzheimer's    B-MetabolicDisorder114084502
Disease    I-MetabolicDisorder114084502
.    O

In    O
January    O
2017    O
,    O
Gastineau    O
revealed    O
that    O
he    O
had    O
been    O
diagnosed    O
with    O
dementia    O
,    O
Parkinson    O
's    O
disease    O
,    O
and    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
in    O
the    O
previous    O
year    O
.    O

In    O
1991    O
,    O
English    O
was    O
diagnosed    O
with    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
and    O
on    O
September    O
29    O
,    O
2005    O
,    O
he    O
died    O
at    O
the    O
age    O
of    O
90    O
at    O
the    O
Silverado    O
Senior    O
Living    O
assisted    O
living    O
community    O
in    O
San    O
Diego    O
,    O
California    O
.    O

Since    O
his    O
days    O
as    O
a    O
teacher    O
at    O
Stanford    O
University    O
,    O
Fossel    O
has    O
studied    O
aging    O
from    O
a    O
medical    O
and    O
scientific    O
perspective    O
with    O
a    O
particular    O
emphasis    O
on    O
premature    O
aging    O
syndromes    O
such    O
as    O
progeria    O
,    O
and    O
since    O
at    O
least    O
1996    O
he    O
has    O
been    O
a    O
strong    O
and    O
vocal    O
advocate    O
of    O
telomerase    O
therapy    O
as    O
a    O
potential    O
treatment    O
of    O
age    O
-    O
related    O
diseases    O
,    O
disorders    O
,    O
and    O
syndromes    O
such    O
as    O
progeria    O
,    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
atherosclerosis    O
,    O
osteoporosis    O
,    O
cancer    O
,    O
and    O
other    O
conditions    O
.    O

It    O
is    O
used    O
to    O
diagnose    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
tumors    O
,    O
infection    O
,    O
inflammation    O
,    O
and    O
other    O
brain    O
disorders    O
.    O

In    O
2004    O
it    O
became    O
known    O
that    O
he    O
suffered    O
from    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
and    O
he    O
fell    O
into    O
a    O
coma    O
the    O
following    O
year    O
.    O

The    O
character    O
made    O
a    O
return    O
to    O
the    O
front    O
burner    O
one    O
last    O
time    O
with    O
a    O
story    O
about    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
in    O
2012    O
.    O

After    O
being    O
on    O
the    O
show    O
for    O
seventeen    O
years    O
and    O
actor    O
Konrad    O
Krauss    O
himself    O
being    O
in    O
his    O
70s    O
,    O
Arno    O
is    O
being    O
diagnosed    O
with    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

Arno    O
is    O
diagnosed    O
with    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

Martiny    O
was    O
born    O
in    O
New    O
Orleans    O
,    O
the    O
second    O
of    O
five    O
children    O
,    O
to    O
the    O
late    O
Wilfred    O
"    O
Wil    O
"    O
E.    O
Martiny    O
(    O
February    O
24    O
,    O
1923    O
-    O
March    O
20    O
,    O
2012    O
)    O
who    O
died    O
of    O
natural    O
causes    O
and    O
Doris    O
Rault    O
(    O
October    O
5    O
,    O
1925    O
–    O
January    O
27    O
,    O
2008    O
)    O
,    O
who    O
died    O
of    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

Having    O
retired    O
from    O
public    O
office    O
in    O
2001    O
,    O
Hay    O
began    O
suffering    O
from    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

Former    O
Grambling    O
coach    O
Eddie    O
Robinson    O
,    O
the    O
first    O
college    O
football    O
coach    O
with    O
400    O
victories    O
in    O
his    O
career    O
,    O
dies    O
at    O
the    O
age    O
of    O
88    O
due    O
to    O
complications    O
from    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
in    O
Grambling    O
,    O
Louisiana    O
.    O

Alexander    O
Schure    O
died    O
from    O
complications    O
of    O
Alzheimer's    B-MetabolicDisorder114084502
Disease    I-MetabolicDisorder114084502
on    O
Long    O
Island    O
on    O
October    O
29    O
,    O
2009    O
,    O
at    O
the    O
age    O
of    O
89    O
.    O

Kennedy    O
was    O
dissatisfied    O
with    O
the    O
deal    O
and    O
continued    O
campaigning    O
,    O
speaking    O
at    O
public    O
meetings    O
and    O
protesting    O
at    O
IG    O
Farben    O
shareholder    O
meetings    O
until    O
he    O
started    O
suffering    O
from    O
Alzheimer's    B-MetabolicDisorder114084502
.    O

Severe    O
or    O
chronic    O
diseases    O
associated    O
with    O
high    O
rates    O
of    O
depression    O
include    O
stroke    O
(    O
30    O
to    O
60    O
percent    O
)    O
,    O
coronary    O
heart    O
disease    O
(    O
8    O
to    O
44    O
percent    O
)    O
,    O
cancer    O
(    O
1    O
to    O
40    O
percent    O
)    O
,    O
Parkinson    O
's    O
disease    O
(    O
40    O
percent    O
)    O
,    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
(    O
20    O
to    O
40    O
percent    O
)    O
,    O
and    O
dementia    O
(    O
17    O
to    O
31    O
percent    O
)    O
.    O

The    O
condition    O
may    O
be    O
etiologically    O
related    O
to    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

He    O
studied    O
with    O
the    O
most    O
eminent    O
neurologists    O
of    O
his    O
time    O
,    O
first    O
in    O
Paris    O
,    O
France    O
,    O
with    O
Pierre    O
Marie    O
and    O
Dupré    O
,    O
then    O
in    O
Munich    O
,    O
Germany    O
,    O
with    O
Emil    O
Kraepelin    O
(    O
the    O
"    O
father    O
"    O
of    O
modern    O
scientific    O
psychiatry    O
)    O
and    O
Alois    O
Alzheimer    O
(    O
the    O
discoverer    O
of    O
the    O
most    O
common    O
form    O
of    O
senile    B-MetabolicDisorder114084502
dementia    I-MetabolicDisorder114084502
,    O
which    O
today    O
bears    O
his    O
name    O
)    O
;    O
and    O
in    O
Heidelberg    O
,    O
with    O
Franz    O
Nissl    O
,    O
a    O
neuropathologist    O
.    O

In    O
his    O
long    O
activity    O
as    O
a    O
psychiatrist    O
and    O
neurologist    O
,    O
Cerletti    O
published    O
113    O
original    O
papers    O
,    O
about    O
the    O
pathology    O
of    O
senile    O
plaques    O
in    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
on    O
the    O
structure    O
of    O
neuroglia    O
,    O
the    O
blood–    O

In    O
the    O
year    O
following    O
Dimant    O
's    O
retirement    O
,    O
B'nai    O
Brith    O
Canada    O
put    O
its    O
"    O
state    O
of    O
the    O
art    O
"    O
care    O
facility    O
for    O
Alzheimer's    B-MetabolicDisorder114084502
patients    O
under    O
insolvency    O
protection    O
while    O
also    O
trying    O
to    O
sell    O
it    O
.    O

After    O
a    O
brief    O
hiatus    O
in    O
which    O
she    O
returned    O
briefly    O
to    O
television    O
production    O
,    O
Hui    O
returned    O
with    O
"    O
Summer    O
Snow    O
"    O
(    O
1995    O
)    O
,    O
about    O
a    O
middle    O
-    O
aged    O
woman    O
trying    O
to    O
cope    O
with    O
everyday    O
family    O
problems    O
and    O
an    O
Alzheimer    B-MetabolicDisorder114084502
-    O
inflicted    O
father    O
-    O
in    O
-    O
law    O
.    O

Exposure    O
to    O
the    O
cyanobacteria    O
neurotoxin    O
BMAA    O
may    O
be    O
an    O
environmental    O
cause    O
of    O
neurodegenerative    O
diseases    O
such    O
as    O
ALS    O
,    O
Parkinson    O
's    O
Disease    O
and    O
Alzheimer's    B-MetabolicDisorder114084502
Disease    I-MetabolicDisorder114084502
.    O

BMAA    O
is    O
being    O
investigated    O
as    O
a    O
potential    O
environmental    O
risk    O
factor    O
for    O
neurodegenerative    O
diseases    O
,    O
including    O
ALS    O
,    O
Parkinson    O
's    O
disease    O
and    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

Auguste    O
Deter    O
(;    O
16    O
May    O
1850    O
–    O
8    O
April    O
1906    O
)    O
was    O
a    O
German    O
woman    O
notable    O
for    O
being    O
the    O
first    O
person    O
to    O
be    O
diagnosed    O
with    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

Important    O
highlights    O
include    O
the    O
discovery    O
of    O
the    O
genetic    O
defect    O
causing    O
Werner    O
syndrome    O
and    O
certain    O
familial    O
forms    O
of    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

He    O
died    O
in    O
2004    O
after    O
developing    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

They    O
decide    O
to    O
form    O
a    O
hacking    O
group    O
,    O
called    O
"    O
Clowns    O
Laughing    O
At    O
You    O
"    O
,    O
nicknamed    O
CLAY    O
,    O
and    O
they    O
use    O
Benjamin    O
's    O
house    O
as    O
a    O
base    O
of    O
operations    O
,    O
since    O
Benjamin    O
was    O
forced    O
to    O
send    O
his    O
grandmother    O
to    O
a    O
nursing    O
home    O
due    O
to    O
her    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

Microinfarcts    O
may    O
be    O
the    O
second    O
most    O
important    O
cause    O
of    O
dementia    O
,    O
after    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

Andrews    O
is    O
the    O
author    O
(    O
with    O
Professor    O
Allan    O
House    O
)    O
of    O
Ten    O
Helpful    O
Hints    O
for    O
Carers    O
of    O
People    O
with    O
Dementia    O
,    O
which    O
has    O
sold    O
65,000    O
copies    O
,    O
and    O
her    O
forthcoming    O
book    O
,    O
The    O
One    O
-    O
Stop    O
Guide    O
to    O
Dementia    O
;    O
Practical    O
Advice    O
for    O
Families    O
,    O
Professionals    O
,    O
and    O
People    O
Living    O
with    O
Dementia    O
and    O
Alzheimer's    B-MetabolicDisorder114084502
Disease    I-MetabolicDisorder114084502
,    O
was    O
published    O
by    O
Profile    O
Books    O
in    O
February    O
2015    O
and    O
has    O
been    O
followed    O
by    O
editions    O
in    O
North    O
America    O
(    O
When    O
Someone    O
You    O
Know    O
Has    O
Dementia    O
)    O
and    O
an    O
international    O
edition    O
(    O
Dementia    O
What    O
You    O
Need    O
To    O
Know    O
)    O
will    O
be    O
published    O
in    O
late    O
2016    O
.    O

He    O
is    O
a    O
spokesperson    O
for    O
breakthrough    O
treatments    O
in    O
the    O
treatment    O
of    O
Alzheimer's    B-MetabolicDisorder114084502
,    O
Parkinson    O
's    O
,    O
Tourette    O
syndrome    O
,    O
and    O
trauma    O
.    O

The    O
drug    O
cures    O
their    O
Alzheimer's    B-MetabolicDisorder114084502
,    O
but    O
also    O
allows    O
them    O
to    O
see    O
the    O
spirits    O
of    O
people    O
who    O
have    O
died    O
in    O
the    O
nursing    O
home    O
and    O
channel    O
them    O
into    O
existence    O
.    O

Schlee    O
died    O
in    O
a    O
Costa    O
Mesa    O
,    O
California    O
hospital    O
in    O
2000    O
of    O
complications    O
from    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

Ron    O
is    O
fast    O
deteriorating    O
with    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

His    O
family    O
said    O
he    O
had    O
been    O
battling    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
diabetes    O
and    O
congestive    O
heart    O
failure    O
.    O

Translocase    O
of    O
outer    O
mitochondrial    O
membrane    O
40    O
(    O
TOMM40    O
)    O
,    O
a    O
protein    O
encoded    O
by    O
the    O
TOMM40    O
gene    O
,    O
whose    O
alleles    O
differentially    O
impact    O
the    O
risk    O
for    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502

Music    O
therapy    O
(    O
MT    O
)    O
has    O
been    O
used    O
as    O
a    O
treatment    O
for    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
(    O
AD    O
)    O
,    O
but    O
its    O
use    O
remains    O
mostly    O
uninvestigated    O
.    O

A    O
gamma    O
secretase    O
inhibitor    O
previously    O
experimented    O
for    O
treating    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
is    O
found    O
to    O
have    O
regenerative    O
effects    O
on    O
inner    O
ear    O
hair    O
cells    O
,    O
potentially    O
allowing    O
for    O
the    O
effective    O
treatment    O
of    O
deafness    O
.    O

American    O
scientists    O
announce    O
that    O
they    O
have    O
identified    O
a    O
number    O
of    O
genetic    O
markers    O
that    O
are    O
associated    O
with    O
an    O
increased    O
risk    O
of    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

The    O
Alzheimer's    B-MetabolicDisorder114084502
drug    O
Gammagard    O
fails    O
to    O
produce    O
results    O
in    O
a    O
large    O
-    O
scale    O
clinical    O
trial    O
.    O

An    O
international    O
team    O
of    O
researchers    O
has    O
doubled    O
the    O
known    O
number    O
of    O
genes    O
linked    O
to    O
Alzheimers    B-MetabolicDisorder114084502
to    O
21    O
.    O

Alzheimer    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
presents    O
specific    O
challenges    O
for    O
caregivers    O
,    O
who    O
need    O
to    O
make    O
the    O
home    O
as    O
accessible    O
as    O
possible    O
to    O
the    O
elderly    O
resident    O
,    O
while    O
keeping    O
safety    O
features    O
in    O
mind    O
.    O

He    O
died    O
in    O
London    O
on    O
20    O
June    O
2017    O
after    O
suffering    O
from    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

In    O
particular    O
,    O
his    O
research    O
has    O
focused    O
on    O
the    O
development    O
of    O
neurotransmitter    O
tracers    O
for    O
the    O
evaluation    O
of    O
religiosity    O
as    O
well    O
as    O
neurological    O
and    O
psychiatric    O
disorders    O
including    O
clinical    O
depression    O
,    O
head    O
injury    O
,    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
and    O
Parkinson    O
's    O
disease    O
.    O

Irwin    O
Silber    O
,    O
84    O
,    O
American    O
writer    O
and    O
journalist    O
,    O
complications    O
of    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

Hence    O
GSAP    O
represents    O
a    O
potential    O
therapeutic    O
target    O
for    O
the    O
treatment    O
of    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
(    O
AD    O
)    O
.    O

9    O
December    O
-    O
Footballer    O
Danny    O
Blanchflower    O
dies    O
of    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
aged    O
67    O
.    O

In    O
them    O
,    O
he    O
advocates    O
nutritional    O
,    O
herbal    O
,    O
and    O
homeopathic    O
options    O
to    O
approach    O
the    O
prevention    O
and    O
treatment    O
of    O
diseases    O
such    O
as    O
poor    O
diet    O
,    O
aging    O
,    O
arthritis    O
,    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
cancer    O
,    O
allergies    O
,    O
cocaine    O
addiction    O
,    O
the    O
common    O
cold    O
,    O
and    O
AIDS    O
.    O

The    O
actively    O
encouraged    O
flexible    O
labor    O
market    O
has    O
imposed    O
an    O
Alzheimer's    B-MetabolicDisorder114084502
-    O
like    O
corporate    O
amnesia    O
on    O
organizations    O
that    O
creates    O
an    O
inability    O
to    O
benefit    O
from    O
hindsight    O
.    O

In    O
2001    O
,    O
he    O
was    O
one    O
of    O
the    O
team    O
describing    O
the    O
work    O
the    O
charity    O
does    O
in    O
Britain    O
,    O
helping    O
victims    O
of    O
early    O
Alzheimer's    B-MetabolicDisorder114084502
or    O
teenagers    O
who    O
are    O
HIV    O
positive    O
.    O

Many    O
diseases    O
can    O
confine    O
a    O
patient    O
to    O
bed    O
,    O
necessitating    O
the    O
use    O
of    O
bedpans    O
,    O
including    O
Alzheimer's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
Parkinson    O
's    O
disease    O
,    O
stroke    O
,    O
and    O
dementia    O
.    O

The    O
result    O
is    O
a    O
disease    O
called    O
multiple    B-MetabolicDisorder114084502
sulfatase    I-MetabolicDisorder114084502
deficiency    I-MetabolicDisorder114084502
(    O
MSD    O
)    O
,    O
in    O
which    O
the    O
accumulation    O
of    O
glycoaminoglycans    O
or    O
sulfolipids    O
can    O
cause    O
early    O
infant    O
death    O
.    O

They    O
further    O
investigated    O
the    O
role    O
of    O
steroid    O
sulfatases    O
in    O
metachromatic    B-MetabolicDisorder114084502
leukodystrophy    I-MetabolicDisorder114084502
and    O
multiple    B-MetabolicDisorder114084502
sulfatase    I-MetabolicDisorder114084502
deficiency    I-MetabolicDisorder114084502
,    O
and    O
they    O
identified    O
acid    O
ceramidase    O
as    O
the    O
enzyme    O
deficient    O
in    O
Farber’s    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

3-Methylglutaconic    B-MetabolicDisorder114084502
aciduria    I-MetabolicDisorder114084502

3-Methylglutaconyl-CoA    B-MetabolicDisorder114084502
hydratase    I-MetabolicDisorder114084502
deficiency    I-MetabolicDisorder114084502

A    O
lyophilised    O
form    O
of    O
hemin    O
is    O
used    O
as    O
a    O
pharmacological    O
agent    O
in    O
certain    O
cases    O
for    O
the    O
treatment    O
of    O
porphyria    O
attacks    O
,    O
particularly    O
in    O
acute    B-MetabolicDisorder114084502
intermittent    I-MetabolicDisorder114084502
porphyria    I-MetabolicDisorder114084502
.    O

Acute    B-MetabolicDisorder114084502
intermittent    I-MetabolicDisorder114084502
porphyria    I-MetabolicDisorder114084502

The    O
patient    O
's    O
underlying    O
condition    O
was    O
probably    O
acute    B-MetabolicDisorder114084502
intermittent    I-MetabolicDisorder114084502
porphyria    I-MetabolicDisorder114084502
,    O
which    O
can    O
be    O
provoked    O
by    O
medicines    O
.    O

During    O
the    O
season    O
,    O
House    O
tries    O
to    O
cope    O
with    O
his    O
feelings    O
for    O
his    O
ex    O
-    O
girlfriend    O
Stacy    O
Warner    O
,    O
who    O
,    O
after    O
House    O
diagnosed    O
her    O
husband    O
with    O
acute    B-MetabolicDisorder114084502
intermittent    I-MetabolicDisorder114084502
porphyria    I-MetabolicDisorder114084502
,    O
has    O
taken    O
a    O
job    O
in    O
the    O
legal    O
department    O
of    O
Princeton    O
-    O
Plainsboro    O
Teaching    O
Hospital    O
.    O

These    O
include    O
epilepsy    O
,    O
bipolar    O
disorder    O
,    O
sunstroke    O
,    O
acute    B-MetabolicDisorder114084502
intermittent    I-MetabolicDisorder114084502
porphyria    I-MetabolicDisorder114084502
,    O
lead    O
poisoning    O
,    O
and    O
Ménière    O
's    O
disease    O
.    O

Arnold    O
and    O
Loftus    O
put    O
forward    O
the    O
diagnosis    O
of    O
Acute    B-MetabolicDisorder114084502
Intermittent    I-MetabolicDisorder114084502
Porphyria    I-MetabolicDisorder114084502
(    O
often    O
referred    O
to    O
as    O
simply    O
"    O
AIP    O
"    O
)    O
.    O

X-linked    B-MetabolicDisorder114084502
ichthyosis    I-MetabolicDisorder114084502

X-linked    B-MetabolicDisorder114084502
ichthyosis    I-MetabolicDisorder114084502
,    O
a    O
form    O
of    O
ichthyosis    O
caused    O
by    O
a    O
hereditary    O
deficiency    O
of    O
the    O
steroid    O
sulfatase    O
(    O
STS    O
)    O
enzyme    O
.    O

X-linked    B-MetabolicDisorder114084502
ichthyosis    I-MetabolicDisorder114084502

An    O
increase    O
in    O
apoC    O
-    O
III    O
levels    O
induces    O
the    O
development    O
of    O
hypertriglyceridemia    B-MetabolicDisorder114084502
.    O

Saroglitazar    O
is    O
indicated    O
for    O
the    O
treatment    O
of    O
diabetic    O
dyslipidemia    O
and    O
hypertriglyceridemia    B-MetabolicDisorder114084502
with    O
type    O
2    O
diabetes    O
mellitus    O
not    O
controlled    O
by    O
statin    O
therapy    O
.    O

Hypertriglyceridaemia    B-MetabolicDisorder114084502

Hypertriglyceridaemia    B-MetabolicDisorder114084502
(    O
elevated    O
blood    O
triglycerides    O
)    O

Fish    O
oils    O
contain    O
the    O
omega-3    O
fatty    O
acids    O
eicosapentaenoic    O
acid    O
(    O
EPA    O
)    O
and    O
docosahexaenoic    O
acid    O
(    O
DHA    O
)    O
,    O
precursors    O
of    O
certain    O
eicosanoids    O
that    O
are    O
known    O
to    O
reduce    O
inflammation    O
in    O
the    O
body    O
,    O
and    O
have    O
other    O
health    O
benefits    O
,    O
such    O
as    O
treating    O
hypertriglyceridemia    B-MetabolicDisorder114084502
,    O
although    O
claims    O
of    O
preventing    O
heart    O
attacks    O
or    O
strokes    O
have    O
not    O
been    O
supported    O
.    O

The    O
US    O
National    O
Institutes    O
of    O
Health    O
lists    O
three    O
conditions    O
for    O
which    O
fish    O
oil    O
and    O
other    O
omega-3    O
sources    O
are    O
most    O
highly    O
recommended    O
:    O
hypertriglyceridemia    B-MetabolicDisorder114084502
(    O
high    O
triglyceride    O
level    O
)    O
,    O
preventing    O
secondary    O
cardiovascular    O
disease    O
,    O
and    O
hypertension    O
(    O
high    O
blood    O
pressure    O
)    O
.    O

The    O
most    O
common    O
adverse    O
reactions    O
(    O
≥30%    O
occurrence    O
,    O
leading    O
to    O
a    O
5%    O
treatment    O
discontinuation    O
rate    O
)    O
observed    O
with    O
sirolimus    O
in    O
clinical    O
studies    O
of    O
organ    O
rejection    O
prophylaxis    O
in    O
individuals    O
with    O
kidney    O
transplants    O
include    O
:    O
peripheral    O
edema    O
,    O
hypercholesterolemia    O
,    O
abdominal    O
pain    O
,    O
headache    O
,    O
nausea    O
,    O
diarrhea    O
,    O
pain    O
,    O
constipation    O
,    O
hypertriglyceridemia    B-MetabolicDisorder114084502
,    O
hypertension    O
,    O
increased    O
creatinine    O
,    O
fever    O
,    O
urinary    O
tract    O
infection    O
,    O
anemia    O
,    O
arthralgia    O
,    O
and    O
thrombocytopenia    O
.    O

In    O
the    O
US    O
it    O
is    O
indicated    O
as    O
a    O
treatment    O
for    O
complications    O
of    O
leptin    O
deficiency    O
,    O
and    O
for    O
the    O
diabetes    O
and    O
hypertriglyceridemia    B-MetabolicDisorder114084502
associated    O
with    O
congenital    O
or    O
acquired    O
generalized    O
lipodystrophy    B-MetabolicDisorder114084502
.    O

Dr    O
Leslie    O
Zieve    O
described    O
patients    O
with    O
a    O
combination    O
of    O
alcoholic    O
liver    O
disease    O
,    O
hemolytic    O
anemia    O
and    O
hypertriglyceridemia    B-MetabolicDisorder114084502
.    O

Consequences    O
of    O
the    O
alcohol    O
induced    O
redox    O
changes    O
in    O
the    O
human    O
body    O
include    O
increased    O
triglyceride    B-MetabolicDisorder114084502
production    O
,    O
increased    O
amino    O
acid    O
catabolism    O
,    O
inhibition    O
of    O
the    O
citric    O
acid    O
cycle    O
,    O
lactic    B-MetabolicDisorder114084502
acidosis    I-MetabolicDisorder114084502
,    O
ketoacidosis    O
,    O
hyperuricemia    B-MetabolicDisorder114084502
,    O
disturbance    O
in    O
cortisol    O
and    O
androgen    O
metabolism    O
and    O
increased    O
fibrogenesis    O
.    O

These    O
are    O
collectively    O
referred    O
to    O
as    O
glycogen    B-MetabolicDisorder114084502
storage    I-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

Modified    O
cornstarch    O
therapy    O
is    O
a    O
form    O
of    O
cornstarch    O
used    O
to    O
treat    O
glycogen    B-MetabolicDisorder114084502
storage    I-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

Glycogen    B-MetabolicDisorder114084502
storage    I-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502

PGM1    O
deficiency    O
is    O
known    O
as    O
glycogen    B-MetabolicDisorder114084502
storage    I-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
type    O
14    O
(    O
GSD    O
XIV    O
)    O
.    O

Glycogen    B-MetabolicDisorder114084502
storage    I-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502

Glycogen    B-MetabolicDisorder114084502
storage    I-MetabolicDisorder114084502
diseases    I-MetabolicDisorder114084502

Glycogen    B-MetabolicDisorder114084502
storage    I-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
type    I-MetabolicDisorder114084502
V    I-MetabolicDisorder114084502
(    O
GSD-V    B-MetabolicDisorder114084502
)    O
is    O
a    O
metabolic    O
disorder    O
,    O
more    O
specifically    O
a    O
glycogen    B-MetabolicDisorder114084502
storage    I-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
caused    O
by    O
a    O
deficiency    O
of    O
myophosphorylase    O
.    O

Glycogen    B-MetabolicDisorder114084502
storage    I-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
(    O
GSD    B-MetabolicDisorder114084502
,    O
also    O
glycogenosis    B-MetabolicDisorder114084502
and    O
dextrinosis    B-MetabolicDisorder114084502
)    O
is    O
the    O
result    O
of    O
defects    O
in    O
the    O
processing    O
of    O
glycogen    O
synthesis    O
or    O
breakdown    O
within    O
muscles    O
,    O
liver    O
,    O
and    O
other    O
cell    O
types    O
.    O

There    O
are    O
other    O
clinical    O
presentations    O
that    O
have    O
been    O
identified    O
,    O
namely    O
:    O
myoglobinuria    O
,    O
dicarboxylic    O
aciduria    O
,    O
feeding    O
difficulties    O
in    O
infancy    O
,    O
muscular    O
hypotonia    O
,    O
hepatic    O
steatosis    B-MetabolicDisorder114084502
,    O
growth    O
delay    O
,    O
hypertrophic    O
cardiomyopathy    O
,    O
dilated    O
cardiomyopathy    O
,    O
hepatic    O
necrosis    O
,    O
and    O
fulminant    O
hepatic    O
failure    O
.    O

Ablation    O
of    O
the    O
estrogen    O
binding    O
site    O
in    O
the    O
PEMT    O
promoter    O
region    O
may    O
increase    O
risk    O
of    O
hepatic    O
steatosis    B-MetabolicDisorder114084502
from    O
choline    O
deficiency    O
.    O

Although    O
steatosis    B-MetabolicDisorder114084502
(    O
fatty    O
liver    O
)    O
will    O
develop    O
in    O
any    O
individual    O
who    O
consumes    O
a    O
large    O
quantity    O
of    O
alcoholic    O
beverages    O
over    O
a    O
long    O
period    O
of    O
time    O
,    O
this    O
process    O
is    O
transient    O
and    O
reversible    O
.    O

Fatty    O
change    O
,    O
or    O
steatosis    B-MetabolicDisorder114084502
is    O
the    O
accumulation    O
of    O
fatty    O
acids    O
in    O
liver    O
cells    O
.    O

Hepatomegaly    O
with    O
steatosis    B-MetabolicDisorder114084502

It    O
also    O
detects    O
and    O
quantifies    O
steatosis    B-MetabolicDisorder114084502
simultaneously    O
using    O
the    O
Controlled    O
Attenuation    O
Parameter    O
(    O
CAP    O
)    O
.    O

Sjögren-Larsson    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
(    O
ILDS    O
Q87.136    O
)    O

Miltefosine    O
is    O
contraindicated    O
in    O
individuals    O
who    O
have    O
a    O
hypersensitivity    O
to    O
this    O
medication    O
,    O
pregnant    O
women    O
,    O
and    O
people    O
who    O
have    O
the    O
Sjögren-Larsson    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
.    O

Atransferrinemia    B-MetabolicDisorder114084502
is    O
associated    O
with    O
a    O
deficiency    O
in    O
transferrin    O
.    O

Galactosialidosis    B-MetabolicDisorder114084502
-    O
CTSA    O

This    O
classification    O
is    O
subjective    O
and    O
patients    O
with    O
complex    O
HSPs    O
are    O
sometimes    O
diagnosed    O
as    O
having    O
cerebellar    O
ataxia    O
with    O
spasticity    O
,    O
mental    O
retardation    O
(    O
with    O
spasticity    O
)    O
,    O
or    O
leukodystrophy    B-MetabolicDisorder114084502
.    O

Leukodystrophies    B-MetabolicDisorder114084502

Jill    O
Waggoner    O
Kelly    O
,    O
wife    O
of    O
Jim    O
Kelly    O
and    O
an    O
American    O
leukodystrophy    B-MetabolicDisorder114084502
activist    O

The    O
year    O
also    O
saw    O
successful    O
new    O
treatments    O
for    O
diseases    O
such    O
as    O
HIV    O
,    O
Usher    O
syndrome    O
and    O
leukodystrophy    B-MetabolicDisorder114084502
,    O
and    O
a    O
major    O
expansion    O
in    O
the    O
use    O
and    O
capabilities    O
of    O
technologies    O
such    O
as    O
3D    O
printing    O
and    O
autonomous    O
cars    O
.    O

New    O
York    O
researchers    O
successfully    O
cure    O
leukodystrophy    B-MetabolicDisorder114084502
in    O
mice    O
by    O
using    O
skin    O
cells    O
to    O
repair    O
damaged    O
myelin    O
sheaths    O
.    O

Italian    O
scientists    O
successfully    O
treat    O
the    O
symptoms    O
of    O
leukodystrophy    B-MetabolicDisorder114084502
in    O
six    O
young    O
children    O
using    O
gene    O
therapy    O
.    O

#    O
exercise-associated    B-MetabolicDisorder114084502
hyponatremia    I-MetabolicDisorder114084502
or    O
other    O
electrolyte    O
imbalance    O
;    O

The    O
exception    O
to    O
this    O
may    O
be    O
latent    O
post    O
-    O
puberty    O
genetic    O
carriers    O
of    O
hereditary    O
coproporphyria    B-MetabolicDisorder114084502
.    O

Patients    O
with    O
the    O
acute    O
porphyrias    O
(    O
AIP    B-MetabolicDisorder114084502
,    O
HCP    B-MetabolicDisorder114084502
,    O
VP    O
)    O
are    O
at    O
increased    O
risk    O
over    O
their    O
life    O
for    O
hepatocellular    O
carcinoma    O
(    O
primary    O
liver    O
cancer    O
)    O
and    O
may    O
require    O
monitoring    O
.    O

Erythropoietic    B-MetabolicDisorder114084502
coproporphyria    I-MetabolicDisorder114084502
(    O
ILDS    O
E80.040    O
)    O

Hereditary    B-MetabolicDisorder114084502
coproporphyria    I-MetabolicDisorder114084502
(    O
ILDS    O
E80.222    O
)    O

Hyperhomocysteinemia    B-MetabolicDisorder114084502
or    O
hyperhomocysteinaemia    B-MetabolicDisorder114084502
is    O
a    O
medical    O
condition    O
characterized    O
by    O
an    O
abnormally    O
high    O
level    O
of    O
homocysteine    O
in    O
the    O
blood    O
,    O
conventionally    O
described    O
as    O
above    O
15    O
µmol    O
/    O
L.    O

Metformin    O
(    O
Glucophage    O
)    O
:    O
Metformin    O
may    O
reduce    O
serum    O
folic    O
acid    O
and    O
vitamin    O
B12    O
levels    O
.    O
Long    O
-    O
term    O
use    O
of    O
metformin    O
substantially    O
increases    O
the    O
risk    O
of    O
B12    O
deficiency    O
and    O
(    O
in    O
those    O
patients    O
who    O
become    O
deficient    O
)    O
hyperhomocysteinemia    B-MetabolicDisorder114084502
,    O
which    O
is    O
"    O
an    O
independent    O
risk    O
factor    O
for    O
cardiovascular    O
disease    O
,    O
especially    O
among    O
individuals    O
with    O
type    O
2    O
diabetes    O
"    O
.    O

Hyperhomocysteinemia    B-MetabolicDisorder114084502
is    O
a    O
medical    O
condition    O
characterized    O
by    O
an    O
abnormally    O
large    O
level    O
of    O
homocysteine    O
in    O
the    O
blood    O
.    O

Inborn    O
errors    O
in    O
CBS    O
result    O
in    O
hyperhomocysteinemia    B-MetabolicDisorder114084502
with    O
complications    O
in    O
the    O
cardiovascular    O
system    O
leading    O
to    O
early    O
and    O
aggressive    O
arterial    O
disease    O
.    O

Hyperhomocysteinemia    B-MetabolicDisorder114084502
also    O
affects    O
three    O
other    O
major    O
organ    O
systems    O
including    O
the    O
ocular    O
,    O
central    O
nervous    O
,    O
and    O
skeletal    O
.    O

mmol    O
/    O
l    O
[    O
338    O
mg    O
/    O
dl    O
]    O
at    O
2:30pm    O
)    O
—    O
and    O
leave    O
her    O
at    O
significant    O
risk    O
of    O
developing    O
diabetic    B-MetabolicDisorder114084502
ketoacidosis    I-MetabolicDisorder114084502
.    O

Diabetic    B-MetabolicDisorder114084502
ketoacidosis    I-MetabolicDisorder114084502
,    O
in    O
which    O
high    O
levels    O
of    O
acidic    O
ketone    O
bodies    O
are    O
produced    O

Another    O
disadvantage    O
of    O
insulin    O
pump    O
use    O
is    O
a    O
higher    O
risk    O
of    O
developing    O
diabetic    B-MetabolicDisorder114084502
ketoacidosis    I-MetabolicDisorder114084502
if    O
the    O
pump    O
malfunctions    O
.    O

Causes    O
of    O
euthyroid    O
sick    O
syndrome    O
include    O
a    O
number    O
of    O
acute    O
and    O
chronic    O
conditions    O
,    O
including    O
pneumonia    O
,    O
fasting    O
,    O
starvation    O
,    O
anorexia    O
nervosa    O
,    O
sepsis    O
,    O
trauma    O
,    O
cardiopulmonary    O
bypass    O
,    O
malignancy    O
,    O
stress    O
,    O
heart    O
failure    O
,    O
hypothermia    O
,    O
myocardial    O
infarction    O
,    O
chronic    O
renal    O
failure    O
,    O
cirrhosis    O
,    O
and    O
diabetic    B-MetabolicDisorder114084502
ketoacidosis    I-MetabolicDisorder114084502
.    O

Biologically    O
,    O
infants    O
display    O
fasting    O
hypoglycemia    O
,    O
postprandial    O
hyperglycemia    O
and    O
hyperinsulinemia    O
,    O
which    O
progress    O
to    O
permanent    O
hyperglycemia    O
and    O
recurrent    O
diabetic    B-MetabolicDisorder114084502
ketoacidosis    I-MetabolicDisorder114084502
.    O

This    O
results    O
in    O
shunting    O
of    O
excess    O
acetyl    O
-    O
CoA    O
into    O
the    O
ketone    O
synthesis    O
pathway    O
via    O
HMG    O
-    O
CoA    O
,    O
leading    O
to    O
the    O
development    O
of    O
diabetic    B-MetabolicDisorder114084502
ketoacidosis    I-MetabolicDisorder114084502
.    O

The    O
dependence    O
on    O
fat    O
would    O
eventually    O
lead    O
to    O
acidosis    B-MetabolicDisorder114084502
,    O
followed    O
by    O
coma    O
and    O
death    O
.    O

This    O
eventually    O
led    O
to    O
acidosis    B-MetabolicDisorder114084502
,    O
followed    O
by    O
coma    O
and    O
death    O
.    O

Allen    O
found    O
that    O
a    O
liquids    O
-    O
only    O
diet    O
could    O
eliminate    O
glycosuria    O
and    O
acidosis    B-MetabolicDisorder114084502
.    O

The    O
diabetes    O
is    O
usually    O
diagnosed    O
in    O
the    O
first    O
3    O
months    O
of    O
life    O
due    O
to    O
continuing    O
poor    O
weight    O
gain    O
,    O
polyuria    O
,    O
or    O
diabetic    B-MetabolicDisorder114084502
ketoacidosis    I-MetabolicDisorder114084502
.    O

Other    O
conditions    O
that    O
can    O
predispose    O
to    O
mild    O
hypermagnesemia    O
are    O
diabetic    B-MetabolicDisorder114084502
ketoacidosis    I-MetabolicDisorder114084502
,    O
adrenal    O
insufficiency    O
,    O
hypothyroidism    O
,    O
hyperparathyroidism    O
and    O
lithium    O
intoxication    O
.    O

Alcohol    O
stimulates    O
the    O
kidneys    O
'    O
excretion    O
of    O
magnesium    O
,    O
which    O
is    O
also    O
increased    O
because    O
of    O
alcoholic    O
and    O
diabetic    B-MetabolicDisorder114084502
ketoacidosis    I-MetabolicDisorder114084502
,    O
low    B-MetabolicDisorder114084502
blood    I-MetabolicDisorder114084502
phosphate    I-MetabolicDisorder114084502
levels    I-MetabolicDisorder114084502
,    O
and    O
hyperaldosteronism    O
resulting    O
from    O
liver    O
disease    O
.    O

Patients    O
with    O
diabetic    B-MetabolicDisorder114084502
ketoacidosis    I-MetabolicDisorder114084502
should    O
have    O
their    O
magnesium    O
levels    O
monitored    O
to    O
ensure    O
that    O
the    O
serum    O
loss    O
of    O
potassium    O
,    O
which    O
is    O
driven    O
intracellularly    O
by    O
insulin    O
administration    O
,    O
is    O
not    O
exacerbated    O
by    O
additional    O
urinary    O
losses    O
.    O

This    O
can    O
be    O
seen    O
in    O
treatment    O
of    O
diabetic    B-MetabolicDisorder114084502
ketoacidosis    I-MetabolicDisorder114084502
,    O
refeeding    O
,    O
short    O
-    O
term    O
increases    O
in    O
cellular    O
demand    O
(    O
e.g.    O
hungry    O
bone    O
syndrome    O
)    O
and    O
acute    O
respiratory    O
alkalosis    O
.    O

Kayser    O
–    O
Fleischer    O
rings    O
are    O
a    O
sign    O
of    O
Wilson's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
which    O
involves    O
abnormal    O
copper    O
handling    O
by    O
the    O
liver    O
resulting    O
in    O
copper    O
accumulation    O
in    O
the    O
body    O
and    O
is    O
characterised    O
by    O
abnormalities    O
of    O
the    O
basal    O
ganglia    O
of    O
the    O
brain    O
,    O
liver    O
cirrhosis    O
,    O
splenomegaly    O
,    O
involuntary    O
movements    O
,    O
muscle    O
rigidity    O
,    O
psychiatric    O
disturbances    O
,    O
dystonia    O
and    O
dysphagia    O
.    O

Wilson's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502

Tetrathiomolybdate    O
was    O
first    O
used    O
therapeutically    O
in    O
the    O
treatment    O
of    O
copper    B-MetabolicDisorder114084502
toxicosis    I-MetabolicDisorder114084502
in    O
animals    O
.    O

It    O
was    O
then    O
introduced    O
as    O
a    O
treatment    O
in    O
Wilson's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
a    O
hereditary    O
copper    O
metabolism    O
disorder    O
in    O
humans    O
;    O
it    O
acts    O
both    O
by    O
competing    O
with    O
copper    O
absorption    O
in    O
the    O
bowel    O
and    O
by    O
increasing    O
excretion    O
.    O

This    O
is    O
the    O
case    O
in    O
Friedreich    O
's    O
ataxia    O
,    O
hereditary    O
spastic    O
paraplegia    O
,    O
and    O
Wilson's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

Kayser    O
-    O
Fleischer    O
rings    O
are    O
caused    O
by    O
copper    O
deposits    O
,    O
and    O
are    O
indicative    O
of    O
Wilson's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
whereas    O
Fleischer    O
rings    O
are    O
caused    O
by    O
iron    O
deposits    O
.    O

Wilson's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502

As    O
an    O
oral    O
daily    O
supplement    O
it    O
is    O
used    O
to    O
inhibit    O
the    O
body    O
's    O
absorption    O
of    O
copper    O
as    O
part    O
of    O
the    O
treatment    O
for    O
Wilson's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

Wilson's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
sickle    O
cell    O
disease    O
,    O
chronic    O
kidney    O
disease    O
,    O
chronic    O
liver    O
disease    O
have    O
all    O
been    O
associated    O
with    O
zinc    O
deficiency    O
.    O

Wilson's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
(    O
WD    O
)    O
is    O
a    O
rare    O
inherited    O
disorder    O
in    O
which    O
patients    O
have    O
a    O
problem    O
metabolizing    O
copper    O
.    O

Samuel    O
Alexander    O
Kinnier    O
Wilson    O
,    O
the    O
neurologist    O
most    O
known    O
for    O
his    O
description    O
of    O
what    O
came    O
to    O
be    O
known    O
as    O
Wilson's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

May    O
12    O
,    O
1937    O
)    O
was    O
an    O
American    O
born    O
-    O
British    O
neurologist    O
who    O
was    O
the    O
first    O
to    O
describe    O
Wilson's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

He    O
described    O
hepatolenticular    B-MetabolicDisorder114084502
degeneration    I-MetabolicDisorder114084502
in    O
his    O
Gold    O
Medal    O
winning    O
M.D.    O
dissertation    O
of    O
1912    O
titled    O
"    O
Progressive    O
lenticular    O
degeneration    O
"    O
from    O
the    O
University    O
of    O
Edinburgh    O
Medical    O
School    O
.    O

He    O
was    O
honored    O
for    O
his    O
research    O
of    O
the    O
disease    O
,    O
and    O
afterwards    O
the    O
disorder    O
became    O
known    O
as    O
"    O
Wilson's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
"    O
.    O

Other    O
causes    O
of    O
chronic    O
liver    O
disease    O
are    O
genetic    O
or    O
autoimmune    O
disease    O
,    O
such    O
as    O
hemochromatosis    O
,    O
Wilson's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
autoimmune    O
hepatitis    O
,    O
and    O
primary    O
biliary    O
cirrhosis    O
.    O

Ammonium    O
tetrathiomolybdate    O
was    O
first    O
used    O
therapeutically    O
in    O
the    O
treatment    O
of    O
copper    B-MetabolicDisorder114084502
toxicosis    I-MetabolicDisorder114084502
in    O
animals    O
.    O

It    O
was    O
then    O
introduced    O
as    O
a    O
treatment    O
in    O
Wilson's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
a    O
hereditary    O
copper    O
metabolism    O
disorder    O
,    O
in    O
humans    O
;    O
it    O
acts    O
both    O
by    O
competing    O
with    O
copper    O
absorption    O
in    O
the    O
bowel    O
and    O
by    O
increasing    O
excretion    O
.    O

Her    O
mother    O
dies    O
of    O
Wilson's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
and    O
her    O
stepfather    O
runs    O
away    O
with    O
all    O
their    O
money    O
.    O

Insulin    O
is    O
used    O
to    O
treat    O
a    O
number    O
of    O
diseases    O
including    O
diabetes    O
and    O
its    O
acute    O
complications    O
such    O
as    O
diabetic    B-MetabolicDisorder114084502
ketoacidosis    I-MetabolicDisorder114084502
and    O
hyperosmolar    B-MetabolicDisorder114084502
hyperglycemic    I-MetabolicDisorder114084502
states    I-MetabolicDisorder114084502
.    O

Hyperosmolar    B-MetabolicDisorder114084502
hyperglycemic    I-MetabolicDisorder114084502
state    I-MetabolicDisorder114084502
(    O
HHS    B-MetabolicDisorder114084502
)    O
is    O
a    O
complication    O
of    O
diabetes    O
mellitus    O
in    O
which    O
high    O
blood    O
sugar    O
results    O
in    O
high    O
osmolarity    O
without    O
significant    O
ketoacidosis    O
.    O

Hyperosmolar    B-MetabolicDisorder114084502
hyperglycemic    I-MetabolicDisorder114084502
state    I-MetabolicDisorder114084502
,    O
also    O
known    O
as    O
hyperosmotic    O
non    O
-    O
ketotic    O
coma    O
,    O
a    O
type    O
of    O
diabetic    O
coma    O

MPS    O
I    O
S    O
Scheie    B-MetabolicDisorder114084502
Syndrome    I-MetabolicDisorder114084502

MyoAdenylate    B-MetabolicDisorder114084502
Deaminase    I-MetabolicDisorder114084502
Deficiency    I-MetabolicDisorder114084502

Hereditary    B-MetabolicDisorder114084502
hyperbilirubinemia    I-MetabolicDisorder114084502
refers    O
to    O
the    O
condition    O
where    O
levels    O
of    O
bilirubin    O
are    O
elevated    O
,    O
for    O
reasons    O
that    O
can    O
be    O
attributed    O
to    O
a    O
metabolic    O
disorder    O
.    O

Glutaric    B-MetabolicDisorder114084502
acidemia    I-MetabolicDisorder114084502
type    O
II    O

Glutaric    B-MetabolicDisorder114084502
aciduria    I-MetabolicDisorder114084502

Familial    O
hypophosphataemia    B-MetabolicDisorder114084502

Alcohol    O
stimulates    O
the    O
kidneys    O
'    O
excretion    O
of    O
magnesium    O
,    O
which    O
is    O
also    O
increased    O
because    O
of    O
alcoholic    O
and    O
diabetic    B-MetabolicDisorder114084502
ketoacidosis    I-MetabolicDisorder114084502
,    O
low    B-MetabolicDisorder114084502
blood    I-MetabolicDisorder114084502
phosphate    I-MetabolicDisorder114084502
levels    I-MetabolicDisorder114084502
,    O
and    O
hyperaldosteronism    O
resulting    O
from    O
liver    O
disease    O
.    O

Hypophosphatemia    B-MetabolicDisorder114084502
,    O
a    O
low    O
concentration    O
of    O
phosphate    O
in    O
the    O
blood    O

Hypophosphatemia    B-MetabolicDisorder114084502
is    O
an    O
electrolyte    O
disturbance    O
in    O
which    O
there    O
is    O
an    O
abnormally    O
low    O
level    O
of    O
phosphate    O
in    O
the    O
blood    O
.    O

Laboratory    O
findings    O
include    O
low    O
-    O
normal    O
serum    O
calcium    O
,    O
moderately    O
low    O
serum    O
phosphate    O
,    O
elevated    O
serum    O
alkaline    O
phosphatase    O
,    O
and    O
low    O
serum    O
1,25    O
dihydroxy    O
-    O
vitamin    O
D    O
levels    O
,    O
hyperphosphaturia    B-MetabolicDisorder114084502
,    O
and    O
no    O
evidence    O
of    O
hyperparathyroidism    O
.    O

Mutations    O
in    O
genes    O
coding    O
for    O
these    O
enzymes    O
leads    O
to    O
the    O
accumulation    O
of    O
partially    O
broken    O
down    O
gangliosides    O
in    O
lysosomes    O
,    O
which    O
results    O
in    O
a    O
group    O
of    O
diseases    O
called    O
gangliosidosis    B-MetabolicDisorder114084502
.    O

A    O
summary    O
showing    O
the    O
causes    O
of    O
sphingolipidosis    O
,    O
including    O
gangliosidosis    B-MetabolicDisorder114084502
.    O

Other    O
gangliosidosis    B-MetabolicDisorder114084502

In    O
the    O
absence    O
of    O
endogenous    O
insulin    O
—    O
type    O
1    O
diabetes    O
,    O
depleted    O
type    B-MetabolicDisorder114084502
2    I-MetabolicDisorder114084502
(    O
in    O
some    O
cases    O
)    O
or    O
latent    B-MetabolicDisorder114084502
autoimmune    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
of    I-MetabolicDisorder114084502
adults    I-MetabolicDisorder114084502
in    O
late    O
stage    O
—    O
insulin    O
glargine    O
needs    O
the    O
support    O
of    O
fast    O
acting    O
insulin    O
taken    O
with    O
food    O
to    O
reduce    O
the    O
effect    O
of    O
prandially    O
derived    O
glucose    O
.    O

It    O
is    O
used    O
to    O
detect    O
most    O
autoantibodies    O
seen    O
in    O
latent    B-MetabolicDisorder114084502
autoimmune    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
.    O

MODY    O
should    O
not    O
be    O
confused    O
with    O
latent    B-MetabolicDisorder114084502
autoimmune    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
of    I-MetabolicDisorder114084502
adults    I-MetabolicDisorder114084502
(LADA)    I-MetabolicDisorder114084502
—    O
a    O
form    O
of    O
type    O
1    O
DM    O
,    O
with    O
slower    O
progression    O
to    O
insulin    O
dependence    O
than    O
child    O
-    O
onset    O
type    O
1    O
DM    O
,    O
and    O
which    O
occurs    O
later    O
in    O
life    O
.    O

Holocarboxylase    B-MetabolicDisorder114084502
synthetase    I-MetabolicDisorder114084502
deficiency    I-MetabolicDisorder114084502

Holocarboxylase    B-MetabolicDisorder114084502
synthetase    I-MetabolicDisorder114084502
deficiency    I-MetabolicDisorder114084502

However    O
,    O
she    O
is    O
now    O
clinically    O
recognized    O
as    O
having    O
likely    O
had    O
the    O
Queen    O
of    O
Punt    O
syndrome    O
,    O
a    O
suite    O
of    O
conditions    O
that    O
include    O
familial    O
obesity    O
,    O
Launois    O
Bensaude    O
lipomatosis    O
,    O
Dercum    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
neurofibromatosis    O
,    O
congenital    O
lipodystrophy    B-MetabolicDisorder114084502
,    O
achondroplasia    O
,    O
X-linked    B-MetabolicDisorder114084502
hypophosphatemia    I-MetabolicDisorder114084502
,    O
and    O
Proteus    O
syndrome    O
.    O

Adiposis    B-MetabolicDisorder114084502
dolorosa    I-MetabolicDisorder114084502
,    O
also    O
known    O
as    O
Dercum's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
or    O
Anders    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
is    O
a    O
rare    O
condition    O
characterized    O
by    O
generalized    O
obesity    O
and    O
fatty    O
tumors    O
in    O
the    O
adipose    O
tissue    O
.    O

Clinically    O
,    O
this    O
condition    O
is    O
called    O
Jamaican    B-MetabolicDisorder114084502
vomiting    I-MetabolicDisorder114084502
sickness    I-MetabolicDisorder114084502
.    O

Hypolipoproteinemia    O
,    O
hypolipidemia    O
,    O
or    O
hypolipidaemia    O
(    O
British    O
English    O
)    O
is    O
a    O
form    O
of    O
dyslipidemia    B-MetabolicDisorder114084502
that    O
is    O
defined    O
by    O
abnormally    O
lowered    O
levels    O
of    O
any    O
or    O
all    O
lipids    O
and/or    O
lipoproteins    O
in    O
the    O
blood    O
.    O

Major    O
trauma    O
,    O
smoking    O
,    O
cocaine    O
use    O
,    O
pregnancy    O
,    O
a    O
thoracic    O
aortic    O
aneurysm    O
,    O
inflammation    O
of    O
arteries    O
,    O
and    O
abnormal    B-MetabolicDisorder114084502
lipid    I-MetabolicDisorder114084502
levels    I-MetabolicDisorder114084502
are    O
also    O
associated    O
with    O
an    O
increased    O
risk    O
.    O

Among    O
the    O
recognized    O
risk    O
factors    O
for    O
aortic    O
dissection    O
,    O
hypertension    O
,    O
dysplipidemia    B-MetabolicDisorder114084502
,    O
and    O
smoking    O
are    O
considered    O
preventable    O
risk    O
factors    O
.    O

Serious    O
side    O
effects    O
that    O
are    O
advised    O
to    O
be    O
reported    O
immediately    O
include    O
symptoms    O
of    O
bradycardia    O
(    O
resting    O
heart    O
rate    O
slower    O
than    O
60    O
beats    O
per    O
minute    O
)    O
,    O
persistent    O
symptoms    O
of    O
dizziness    O
,    O
fainting    O
and    O
unusual    O
fatigue    O
,    O
bluish    O
discoloration    O
of    O
the    O
fingers    O
and    O
toes    O
,    O
numbness    O
/    O
tingling    O
/    O
swelling    O
of    O
the    O
hands    O
or    O
feet    O
,    O
sexual    O
dysfunction    O
,    O
erectile    O
dysfunction    O
(    O
impotence    O
)    O
,    O
hair    O
loss    O
,    O
mental    O
/    O
mood    O
changes    O
,    O
depression    O
,    O
trouble    O
breathing    O
,    O
cough    O
,    O
dyslipidemia    B-MetabolicDisorder114084502
,    O
and    O
increased    O
thirst    O
.    O

Dyslipidemia    B-MetabolicDisorder114084502
&    I-MetabolicDisorder114084502
Metabolic    I-MetabolicDisorder114084502
Syndrome    I-MetabolicDisorder114084502

Infrequent    O
ADRs    O
include    O
:    O
dyslipidemia    B-MetabolicDisorder114084502
,    O
increased    O
serum    O
creatinine    O
concentration    O
,    O
hypocalcemia    O
,    O
rash    O
.    O

Major    O
risk    O
factors    O
for    O
cerebral    O
infarction    O
are    O
generally    O
the    O
same    O
as    O
for    O
atherosclerosis    O
:    O
high    O
blood    O
pressure    O
,    O
Diabetes    O
mellitus    O
,    O
tobacco    O
smoking    O
,    O
obesity    O
,    O
and    O
dyslipidemia    B-MetabolicDisorder114084502
.    O

Saroglitazar    O
(    O
INN    O
,    O
trade    O
name    O
Lipaglyn    O
)    O
is    O
a    O
drug    O
for    O
the    O
treatment    O
of    O
type    B-MetabolicDisorder114084502
2    I-MetabolicDisorder114084502
diabetes    I-MetabolicDisorder114084502
mellitus    I-MetabolicDisorder114084502
and    O
dyslipidemia    B-MetabolicDisorder114084502
.    O

Dyslipidemia    B-MetabolicDisorder114084502
:    O
0.263(0.014    O
)    O

Of    O
the    O
components    O
of    O
the    O
cardiometabolic    O
syndrome    O
,    O
only    O
the    O
prevalence    O
of    O
dyslipidemia    B-MetabolicDisorder114084502
has    O
declined    O
in    O
the    O
United    O
States    O
.    O

Animals    O
administered    O
Monocrotophos    O
exhibited    O
mild    O
hyperglycemia    O
and    O
dyslipidemia    B-MetabolicDisorder114084502
in    O
the    O
blood    O
.    O

Glycogen    B-MetabolicDisorder114084502
storage    I-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
type    I-MetabolicDisorder114084502
VI    I-MetabolicDisorder114084502
-    O
liver    O
glycogen    O

An    O
example    O
is    O
Hers    O
'    O
disease    O
-    O
Glycogen    B-MetabolicDisorder114084502
storage    I-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
type    I-MetabolicDisorder114084502
VI    I-MetabolicDisorder114084502
-    O
caused    O
by    O
deficiency    O
of    O
hepatic    O
phosphorylase    O
associated    O
with    O
an    O
enlarged    O
liver    O
and    O
mild    O
hypoglycaemia    O
.    O

The    O
medical    O
names    O
of    O
the    O
different    O
conditions    O
are    O
derived    O
from    O
the    O
vitamin    O
involved    O
:    O
an    O
excess    O
of    O
vitamin    O
A    O
,    O
for    O
example    O
,    O
is    O
called    O
"    O
hypervitaminosis    B-MetabolicDisorder114084502
A    I-MetabolicDisorder114084502
"    O
.    O

Hypervitaminosis    B-MetabolicDisorder114084502
A    I-MetabolicDisorder114084502

De    O
Veer    O
kept    O
a    O
diary    O
of    O
the    O
voyages    O
and    O
in    O
1597    O
was    O
the    O
first    O
person    O
to    O
observe    O
and    O
record    O
the    O
Novaya    O
Zemlya    O
effect    O
,    O
and    O
the    O
first    O
westerner    O
to    O
observe    O
hypervitaminosis    B-MetabolicDisorder114084502
A    I-MetabolicDisorder114084502
caused    O
by    O
consuming    O
polar    O
bear    O
liver    O
.    O

The    O
liver    O
of    O
the    O
polar    O
bear    O
is    O
unsafe    O
to    O
eat    O
because    O
it    O
is    O
very    O
high    O
in    O
vitamin    O
A    O
and    O
can    O
cause    O
hypervitaminosis    B-MetabolicDisorder114084502
A    I-MetabolicDisorder114084502
,    O
a    O
dangerous    O
disorder    O
.    O

The    O
liver    O
and    O
liver    O
products    O
(    O
such    O
as    O
cod    O
liver    O
oil    O
)    O
of    O
fish    O
and    O
many    O
animals    O
(    O
such    O
as    O
seals    O
and    O
whales    O
)    O
contain    O
omega-3    O
,    O
but    O
also    O
the    O
active    O
form    O
of    O
vitamin    O
A.    O
At    O
high    O
levels    O
,    O
this    O
form    O
of    O
the    O
vitamin    O
can    O
be    O
dangerous    O
(    O
Hypervitaminosis    B-MetabolicDisorder114084502
A    I-MetabolicDisorder114084502
)    O
.    O

Vitamin    O
D    O
or    O
vitamin    B-MetabolicDisorder114084502
A    I-MetabolicDisorder114084502
intoxication    I-MetabolicDisorder114084502

Typical    O
undesired    O
effects    O
of    O
glucocorticoids    O
present    O
quite    O
uniformly    O
as    O
drug    O
-    O
induced    O
Cushing's    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
.    O

In    O
Cushing    O
's    O
disease    O
a    O
pituitary    O
tumor    O
is    O
the    O
cause    O
of    O
elevated    O
ACTH    O
(    O
from    O
the    O
anterior    O
pituitary    O
)    O
and    O
an    O
excess    O
of    O
cortisol    O
(    O
hypercortisolism    O
)    O
–    O
this    O
constellation    O
of    O
signs    O
and    O
symptoms    O
is    O
known    O
as    O
Cushing's    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
.    O

Cushing's    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
,    O
hypercorticism    O
,    O
one    O
of    O
the    O
causes    O
is    O
hypersecretion    O
of    O
ACTH    O

A    O
productive    O
form    O
arising    O
from    O
the    O
anterior    O
pituitary    O
is    O
the    O
primary    O
cause    O
of    O
Cushing's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
of    O
dogs    O
.    O

This    O
is    O
problematic    O
long    O
-    O
term    O
and    O
can    O
lead    O
to    O
ACTH    O
-    O
receptor    O
pathway    O
-    O
related    O
side    O
effects    O
including    O
:    O
Cushing's    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
,    O
fluid    O
retention    O
,    O
glaucoma    O
,    O
and    O
cardiovascular    O
disorders    O
.    O

It    O
is    O
often    O
associated    O
with    O
Cushing's    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
or    O
steroid    O
treatment    O
(    O
especially    O
corticosteroids    O
)    O
,    O
which    O
has    O
led    O
to    O
it    O
being    O
known    O
as    O
Cushingoid    O
facies    O
(    O
"    O
Cushings    O
-    O
like    O
face    O
"    O
)    O
.    O

The    O
release    O
of    O
adrenocorticotropic    O
hormone    O
is    O
usually    O
regulated    O
within    O
the    O
sympathoadrenal    O
system    O
as    O
it    O
is    O
tasked    O
with    O
maintenance    O
of    O
homeostasis    O
;    O
however    O
,    O
there    O
are    O
certain    O
cases    O
in    O
which    O
the    O
levels    O
of    O
adrenocorticotropic    O
hormones    O
may    O
be    O
in    O
excess    O
,    O
causing    O
hypertension    O
,    O
or    O
even    O
Cushing’s    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
.    O

Cushing's    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502

Cushing's    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
(    O
hyperadrenocorticism    O
)    O

Adrenal    O
gland    O
tumors    O
,    O
adrenocortical    O
adenomas    O
,    O
and    O
adrenocortical    O
carcinoma    O
,    O
as    O
well    O
as    O
adrenal    O
hyperplasia    O
due    O
to    O
pituitary    O
adenomas    O
(    O
as    O
in    O
Cushing's    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
)    O
.    O

A    O
study    O
of    O
60    O
persons    O
with    O
Cushing's    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
found    O
CSR    O
in    O
3    O
(    O
5%    O
)    O
.    O

Long    O
-    O
term    O
side    O
effects    O
include    O
Cushing's    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
,    O
steroid    O
dementia    O
syndrome    O
,    O
truncal    O
weight    O
gain    O
,    O
osteoporosis    O
,    O
glaucoma    O
and    O
cataracts    O
,    O
diabetes    O
mellitus    O
type    B-MetabolicDisorder114084502
2    I-MetabolicDisorder114084502
,    O
and    O
depression    O
upon    O
dose    O
reduction    O
or    O
cessation    O
.    O

Excessive    O
glucocorticoid    O
levels    O
resulting    O
from    O
administration    O
as    O
a    O
drug    O
or    O
hyperadrenocorticism    B-MetabolicDisorder114084502
have    O
effects    O
on    O
many    O
systems    O
.    O

Hypercortisolemia    O
with    O
prolonged    O
or    O
excessive    O
use    O
(    O
also    O
known    O
as    O
,    O
exogenous    O
Cushing's    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
)    O

Oral    O
use    O
of    O
cortisone    O
has    O
a    O
number    O
of    O
potential    O
systemic    O
side    O
-    O
effects    O
:    O
hyperglycemia    O
,    O
insulin    B-MetabolicDisorder114084502
resistance    I-MetabolicDisorder114084502
,    O
diabetes    O
mellitus    O
,    O
osteoporosis    O
,    O
anxiety    O
,    O
depression    O
,    O
amenorrhoea    O
,    O
cataracts    O
,    O
Cushing's    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
and    O
glaucoma    O
,    O
among    O
other    O
problems    O
.    O

Overproduction    O
of    O
cortisol    O
leads    O
to    O
Cushing's    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
,    O
whereas    O
insufficient    O
production    O
is    O
associated    O
with    O
Addison    O
's    O
disease    O
.    O

These    O
disorders    O
affect    O
the    O
gland    O
either    O
directly    O
(    O
as    O
with    O
infections    O
or    O
autoimmune    O
diseases    O
)    O
or    O
as    O
a    O
result    O
of    O
the    O
dysregulation    O
of    O
hormone    O
production    O
(    O
as    O
in    O
some    O
types    O
of    O
Cushing's    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
)    O
leading    O
to    O
an    O
excess    O
or    O
insufficiency    O
of    O
adrenal    O
hormones    O
and    O
the    O
related    O
symptoms    O
.    O

Cushing's    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
is    O
the    O
manifestation    O
of    O
glucocorticoid    O
excess    O
.    O

Acquired    O
tracheal    O
collapse    O
can    O
be    O
caused    O
by    O
Cushing's    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
,    O
heart    O
disease    O
,    O
and    O
chronic    O
respiratory    O
disease    O
and    O
infection    O
.    O

Cushing's    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
is    O
a    O
hormonal    O
disorder    O
that    O
causes    O
hypercortisolism    O
,    O
which    O
is    O
elevated    O
levels    O
of    O
cortisol    O
in    O
the    O
blood    O
.    O

Image    O
:    O
Calcinosis    O
cutis    O
dog.jpg|Calcinosis    O
cutis    O
in    O
a    O
dog    O
with    O
Cushing's    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502

|    O
Alstrom    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502

Autosomal    O
recessive    O
(    O
as    O
found    O
,    O
for    O
example    O
,    O
in    O
Alström    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
)    O
,    O
X    O
-    O
linked    O
(    O
as    O
in    O
Duchenne    O
muscular    O
dystrophy    O
)    O
,    O
and    O
mitochondrial    B-MetabolicDisorder114084502
inheritance    O
of    O
the    O
disease    O
is    O
also    O
found    O
.    O

Biedl    O
syndrome    O
,    O
polycystic    O
kidney    O
and    O
liver    O
disease    O
,    O
nephronophthisis    O
,    O
Alstrom    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
,    O
and    O
some    O
forms    O
of    O
retinal    O
degeneration    O
.    O

Adjustable    B-MetabolicDisorder114084502
gastric    I-MetabolicDisorder114084502
banding    I-MetabolicDisorder114084502
surgery    I-MetabolicDisorder114084502

Tina    O
supports    O
Sonia    O
when    O
she    O
falls    O
ill    O
,    O
and    O
she    O
confides    O
in    O
her    O
that    O
she    O
spent    O
the    O
money    O
from    O
the    O
charity    O
calendar    O
she    O
organised    O
on    O
a    O
gastric    B-MetabolicDisorder114084502
band    I-MetabolicDisorder114084502
in    O
Bulgaria    O
,    O
to    O
impress    O
her    O
husband    O
Martin    O
(    O
James    O
Bye    O
)    O
.    O

These    O
bariatric    O
procedures    O
include    O
the    O
Laparoscopic    O
Adjustable    B-MetabolicDisorder114084502
Gastric    I-MetabolicDisorder114084502
Band    I-MetabolicDisorder114084502
(    O
LAP    O
-    O
BAND    O
)    O
System    O
,    O
Laparoscopic    O
Roux    O
-    O
en    O
-    O
Y    O
Gastric    O
Bypass    O
,    O
Open    O
or    O
Laparoscopic    O
Duodenal    O
Switch    O
and    O
Laparoscopic    O
Sleeve    B-MetabolicDisorder114084502
Gastrectomy    I-MetabolicDisorder114084502
.    O

In    O
1999    O
Osbourne    O
lost    O
after    O
lap-band    B-MetabolicDisorder114084502
surgery    O
(    O
adjustable    O
gastric    O
band    O
)    O
.    O

In    O
"    O
Little    O
Britain    O
USA    O
"    O
,    O
Marjorie    O
is    O
offended    O
when    O
Jenny    O
uses    O
a    O
gastric    B-MetabolicDisorder114084502
band    I-MetabolicDisorder114084502
to    O
lose    O
weight    O
,    O
accusing    O
her    O
of    O
being    O
a    O
cheat    O
,    O
and    O
proceeds    O
to    O
pull    O
the    O
band    O
out    O
of    O
Jenny    O
's    O
stomach    O
by    O
shoving    O
her    O
arm    O
into    O
her    O
mouth    O
.    O

Lubomyr    O
Kuzmak    O
was    O
a    O
pioneer    O
within    O
the    O
bariatric    B-MetabolicDisorder114084502
surgical    I-MetabolicDisorder114084502
community    O
inventing    O
the    O
adjustable    B-MetabolicDisorder114084502
silicone    I-MetabolicDisorder114084502
band    I-MetabolicDisorder114084502
.    O

Glycogen    B-MetabolicDisorder114084502
storage    I-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
type    I-MetabolicDisorder114084502
II    I-MetabolicDisorder114084502

A    O
pilot    O
screening    O
program    O
for    O
four    O
lysosomal    O
storage    O
diseases    O
(    O
Gaucher    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
Pompe    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
Fabry    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
and    O
Niemann-Pick    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
was    O
undertaken    O
using    O
anonymised    O
dried    O
blood    O
spots    O
was    O
completed    O
in    O
Austria    O
in    O
2010    O
.    O

Glycogen    B-MetabolicDisorder114084502
storage    I-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
type    I-MetabolicDisorder114084502
II    I-MetabolicDisorder114084502
,    O
also    O
called    O
Pompe    O
disease    O

|    O
GSD    B-MetabolicDisorder114084502
type    I-MetabolicDisorder114084502
II    I-MetabolicDisorder114084502

Glycogen    B-MetabolicDisorder114084502
storage    I-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
type    I-MetabolicDisorder114084502
II    I-MetabolicDisorder114084502
(    O
Pompe    O
disease    O
)    O

William    O
Canfield    O
is    O
a    O
glycobiologist    O
,    O
chief    O
scientific    O
officer    O
and    O
founder    O
of    O
an    O
Oklahoma    O
City    O
-    O
based    O
biotechnology    O
company    O
,    O
Novazyme    O
,    O
which    O
was    O
acquired    O
by    O
Genzyme    O
in    O
August    O
2001    O
and    O
developed    O
,    O
among    O
other    O
things    O
,    O
an    O
enzyme    O
that    O
can    O
stabilize    O
(    O
but    O
not    O
cure    O
)    O
Pompe    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
based    O
on    O
Canfield    O
's    O
ongoing    O
research    O
since    O
1998    O
.    O

John    O
Crowley    O
took    O
over    O
a    O
position    O
as    O
a    O
CEO    O
in    O
Novazyme    O
after    O
leaving    O
Bristol    O
-    O
Myers    O
Squibb    O
in    O
March    O
2000    O
and    O
together    O
with    O
at    O
Duke    O
University    O
pushed    O
for    O
expedited    O
approval    O
by    O
the    O
U.S.    O
Food    O
and    O
Drug    O
Administration    O
(    O
FDA    O
)    O
of    O
a    O
new    O
drug    O
compound    O
,    O
NZ-1001    O
under    O
orphan    O
drug    O
designation    O
for    O
the    O
treatment    O
of    O
Glycogen    B-MetabolicDisorder114084502
storage    I-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
type    I-MetabolicDisorder114084502
II    I-MetabolicDisorder114084502
in    O
October    O
2005    O
.    O

Histidinemia    B-MetabolicDisorder114084502

Mutation    O
of    O
PHEX    O
leads    O
to    O
X-linked    B-MetabolicDisorder114084502
hypophosphatemia    I-MetabolicDisorder114084502
.    O

However    O
,    O
she    O
is    O
now    O
clinically    O
recognized    O
as    O
having    O
likely    O
had    O
the    O
Queen    O
of    O
Punt    O
syndrome    O
,    O
a    O
suite    O
of    O
conditions    O
that    O
include    O
familial    O
obesity    O
,    O
Launois    O
Bensaude    O
lipomatosis    O
,    O
Dercum    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
neurofibromatosis    O
,    O
congenital    O
lipodystrophy    B-MetabolicDisorder114084502
,    O
achondroplasia    O
,    O
X-linked    B-MetabolicDisorder114084502
hypophosphatemia    I-MetabolicDisorder114084502
,    O
and    O
Proteus    O
syndrome    O
.    O

X-linked    B-MetabolicDisorder114084502
hypophosphatemia    I-MetabolicDisorder114084502

Beriberi    O
is    O
one    O
of    O
several    O
thiamine    O
-    O
deficiency    O
related    O
conditions    O
,    O
which    O
may    O
occur    O
concurrently    O
,    O
including    O
Wernicke's    B-MetabolicDisorder114084502
encephalopathy    I-MetabolicDisorder114084502
(    O
mainly    O
affecting    O
the    O
central    O
nervous    O
system    O
)    O
,    O
Korsakoff    O
's    O
syndrome    O
(    O
amnesia    O
with    O
additional    O
psychiatric    O
manifestations    O
)    O
,    O
and    O
Wernicke–    O

Symptoms    O
may    O
occur    O
concurrently    O
with    O
those    O
of    O
Wernicke's    B-MetabolicDisorder114084502
encephalopathy    I-MetabolicDisorder114084502
,    O
a    O
primarily    O
neurological    O
thiamine    O
-    O
deficiency    O
related    O
condition    O
.    O

All    O
these    O
causes    O
mainly    O
affect    O
the    O
central    O
nervous    O
system    O
,    O
and    O
provoke    O
the    O
development    O
of    O
what    O
is    O
known    O
as    O
Wernicke's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
or    I-MetabolicDisorder114084502
Wernicke's    I-MetabolicDisorder114084502
encephalopathy    I-MetabolicDisorder114084502
.    O

These    O
conditions    O
include    O
beriberi    O
,    O
Korsakoff    O
's    O
syndrome    O
,    O
Wernicke's    B-MetabolicDisorder114084502
encephalopathy    I-MetabolicDisorder114084502
and    O
diabetic    O
neuropathy    O
.    O

Chronic    O
alcoholism    O
often    O
leads    O
to    O
a    O
thiamine    O
(    O
vitamin    O
B1    O
)    O
deficiency    O
in    O
the    O
brain    O
,    O
causing    O
Korsakoff    O
's    O
syndrome    O
,    O
a    O
neurological    O
disorder    O
which    O
is    O
generally    O
preceded    O
by    O
an    O
acute    O
neurological    O
condition    O
known    O
as    O
Wernicke's    B-MetabolicDisorder114084502
encephalopathy    I-MetabolicDisorder114084502
(    O
WE    O
)    O
.    O

Fructose    B-MetabolicDisorder114084502
malabsorption    I-MetabolicDisorder114084502

The    O
disorder    O
fructose    B-MetabolicDisorder114084502
malabsorption    I-MetabolicDisorder114084502
causes    O
improper    O
absorption    O
of    O
tryptophan    O
in    O
the    O
intestine    O
,    O
reduced    O
levels    O
of    O
tryptophan    O
in    O
the    O
blood    O
,    O
and    O
depression    O
.    O

Fructose    B-MetabolicDisorder114084502
malabsorption    I-MetabolicDisorder114084502
and    O
lactose    O
intolerance    O
may    O
produce    O
IBS    O
symptoms    O
through    O
the    O
same    O
mechanism    O
but    O
,    O
unlike    O
with    O
other    O
FODMAPs    O
,    O
poor    O
absorption    O
is    O
found    O
only    O
in    O
a    O
minority    O
of    O
people    O
.    O

Hydrogen    O
breath    O
test    O
-    O
it    O
is    O
becoming    O
more    O
and    O
more    O
common    O
for    O
people    O
to    O
undertake    O
a    O
medical    O
test    O
for    O
clinical    O
diagnosis    O
of    O
dietary    O
disabilities    O
such    O
as    O
fructose    B-MetabolicDisorder114084502
intolerance    I-MetabolicDisorder114084502
,    O
fructose    B-MetabolicDisorder114084502
malabsorption    I-MetabolicDisorder114084502
,    O
lactose    O
intolerance    O
and    O
lactulose    O
intolerance    O
.    O

Morquio    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502

A    O
medical    O
condition    O
,    O
Morquio    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
(    O
mucopolysaccharidosis    O
IV    O
)    O
,    O
is    O
named    O
in    O
his    O
honor    O
.    O

A    O
medical    O
condition    O
known    O
as    O
mucopolysaccharidosis    O
type    O
IV    O
,    O
which    O
he    O
described    O
,    O
was    O
named    O
Morquio    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
in    O
his    O
honor    O
.    O

Morquio    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
is    O
a    O
rare    O
birth    O
defect    O
caused    O
by    O
a    O
deficiency    O
in    O
this    O
essential    O
enzyme    O
.    O

Cow    O
's    O
milk    O
protein    O
intolerance    O
,    O
a    O
food    B-MetabolicDisorder114084502
intolerance    I-MetabolicDisorder114084502

Food    B-MetabolicDisorder114084502
intolerance    I-MetabolicDisorder114084502

Food    B-MetabolicDisorder114084502
intolerance    I-MetabolicDisorder114084502
is    O
a    O
detrimental    O
reaction    O
,    O
often    O
delayed    O
,    O
to    O
a    O
food    O
,    O
beverage    O
,    O
food    O
additive    O
,    O
or    O
compound    O
found    O
in    O
foods    O
that    O
produces    O
symptoms    O
in    O
one    O
or    O
more    O
body    O
organs    O
and    O
systems    O
,    O
but    O
generally    O
refers    O
to    O
reactions    O
other    O
than    O
food    O
allergy    O
.    O

Allergies    O
,    O
food    B-MetabolicDisorder114084502
intolerance    I-MetabolicDisorder114084502
are    O
also    O
reported    O
in    O
some    O
children    O
.    O

Batter    O
made    O
from    O
buckwheat    O
flour    O
is    O
gluten    O
-    O
free    O
,    O
which    O
makes    O
it    O
possible    O
for    O
people    O
who    O
have    O
a    O
gluten    O
allergy    O
or    O
intolerance    B-MetabolicDisorder114084502
to    O
eat    O
this    O
type    O
of    O
crêpe    O
.    O

The    O
company    O
is    O
reported    O
to    O
have    O
actively    O
researched    O
the    O
issue    O
with    O
an    O
independent    O
party    O
and    O
suspected    O
soy    O
or    O
sucralose    O
intolerance    B-MetabolicDisorder114084502
.    O

No    O
evidence    O
supports    O
broad    O
claims    O
that    O
food    O
coloring    O
causes    O
food    B-MetabolicDisorder114084502
intolerance    I-MetabolicDisorder114084502
and    O
ADHD    O
-    O
like    O
behavior    O
in    O
children    O
.    O

A    O
variety    O
of    O
disorders    O
can    O
be    O
caused    O
by    O
nuclear    O
mutations    O
of    O
oxidative    O
phosphorylation    O
enzymes    O
,    O
such    O
as    O
coenzyme    O
Q10    O
deficiency    O
and    O
Barth    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
.    O

This    O
family    O
also    O
includes    O
tafazzin    O
,    O
the    O
Barth    B-MetabolicDisorder114084502
syndrome    I-MetabolicDisorder114084502
gene    O
.    O

|    O
GSD    B-MetabolicDisorder114084502
type    I-MetabolicDisorder114084502
III    I-MetabolicDisorder114084502

Micrograph    O
of    O
glycogen    O
storage    O
disease    O
with    O
histologic    O
features    O
consistent    O
with    O
Cori    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
.    O

Disorders    O
of    O
the    O
distal    O
urea    O
cycle    O
,    O
such    O
as    O
citrullinemia    B-MetabolicDisorder114084502
,    O
argininosuccinic    O
aciduria    O
and    O
argininemia    B-MetabolicDisorder114084502
are    O
included    O
in    O
newborn    O
screening    O
programs    O
in    O
many    O
jurisdictions    O
that    O
using    O
tandem    O
mass    O
spectrometry    O
to    O
identify    O
key    O
amino    O
acids    O
.    O

Citrullinemia    B-MetabolicDisorder114084502

Citrullinemia    B-MetabolicDisorder114084502
type    I-MetabolicDisorder114084502
II    I-MetabolicDisorder114084502

CLDF    O
’s    O
literature    O
series    O
includes    O
a    O
medical    O
series    O
,    O
with    O
leaflets    O
on    O
the    O
main    O
liver    O
diseases    O
affecting    O
children    O
(    O
biliary    O
atresia    O
,    O
alpha    B-MetabolicDisorder114084502
1-antitrypsin    I-MetabolicDisorder114084502
deficiency    I-MetabolicDisorder114084502
,    O
autoimmune    O
hepatitis    O
,    O
hepatitis    O
A    O
,    O
hepatitis    O
B    O
,    O
hepatitis    O
C    O
,    O
Wilson's    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
etc    O
.    O
)    O

To    O
give    O
α1    O
antitrypsin    O
to    O
someone    O
who    O
is    O
deficient    O
in    O
α1    B-MetabolicDisorder114084502
antitrypsin    I-MetabolicDisorder114084502
.    O

Alpha-1-antitrypsin    B-MetabolicDisorder114084502
deficiency    I-MetabolicDisorder114084502

alpha-1    B-MetabolicDisorder114084502
antitrypsin    I-MetabolicDisorder114084502
deficiency    I-MetabolicDisorder114084502

The    O
company    O
focuses    O
on    O
treatments    O
for    O
Hepatitis    O
B    O
,    O
the    O
liver    O
disease    O
associated    O
with    O
alpha    B-MetabolicDisorder114084502
1-antitrypsin    I-MetabolicDisorder114084502
deficiency    I-MetabolicDisorder114084502
(    O
AATD    O
)    O
and    O
cardiovascular    O
disease    O
.    O

Alpha    B-MetabolicDisorder114084502
1-antitrypsin    I-MetabolicDisorder114084502
deficiency    I-MetabolicDisorder114084502
is    O
a    O
fairly    O
rare    O
genetic    O
condition    O
that    O
results    O
in    O
COPD    O
(    O
particularly    O
emphysema    O
)    O
due    O
to    O
a    O
lack    O
of    O
the    O
antitrypsin    O
protein    O
which    O
protects    O
the    O
fragile    O
alveolar    O
walls    O
from    O
protease    O
enzymes    O
released    O
by    O
inflammatory    O
processes    O
.    O

Alpha    B-MetabolicDisorder114084502
1-antitrypsin    I-MetabolicDisorder114084502
deficiency    I-MetabolicDisorder114084502
,    O
a    O
genetic    O
disorder    O
that    O
leads    O
to    O
emphysema    O
,    O
COPD    O
,    O
and    O
liver    O
problems    O

Elevated    O
levels    O
of    O
tryptophan    O
are    O
also    O
seen    O
in    O
Hartnup    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502
,    O
a    O
disorder    O
of    O
amino    O
acid    O
transport    O
.    O

Hartnup    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502

Hartnup    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502

Hartnup    B-MetabolicDisorder114084502
disease    I-MetabolicDisorder114084502

Lipoatrophy    B-MetabolicDisorder114084502
/    O
lipodystrophy    B-MetabolicDisorder114084502
(    O
fat    O
redistribution    O
/    O
accumulation    O
)    O

Lipoatrophy    B-MetabolicDisorder114084502
is    O
the    O
term    O
describing    O
the    O
localized    O
loss    O
of    O
fat    O
tissue    O
.    O

Inactivating    O
PH    O
mutation    O
in    O
either    O
the    O
EVER1    O
or    O
EVER2    O
genes    O
,    O
which    O
are    O
located    O
adjacent    O
to    O
one    O
another    O
on    O
chromosome    O
17    O
causes    O
Epidermodysplasia    B-MetabolicDisorder114084502
verruciformis    I-MetabolicDisorder114084502
.    O

Stefania    O
Jabłońska    O
,    O
Polish    O
physician    O
;    O
in    O
1972    O
Jabłońska    O
proposed    O
the    O
association    O
of    O
the    O
human    O
papilloma    O
viruses    O
with    O
skin    O
cancer    O
in    O
epidermodysplasia    B-MetabolicDisorder114084502
verruciformis    I-MetabolicDisorder114084502
;    O
in    O
1978    O
Jabłońska    O
and    O
Gerard    O
Orth    O
at    O
the    O
Pasteur    O
Institute    O
discovered    O
HPV-5    O
in    O
skin    O
cancer    O
;    O
Jabłońska    O
was    O
awarded    O
the    O
1985    O
Robert    O
Koch    O
Prize    O

Dede    B-MetabolicDisorder114084502
Koswara    I-MetabolicDisorder114084502
,    O
Indonesian    O
man    O
known    O
as    O
"    O
Treeman    O
"    O

Tyrosinemia    B-MetabolicDisorder114084502
II    I-MetabolicDisorder114084502

Aceruloplasminemia    B-MetabolicDisorder114084502

Deferoxamine    O
is    O
also    O
used    O
to    O
minimize    O
doxorubicin    O
's    O
cardiotoxic    O
side    O
effects    O
and    O
in    O
the    O
treatment    O
of    O
a    O
patient    O
with    O
aceruloplasminemia    B-MetabolicDisorder114084502
.    O


